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1 Introduction 
1.1 Cancer 
Cancer is the second most common cause of death in Germany and the Western world after 
cardio-vascular diseases. According to estimations by the World Health Organization (WHO), 
cancer causes around 25 % of all deaths worldwide. In Germany in 2006, 22 % and 28 % of 
all deaths in women and men, respectively, were cancer-related (Figure 1-1). More recent 
health statistics show an increase in cancer-related deaths in Western countries. Jemal et al. 
(2008) estimated that cancer will be the most frequent cause of death in the next years.  
 
 
Figure 1-1: Most frequent causes of death among women and men in Germany in 2006 
(modified from Statistisches Bundesamt Deutschland (2008); 
http://www.destatis.de) 
 
The development of cancer is the result of microevolution of an initial cell clone towards 
malignancy. Such aberrant development is suppressed in healthy organisms by multiple 
defense systems (Klein et al., 2007). Clearly, all tumors arise from normal tissue, which is 
due to the great tissue plasticity created by autonomous and versatile cells. Every cell of an 
organism carries in its genome all the information required for the function of that organism, 
but the shape and function of a single differentiating cell is tightly regulated by expression of 
a distinct set of genes required for the function of the cell in its tissue environment. Non-
malignant cells are programmed to construct and maintain the function of the tissues they 
are part of. However, malignant cells ignore this cellular program and acquire uncontrolled 
growth, prevention of apoptosis and/or tissue-invasion. These phenotypic abilities are 
acquired by alterations of the genomic sequence or the epigenome or by loss of the 
regulated expression in malignant cells. This can lead to a malignant phenotype and 
tumorigenic deregulation of tissue growth. Thus, versatility and autonomy of individual cells 
bear the danger of loss of tissue integrity, especially when individual cells gain access to 
information in their genomes which is normally denied to them (Weinberg, 2007). 
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Alterations of the genomic information in malignant cells can be point mutations, deletions, 
gains of genomic material or translocations as well as epimutations. It has been discussed 
that tumorigenesis involves loss other than gain of functions, which affects one or several of 
the numerous cellular surveillance mechanism that are normally involved in cancer 
prevention (Klein et al., 2007). Cellular pathways that are affected in cancer by 
(epi)mutations are e.g. loss of function of DNA repair and cell cycle check-point controls, 
apoptosis, chromatin structure integrity and imprinting stringency as well as tumor 
microenvironment (Klein et al., 2007). 
To date, the process of cancer development can solely be explained from an evolutionary 
point of view. The evolution of cells led to development of very effective defense 
mechanisms that prevent transformation of malignant cells and therefore cancer. Cancer 
cells must go through a process very similar to natural selection. Within tumors, only those 
cells with mutations that best promote growth and enhance survival are selected to multiply, 
whereas malignant cells with less efficient mutations are outcompeted within the tumor; this 
process is called clonal evolution (Nowell, 1976; Gao et al., 2007).  
Tumorigenesis of cells from certain tissues is more frequent than of others, which is e.g. 
depending on exposure of this tissue to carcinogens. The genetic abnormalities in malignant 
cells can be caused by a variety of carcinogens, e.g. chemicals, radiation, infectious agents 
and tobacco smoke. Those carcinogens mostly cause errors in the DNA repair machinery 
(Spadari et al., 1987; Maher and McCormick, 1986; Ahmed, 1980). Additionally, mutations 
and abnormalities of the genetic material can be randomly acquired through errors in DNA 
replication. The consequence of these inherited mutations is their presence in every cell of 
an organism. Thus, every cell with such a mutation is prone to malignant transformation 
(Weinberg, 2007). 
 
 
Figure 1-2: Frequency of of new tumor cases according to tumor localization. Shown 
are percentages of selected tumor loci of all new diagnosed cancer cases, 
in Germany in 2004 by the Dachdokumentation Krebs within the Robert 
Koch-Institut (modified from Robert-Koch-Institut, 2008). 
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Nonetheless, almost every tissue of an organism can be affected by cancer. The most 
frequently affected tissues are given in Figure 1-2. The frequency of these tumor entities is 
different in women and men. However, frequently affected tissues in both genders are gut, 
lung, stomach and bladder. In women, the most commonly affected tissue is breast tissue, 
whereas in men prostate tissue is most commonly affected by tumorigenic transformation 
(Robert-Koch-Institut, 2008). Often tumors continue the evolutionary process that initially led 
to its formation. The tumor cells undergo natural selection in response to chemotherapy 
whereby they can acquire resistance to particular therapeutic agents (O'Dwyer et al., 2002). 
Finally, cancer is a disease that is common in many multicellular organisms, however, the 
risk of tumor development increases with age (see chapter 1.1.2 for more details). 
1.1.1 Molecular biology and genetics of cancer cells 
In the year 2000, Douglas Hanahan and Robert A. Weinberg summarized six universal 
“hallmarks of cancer”, which describe six crucial steps of the transformation process of a 
normal to a malignant cell. These steps are functions that are gained during the process of 
malignant transformation of a cell (Hanahan and Weinberg, 2000). The mechanistic 
pathways vary from cell to cell and not all six hallmarks have to be fulfilled in each malignant 
cellular transformation. Nonetheless, most tumor cells have acquired this set of tumorigenic 
functional capabilities (Table 1-1). 
 
Table 1-1: The six capabilities or hallmarks of cancer (Hanahan and Weinberg, 2000) 
No. Hallmark of cancer Cellular effects 
1 Evasion of apoptosis Allows cell growth despite of genetic mutations and 
internal or external anti-growth signal(s) 
2 Self-suffiency in growth 
signals 
Unchecked growth 
3 Insensitivity to anti-
growth signals 
Unchecked growth 
4 Sustained angiogenesis Allows tumors to grow beyond limitations of passive 
nutrition 
5 Limitless replicative 
potential 
Immortality of cancer cells 
6 Tissue invasion Metastasis 
 
These hallmarks have been described in carcinomas, but neither in carcinomas nor in other 
tumor entities all hallmarks need to be achieved. For instance, properties of normal non-
malignant blood cells are tissue invasion and displacement to distant tissue sites, so there is 
no need of acquiring these functions in the development of leukemia. The capabilities 
described in malignant cells are gained during the transformation process by genomic and/or 
epigenetic mutations. This does not imply that every hallmark needs to be caused by an 
individual mutation. So-called mutator changes in genes with diverse control functions can 
cause gain of several functions at once. These mutator changes can be point mutations, 
microsatellite instability or loss of heterozygosity, and they affect genes that control DNA 
replication, check-points of the cell cycle and the efficacy of DNA repair. Reducing the 
efficacy of DNA repair, leads to an increased mutation rate and genomic instability and 
thereby accelerates the rate of genomic change in malignant cells. A prominent example is 
the TP53 gene, which is lost in a large number of cancers. Loss of P53 protein leads to 
genomic instability, evasion of apoptosis and increased angiogenesis as it is involved in 
control of all of these processes (Klein et al., 2007). 
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The most essential components of tumorigenic transformation are resistance to apoptosis 
and cell cycle dysregulation (Klein et al., 2007). The prevention of apoptosis in cancer cells is 
achieved on several levels. The first level can frequently be overexpression of apoptosis 
inhibitors, like for instance BCL2. The second can be inactivation of executive caspases by 
mutations. The third level of apoptosis prevention can be the downregulation and mutation 
of proapoptotic genes, for example of Bax, Apaf1 or the death receptor CD95. The fourth 
and last level is the alteration of PI3K/AKT signaling pathways (Klein et al., 2007). Tumor 
cells are more resistant to apoptosis than non-malignant cells. However, a cell that is 
completely apoptosis-resistant is not known. As many tumors can be treated by X-ray 
irradiation or by cytotoxic drugs, a residual activity of apoptotic pathways can still be 
triggered in cancer cells (Klein et al., 2007). 
In general, cancer cells acquire their functional capabilities by mutations that typically affect 
two classes of genes: oncogenes and tumor suppressor genes (TSG). Cancer-promoting 
oncogenes are activated through gain-of-function mutations and are mostly involved in 
pathways that confer a variety of properties to the transformed cells including proliferation, 
apoptosis prevention, loss of tissue boundaries and invasion. Tumor suppressor genes are 
inactivated in tumors by loss-of-function mutations. They are normally involved in regulation 
of DNA replication, DNA repair, cell cycle control, cellular orientation within a tissue and 
adhesion within tissues or promotion of apoptosis. 
 
The first oncogene was discovered in 1970 by G. Steve Martin from an avian Rous sarcoma 
virus and was named src for sarcoma (Martin, 1970). Six years later J. Michael Bishop and 
Harold E. Varmus could demonstrate that oncogenes are defective proto-oncogenes 
(Stehelin et al., 1976b), which can originate from retroviruses (Stehelin et al., 1976a). Proto-
oncogenes give rise to a number of protein classes including transcription factors, proteins 
involved in signal transduction or cell cycle regulators. Thus, in normal cells proto-oncogenes 
have diverse functions and are critical in cell growth, control of differentiation, and in 
different signal transduction pathways. Proto-oncogenes are quiescent counterparts of 
oncogenes. They are critical for growth, repair and homeostasis of an organism, whereas 
oncogenes promote uncontrolled cell growth. Activation of proto-oncogenes leads to 
conversion into an oncogene with tumor-promoting activity, e.g. due to imbalance of cell 
cycle regulation. This activation is often based on point mutations, so called “gain-of-
function” mutations of proto-oncogenes that directly lead to increased expression of the 
oncogenic product. Other mechanisms of oncogene-activation are loss of regulation either by 
alteration of gene expression, activity of the protein product or by chromosomal 
translocations, which may lead to overexpression of oncogenes in the wrong cell type or 
expression at the wrong time. A prominent example for a proto-oncogene is Ras, which 
functions as molecular switch between apoptosis and survival of normal cells. Ras is a 
proapoptotic oncogene, like MYC, E2F1 or E1A, which all normally upregulate components of 
the apoptosome that are associated with the mitochondrial pathway. Ras is frequently 
activated through point mutations in a diverse range of tumors. It promotes survival of these 
tumor cells because oncogenic Ras is constitutively active and therefore insensitive to cellular 
negative control mechanisms (Klein et al., 2007). 
 
Tumor suppressor genes (TSGs) normally protect cells from cancer; only if TSG functions are 
lost, cells can undergo malignant transformation. Normal functions of TSGs are regulation of 
cell cycle, induction of apoptosis or cellular adhesion. TSGs repress other genes that are 
responsible for progression in cell cycle and they link DNA damage to cell cycle and to 
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apoptosis. Some tumor suppressors are involved in cell adhesion and prevent normal cells 
from dispersion, block loss of contact inhibition and thus inhibit metastases. 
The first TSG, RB1, was discovered by its protein product, the tumor suppressor 
retinoblastoma (pRb) in human retinoblastoma (Friend et al., 1986). The function of pRb is 
lost in retinoblastomas through germline and somatic mutations of the RB1 TSG in retinal 
cells, leading to formation of retinoblastomas. The most famous example of a TSG is TP53, 
which is affected in nearly all cancers. Homozygous loss of TP53 is found, for example, in 
70 % of colon cancers, in 30-50 % of breast cancers and in 50 % of lung cancers. 
Additionally, mutated TP53 is involved in the pathophysiology of leukemias, lymphomas, 
sarcomas and neuronal tumors (Weinberg, 2007). Normal TP53 has many cellular functions. 
It acts as a transcription factor, is involved in the cell cycle control upon DNA damage, and 
contributes to genomic integrity, DNA repair and recombination (Vogelstein et al., 2000; Goi 
et al., 1997; Guillouf et al., 1995). A second important example for a TSG is PTEN 
(phosphatase and tensin homolog deleted on chromosome 10), a tumor suppressor that is 
part of the PI3K (phosphatidylinositol 3-kinase)/AKT signaling pathway that regulates 
signaling of cellular processes such as apoptosis, cell proliferation and cell growth. PTEN 
encodes a dual protein/lipid phosphatase, whose main substrate is phosphatidyl-inositol-
3,4,5-triphosphate (PIP3) which is a product of the PI3K. An increase in PIP3 within the 
cytoplasm recruits AKT to the cellular membrane where it is further activated by other 
kinases that are similarly dependent on PIP3. Loss of activity of the PTEN TSG by either 
mutations, deletions or silencing by promoter hypermethylation is frequently observed in 
many human cancers (Blanco-Aparicio et al., 2007) and leads to deregulated AKT-signaling 
in the malignant cells. The most common mechanisms of inactivation of TSGs are loss-of-
function mutations and inactivation of signaling components that are involved in TSG-
activation pathways. Besides this, recessive germline mutations can occur and are inherited 
by the offspring, which predisposes to cancer without producing a phenotype. 
The two-hit-hypothesis by Alfred Knudson states that an inherited germline mutation in a 
TSG only causes cancer if a second mutation occurs in the second allele of the same TSG 
(Knudson, 1971). The first hit does not necessarily lead to cancer as the function of TSGs 
can counteract on the mutated oncogene. Only a second hit, which inactivates the second 
copy of the TSG, leads to malignant transformation. Alfred Knudson performed statistical 
analyses on inherited and sporadic retinoblastomas to explain age differences between the 
two types of retinoblastomas. Inherited retinoblastoma develops early in children, as the first 
mutation of the RB1 gene is inherited and therefore a second mutation rapidly leads to 
cancer. In contrast, sporadic retinoblastomas occur later in life because two mutations have 
to take place before development of the cancer (Knudson, 1971). The two hit hypothesis by 
Knudson can be extended to more recent findings of epigenetic aberrations in cancer, as the 
second hit may be the epigenetic silencing of a TSG or the epigenetic activation of an 
oncogene. 
Nonetheless, the two-hit-hypothesis had also been challenged by the finding that a mutation 
in one allele of a TSG is sufficient to cause cancer, even if it is a recessive mutation. This 
phenomenon occurs in haploinsufficient TSGs and tumors caused by haploinsufficiency are 
characterized by an earlier age of onset (Cabelof et al., 2006). Haploinsufficiency is 
described as a dominant loss of function mutation of a haploinsufficient gene of which one 
copy does not produce sufficient protein to generate the wild type condition. Thus, 
haploinsufficiency leads to an abnormal disease state since a haploinsufficient gene needs 
expression from both alleles to establish the wild type state. A wide range of cancers are 
caused by haploinsuffiency, including for example lymphomas, leukemias, prostate, breast, 
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colorectal, and skin cancers (Santarosa and Ashworth, 2004; Le Toriellec et al., 2008). After 
discussion of the chromatin remodeling in normal and malignant development, a short 
overview of described epigenetic events in cancer will be given at the end of chapter 1.1.2. 
1.1.2 Chromatin remodeling in normal and malignant development 
The cellular plasticity in non-malignant cells and disease is generally achieved by a complex 
regulatory network that involves modulation of chromatin structure and thereby genome 
function. The molecular basis of a part of this network is chromatin remodelling, which 
describes all chemical and biological modifications to DNA and histone proteins. The 
mechanisms by which epigenetic changes determine how the genetic information is used 
accross the highly variable background of developmental stages, tissue types and disease 
states is not yet fully understood (Bernstein et al., 2007).  
A simplified view of decisions of cellular fate that are made in the nucleus is presented in 
Figure 1-3. External signals are translocated by signal transduction cascades into the nucleus 
and lead to changes of genome organization. In turn, gene expression patterns are altered 
and decisions are provoked that lead to differentiation, proliferation, senescence, apoptosis 
or specific metabolic states of the cell (Rippe, 2007). Thus, the tight regulation of epigenetic 
states and chromatin remodeling potential is essentially indispensable for the regulation of 
any cell. 
 
 
Figure 1-3: Schematic view of cell fate decisions in the nucleus (Rippe, 2007) 
 
Many proteins are involved in the different chromatin remodeling processes, for example 
DNA-methyltransferases (DNMTs) and DNA-demethylases, histone-methyltransferases 
(HMTs), histone-acteyltransferases (HATs), histone-deacetylases (HDACs) and members of 
the chromatin remodeling protein-complexes. Here, a short introduction to general aspects 
of epigenetics will discuss DNA-methylation, histone modifications and the histone code as 
well as epigenetic changes during aging. The function of DNA-methylation in non-malignant 
cells and its role in monoallelic expression will be described below (chapter 1.3.3). 
DNA-methylation in vertebrates occurs almost exclusively at cytosines within CpG-
dinucleotides, whereby most CpGs in the genome are methylated (Bird, 2002; Goll and 
Bestor, 2005). 
The four core histones, H2A, H2B, H3 and H4, build the nucleosomes and are subject to over 
100 posttranslational modifications of residues in their histone tails. These posttranslational 
modifications include acetylation, methylation, phosphorylation and ubiquitination and they 
regulate chromatin accessibility and transcriptional activity (Kouzarides, 2007). Distinct 
histone modifications influence each other and may interact with DNA-methylation (Figure 
1-4). The epigenomic state of a particular cell is the result of genetic determinants, lineage 
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specific cues and the environment (Figure 1-4). Epigenetic modifications are read by protein 
complexes that can bind to modified histones or to methylated cytosines (Li et al., 2007). 
The term epigenome sums up all epigenetic modifications of a given cell, but it has been 
shown that although DNA-methylation patterns are epigenetically inheritable, only a subset 
of histone modifications are (Bernstein et al., 2007). 
 
 
Figure 1-4: Schematic representation of the epigenetic network that modulates 
chromatin structure and genome function (modified from Bernstein et al., 
2007). 
 
DNA-methylation is the covalent modification of cytosine bases by methyl-groups that are 
transferred from the donor S-adenosylmethionine to the C5-position of the cytosine by DNA-
methyltransferase enzymes (DNMTs). In mammals, three different DNMT enzymes with 
different specificities and functions have been described. DNMT1 has the function of 
maintaining DNA-methylation and during replication it copies the DNA-methylation patterns 
from the template strand to the daughter strands. DNMT1 was found to be critical for proper 
embryonic development, for genomic imprinting and also for inactivation of the female X 
chromosome (Cervoni et al., 1999; Bhattacharya et al., 1999; Wolffe et al., 1999). The two 
other mammalian DNMTs, DNMT3a and DNMT3b, are de novo methyltransferases that set 
up the DNA-methylation pattern in early development. Both DNA-methylation and DNA 
demethylation are essential for the regulation of gene expression. Several enzymatic 
activities have been described that demethylate DNA in vivo and in vitro (Cervoni et al., 
1999; Bhattacharya et al., 1999; Szyf and Bhattacharya, 2002; Hattori et al., 2001). 
However, it is still highly debated whether these functions are present in vivo or if DNA-
demethylation occurs during replication as a passive process after loss of DNMT1 activity 
(Suzuki and Bird, 2008). The regulatory role of DNA-methylation is complex, includes a 
variety of cellular functions and its deregulation results in a number of pathologies. It 
regulates tissue-specific gene expression, differentiation, genomic imprinting, regulation of 
chromatin structure, aging and carcinogenesis (Bird, 2002). DNA-methylation is crucial for 
normal development and for the survival of differentiated cells (Li et al., 1992; Okano et al., 
1999; Jackson-Grusby et al., 2001). CpG-dinucleotides of the mammalian genome are 
globally methylated, while specialized structures, called CpG-islands, are unmethylated. 
Especially repetitive sequences and transposable elements, but also gene bodies and 
intergenic regions are highly methylated in order to maintain chromosomal stability 
(Kouzarides, 2007).  DNA-methylation patterns are highly dynamic throughout development 
and disease. It has been shown that in normal early development, paternal and maternal 
genomes are demethylated. While the paternal genome is actively demethylated, the 
maternal genome is demethylated later passively (Reik et al., 2001; Santos et al., 2002). In 
the blastocyst state, genomewide levels of DNA-methylation increase rapidly to produce the 
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majority of the methylation patterns that are later found in adult tissues. In addition to these 
coordinated changes during normal development, the totality of DNA-methylation (the so-
called DNA methylome (Esteller, 2007)) undergoes characteristic changes in malignant 
transformation (see chapter 1.1.3). DNA-methylation in normal and diseased cells affects 
recruitment of regulatory proteins. Two mechanisms have been described so far. The first 
one is the exclusion of DNA-binding proteins from their target sites by methylated DNA. One 
well investigated example is the imprinted H19 locus. A differentially methylated region 
(DMR) at the locus leads to inhibition of CTCF-binding and activates gene expression at this 
allele (Hark et al., 2000). In contrast, the methylated CpG-dinucleotides of the inactive allele 
recruit HDACs to methylated genomic loci that further deacetylate the histone tails leading to 
transcriptional repression (Bird, 2002). This leads to further silencing of inactive genomic loci 
by DNA-methylation. 
 
 
         
Figure 1-5: Schematic representation of the sequence of the four human core histone 
tails and of the variants CENP-A and H2A.X and all of their published post-
translational modifications. 
(http://www.millipore.com/techpublications/tech1/pb1014en00-74xp9g). 
 
Modifications of histone tails are involved in regulation of the chromatin structure and the 
regulation of accessibility and expression of genomic loci. The DNA-helix is wrapped around 
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nucleosomes that are formed by histone proteins and regulated by modifications of the DNA 
and the histone tails. The nucleosomes of the chromatin fiber are functional and structural 
subunits and form a nucleosomal chain. Each nucleosome consists of four core histones, 
H2A, H2B, H3 and H4, that form an octamer, the nucleosomal core particle, which is 
generated by one H3-H4-tetramer and two H2A-H2B-dimers. 146 base pairs of the DNA-helix 
are wrapped slightly less than two turns around this core particle. The nucleosomes are 
connected by a linker DNA sequence that is variable in length (15 to 55 base pairs), and the 
linker histone H1 that is bound to the DNA-helix can attach one nucleosome to the other 
(Lodish, 2000).  
The histones themselves are small basic proteins each consisting of a globular domain, which 
is part of the nucleosomal core particle and of a more flexible and charged N-terminus of 20 
to 140 amino acid residues, the histone tail. The globular domains of the four core histones 
constitute the nucleosomal core whereas the histone tails protrude from the nucleosomes 
and are subject to over 100 known chemical posttranslational modifications including 
acetylation, methylation, phosphorylation and ubiquitination (see Figure 1-5). Those histone 
tail modifications have regulatory function in modulating chromatin accessibility and 
transcriptional activity (Kouzarides, 2007). It was already recognized in the beginning of 
epigenetic studies that particularly the histone acetylation and methylation has direct effects 
on a great variety of nuclear processes including gene transcription, DNA repair, DNA 
replication and the organization of chromosomes (Esteller, 2008; Lodish, 2000). 
The combinations of several histone modifications are recognized by distinct proteins and 
thus, the modifications can influence gene expression in normal and malignant cells. At first, 
histone modifications were only recognized to have an effect on the structure and 
condensation of chromatin. The methylation of lysine residues in histone tails was considered 
to only result in compaction of chromatin, while acetylation leads to opening of chromatin. 
This view was supported by findings that the heterochromatin protein 1 (HP1) selectively 
binds to methylated lysine 9 residues in the tail of histone H3, which promotes 
heterochromatin formation. Euchromatinization, on the other hand, could be linked to the 
acetylation of histones (Lodish, 2000). Since then, many studies have shown that this is only 
a simplified view of how chromatin structure regulates cellular functions. 
Apart from the canonical histones (H1, H2A, H2B, H3 and H4), a variety of histone variants 
has been described; a short selection is listed in Table 1-2. The most extensively studied 
histone variant is histone H3.3, which is a variant of the canonical histone H3 (H3.1). The 
exchange of H3.1 with the variant H3.3 was the clue to the puzzle of how histone tails are 
demethylated and deacetylated outside of replication. All modifications on the histone tail of 
H3 are erased at once by replacing H3.1 with its variant H3.3 thereby making the chromatin 
at this site more or less accessible for transcription depending on the preceding modifications 
of the canonical H3 (Ahmad and Henikoff, 2002; Wirbelauer et al., 2005). 
Another interesting histone variant is macroH2A, which contains an unusual additional 
globular domain in place of the histone tail (Pehrson and Fried, 1992). If macroH2A instead 
of H2A is incorporated into the nucleosomal core the chromatin is transcriptionally 
inactivated. MacroH2A was shown to have repressive effects on gene expression and has 
been shown to be enriched at the human female inactivated X chromosome (Changolkar and 
Pehrson, 2006; Costanzi and Pehrson, 1998). Additionally, it was shown that macroH2A is 
allele-specifically enriched at imprinting control regions within imprinted loci (Choo et al., 
2006). This monoallelic enrichment of macroH2A was suggested to be present at all 
monoallelically enriched loci, which is why the enrichment of macroH2A at the monoallelically 
expressed locus within 13q14 was analyzed in this work. 
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Table 1-2: Description of selected nucleosomal histones, their variants and potential unique functions 
of the histone variants (modified from Culhane and Cole, 2007) 
Histone protein/ 
variant 
Property/ 
Proposed function (prop. fct.) 
% of identity to 
major isotype 
H2A, H2B, H3 and H4 Canonical core histones, encoded by replication-
coupled genes 
- 
MacroH2A Vertebrate-specific H2A variant with a C-terminal 
globular domain; enriched on mammalian inactive X-
chromosome; 
proposed function: X-chromosome inactivation; gene 
expression 
64 (in histone 
region) 
H2A.X H2A variant with a four amino acid SQ[E or D]-C-
terminal motif that becomes serine-phosphorylated at 
sites of double-strand breaks 
- 
H3.3  
(H3.2 in plants) 
H3 variant that replaces H3 and differs at position 31 
and at a few residues on helix 2 that enable 
deposition outside of replication 
- 
CENP-A Essential for viability in mouse; 
proposed function: kinetochore assembly 
62 
 
Brian D. Strahl and C. David Allis proposed the histone code hypothesis in the year 2000, 
which was later refined by Allis together with Thomas Jenuwein (Strahl and Allis, 2000; 
Jenuwein and Allis, 2001). According to this hypothesis, the histone code consists of distinct 
histone modifications on one or several histone tails that together form a code, which is 
established and read by specialized proteins. 
 
Table 1-3: Differential distribution of histone modification marks in interphase nuclei of Drosophila, 
mammals and Arabidopsis (modified from Henikoff et al., 2004). 
 
 
The read-out of the histone code by specialized proteins at specific chromatin sites leads to 
distinct downstream events. Jenuwein and Allis (2001) postulated three features of the 
histone code: Firstly, distinct histone tail modifications induce the interaction with chromatin 
associated proteins; secondly, modifications on the same or on different histone tails can be 
interdependent and thus generate various combinations or codes on the nucleosomes, and 
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thirdly the concentration and combination of differently modified nucleosomes is responsible 
for distinct qualities of higher order chromatin, which simply means that the combinations of 
histone modifications generate euchromatic and heterochromatic sites (Jenuwein and Allis, 
2001). In addition, single histone marks can be linked to heterochromatic and euchromatic 
sites, like for example mono-, di- or tri-methylation of lysine 4 of histone H3 (H3K4me1-3), 
which is a mark of euchromatin regardless of methylation states in all species that are 
depicted in Table 1-3. Other single histone marks for euchromatin in mammals include H3K9 
acetylation, H3S10 phosphorylation and mono- and dimethyation of H4K20. Mammalian 
marks of heterchromatin are deacetylated histones, and methylation of H3K9 and H3K27. 
Table 1-3 shows that the histone marks themselves seem to be highly conserved among 
species (in plants, insects and mammals), while the suggested functions, i.e. the coding, can 
vary from species to species (Henikoff et al., 2004). 
 
Not only histone modifications are conserved among species, but also the protein domains 
that establish and read those marks. The protein domains that interact with histone 
modifications are mainly bromo-, chromo- and SET-domains (Jenuwein and Allis, 2001). 
These are found in two classes of antagonizing chromatin regulators, the Polycomb (PcG) 
and trithorax (trxG) groups. Generally, PcG and trxG genes are important for the 
maintenance of expression boundaries of homeotic selector genes (Hox genes) and several 
other key developmental regulator genes. The regulation by PcG and trxG mostly occurs 
through the modulation of chromatin structure of their target loci (Orlando et al., 1998; van 
Lohuizen, 1999). The mammalian trithorax proteins contain bromodomains that bind for 
example to acetylated histones (Strahl and Allis, 2000). In contrast to that, the 
chromodomains of Polycomb and HP1 proteins were found to preferentially bind to 
methylated histone lysine residues. Finally, the SET-domains are shared within both classes 
of chromatin regulators, PcG and trxG, and these domains have a methylating activity 
(Jenuwein et al., 1998; Xiao et al., 2003). No methylating activity can be assigned to the 
bromo- and chromodomains, which are solely reading and translating the histone signals 
through their binding to specific modified epitopes. Those protein domains are therefore the 
basis for establishing and reading the histone code (Strahl and Allis, 2000). Another group of 
enzymes that regulate the site-specific methylation are homologs of the Drosophila 
Su(var)3-9. The Su(var)3-9 protein and its homologs, which are Clr4 in yeast and SUV39H1 
in human, were shown to encode a histone methyltransferase (HMT) with specificity for the 
methylation of histone H3 at the lysine 9 residue (H3K9) (Rea et al., 2000). The methylation 
activity of these enzymes comes from the highly conserved SET-domains of these HMTs. The 
methylation of the H3K9 epitope induces further binding of HP1 by its chromodomains, and 
thus a heterochromatic mark is stably established (Bannister et al., 2001; Lachner et al., 
2001). The sum of these findings generates a strong link between Su(var)-function, gene-
silencing and the assembly of heterochromatin. 
The first protein module for which direct and selective interaction with acetylated lysines of 
the histone tails could be shown was the bromodomain. Sequentially, a class of proteins was 
found to recognize and bind to these bromodomain-containing proteins, which fullfills the 
second prediction of the histone code hypothesis of a combinatorial readout (Strahl and Allis, 
2000). 
The histone code hypothesis has been challenged since it was published in 2000. However, it 
has been confirmed in a number of studies that distinct combinations of several histone 
modifications mark chromatin for transcriptional activity or transcriptional silence. In 
addition, histone modifications distinctively mark functional and structural chromatin domains 
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like transcriptional start sites or enhancer regions (Barski et al., 2007). Moreover, features 
like the binding of chromatin remodeler proteins and DNA-methylation contribute as 
epigenetic marks to chromatin. It has been shown that the histone code is not comparable 
to the genetic code in its universitality and stringency. Thus, the original model of a histone 
code has been displaced by the view of a more general epigenetic code that includes all 
chromatin modifications that lead to distinct functions and transcriptional regulation of the 
genome. The term “epigenome” has been used to describe all epigenetic modifications and 
regulation patterns within a given cell, and this term is used analog to the term genome 
(Fraga and Esteller, 2007). 
The epigenome is described to include all inheritable changes and marks of distinct gene 
functions that occur without changes to the DNA nucleotide sequence itself. The epigenetic 
modifications that constitute the epigenome were found to be variable, both intraindividually 
and interindividually, and tissue-specific (Fraga and Esteller, 2007). It was shown in 
monozygotic twin studies (Fraga et al., 2005a) that epigenetic variations accumulate during 
aging independently of changes in the genetic sequence. This so-called epigenetic drift 
between twins during aging is associated with phenotypic discordance, probably because of 
a different environmental input. According to this study, it is strongly suggested that 
epigenetic modulation is the response to environmental factors. However, there are also 
stochastic events of epigenetic changes occurring during ontogenic development that cannot 
be related to environmental effects alone. These stochastic epigenetic recombination events 
are the basis for the concept of epigenotypes, which explain the differences of epigenetic 
patterns in young individuals (Fraga et al., 2007). 
Aberrant epigenetic silencing has been established to be a hallmark in tumorigenesis (see 
chapter 1.1.3). In addition, epigenetic silencing is also important in cellular aging and 
senescence (Fraga et al., 2005a; Issa, 2003). Altogether, four epigenetic events could be 
associated with the aging process. The first event includes environmental and stochastic 
changes of the epigenetic landscape during the lifetime of an organism and these changes 
have been described for example in the twin study by Fraga et al. (2005a). Secondly, the 
aging process itself leaves a mark in the cellular DNA-methylation pattern. The third 
epigenetic event associated with aging includes genetic and epigenetic disturbances of 
progeroid genes, which converge in aged and cancer cells. Lastly, the histone marks 
H4K16ac and H4K20me3 are associated with the aging process (Fraga and Esteller, 2007). 
Manel Esteller postulated in 2007 that in the future a DNA methylome and histone map of 
aging will be available, analog to that established for cancer cells (Esteller, 2007), and this 
map will make it possible to define a young versus an old (aged) cell on the basis of their 
distinct epigenetic pattern (Fraga and Esteller, 2007). 
The DNA-methylation pattern is propagated after each cell division by DNMTs, such as 
DNMT1 in human cells. However, aging cells undergo an epigenetic drift, which includes for 
example, a global decrease of DNA-methylation in many tissue types. This global DNA-
hypomethylation is probably the result of passive demethylation, which in turn is the effect 
of progressive loss of DNMT1-efficacy and of false targeting of DNMT1 by other cofactors. 
Another mechanism that may lead to aberrant DNA-methylation patterns in aged cells is the 
overexpression of the DNMTs with a de novo DNA methylating activity, i.e. DNMT3b, as a 
response to the DNA-hypomethylation in repetitive sequences (Casillas et al., 2003). The 
resulting outcome of DNMT3b overexpression is aberrant hypermethylation of promoter CpG-
islands of tumor suppressor genes (Issa, 2003). 
Interestingly, epigenetic events associated with the aging process are reminiscent of the 
epigenetic events that lead to tumorigenesis. The links between aging and cancer are global 
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DNA hypomethylation, aberrant promoter hypermethylation and modest DNMT 
overexpression (Esteller, 2003). This observed accumulation of epigenetic aberrations during 
aging might contribute to tumorigenic transformation. Many examples of genes are known 
that show increased promoter methylation during aging in non-tumorigenic tissues (Issa, 
2003; Oakes et al., 2003). Thus there is a potential association of the accumulation of 
promoter hypermethylation of TSGs during aging with the predisposition to develop cancer. 
However, a direct relationship between the methylation status of these genes and the aging 
process itself has not been proven, except for the notion that most cancer types only arise 
late in adult life. 
1.1.3 Epigenetic events in cancer 
Epigenetics is defined as regulation of gene expression by modifications of DNA and 
chromatin structure that is not reflected by differences in the DNA nucleotide sequence itself. 
Both DNA hypo- and hypermethylation has been described to be part of malignant 
transformation of cancer cells (reviewed in Esteller, 2006). DNA hypomethylation frequently 
occurs as global loss of DNA-methylation in tumors and is most often found at repetitive DNA 
sequences. Aberrant DNA-hypomethylation could result in chromosomal instability, 
translocations and gene disruptions caused by reactivation of transposable elements 
(Esteller, 2005; Feinberg and Tycko, 2004). A second major epigenetic event in cancer is 
hypermethylation of CpG-islands of tumor suppressor gene promoters that leads to gene 
silencing (Esteller, 2006; Jones and Baylin, 2002). The first described TSG found to be 
inactivated by hypermethylation of its promoter-CpG-island was RB1 (Greger et al., 1989; 
Sakai et al., 1991). Since then, many other TSGs have been reported to be inactivated by 
promoter-CpG-island-hypermethylation, including VHL (Herman et al., 1994), p16INK4a (Merlo 
et al., 1995; Herman et al., 1995; Gonzalez-Zulueta et al., 1995), hMLH1 and BRCA1 
(Herman and Baylin, 2003). More recently, the role of histone modifications in epigenetic 
control of gene expression and chromatin structure has been recognized. Histone tail 
modifications have been found to be closely involved in the epigenetic regulation, and at 
some loci have been shown to recruit the DNA-methylation machinery (Fraga and Esteller, 
2005). Only little is known about the role of histone modifications in cancer cells. However, it 
has been shown that histone modifications together with CpG-island-hypermethylation can 
silence TSGs (Ballestar et al., 2003; Fahrner et al., 2002). Conversely, it has also been 
described that in some cases, for example in the TSG p21WAF1, histone modifications can 
promote silencing independently of CpG-island-hypermethylation (Fahrner et al., 2002). 
Frequently, the hypermethylation of promoter-CpG-islands of TSGs is linked to a distinct 
combination of histone marks. Several histone modifications have been defined as markers 
for cancer. These marks are global deacetylation of histones H3 and H4, loss of 
trimethylation at lysine 4 of histone H3 (H3K4me3) and gain of methylation and 
trimethylation at lysine 9 (H3K9) and lysine 27 (H3K27) of histone H3, respectively (Esteller, 
2007). Fraga et al. (2005b) showed that many human tumors are subject to overall loss of 
monoacetylation of lysine 16 and of trimethylation of lysine 20 in the tail of histone H4. 
These two distinct histone marks are considered as universal epigenetic markers for 
malignant transformation (Fraga et al., 2005b). Finally, loss of H3K4 dimethylation 
(H3K4me2) and of H3K18 acetylation (H3K18ac) has been proposed as a marker of high risk 
recurrence in prostate cancer (Seligson et al., 2005). Thus the global pattern of distinct 
histone modifications may even have a prognostic value. 
In summary, epigenetic events that have been related to malignant transformation in cancer 
are a global DNA-hypomethylation, CpG-island-hypermethylation and overall loss of H4K16ac 
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and of H4K20me3. Finally, two recent examples of genetic lesions that have also an impact 
on the epigenetic landscape of cancer cells should be mentioned. The first is the expression 
pattern of histone and DNA modifying enzymes, such as DNA-methyltransferases (DNMTs), 
histone-methyltransferases (HMTs) and histone-acetyltransferases (HATs), which can vary 
between cancer and normal tissues and also between different tumor types (Ozdag et al., 
2006). In leukemia and sarcoma entities characteristic chromosomal translocations that 
create aberrant fusion proteins frequently involve the genes encoding histone modifying 
enzymes like HATs and HMTs (Esteller, 2006). The second example for genetic lesions with 
an epigenetic impact is the deregulation of microRNAs (miRNA) that has been linked to 
cancer development. Downregulation of miRNAs that degrade or inhibit translation of mRNAs 
is frequently found in cancer and implies a tumor suppressive function for these miRNAs 
(Chen, 2005; Calin and Croce, 2006). Furthermore, hypermethylation of the miRNA 5’-
regulatory regions can account for the downregulation of miRNAs just as for coding genes 
(Saito et al., 2006; Lujambio et al., 2007). Two examples of miRNAs that have been found to 
be downregulated in distinct tumors are the let-7 miRNA, targeting the RAS oncogene in 
lung tumors, and miR15/miR16, targeting BCL2 in leukemia (Johnson et al., 2005; Cimmino 
et al., 2005). 
 
1.2 Leukemias and lymphomas 
Generally, tumors are classified according to the tissue they originate from. The majority of 
human cancers arise from epithelial tissues; these carcinomas are responsible for more than 
80 % of cancer-related deaths in the Western world. Three groups of tumors with 
nonepithelial origin can be classified in addition to carcinomas. The first group consists of 
tumors that are derived from various connective tissues like bones or muscles; these entities 
are called sarcomas. Sarcomas only account for 1 % of all human tumors. The second group 
comprises all tumors that arise from various cell types of the central and peripheral nervous 
system. Tumors of this group are classified as neuroectodermal tumors according to their 
origin from the embryonic ectodermal layer, including gliomas, glioblastomas, 
medulloblastomas or neuroblastomas. Interestingly, only 1.3 % of all diagnosed cancers are 
neuroectodermal tumors, but they are responsible for 2.5 % of cancer-related deaths 
(Weinberg, 2007). The third group comprises tumors that can arise from every 
hematopoietic tissue including cells of the immune system. Leukemias and lymphomas are 
the two main subtypes of hematological neoplasias. Literally, leukemia means “white blood”, 
which refers to nonpigmented malignant progeny of several hematopoietic cell lineages. 
Leukemias form dispersed, single-cell populated tumor cells in the blood where the tumor 
populations can move freely. Lymphomas are tumors arising in the lymphoid organs, like 
lymph nodes, spleen and thymus. This category includes all tumors originating from the 
lymphoid cell lineage, for example from B- and T-lymphocytes. Aberrant lymphoid cells 
aggregate to form solid tumor masses, most frequently found in lymph nodes (Weinberg, 
2007). The most common hematopoietic malignancies are Acute Lymphoblastic Leukemias 
(ALL), Acute Myelogenous Leukemias (AML), Chronic Myelogenous Leukemias (CML), 
Chronic Lymphocytic Leukemias (CLL), Multiple Myeloma (MM), Non-Hodgkin’s Lymphoma 
(NHL) and Hodgkin’s Disease (Weinberg, 2007). 
 
Leukemias can be roughly subdivided into acute and chronic leukemias according to the 
course of the disease. The characteristic of acute leukemias is a rapid increase of immature 
blood cells that crowd the bone marrow, which is in turn unable to produce healthy blood 
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cells. Acute leukemias occur mainly in children and young adults and are the most common 
cause of cancer-related deaths in children in the U.S. (Jemal et al., 2005). Acute forms of 
leukemia usually need immediate treatment as they are rapidly progressing with malignant 
cells accumulating in the blood and spreading to other organs. In comparison, chronic 
leukemias are progressing very slowly and abnormal cells of chronic leukemias can mature 
regardless of their lack of functionality. Moreover, the leukemic cells are usually long-lived 
and essentially outlive other healthy blood cells. In chronic leukemias, aberrant cells are 
excessively accumulating, but it can take months or even years for the progression of the 
disease. The malignant cells are produced at a much higher rate than non-malignant cells 
resulting in a slow but steady accumulation of aberrant leukemic cells in the blood and 
sometimes secondary lymphoid organs. Chronic leukemias occur mostly but not exclusively 
in older people and are often only diagnosed in a routine blood test, as no symptoms 
manifest until the disease reaches an advanced stage. In contrast to the requirement of 
immediate treatment of acute leukemias, chronic lymphocytic leukemia is monitored before 
treatment, which maximizes overall survival. 
 
Leukemias can be subdivided further into lymphoblastic (or lymphocytic) and myeloid (or 
myelogenous) leukemias depending on the type of the affected blood cells. In lymphocytic 
leukemias, lymphocytes or lymphocytic progenitor cells are transformed. In myelogenous 
leukemia, a progenitor cell that would normally differentiate into red or white blood cells or 
into platelets has transformed to malignancy. 
Two types of acute leukemias have been classified according to the affected blood cell type: 
AML and ALL. Acute Myelogenous Leukemia (AML) involves myeloid lineage cells including 
granulocytes, monocytes and platelets, while in Acute Lymphoblastic Leukemia (ALL) cells of 
the lymphoid lineage are affected, including B- and T-lymphocytes (Catovsky, 1982). Analog 
to acute leukemias, the two categories of chronic leukemias are Chronic Lymphocytic 
Leukemias (CLL) and Chronic Myelogenous Leukemia (CML). ALL is the most common 
leukemia in children, but it affects also adults at an age of 65 years and older. The survival 
rates of ALL patients vary between groups of different age, but approximately 85 % of 
children and 50 % of adults survive the disease (Zippin et al., 1971). CLL is the most 
common leukemia in adults, and patients have a median age at onset of 72 (Seiler et al., 
2006). Men are slightly more frequently affected with an incidence ratio of 2:1, in 
men:women. The five-year survival rate is 75 %, depending on the genomic alterations that 
are present (see chapter 1.3). CLL patients are frequently without symptoms for a prolonged 
period of time. In addition, the majority of CLL patients respond well to treatment, with 
current first-line regimens resulting in overall response rates of 95 %. However, all patients 
finally relapse and the disease remains incurable outside of transplantation procedures 
(Boyiadzis et al., 2007). The myeloid leukemias AML and CML occurr also predominantly in 
adults. While AML patients need treatment with several chemotherapeutica (Burnett, 2005), 
first-line treatment of CML is imatinib (Gleevec) (Avery et al., 2004; Hirose et al., 2002). In 
AML, the five-year survival rate is only 40 %, while it is 90 % in CML. Hairy cell leukemia 
(HCL) is not categorized to one of these groups. HCL is sometimes considered a subset of 
CLL, but shows somewhat different features (Gine et al., 2002). About 80 % of affected 
patients are adult men; the disease has not been reported in young children. HCL is 
incurable, but easily treatable with a ten-year-survival rate of 96-100 % (Jansen et al., 
1984).  
 
1 Introduction 
 16
1.2.1 Hematopoiesis 
Hematopoiesis is the process by which all blood lineages arise from pluripotent 
hematopoietic stem cells (HSC; Figure 1-6). Blood lineages include T- and B-cells that 
constitute the lymphoid lineage, and neutrophils, eosinophils, basophils, monocytes, 
macrophages, megakaryocytes, platelets and erythrocytes that are part of the myeloid 
lineage (Zhu and Emerson, 2002). All these components of the blood are derived from HSCs 
through asymmetric division that produces a HSC and a hematopoietic progenitor cell (HPC). 
HPCs are multipotent cells that partially retain the self-renewal capacity of HSCs and give 
rise to lineage commited progenitor cells that can differentiate into all cells of the 
hematopoietic system (in Figure 1-6). First, HPCs generate either lymphoid or myeloid 
progenitor cells (CMP or CLP, respectively) that further differentiate into cell types of the 
hematopoietic system (depicted in Figure 1-6). In the myeloid lineage, CMPs differentiate 
into a large variety of human blood cells like erythrocytes, platelets, neutrophils, eosinophils, 
basophils and macrophages (Figure 1-6). In contrast, lymphoid progenitor cells differentiate 
into B- and T-lymphocytes or natural killer (NK) cells (Figure 1-6). A more detailed view of 
the development of B-cells will be given in the following chapter. 
 
 
Figure 1-6: Ontogeny of human blood cells. 
(http://daley.med.harvard.edu/assets/Willy/haematopoiesis.jpg) 
 
  Leukemias and lymphomas 
 17
1.2.2 B-cell development 
B-cell development starts in the bone marrow, where immature B-cells are produced, and 
proceeds through different stages of rearrangement of the genomic immunoglobulin loci 
(Edry and Melamed, 2004). Immunoglobulins (Ig) are composed of light (L) and heavy (H) 
chains. These genes are found in distinct genomic clusters. Both, H and L chains consist of a 
variable (V) and a constant (C) region. In a process called V(D)J recombination the variable 
regions of H and L chains are assembled to produce a unique complete V-domain in the 
immunoglobulin of a B-cell. The genetic locus of the variable region is organized into several 
gene segments, two segments in the VL-region (V and J) and three gene segments (V, D and 
J) in the VH-region (Matsuda and Honjo, 1996). Recombinations between the gene segments 
of the VL and VH locus take place in a stepwise fashion during the development of B-
lymphocytes. After V(D)J-recombination, precursor B-cells have functional immunoglobulin 
genes, which constitute the B-cell receptor (Bassing et al., 2002). Only those B-cells with a 
functional BCR on their surface survive and can develop into mature naïve B-cells, leave the 
bone marrow and participate in the immune response.  
In the germinal center of the lymph node, B-cells mature and are activated by antigen 
presenting cells. Mature naïve B-cells are activated by binding of an antigen to the BCR, 
which upon binding triggers specific cytoplasmic signaling cascades depending on the 
maturation stage of the B-cell (Gauld et al., 2002). The activation of B-cells often depends 
on antigen-presenting T-cells and takes place in the germinal centers of lymph nodes (Figure 
1-7). A T-cell-independent maturation of B-cells is also possible, and this takes place in 
marginal zones around lymphoid follicles (depicted in Figure 1-9). T-cell-activated B-
lymphocytes undergo clonal expansion and genetic changes (see below) as part of their 
affinity maturation process within the germinal centers (Küppers, 2005). 
 
 
Figure 1-7: B-cell differentiation in the germinal-centre reaction (Küppers, 2005). 
 
In the dark zone of the germinal centers, B-cells undergo clonal expansion, and in a process 
called somatic hypermutation the immunoglobulin genes of B-cell clones are mutated in 
order to increase antigen affinity. However, only if affinity to the antigen is increased, 
mature B-cells carrying these optimized BCRs are positively selected within the germinal 
centers and transit from the dark to the light zone of this tissue. Mature B-cells with a 
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reduced antigen affinity of the BCR after somatic hypermutation do not receive sufficient 
survival signals and go into apoptosis (Figure 1-7). 
Somatic hypermutations in the variable regions of immunoglobulin genes mark the first step 
of the affinity maturation process of B-cells in the germinal centers of the lymph nodes. This 
process introduces point mutations into the variable regions of recombined VH and VL genes. 
The mechanism of somatic hypermutation is not fully understood (Janeway, 2002), but some 
aspects have been elucidated. Mutations in the variable regions are induced by double-
strand breaks of the DNA, which are repaired inaccurately and thus produce sequence 
variations (Neuberger et al., 1998). Expression of hypermutated IgVH genes stochastically 
alters the binding specificity and affinity of resulting antibodies, i.e. of the BCR, produced by 
the B-cell clones (Janeway, 2002). 
In the light zone of germinal centers, B-cells undergo the next maturation step, clonal 
selection, which is taken out by follicular dendritic cells (FDC) and T-cells in the light zone of 
germinal centers. These cells present antigens to the B-cells after somatic hypermutation 
and only those B-cells with the highest affinities for the antigens are selected and in turn 
survive and can differentiate further (Küppers, 2005). The following last step of affinity 
maturation is class switch recombination, through which the constant regions of 
immunoglobulin heavy chains can be switched to other classes of constant immunoglobulin 
C-regions. The C-regions determine the Ig classes of the antibody and thus the different 
effector functions of the B-cells. In humans, five immunoglobulin classes exist: IgM, IgD, 
IgG, IgA, and IgE. After class switch recombination, the resulting B-cells have different 
cellular functions and can develop into mature B-cells, into memory B-cells or plasma cells 
(Figure 1-7). 
 
Allelic exclusion in the immune system 
Discussed above are several mechanisms that exist to generate the required repertoire of 
diverse and adaptable B-lymphocytes that are part of the immune system. Another 
interesting mechanism essential in B-cell development is called allelic exclusion. This is a 
form of monoallelic expression of immunoglobulin genes in lymphocytes (Goldmit and 
Bergman, 2004). The diversity of the antigen-receptor repertoire is created from a relatively 
small number of V, D and J segments by their shuffling in DNA rearrangement in somatic 
cells (=V(D)J recombination, see above). Allelic exclusion is required to ensure exclusive 
production of a single antigen receptor per B- or T-cell. If both copies of the immunoglobulin 
loci would be expressed, BCR (and TCR) rearrangement would lead to two different BCR (or 
TCR) molecules with different affinities on the same lymphocyte and thereby make positive 
and negative selection of the cell impossible. 
Allelic exclusion is achieved by differential chromatin marks on the two alleles. These marks 
are established in the early embryo and lead to asynchronous replication of the maternal and 
the paternal allele of immune receptor loci (Figure 1-8). The choice of alleles for early or late 
replication is a stochastic event. However, the resulting replication timing is an instructive 
mark for the two alleles and directs further allele-specific epigenetic events in the immune 
system. Both alleles are packaged into a closed chromatin structure and are DNA methylated 
until the pre-B-cell stage. At this stage, early replicating alleles undergo programmed histone 
modification, specific nuclear localization and DNA demethylation (Cedar and Bergman, 
2008), which make these alleles accessible to rearrangement (Figure 1-8). The result of this 
epigenetically regulated selective monoallelic access to rearrangement is that only one allele 
of the antigen receptor is expressed, whereas the second one is silenced. The first step of 
allelic exclusion is the rearrangement of the IgVH genes on one allele, which results in shut-
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down of the rearrangement process on the second allele. If no successful rearrangement 
occurs on the first allele, it is silenced and rearrangement takes place on the second 
chromosome copy. If this rearrangement is also not successful the cell will go into apoptosis. 
This process of allelic exclusion thus results in Ig antibodies on the surface of individual B-
lymphocytes that are all the same (Goldmit and Bergman, 2004). Recent studies show that 
both the initial selection of one allele for rearrangement and the maintenance of silencing of 
the other allele are controlled by epigenetic mechanisms, but these are not yet fully 
understood (Bergman et al., 2003). 
 
 
Figure 1-8: Allelic exclusion in the immune system (Goldmit and Bergman, 2004). 
 
1.2.3 Aberrant B-cell development 
As detailed above, distinct stages of B-cell development are characterized by distinct 
rearrangement of Ig-genes and by the structures of antigen receptors on the surface of B-
cells. These features can be used to determine the cellular origin of several human B-cell 
lymphomas (Küppers et al., 1999). As depicted in Figure 1-9, B-cell lymphomas can arise 
from B-cells at virtually every step of the differentiation process. 
The most immature cells, the naïve B-cells, can give rise to Splenic Marginal Zone 
Lymphomas, while antigen-experienced but not somatically hypermutated B-cells could be 
the origin of an aggressive form of B-cell Chronic Lymphocytic Leukemia (CLL). Mature and 
somatically hypermutated B-cells (plasma cells), can give rise to Multiple Myeloma, Diffuse 
Large B-cell Lymphoma (DLBCL), Hairy-cell Leukemia, Prolymphocytic Leukemia and a more 
indolent form of CLL (memory B-cells; see Figure 1-9). All B-cell lymphomas can thus be 
correlated according to their phenotype to a distinct differentiation state of normal 
hematopoiesis (Küppers et al., 1999). Several tumors are thought to originate from different 
B-cell origins, among them DLBCL and CLL (Figure 1-9). B-cell origins determine the 
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subtypes of DLBCL and CLL diseases that have different outcome and prognosis depending 
on the maturity of those cells the tumor originates from. Often tumors that are similar to 
more immature developmental stages are more aggressive. In CLL, for example, patients 
with CLL cells with mutated VH genes have a better prognosis than those with unmutated VH 
genes (Hamblin et al., 1999). 
 
 
Figure 1-9: Human B-cell lymphomas are assigned to their proposed normal B-cell 
counterpart (Küppers et al., 1999). 
 
 
1.3 CLL 
B-cell Chronic Lymphocytic Leukemia (CLL) is the most common leukemia among adults in 
the Western world. It affects elderly people with a median age of 72 years at diagnosis. 
However, a third of all patients is less than 60 years old at diagnosis (Seiler et al., 2006). 
Frequently, the diagnosis of CLL is based on the initial diagnosis of a blood lymphocytosis. As 
a diagnostic cut-off, patients with a B-cell count of greater than 5000 cells/µL of blood are 
diagnosed with CLL while elevated lymphocyte counts that are below this threshold are 
called Monoclonal B-cell Lymphocytosis (MBL). The diagnosis further requires a specific 
makeup of CLL/MBL specific surface antigens. CLL cells present a specific combination of 
surface markers (CD5, CD19 and CD23), which are usually suppressed during B-cell 
differentiation. Furthermore, CLL cells are clonal and originate from one single cell, which is 
detectable because the normally diverse population of antibody L chains, kappa or lambda, 
are homogeneous in the clonal CLL cell population. CLL is a prognostically very 
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heterogeneous disease and the clinical course of the disease can be highly divergent (see 
chapter 1.3.1). 
CLL is currently not treated in patients with an early stage of the disease and markers that 
correlate with a good prognosis (Rai 0-II; Binet A and B). In low-risk CLL, no treatment is 
given before progression (“watch-and-wait”) because no survival benefit has been associated 
with early treatment of asymptomatic CLL (Zenz et al., 2008). However, if the disease 
becomes symptomatic, CLL has been treated with a variety of chemotherapeutica like 
chlorambucil, the purine analogs fludarabine, pentostatin and cladiribine, and the monoclonal 
antibodies rituximab and alemtuzumab (Tam and Keating, 2007; Begleiter et al., 1996; Kay 
et al., 2006; Byrd et al., 2006; Cheson, 2006). The current recommended first-line treatment 
is a combination of fludarabine, cyclophosphamid and rituximab (“FCR”). In younger patients 
whose disease shows markers associated with a bad prognosis, bone marrow, i.e. stem cell 
transplantation, is the therapeutic strategy (Boyiadzis et al., 2007; Gine et al., 2007). 
Unfortunately, all patients outside of transplantation relapse and CLL remains an uncurable 
disease (Boyiadzis et al., 2007) with a yet unknown pathomechanism. 
 
The origin of CLL cells is a highly debated question. Evidence suggests that CLL is derived 
from an antigen-experienced B-cell (Ghia and Caligaris-Cappio, 2006). IgVH gene mutations 
can be detected in a portion of CLL, which indicates their encounter with an antigen (Ghia 
and Caligaris-Cappio, 2006; Kröber et al., 2002; Damle et al., 1999). Furthermore, it was 
shown that both, IgVH unmutated and mutated CLL cells show a common surface phenotype, 
which is similar to that of antigen-experienced B-cells. In addition, the BCR in CLL cells 
resembles the BCR of normal B-cells upon antigen interaction. As shown above CLL cells 
share similarities with mutated memory B-cells as well as with naïve unmutated B-cells 
(Figure 1-7, Küppers et al., 1999). The rearrangements of VHDJH gene segments are 
strikingly similar in unmutated and in mutated forms of CLL and this similarity suggests an 
antigenic selection in both disease subsets (Ghia and Caligaris-Cappio, 2006). 
Clonal evolution is a common process in cancer cells. As described in chapter 1.1.1, the 
malignant cells that form a tumor are clonal, as they are derived from a single tumor 
initiating cell. Clonal evolution in CLL is described as the acquisition of additional 
chromosomal aberrations. Stilgenbauer et al. (2007) showed that 17 % of analyzed patients 
showed additional aberrations within 42 months of observation. Interestingly, deletion of the 
first copy of 13q14 is never observed as secondary aberration in clonal evolution. The most 
frequent acquired secondary aberration in CLL is deletion of 17p13 and the second most 
frequent one is biallelic loss of 13q14. Furthermore, Stilgenbauer et al. (2007) found that 
clonal evolution correlates with a poor outcome of CLL, which can be explained on the one 
hand by the most frequent loss of 17p13, which itself is correlated with a bad prognosis 
(Döhner et al., 2000). On the other hand, these observations point to a selective advantage 
of those CLL cells that have lost both copies of 13q14. The estimated survival times of 21.7 
months was much shorter than before the occurrence of clonal evolution in CLL cells. 
Interestingly, clonal evolution only occurred in patients with unmutated VH genes, which 
suggests that their karyotypic chromosomal instability is a potential molecular 
pathomechanism. 
CLL patients can be roughly subdivided into two subgroups of different prognosis according 
to the mutational status of immunoglobulin variable heavy chain genes (IgVH) of the CLL 
cells. Both CLL cell types, i.e. with mutated and unmutated IgVH genes, are mature and most 
likely not antigen experienced. However, only mutated CLL cells may have undergone 
somatic hypermutation in germinal centers (Figure 1-9). Patients with mutated IgVH gene 
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CLL cells have a far better prognosis (median survival 10-20 years) than those patients with 
unmutated IgVH genes (median survival only 5-10 years) (Küppers et al., 2001; Kröber et al., 
2002). A surrogate marker for the VH mutational status is the differential expression of a BCR 
associated gene, the zeta-associated protein 70 (ZAP-70; (Kienle et al., 2005)). ZAP-70 is a 
tyrosine kinase, which normally functions in T-cell signaling (Isakov et al., 1995; Madrenas et 
al., 1995). However, the correlation between VH mutational status and ZAP-70 expression 
does not hold true in every patient (Del Principe et al., 2006; Kröber et al., 2006; Rassenti et 
al., 2004). 
1.3.1 Genomic aberrations in CLL and prognostic relevance 
In CLL, prognostic subgroups have been identified defined by genomic aberrations 
(Stilgenbauer et al., 2002; Kröber et al., 2002; Döhner et al., 2000; Cotter and Auer, 2007; 
Hamblin et al., 2002). Interestingly, translocations are rare in CLL, and the most common 
genetic aberrations in CLL are deletions of chromosomal material and trisomy 12 (Döhner et 
al., 1997). Chromosomal aberrations are detectable in over 80 % of CLL cases. Table 1-4 
depicts the most common aberrations and their frequency in CLL patients. 
 
Table 1-4: Incidence of chromosomal abnormalities in 325 patients with chronic lymphocytic 
leukemia. *175 patients had one aberration, 67 had two aberrations, and 26 had more 
than two aberrations (modified from Döhner et al., 2000). 
Aberration No. of Patients (%)*
13q deletion 178 (55) 
11q deletion 58 (18) 
12q trisomy 53 (16) 
17p deletion 23 (7) 
6q deletion 21 (6) 
8q trisomy 16 (5) 
t(14q32) 12 (4) 
3q trisomy 9 (3) 
Clonal abnormalities 268 (82) 
Normal karyotype 57 (18) 
 
The most frequent aberration is deletion of 13q14, which occurs in 55 % of CLL patients. 
Additional frequent aberrations are deletion of 11q22-23 (in 18 % of patients), trisomy 12 (in 
16 %), deletion of 17p13 (in 7 %) and deletion of 6q21 in 6 % of patients (Döhner et al., 
2000). These aberrations are prognostically linked to survival of CLL patients. Patients with a 
deletion of 13q as single aberration have the best prognosis with a median survival time of 
133 months (Figure 1-10). The worst prognosis in CLL is associated with loss of the TP53 
gene in 17p-deleted patients, where the median survival time is only 32 months. The 
deletion of 11q leads to the loss of function of the tumor suppressor gene ATM in a subset of 
patients, and correlates with a median survival of only 79 months (Figure 1-10). Median 
survival times of patients with a normal karyotype and trisomy 12 are 111 and 114 months, 
respectively (Döhner et al., 2000). Despite the good characterization of CLL karyotypes the 
pathomechansim of CLL remains still unclear. While distinct genotypes have been linked to 
distinct prognosis of CLL subtypes they have not identified one tumor suppressor gene that 
is responsible for the development of CLL. Loss of function of ATM on 11q and TP53 on 17p 
can serve only as an explanation for the worse outcome of these karyotypic subgroups, but 
are most likely not causative events responsible for the original development of the 
malignant CLL cell clone. In contrast, the chromosomal band 13q14 and the genes localized 
in this region are strong candidates for playing a role in the development of CLL cells for 
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several reasons. The critical region in 13q14.3 is lost in more than 54 % of CLL cases, 
making it the most common aberration in CLL. In addition, while deletions of 17p and 11q 
can be detected as secondary effects in clonal evolution of the disease, loss of the first copy 
of 13q14 is always the primary event (Stilgenbauer et al., 2007). 
 
 
Figure 1-10: Kaplan-Meier-Plots showing survival of CLL patients from the date of 
diagnosis among patients in the five genetic categories (Döhner et al., 
2000). 
 
1.3.2 Chromosomal band 13q14.3 
Deletion of chromosomal material from 13q14 is the most common aberration in CLL and 
correlates with a good prognosis (Döhner et al., 2000). As it is the most common genomic 
aberration in CLL, it is possible that despite the good prognosis of del(13q) patients, 13q14 
might harbor the tumor suppressor mechanism responsible for development of CLL. 
However, no single tumor suppressor gene could be identified so far despite extensive 
studies (Chena et al., 2008; Mertens et al., 2002; Stilgenbauer et al., 1998; Hammarsund et 
al., 2004; Mabuchi et al., 2001). Figure 1-11 represents a schematic overview of the most 
commonly deleted region in 13q14.3 telomeric to the RB1 locus that is located about one 
mega base pairs centromeric to the gene KPNA3 of 13q14.3. The region contains several 
protein-coding genes, KPNA3, C13ORF1, KCNRG and RFP2, as well as two large noncoding 
RNA genes BCMS (DLeu1) and BCMSUN (DLeu2, RFP2OS), which will be discussed in more 
detail below. Two microRNAs miR15a and miR16-1 are located within an intron of 
BCMSUN/DLeu2 (Lagos-Quintana et al., 2001) and have been postulated to play an 
important role for the pathogenesis of CLL (Calin et al., 2007). The majority of these genes 
(but not the microRNA genes) have been assigned to promoters each consisting of a CpG-
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island that most likely regulate expression of these 13q14 genes (CpG-islands A, B, C, D and 
E; see Figure 1-11). 
 
 
Figure 1-11: Schematic view of chromosomal region 13q14.3. The depicted minimally 
deleted region is shown as defined in (Stilgenbauer et al., 1998). 
 
In close vicinity to the locus in 13q14 represented in Figure 1-11, the RB1 gene is located. 
The function of RB1 led to the Knudson two-hit-model of tumor suppressor genes (Knudson, 
1971, see chapter 1.1.1). The proximity to the minimally deleted locus in CLL made it 
reasonable that RB1 might be involved in the tumor suppressor mechanism of 13q14. 
However, several analyses could show that at least one intact copy of RB1 and along with it 
the tumor suppressive function of RB1 can be found in a subset of CLL patients with loss of 
13q14 (Stilgenbauer et al., 1993; Liu et al., 1993) formally showing that a del(13q14) affects 
an additional tumor suppressor mechanism distinct from RB1. Consecutively, it was shown 
that a region telomeric to the RB1 gene was more frequently deleted than the TSG itself (Liu 
et al., 1993). Much effort was invested to determine the minimally deleted region of 13q14.3 
in CLL patients. Several minimally deleted regions have been proposed (see Wolf et al., 
2001), but a segment flanked by chromosomal markers D13S273 and D13S25 was defined 
to be the critical region of loss of 13q14.3 (Wolf et al., 2001; Stilgenbauer et al., 1998). This 
critical minimally deleted region (Figure 1-11) comprises the noncoding RNA genes BCMS, 
RFP2OS and BCMSUN/DLeu2, the two microRNA genes miR15a and miR16-1 and the 
protein-coding genes RFP2 and KCNRG.  
 
The candidate genes of 13q14 
The protein coding genes of 13q14 have been characterized extensively in mutational and 
functional analyses as they were the most likely candidates for the tumor suppressor in the 
region (Stilgenbauer et al., 1998; Wolf et al., 2001; Mertens et al., 2002; Hammarsund et 
al., 2004; Tschuch, 2006; Serra-Barrionuevo, 2008). These protein coding genes are highly 
conserved across species and downregulated in CLL patients (Kapanadze et al., 2000; 
Mertens et al., 2002). However, no point mutation in the coding sequence of any of these 
candidate genes could be determined so far that would lead to an obvious loss of function. 
Thus, other possible mechanisms have been considered relevant for the development of CLL 
due to 13q14 loss. The candidate genes of 13q14.3 are downregulated in CLL patients 
(Mertens et al., 2002), this suggests that the pathomechanism of CLL involves a deregulation 
of gene expression of 13q14-genes. Downregulation of the two microRNAs, miR15a and 
miR16-1, probably leads to downstream deregulation of the apoptosis inhibitor BCL2 (Calin 
et al., 2008; Cimmino et al., 2005). BCL2-deregulation by the 13q14-microRNAs thus links 
13q14-deletions to BCL2-overexpression, which is frequently observed in CLL-patients and 
may be one cause for the inhibition of apoptosis in CLL cells (Kitada et al., 1998). 
Aside from the microRNAs, it was also proposed that the large noncoding RNAs might play a 
role in the pathomechanism of the critical region (Kapanadze et al., 1998; Wolf et al., 2001). 
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Recently, diverse epigenetic regulatory mechansims of 13q14 have been postulated to play a 
role for CLL pathogenesis (Yu, 2006; Mertens et al., 2006; Calin et al., 2005). In 2006 it was 
shown by our group that the critical region 13q14 is monoallelically expressed due to 
epigenetic regulation of the candidate genes (Mertens et al., 2006). An epigenetic regulation 
of the region coud explain i) the lack of genetic aberrations in gene copies and ii) the high 
level of downregulation detected for candidate genes upon loss of only one gene copy 
(Mertens et al., 2002). As one allele is epigenetically silenced in normal cells, loss of the 
single active copy in CLL cells would lead to complete inactivation of the tumor suppressor 
locus. Although many possible pathomechanisms for CLL have been postulated and are 
discussed, the mechanism has not yet been elucidated. This is why in the present study the 
epigenetic modifactions of the tumor suppressor locus in 13q14 and their possible regulation 
were analyzed. 
 
A short introduction into proposed molecular functions of 13q14 candidate genes 
The candidate tumor suppressor gene RFP2 (LEU5; TRIM13) is located in the minimally 
deleted region of 13q14.3, and expression of RFP2 is downregulated in both patients with 
monoallelic deletion of 13q14 and retention of both copies of 13q14 (Mertens et al., 2002). It 
is the only protein-coding gene within the minimally deleted region and therefore the most 
likely candidate for the TSG of 13q14. The organization of the RFP2 gene locus is conserved 
in human and mouse (Baranova et al., 2003). The human RFP2 promoter region was 
described to have a unique structure and unusual strength (Skoblov et al., 2006). In human 
and murine cells, several mRNA isoforms of RFP2 are expressed, and the RFP2OS antisense 
RNA-transcript is unique in humans (Baranova et al., 2003). Furthermore, the RFP2 locus 
contains a second open reading frame (ORF) encoding KCNRG that functions homologous to 
potassium channel proteins. KCNRG probably has regulatory function for other potassium 
channels by binding to them (Ivanov et al., 2003). The RFP2-promoter region contains a 
CpG-island (CGI C; Figure 1-11), is TATA-less and contains GGGGA-repeats. Additionally, the 
promoter was found to have low potential in formation of nucleosomes (Skoblov et al., 
2006). Sequence analyses are negative for mutations in the coding sequence of the RFP2-
locus that was previously regarded as the candidate tumor suppressor gene in the critical 
region in 13q14.3 (Migliazza et al., 2001). RFP2 encodes a protein of 510 amino acids, which 
by homology belongs to a family of TRIM proteins (“TRIpartite Motif”; (Reymond et al., 
2001; van Everdink et al., 2003)). TRIM-proteins contain three domains: a RING finger 
domain, a B-box domain and a coiled-coil domain. Recently, RFP2 was described to be a 
transmembrane E3 ubiquitin ligase involved in the endoplasmatic reticulum associated 
degradation, ERAD (Lerner et al., 2007). It was shown that the transmembrane domain of 
RFP2 is localized within the ER membrane. Biochemical characterization of RFP2 is difficult 
because it is a very unstable protein due to a self-degradation property (Lerner et al., 2007). 
Previous studies in our group indicate involvement of RFP2 in apoptosis (Ruppel, 2003; 
Tschuch, 2006) and in NFκB signalling (Tschuch, 2006). 
In addition to the molecular function of RFP2, it is essential to determine the epigenetic 
regulation of the locus in normal and malignant B-cells in order to understand how 13q14 is 
involved in the pathomechanism of CLL. To this end, the epigenetic status of the critical 
region in 13q14 was characterized. 
 
Two protein-coding genes of 13q14.3 are localized just proximal to the minimally deleted 
region, KPNA3 and C13ORF1. Their relevance for the pathomechanism of CLL is not known 
as their molecular function is unclear. 
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Karyopherin α-3 (KPNA3) consists of 521 amino acids, a basic N-terminus and a strongly 
acidic C-terminus (Takeda et al., 1997). The functional domains of the protein are an 
importin-beta binding domain and several armadillo repeats that promote protein-protein 
interactions. KPNA3 belongs to a family of importin proteins that mediate transport from the 
cytoplasm into the nucleus. KPNA3 was shown to be specifically involved in the nuclear 
transport of RCC1, which is a guanine exchange factor for Ran (Talcott and Moore, 2000). It 
is further proposed that KPNA3 is involved in the nuclear import of NFκB, however, direct 
interaction with NFκB was only shown for KPNA4 (Fagerlund et al., 2005). Involvement of 
KPNA3 in import of either NFκB or RCC1 would generate an interesting link between the 
13q14 locus and cell cycle control. Therefore, 13q14 was epigenetically analyzed in this 
study including the potentially relevant KPNA3 locus and its possible impact on CLL 
pathogenesis. 
C13ORF1 (CLLD6) encodes a protein with 196 amino acids. The gene shows high 
conservation between human and mouse with a nucleotide sequence similarity of 97 % 
(Baranova et al., 2004) that might highlight the functional relevance of C13ORF1. The single 
homology domain of C13ORF1, the SPRY domain, is only poorly characterized. In proteins 
that contain a SPRY-domain it has been shown that the domain mediates protein-protein 
interaction and homo-oligomerization (Blayney et al., 2004). A common feature of SPRY-
domains is to bind partner proteins in target specific manner. Interestingly, the RFP protein, 
a repressive transcription factor and homolog of RFP2, also contains a SPRY domain in 
addition to the TRIM domain. Considering the co-evolved genomic localization of RFP2 and 
C13ORF next to each other in 13q14, it is possible that these two proteins interact with each 
other and together might have a similar function as RFP. 
The two microRNA genes localized in 13q14.3, miR15a and miR16-1, are encoded within an 
intron of BCMSUN/DLeu2, and this localization is conserved in mouse (Cimmino et al., 2005). 
These two microRNAs possibly target the anti-apoptotic gene BCL2. Calin et al. proposed in 
2005 a direct correlation between the frequent loss of miR15/16 by 13q14-deletion and the 
previously shown upregulation of BCL2 in CLL patients. 
Not much is known about the two large noncoding RNA (ncRNA) genes, BCMS (DLEU1) and 
BCMSUN (DLEU2) that are both localized in the critical region in 13q14.3. However, their 
importance in the regulatory mechanism of the region is stressed by the high degree of 
conservation of the ncRNA DLeu2/BCMSUN itself, of their nucleotide sequence and of the 
topological organization in human and mouse (Corcoran et al., 2004). The BCMS RNA was 
found to be heavily spliced, but no molecular function could be assigned to the ncRNA 
transcript (Wolf et al., 2001). Recently, Stelzl et al. (2005) performed a large yeast two-
hybrid screen with consecutive co-immunoprecipitation assays. In this large screen, DLeu1 
was expressed as a fusion protein, and intriguingly the product of this short predicted ORF 
interacted with other proteins. The second large noncoding RNA of 13q14, BCMSUN/DLeu2, 
spans a large part of the minimally deleted region. The orientation of the BCMSUN gene is 
opposite to that of the genes BCMS and RFP2 (Corcoran et al., 2004) and consequently, the 
two large noncoding RNA loci are organized in opposite orientation to each other and 
actually overlap without sharing coding sequence (Figure 1-11). The organization and 
conservation of the two large noncoding RNA genes in 13q14 suggests that they are part of 
a complex regulatory mechanism. Other human ncRNA genes, for example Air or Xist, have 
been described to regulate the expression of neighboring genes in imprinted and 
monoallelically expressed loci (Rougeulle and Heard, 2002). 
As BCMS and BCMSUN are likewise long ncRNA genes, it is possible that they have similarly a 
role in the regulation of expression of the genes localized in cis in 13q14 and that they take 
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part in the transcriptional control of the whole region. In this model, the aberrant expression 
of BCMSUN and BCMS would lead to the deregulated expression of the 13q14 protein coding 
genes that has been described (Calin et al., 2002; Mertens et al., 2002). 
 
A subset of CpG-dinucleotides of the human genome are clustered in distinct regions termed 
CpG-islands that cover about 1 % of the human genome (Bird, 2002; Lander et al., 2001). 
These CpG-islands are found to be associated with 60 % of human gene promoters. 
Although most of the cytosines within CpG dinucleotides are unmethylated, the subset 
contained in promoter-CpG-islands has been shown to be differentially methylated during 
development in a tissue-specific manner (Bird, 2002). The CpG-island promoters are not 
exclusively subjected to regulation by differential DNA-methylation. However, some studies 
could show that promoters that lack CpG-islands according to the original strict definition, 
also have tissue-specific methylation patterns that correlate with transcriptional activity 
(examples in Blelloch et al., 2006; Hattori et al., 2004). Therefore, recently it has been 
suggested to amend the definition of a CpG-island (Illingworth et al., 2008). Five CpG-islands 
in the 13q14-region meet the stringent criteria (see Figure 1-11). These CpG-islands (CGIs A 
to E) have been analyzed in detail in this work to characterize their epigenetic status. In 
prior studies, only the RFP2 promoter region was analyzed in great detail (Skoblov et al., 
2006), and in our group it was shown that CpG-island E is DNA methylated in cultured cells 
(Mertens et al., 2006). Here, a detailed analysis of five promoter-CpG-islands with respect to 
chromatin modifications (i.e. histone modifications and DNA-methylation) was performed in 
healthy and in CLL cells in order to gain insight in the epigenetic regulatory pattern of 
candidate genes in the critical region 13q14. 
To date, several effects resulting in deregulated expression of 13q14 candidate genes can be 
related – at least in theory – to epigenetic regulation of the locus: Downregulation of several 
genes in the critical region, namely of RFP2, BCMSUN, CLLD7, C13ORF1 and also of RB1 in 
13q14-deleted CLL patients, could be due to epigenetic silencing. The only gene found to be 
significantly down-regulated also in patients with retention of both copies of the critical 
region was RFP2, which was found along with significant upregulation of BCMS (Mertens et 
al., 2002). The fact that no point mutations have been identified in the protein-coding and 
microRNA genes in CLL patients also suggests epigenetic regulation being responsible for 
deregulated expression of the genes. Recently, asynchronous replication of the two 13q14 
copies and monoallelic expression of most genes localized in the critical region was shown by 
our group, and a possibly epigenetic pathomechanism of CLL localized in 13q14 was 
postulated (Mertens et al., 2006). According to Knudsons “two-hit hypothesis”, epigenetic 
silencing of one allele in normal cells would require a “second hit” for complete loss of 
function. This second hit might be the deletion of 13q14 in CLL patients.  
1.3.3 Mechanisms of regulating gene expression 
Gene expression can be regulated by distinct epigenetic modifications. The epigenetic code 
determines the function of distinct genomic sites in different tissues by regulating the extent 
of transcriptional activity (see chapter 1.1.2). Monoallelic expression has recently been 
shown to be more common in the human genome than expected (Verlaan et al., 2008; 
Gimelbrant et al., 2007). Different mechanisms have been found to contribute to several 
forms of monoallelic expression of genes. The mechanisms of autosomal monoallelic 
expression and imprinting and the associated epigenetic marks are described in this chapter. 
 
1 Introduction 
 28
One of the best described examples for monoallelic expression is genomic imprinting. 
Imprinted genes are expressed in a parent-of-origin specific manner, where always either 
the maternal or the paternal allele is monoallelically expressed (Goldmit and Bergman, 
2004).  
 
 
Figure 1-12: Schematic representation of the establishment of epigenetic imprinting 
marks during development. DNA-methylation = red balloons, replication 
timing: purple ribbon = early replicating, black ribbon = late replicating, 
chromatin structure: yellow circles = nucleosomes, green flags = 
acetylated (Ac) histones (Goldmit and Bergman, 2004). 
 
The process of establishment and maintenance of genomic imprinting is well characterized 
and implies several steps of epigenetic control. The first epigenetic marks on imprinted 
genes are established very late during gametogenesis to identify each allele according to its 
origin as paternal (P) or maternal (M; Figure 1-12). The epigenetic marks include DNA-
methylation, replication timing (Figure 1-12; see also allelic exclusion, chapter 1.2.2) and 
chromatin structure. These epigenetic marks are stably maintained through somatic cell 
divisions after fertilization. Maintenance of imprints is achieved by differentially methylated 
regions (DMR) or imprinting control elements (ICE) that are located within or near the 
imprinted loci. The DMRs are differentially methylated at their two parental copies; however, 
the parental copy carrying the methylated DMR is not necessarily silenced, as the DMRs are 
only one part in the regulatory system of imprinted loci. Often DMRs are involved in the 
regulation of expression of noncoding RNAs that are frequently localized at imprinted 
genomic loci. One example for a large noncoding RNA that is regulated by a DMR and in turn 
regulates expression and silencing of the imprinted locus is Air at the Igfr2-locus (Rougeulle 
and Heard, 2002). Physiological functions of imprinted genes are frequently the control of 
embryonic growth and development, development of the placenta and also post-natal 
development (Tycko and Morison, 2002). According to the parental-conflict hypothesis, 
paternally expressed (maternally imprinted) genes are promoting growth of the 
embryo/fetus, whereas maternally expressed (paternally imprinted) genes are growth 
limiting (Moore and Haig, 1991). 
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Loss of imprinting (LOI) is associated with several human syndromes like Beckwith-
Wiedemann syndrome, which is caused by loss of imprinting on chromosome 11 (Grundy et 
al., 1998). The two different diseases Angelman’s and Prader-Willi syndrome are caused by 
deletion of a region of chromosome 15q. Which of the two syndromes develops depends on 
whether maternal or paternal imprinting is lost, i.e. whether the mutation is inherited from 
the father or the mother (Zeschnigk et al., 1997). Finally, it was shown that global LOI can 
lead to widespread tumorigenesis in adult mice, which proves a direct predisposition of cells 
to tumorigenesis caused by LOI (Holm et al., 2005). Thus, imprinting can also play a role in 
the development of cancer by its homeostatic function that provides tumor suppressor 
activity in adult tissues (Klein et al., 2007). Most of the genes in the human genome of 
diploid cells are expressed from both maternally and the paternally derived copies of each 
gene. However, recently it has been shown that more genes than previously known are 
expressed from only one of the two gene copies (Gimelbrant et al., 2007; Verlaan et al., 
2008). Monoallelically expressed genes are grouped into three categories. The first category 
comprises imprinted genes that were described above. The second category of 
monoallelically expressed genes consists of X-inactivated genes that are mostly randomly 
inactivated early in development. The third category comprises autosomal genes that are 
subject to random monoallelic expression. The third category was considered to consist only 
of a very small number of genes, however, Gimelbrant et al. (2007) assessed in a genome-
wide screen allele-specific transcription of about 4000 human genes and could show that 
more than 5 % of these are subject to random monoallelic expression. Thus it becomes clear 
that monoallelic expression is a quite frequent phenomenon independent of gene function or 
tissue environment. Autosomal monoallelically expressed genes that were known before this 
study, include odorant receptor genes, immunoglobulin genes (chapter 1.2.2), T-cell 
receptor genes, natural killer cell receptor genes and interleukins. The genes that were found 
in the study by Gimelbrant et al. to be monoallelically expressed encode proteins with 
various functions and tissue-specificities, except for a large group of genes that encode cell 
surface proteins (Gimelbrant et al., 2007). The most interesting genes identified in the study 
are those that have been previously assigned roles in human leukemias, like for example 
ABR (active BCR related gene), EBF (early B-cell factor), TCL1A (T-cell leukemia/lymphoma 
1A) and ZNFN1A1 (Zinc finger protein, subfamily 1A, Ikaros) (Gimelbrant et al., 2007). These 
examples clearly show the other side of monoallelic expression that can rapidly lead to 
cancer. 
An additional epigenetic mark of monoallelically expressed genes was determined by 
Rougeulle et al. (2003). In their study it was shown that all monoallelically expressed genes 
have a distinct histone modification pattern, consisting of promoter-restricted dimethylation 
of histone H3 at lysine 4 (H3K4me2). Promoter-restricted H3K4me2 was proposed as a 
distinct epigenetic mark for monoallelic expression. Since the genes of 13q14 are 
monoallelically expressed (chapter 1.3.2), this epigenetic mark was analyzed at the genomic 
region 13q14 in this work. 
 
Monoallelic expression is often regulated by locus control regions (LCR), which are cis-
regulatory elements that have the ability to enhance gene expression of linked genes to 
physiological levels. They influence gene expression depending on the tissue and may vary in 
their composition and location relative to regulated genes (Li et al., 2002). The first LCR was 
identified about 20 years ago in the mouse β-globin locus (Jimenez et al., 1992; Moon and 
Ley, 1990). Since then, many LCRs have been described in mammalian gene systems and 
they are now considered to be common functional elements in mammalian developmental 
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and cell-lineage specific regulation of gene expression (Li et al., 2002). This regulation not 
only depends on promoters, enhancers and silencers but also on interactions of diverse cis-
regulatory elements, including LCRs, and on dynamic chromatin interactions (Li et al., 2002). 
The functionally and structurally conserved composition of the region 13q14 points to an 
epigenetically regulated pathomechanism that may involve a control element comparable to 
the LCRs explained above. 
1.3.4 Epigenetic aberrations in CLL 
The epigenetic alterations described in CLL include the deregulation of miR15/16 (Calin et 
al., 2002), global DNA-hypomethylation (Wahlfors et al., 1992) and DNA-hypermethylation of 
for instance the death-associated protein kinase 1 (DAPK1) gene (Raval et al., 2007). Also 
genomewide promoter hypermethylation has been described in CLL (Raval et al., 2006) and 
DNA-methylation profiles specific for CLL have been established by several groups (Rush et 
al., 2004; Plass et al., 2007). The two miRNA genes of 13q14, miR15a and miR16-1, are 
frequently down-regulated in CLL resulting in removal of their tumor suppressive influence 
on their target BCL2 (Cimmino et al., 2005). However, to date no mechanisms for this 
observed deregulation has been described, i.e. it is unclear how these candidate tumor 
suppressor genes are downregulated in CLL. Further epigenetic changes described in CLL 
concerning miRNAs is description of a miRNA signature that distinguishes CLL cells from 
normal B-cells (Calin et al., 2004) and is supposed to be associated with prognosis and 
disease progression. Several findings suggest an epigenetic pathomechanism that is localized 
in the critical region 13q14 in the development of CLL. The absence of pathogenic point 
mutations that would result in a functional loss within the candidate genes of the critical 
region suggests that the downregulation of these genes in monoallelically deleted patients is 
either due to haploinsufficiency or epigenetic suppression (Cotter and Auer, 2007). 
Epigenetic suppression of the single retained 13q14 copy in CLL patients is suggested by 
data from several studies (Kienle et al., 2005; Mertens et al., 2002; Dickinson et al., 2006; 
Haslinger et al., 2004; Mertens et al., 2006). Asynchronous replication timing of the 13q14 
critical region was demonstrated by Mertens et al. (2006), which points to differential 
packaging of chromatin of the two alleles. Also, monoallelic expression of almost all 
candidate genes in 13q14 was detected in B- and T-cells of healthy donors, which could be 
the result of the differential allelic chromatin packaging. Both findings explain the nearly 
complete downregulation of candidate 13q14 genes (Mertens et al., 2002) and microRNAs 
(Calin et al., 2002) frequently observed in CLL patients with a monoallelic deletion of 13q14. 
Thus, it becomes clear that epigenetic modifications seem to play a major role for the 
pathogenesis of CLL. 
 
In the present study, a detailed analysis of several epigenetic modifications of the critical 
region 13q14 was performed in order to elucidate the epigenetic regulatory pathomechanism 
of 13q14 that we propose to be involved in the development of CLL. 
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1.4 Aims of this work 
Deletion of genetic material from a critical region in 13q14.3 is the most frequent 
chromosomal aberration in CLL. Several candidate genes from the critical region including 
protein-coding and noncoding RNA genes have been proposed to participate in the 
pathomechanism of CLL. Since neither pathogenic point mutations nor a single tumor 
suppressor gene were identified that would explain the downregulation of these candidate 
genes in CLL, in addition to the finding that most of them are monoallelically expressed, it is 
proposed that the regulatory mechanism of 13q14.3 is epigenetically controlled. 
In the present work, the genes and CpG-islands of the critical region in 13q14 were 
epigenetically characterized. The aim was to identify an epigenetic regulatory mechanism 
that controls gene expression in the region 13q14.3 and to describe how its function is lost in 
CLL. Thus, the wild type epigenetic code of 13q14.3 was determined and subsequently, CLL 
cells were screened for aberrant epigenetic modifications. 
Chromatin immunoprecipitation (ChIP) was used to study epigenetic modifications at the 
critical region in different tissues. ChIP methodology was established and optimized to work 
with hematopoietic tissue. ChIP was used to quantify two epigenetic modifications, 
H3K4me2- and macroH2A-enrichment at 13q14.3 in non-malignant cells and CLL cells. 
The critical region in 13q14.3 shares similarities with imprinted regions including the 
regulatory large noncoding RNA genes, monoallelic expression of the genes and regulation of 
gene expression by distinct epigenetic modifications. The transcription of imprinted ncRNA 
genes is often dependent on differentially methylated imprinting control elements (ICE) 
located in the vicinity of the genes. Thus, the existence of a locus control region (LCR) in the 
critical region in 13q14.3 is postulated to control the transcription of the ncRNA genes in the 
critical region analogous to ICEs in imprinted regions. The aim of this work was to identify 
such an epigenetically regulated region control element in chromosomal region 13q14.3, 
which might be functionally inactivated in CLL cells either together with the minimally 
deleted region or by epigenetic silencing (epimutation). The characterization of the 
epimutation in 13q14.3 in this work is an essential step towards elucidation of the underlying 
molecular cause for the development of CLL. 
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2 Material & Methods 
Material 
2.1 Biological material 
2.1.1 Cultured cell lines 
 
Table 2-1: Cultured cell lines 
Cell line 
(DSMZ no.) 
Origin/tumor tissue Culture conditions 
characteristics 
Reference 
GRANTA-519 
(ACC 342) 
Human B-cell lymphoma; 
high-grade B-NHL; 
established from peripheral blood 
of 58-year-old female patient 
90 % Dulbecco's MEM (4.5 g/L 
glucose) + 10 % FBS + 2 mM L-
glutamine; 
spheroid cells in suspension, single 
or in clumps 
(Jadayel et al., 
1997) 
HL60 
(ACC 3) 
Human acute myeloid leukemia; 
(AML FAB M2); 
established from peripheral blood 
of 35-year-old female patient 
90 % RPMI 1640 + 10 % FBS; 
round, single cells in suspension 
(Collins et al., 
1977) 
JURKAT 
(ACC 282) 
Human T-cell leukemia; 
acute lymphoblastic leukemia 
(ALL); 
established from peripheral blood 
of 14-year-old male patient 
90 % RPMI 1640 + 10 % FBS; 
round cells in suspension; single or 
in clumps  
(Schneider et al., 
1977) 
NAMALWA 
(ACC 24) 
Human Burkitt lymphoma; 
established from tumor mass of 
an African child in 1967 
90 % RPMI 1640 + 10 % FBS; 
lymphoblastoid, single cells or 
small clusters in suspension 
(Nadkarni et al., 
1969) 
 
2.1.2 Primary cell samples 
 
Table 2-2: Tumor samples from the peripheral blood of B-CLL patients (n.k. = not known). 
Sample 
No. 
Tumor 
No. 
sample age 
at income 
[years] 
Binet 
stage 
Karyotype Tumor cell 
content [ %] 
VH status Gender
CLL1 02PB2757 51 A 17p deletion, 
+12q13 
74 (17p), 
14 (12q) 
Unmutated Male 
CLL2 05PB3784 76 n.k. 13q deletion 85 Mutated Female 
CLL3 04PB3493 54 B Normal n.k. Unmutated Male 
CLL4 05PB3867 81 C 13q single 
deletion 
93.5 Unmutated Male 
CLL5 05PB3937 63 B 13q single 
deletion 
83 Unmutated Male 
Coding of tumors in anonymous and assigned by the Universitätsklinik Ulm. 
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Table 2-3: Primary wild type samples from the peripheral blood of healthy probands. (PBL = 
peripheral blood lympocytes) 
Sample 
No. 
Tissue type Sample age at income 
[years] 
Gender Sample type 
P1 Wild type PBL 33 Male Young subgroup 
P2 Wild type PBL 23 Female Young subgroup 
P3 Wild type PBL 37 Male Young subgroup 
P4 Wild type PBL 25 Female Young subgroup 
P5 Wild type PBL 43 Male Young subgroup 
PB5 Wild type PBL 52 Male Old subgroup 
PB6 Wild type PBL 48 Male Old subgroup 
PB7 Wild type PBL 48 Male Old subgroup 
PB17 Wild type PBL 54 Male Old subgroup 
PB18 Wild type PBL 49 Male Old subgroup 
PB19 Wild type PBL 50 Male Old subgroup 
PB9 CD19+ B-cells 70 Male Wild type B-cells 
PB9 CD19- T-cells 70 Male Wild type T-cells 
PB12 CD19+ B-cells 47 Male Wild type B-cells 
PB12 CD19- T-cells 47 Male Wild type T-cells 
PL1 Wild type PBL 27 Female E6 (rs9568354) heterozygote  
PU1 Wild type PBL 35 Female E6 (rs9568354) heterozygote  
PU2 Wild type PBL 40 Female E6 (rs9568354) heterozygote  
PU3 Wild type PBL 39 Female E6 (rs9568354) heterozygote  
PU4 Wild type PBL 33 Female E6 (rs9568354) heterozygote  
PU5 Wild type PBL 24 Female D6 (rs12100048) heterozygote 
PU6 Wild type PBL 42 Female D6 (rs12100048) heterozygote 
PU7 Wild type PBL 37 Male D6 (rs12100048) heterozygote 
PU8 Wild type PBL 38 Male D6 (rs12100048) heterozygote 
PU9 Wild type PBL 25 Male D6 (rs12100048) heterozygote 
PU10 Wild type PBL 29 Female D6 (rs12100048) heterozygote 
PU11 Wild type PBL 30 Male D6 (rs12100048) heterozygote 
PU12 Wild type PBL 26 Female D6 (rs12100048) heterozygote 
 
2.2 Chemicals and biochemicals 
Table 2-4: Chemicals and biochemicals 
Chemical Supplier 
2-mercaptoethanol (thioethylene glycol) Sigma-Aldrich, Munich 
2-Propanol (isopropanol) Merck, Darmstadt 
Acetic acid Roth, Karlsruhe 
Acrylamide/Bis-Acrylamide (30 % w/v) Bio-Rad Laboratories, Munich 
Agarose Sigma-Aldrich, Munich 
Ampicillin Roche Diagnostics, Mannheim 
Aprotinin Sigma-Aldrich, Munich 
Benzamidin Sigma-Aldrich, Munich 
Betaine Sigma-Aldrich, Munich 
Bicinchoninic acid (BCA) Sigma-Aldrich, Munich 
Bovine serum albumine (BSA) New England Biolabs, Frankfurt am Main 
Chloroform Merck, Darmstadt 
Complete EDTA-free protease inhibitor cocktail 
tablets 
Roche Diagnostics, Mannheim 
Copper-(III)-sulfate Sigma-Aldrich, Munich 
CotI human DNA Roche Diagnostics, Mannheim 
Cyanin3-dUTP Amersham Bioscience, Freiburg 
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Chemical Supplier 
Cyanin5-dUTP Amersham Bioscience, Freiburg 
Deoxynucleotide (dNTP) set Amersham Bioscience, Freiburg 
DNA 10 bp ladder Invitrogen Karlsruhe 
Dithriotheital (DTT) Sigma-Aldrich, Munich 
Ethylenediaminetetraacetic acid (EDTA) Merck, Darmstadt 
Ethanol Merck, Darmstadt 
Ethanolamine Sigma-Aldrich, Munich 
Ethidium bromide Sigma-Aldrich, Munich 
Ficoll 400 Biochrom AG, Berlin 
Fluorescein Avidin D Vector Laboratories, Burlingame, USA 
Formamide Merck, Darmstadt 
Glycerine Roth, Karlsruhe 
Glycine Roth, Karlsruhe 
Karyomax Colcemid Invitrogen, Karlsruhe 
Hepes Sigma-Aldrich, Munich 
Hydrochloride acid (HCl) Merck, Darmstadt 
Isoamylalcohol Merck, Darmstadt 
Leupeptin Sigma-Aldrich, Munich 
Lithium chloride (LiCl) Merck, Darmstadt 
Magnesium chloride Merck, Darmstadt 
Methanol Merck, Darmstadt 
Milk powder Sigma-Aldrich, Munich 
Nonidet P-40 Amersham Bioscience, Freiburg 
Paraformaldehyde Sigma-Aldrich, Munich 
Pepsin Sigma-Aldrich, Munich 
Phenol-chloroform-isoamylalcohol Carl Roth, Karlsruhe 
Phenol Roth, Karlsruhe 
Phenylmethylsulphonyl fluoride (PMSF) Fluka/Sigma-Aldrich, Munich 
Potassium chloride (KCl) Sigma-Aldrich, Munich 
Potassium dihydrogen phosphate (KH2PO4) Carl Roth, Karlsruhe 
Protein A sepharose Amersham Bioscience, Freiburg 
Protein G sepharose Amersham Bioscience, Freiburg 
Rainbow molecular weight marker Amersham Bioscience, Freiburg 
Random primer (random hexamers) Roche Diagnostics, Mannheim 
Salmon sperm DNA Invitrogen, Karlsruhe 
Salmon sperm DNA/protein A agarose Millipore, Schwalbach 
SeaBlue Plus2 pre-stained standard Invtrogen, Karlsruhe 
Sodium acetate (NaAc) Merck, Darmstadt 
Sodium chloride (NaCl) Merck, Darmstadt 
Sodium citrate Merck, Darmstadt 
Sodium dodecyl sulfate (SDS) Carl Roth, Karlsruhe 
Sodium hydrogen phosphate (Na2HPO4) Sigma-Aldrich, Munich 
Sodium hydroxide (NaOH) Merck, Darmstadt 
Spermidine Sigma-Aldrich, Munich 
Spermine Sigma-Aldrich, Munich 
T4 gene 32 protein USB, Cleveland, USA 
TEMED Bio-Rad Laboratories, Munich 
Tricine Carl Roth, Karlsruhe 
Tris-Base Sigma-Aldrich, Munich 
Triton X-100 Sigma-Aldrich, Munich 
Tween-20 Merck, Darmstadt 
ULTRAhyb hybridization buffer Ambion, Austin, USA 
VECTASHIELD with DAPI Linaris, Wertheim-Bettingen 
Yeast tRNA Invitrogen, Karlsruhe 
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2.3 Enzymes 
 
Table 2-5: Enzymes 
Enzyme Supplier 
Advantage cDNA polymerase mix BD Bioscience Clontech, Heidelberg 
DNase I (10 U/µL) Roche Diagnostics, Mannheim 
ExoKlenow (1 U/µL) Invitrogen, Karlsruhe 
Proteinase K (20 mg/mL) Quiagen, Hilden 
Restriction enzymes 
BstUI 
HpaII 
MseI 
McrBcr 
New England Biolabs, Beverly, USA 
SuperScript II reverse transcriptase (200 U/µL) Invitrogen, Karlsruhe 
T4 DNA ligase (1 U/µL) Roche, Grenzach-Whylen 
  
 
2.4 Antibodies 
 
Table 2-6: Commercial antibodies. WB = Western Blot; “-“ = not used in ChIP. 
Antibody Supplier Dilution (WB) Amount per ChIP 
Anti-CTCF Upstate/Millipore, Schwalbach 1:1000 5 µg 
Anti-Digoxigenin-Fluorescein Fab 
Fragment 
Roche Diagnostics, Mannheim - - 
Anti-E2F4 Santa Cruz, Heidelberg - 7 µg 
Anti-histone H3 dimethylated Lys 4 
(anti-H3K4me2) 
Upstate/Millipore, Schwalbach 1:2000 4 µg 
Anti-histone H3 trimethylated Lys 4 
(anti-H3K4me3) 
Abcam, Cambridge, UK 1:1000 5 µg 
Anti-histone H3 trimethylated Lys 9 
(anti-H3K9me3) 
Abcam, Cambridge, UK 1:500 5 µg 
Anti-histone H3 unmodified Upstate/Millipore, Schwalbach 1:7500 4 µg 
Anti-histone H3 trimethylated Lys 27 
(anti-H3K27me3) 
Upstate/Millipore, Schwalbach 1:500 5 µg 
Anti-histone H4 unmodified Upstate/Millipore, Schwalbach 1:2000 4 µg 
Anti-HP1γ Upstate/Millipore, Schwalbach 1:1000 6 µg 
Anti-Ikaros Santa Cruz, Heidelberg 1:1000 5 µg 
Anti-macroH2A1.2 Upstate/Millipore, Schwalbach 1:1000  
HRP-conjugated anti-goat IgG Dianova, Germany 1:5000 - 
HRP-conjugated anti-mouse IgG Amersham Bioscience, 
Freiburg 
1:5000 - 
HRP-conjugated anti-rabbit IgG Abcam, Cambridge, UK 1:5000 - 
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2.5 Primer sequences 
 
All primer sequences designed during this work are listed in the appendix (Appendix B). 
 
Table 2-7: Additional primers used in aCGH and aPRIMES. Primer sequences designed by S. Pfister; 
B. Radlwimmer. 
Primer name Sequence (5’  3’)
pGEM-forward GGCCGCGGGATATCACTA- 
pGEM-reverse CTCAAGCTATG CATCCAACG 
ddMse11 TAACTGACAG 
Lib1 AGTGGGATTCCTGCTGTCAGT 
  
 
2.6 Cell culture material 
 
Table 2-8: Cell culture material 
Material Supplier 
Dimethyl sulfoxid (DMSO) Sigma-Aldrich, Munich 
DMEM (Dulbecco’s Modified Eagle Medium) Gibco BRL/Invitrogen, Karlsruhe 
RPMI Gibco BRL/Invitrogen, Karlsruhe 
FCS (fetal cow serum) Biochrom AG, Berlin 
Penicillin (10,000 U/mL) Gibco BRL/Invitrogen, Karlsruhe 
Streptomycin (100 μg/mL) Gibco BRL/Invitrogen, Karlsruhe 
L-Glutamine (200 mM) Gibco BRL/Invitrogen, Karlsruhe 
Streptomycin (10,000 U/mL) Gibco BRL/Invitrogen, Karlsruhe 
  
 
2.7 Kits 
 
Table 2-9: Kits 
Kit Supplier 
AbsoluteTM QPCR SYBR Green ROX dUTP mix ABgene, Epsome, UK 
BCA Protein Assay  Pierce/Thermo Scientific, Rockford, USA 
Concert Rapid Gel Extraction System Marligen Biosciences, Ijamsville, USA 
ECL Western Blot detection Kit Amersham Bioscience, Freiburg 
ECL+ Western Blot detection kit Amersham Bioscience, Freiburg 
Plasmid Maxi Kit Quiagen, Hilden 
PCR rapid purification kit Marligen Biosciences, Ijamsville, USA 
PRISM Big DyeDeoxy Terminator Cycle PE Applied Biosystems, Darmstadt 
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2.8 Other materials 
 
Table 2-10: Other materials 
Material Supplier 
3MM paper Whatman, Maidstone, UK 
Cover slips Sigma-Aldrich, Munich 
FalconTM 50 mL conical tubes BD Biosciences, San Jose, USA 
FalconTM 15 mL conical tubes BD Biosciences, San Jose, USA 
ImmobilonTM-P-PVDF membrane Millipore, Schwalbach 
Hyperfilm ECL Amersham Bioscience, Freiburg 
MicroAmp plates, optical 384-well reaction plate PE Applied Biosystems, Weiterstadt 
MicroAmp plates, optical 96-well reaction plate PE Applied Biosystems, Weiterstadt 
MicroAmp, optical caps PE Applied Biosystems, Weiterstadt 
Microcentrifuge tubes, PCR clean, 0.5 mL Eppendorf, Hamburg 
Microcentrifuge tubes, PCR clean, 1.5 mL Eppendorf, Hamburg 
Microcentrifuge tubes, PCR clean, 2 mL Eppendorf, Hamburg 
Poly-Prep L-lysine coated slides Sigma-Aldrich, Munich 
TOPO TA vector Invitrogen, Karlsruhe 
  
 
2.9 Standard solutions and buffers 
 
2.9.1 Nuclei extraction (ChIP/IP) 
 
Isotonic buffer 150 mM NaCl 
 1.5 mM MgCl2 
 10 mM Tris-HCl, pH 7.5 
 0.5 % Nonidet P-40 
 ddH2O 
  
Lysis buffer 250 mM NaCl 
 20 mM Na-phosphate 
 30 mM Na-pyrophosphate 
 0.5 mM EDTA 
 10 mM NaF 
 0.1 % (v/v) Nonidet P-40 
 10 % (v/v) Glycerol 
 ddH2O 
Protease inhibitors, 0.1 M PMSF and 0.1 M DTT were added freshly prior to use of buffers. 
 
2.9.2 ChIP-buffers – xChIP 
 
SDS-Lysis buffer 1 % (w/v) SDS 
 50 mM Tris, pH 8.1 
 10 mM EDTA 
 ddH2O 
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Low salt buffer 0.1 % (w/v) SDS 
(ChIP wash buffer 1) 1 % Triton X-100 
 2 mM EDTA 
 20 mM Tris-HCl, pH 8.0 
 150 mM NaCl 
 ddH2O 
High salt buffer 0.1 % (w/v) SDS 
(ChIP wash buffer 2) 1 % Triton X-100 
 2 mM EDTA 
 20 mM Tris-HCl, pH 8.0 
 500 mM NaCl 
 ddH2O 
  
LiCl buffer 0.25 M LiCl 
(ChIP wash buffer 3) 1 % (v/v) Nonidet P-40 
 1 % (w/v) Na-deoxycholate 
 1 mM EDTA 
 10 mM Tris-HCl, pH 8.0 
 ddH2O 
 
2.9.3 ChIP-buffers – nChIP 
 
CIB buffer 5 mM Tris, pH 7.4 
 0.5 mM EDTA 
 20 mM KCl 
 ddH2O 
freshly added: 0.5 mM DTT 
 0.2 mM PMSF 
 0.05 mM Spermine 
 0.125 mM Spermidine 
  
WASH buffer 20 mM Hepes, pH 8.0 
 20 mM KCl 
 0.5 mM EDTA 
 ddH2O 
freshly added: 0.5 mM DTT 
 0.1 mM PMSF 
  
WASH 0.3 M buffer 20 mM Hepes, pH 8.0 
 20 mM KCl 
 0.5 mM EDTA 
 0.3 M NaCl 
 ddH2O 
freshly added: 0.5 mM DTT 
 0.05 mM PMSF 
  
NET buffer 150 mM NaCl 
 50 mM Tris, pH 7.5 
 1 mM EDTA 
 0.1 % (v/v) Nonidet P-40 
 0.25 % (w/v) Gelatine 
 ddH2O 
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2.9.4 Acid extraction of histones 
 
Lysis buffer 10 mM Hepes, pH 7.9 
 1.5 mM MgCl2 
 10 mM KCl 
 ddH2O 
freshly added: 0.5 mM DTT 
 1.5 mM PMSF 
 
2.9.5 Western Blot 
 
Blocking solution 10 g Milk powder 
 3 g BSA 
 1 % (v/v) Tween-20 
 ddH2O 
  
2x Laemmli loading buffer 50 mM Tris-HCl, pH 8.0 
 2.4 % (w/v) SDS 
 8 % (v/v) Glycerin 
 0.2 % (w/v) Bromophenolblue 
 ddH2O 
  
5x SDS-PAGE running buffer 25 mM Tris-Base 
 200 mM Glycine 
 10 % (w/v) SDS 
 ddH2O 
  
1x TricinePAGE running buffer 17.9 g Tricine 
 1 g SDS 
 12.11 g Tris-Base 
 1 L ddH2O 
  
10x Blotting buffer 25 mM Tris-Base 
 192 mM Glycine 
 ddH2O 
Added at preparation of 1x buffer: 20 % (v/v) Methanol 
  
TBS-Tween 20 mM Tris-Base 
 137 mM NaCl 
 3.8 mM HCl 
 0.1 % (v/v) Tween-20 
 ddH2O 
 
2.9.6 ChIP-on-chip (mCGH) 
Blocking solution 50 mM Ethanolamine 
 0.1 % (v/v) SDS 
 0.1 M Tris, pH 9.0 
 ddH2O 
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Wash A 50 % (v/v) Formamide 
 0.1 % (v/v) Tween 20 
 2x SSC 
 pH 7.0 
  
2x SSC 0.05 % (v/v) Tween 20 
 2x SSC 
 pH 7.0 
  
PBS-T 0.05 % (v/v) Tween 20 
 1x PBS 
 pH 7.0 
 
2.9.7 FISH 
 
Wash A 50 % (v/v) Formamide pH 7.0 
 30 mL 20x SSC 
 120 mL ddH2O 
  
Wash B 0.5x SSC 
  
Wash C 0.1 % (v/v) Tween-20 
 4x SSC 
  
Blocking 3 % (w/v) BSA 
 4x SSC 
  
Detection 1% (w/v) BSA 
 4x SSC 
  
DAPI 60 mL 2x SSC, pH 7.0 
 45 µL DAPI 
  
DAPI-Wash 0.05% (v/v) Tween-20 
 2xSSC 
  
Column buffer 10 mM Tris-HCl pH 8.0 
(Sephadex columns) 1 mM EDTA pH 8.0 
 0.1 % (w/v) SDS 
 ddH2O 
 
2.9.8 Standard solutions 
 
5x Loading buffer 100 mM EDTA 
 30 % (v/v) Glycerine 
 0.25 % (w/v) Bromophenolblue 
 ddH2O 
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5x TBE 455 mM Tris-Borate 
 10 mM EDTA 
 ddH2O 
  
TE 20 mM Tris-HCl, pH 8.0 
 1 mM EDTA, pH 8.0 
 ddH2O 
  
20x SSC 0.3 M NaCl 
 0.03 M Sodium citrate 
 ddH2O 
  
Hepes 50 mM Hepes 
 150 mM NaCl 
 10 % (v/v) Glycerine 
 0.2 % (v/v) Nonidet P-40 
 20 mM NaF 
 1.5 mM MgCl2 
 0.2 mM EDTA 
 ddH2O 
  
10x PBS 137 mM NaCl 
 27 mm KCl 
 100 mM NaH2PO4 
 17 mM KH2PO4 
 ddH2O 
  
RIPA 150 mM NaCl 
 50 mM Tris-HCl, pH 8.0 
 1 mM EGTA 
 1 mM EDTA 
 0.25 % (w/v) Na-deoxycholate 
 1 % (v/v) Nonidet P-40 
 0.1 % (w/v) SDS 
 ddH2O 
 
2.10 Instruments 
 
Table 2-11: Instruments 
Instrument Supplier 
ABI PRISM 3100 Genetic Analyzer, 16 Capillary 
DNA Sequencer 
PE Applied Biosystems, Langen 
 
ABI PRISM 7900 Sequence Detection System Applied Biosystems, Forster City, USA 
Agilent DNA microarray scanner Agilent Technologies, Palo Alto, USA 
Automatic developing machine Amersham, Freiburg 
Axioplan microscope Carl Zeiss, Jena 
Biofuge Fresco refrigerated tabletop centrifuge Heraeus/Kendro, Hanau 
Centrifuge 5810 R Eppendorf, Hamburg 
Cytospin 3 Shandon Life Sciences International, England 
Digital camera Hamamatsu ORCA-ER Hamamatsu Photonics, Herrsching am Ammersee 
EAS Gel Documentation System Herolab, Wiesloch 
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Instrument Supplier 
EL800 Universal Microplate Reader BIO-TEK, Neufahrn 
Gel electrophoresis power supply E-C Apparatus Corporation, USA 
GeneAmp PCR-System 2400, 9600 and 9700 PE Applied Biosystems, Weiterstadt 
Gene Pulser Xcell Bio-Rad Laboratories, Munich 
Gene Tac hybridization station 
 
Genomic Solutions (GeneMAchines), Ann Arbor, 
USA 
GS 6, GS 6KR, Centrifuge Beckmann, Wiesloch 
GSA- and SS34-Rotor DuPont, Boston, USA 
Heating block QBT2 Grant Instruments/CLF, Emersacker 
HMT 702 C Microwave oven Robert Bosch GmbH, Stuttgart 
Mastercycler PCR-Maschine Eppendorf, Köln 
Micro-centrifuge NeoLab Laborbedarf, Heidelberg 
Mini-Protean 3 gel and electrophoresis system Bio-Rad Laboratories, Munich 
Mini Trak CSS Packard 
Multifuge 3 SR Heraeus/Kendro, Hanau 
NanoDrop ND-1000 Spectrophotometer NanoDrop Technologies, San Diego 
Sigma 4K10-Coldcentrifuge Sigma-Aldrich, Heidelberg  
Sonopuls HD2070 Bandelin Electronic GmbH, Berlin 
Thermomixer compact Eppendorf, Köln 
Ultrospec 2000 Photometer Amersham, Freiburg 
Unimax 1010 Shaker Heidolph Instruments, Schwabach 
Varifuge 3.0/3.0R Laborcentrifuge Heraeus/Kendro, Hanau 
Waterbad SW22 Julabo Labortechnik, Seelbach 
Waterfiltrationsmachine Millipore-Q UF Plus Millipore, Eschborn 
Weighing machine BL 610 und BL150S Sartorius AG, Göttingen 
  
 
2.11 Software 
 
Table 2-12: Software 
Software Supplier 
Adobe Illustrator CS Adobe, USA 
AnalySIS Olympus, Germany 
Bioconductor 1.7 Open source (http://www.bioconductor.org/) 
Endnote X Thomson Reuters, New York, USA 
Excel 2003 Microsoft, USA 
Gene Pix Pro 6.0 Axon Instruments, Burlingame, USA 
Ingenuity Pathway Analysis Ingenuity Systems, San Diego, USA 
Photoshop 7.0 Adobe, USA 
Primer3 Open source (http://frodo.wi.mit.edu/) 
R 2.2.1 Open source (http://www.r-project.org/) 
SDS 2.2.2 Applied Biosystems, Forster City, USA 
Sigma Plot Systat System Inc., USA 
Vector NTI Invitrogen, USA 
Word 2003 Microsoft, USA 
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Methods 
 
2.12 Preparation of proteins 
2.12.1 Isolation of peripheral blood lymphocytes from whole blood 
Human lymphocytes can be isolated from peripheral blood by density centrifugation over a 
step gradient consisting of a mixture of the carbohydrate polymer FicollTM and the density 
iodine-containing compound metrizamide. This yields a population of mononuclear cells, 
lymphocytes, at the interface that has been depleted of erythrocytes and most 
polymorphonuclear leukocytes and monoytes. The lymphocytes were isolated from whole 
blood according to the manufacturer’s instructions (Biochrom AG, Berlin). 
2.12.2 Cell lysis for whole protein extraction  
Cell lysates were prepared from cultured cells using RIPA-buffer, which was freshly 
supplemented with the Complete EDTA-free protease inhibitor cocktail-tablets (Roche 
Diagnostics, Mannheim) prior to lysis. Buffers were used at 4°C and 150 µL buffer per 5*105-
1*106 cells were used for the cell lysis. Cells were lysed in 1x RIPA buffer for 30 min on ice 
and lysates were used for Western blot detection of proteins. After lysis, all cell extracts were 
centrifuged at 13.000 rpm for 10 min at 4°C. The supernatants were then mixed with 
3x Laemmli loading buffer for acrylamid gel analysis, or stored at -80°C. 
2.12.3 Isolation of nuclei from whole cell extracts  
Nuclei extraction was used for two purposes, the first was to generate input-fractions for 
ChIP analyses and the second was to gain proper controls for ChIP-fractions in Western blot 
analyses. Nuclei extracts were prepared from cultured cells or frozen cell material using 
isotonic and lysis buffer (chapter 2.9.1). 1 mL isotonic buffer was added to 1*108 cells and 
incubated at 4°C for 5 min. Then these samples were centrifuged for 5 min at 13.000 rpm 
and 4°C. Afterwards the lysis buffer was added (1 mL/1*108 cells) following incubation at 
4°C for 5 min. Subsequently, lysed nuclei extracts were centrifuged at 13.000 rpm for 5 min 
at 4°C again, and thereafter supernatants included nuclei for further use. 
2.12.4 Acid extraction of histones  
Another control tissue for use in Western blot analyses to control ChIP-fractions including 
precipitated modified histones, were histone proteins. Histone extracts were prepared from 
1*108 cells, which were pelleted by centrifugation at 200 g for 10 min. The cell pellet was 
resuspended with 10-15 volumes of 1x PBS and then again centrifuged for 10 min at 200 g. 
After the PBS-washing step the cell-pellet was resuspended in 5-10 volumes of lysis buffer 
(chapter 2.9.4) and hydrochloric acid was added to a final concentration of 0.2 M. Following 
incubation for 30 min at 4°C, the cells were centrifuged for 10 min at 11.000 g and 4°C. The 
supernatant thus contained the acid soluble proteins, for example histones, whereas the 
acid-insoluble pellet was discarded. The histone-containing supernatant was then dialyzed 
twice against 200 mL of 0.1 M acetic acid for 1-2 h each. Afterwards the supernatant was 
dialyzed against 200 mL 1x PBS for 1 h, 3 h and over night, respectively. The yielded histone 
extracts could be quantified and lyophilized or stored at -70°C. 
  Methods 
 
 
45
2.13 Immunoprecipitation of proteins 
Cultivated cells were harvested and nuclei were extracted according to the protocol 
described in chapter 2.12.2. These nucleic extracts were then incubated with the 
precipitating antibody overnight at 4°C on a rotator. Afterwards, 10 % protein A sepharose 
(Amersham Bioscience, Freiburg) was added and precipitation of antibody-protein complexes 
was allowed for 2-4 h at 4°C while rotating. Precipitated sepharose-antibody-protein 
complexes were washed with 1x PBS and further analyzed by Western blot. 
2.14 Chromatin immunoprecipitation (ChIP) assay 
Two distinct standard approaches for the ChIP assay were tested prior to establishment of 
the adjusted protocol. A scheme of the general procedures during ChIP assays is shown in 
Figure 2-1: 
 
 
Figure 2-1: Schematic overview of the chromatin immunoprecipitation procedure; 
adapted from (Collas and Dahl, 2008). 
 
A brief introduction to the characteristic features of native ChIP (nChIP) and of cross-linking 
ChIP (xChIP) will be given before description of the protocol established during the work of 
this thesis. 
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2.14.1 nChIP assay 
The native ChIP or nChIP protocol includes preparation of native chromatin fragments by 
Micrococcal nuclease enzymatic digestion after cell lysis (O'Neill and Turner, 2003). Digestion 
with nuclease enzymes lead to a mixture of nucleosomal chains with different lengths. 
Micrococcal nuclease cleaves chromatin at linker DNA sequences between the nucleosomes 
and thus generates a mixture of mono- to heptanucleosomes. Digestion was checked by 
agarose gel electrophoresis, by which the nucleosomal chain mixture is visible as 
nucleosomal ladder according to separation by size of nucleosomal DNA in multiples of 
146 bp on agarose gels. 
The native ChIP protocol was applied according to the protocol established in the lab of 
Kinya Yoda and described in (Ando et al., 2002) with instructions by Alicia Alonso. 
2.14.2 xChIP assay 
The cross-linking ChIP protocol was originally established to efficiently precipitate proteins 
that are bound directly to the DNA by specific antibodies. Here, the instructions and buffers 
described in (Orlando, 2000 and; Spencer et al., 2003) were followed for xChIP-protocol and 
the stringent washing procedure including immune complex wash buffers, to ensure removal 
of unspecifically bound chromatin, was adapted in the self-developed ChIP protocol. 
2.14.3 ChIP protocol established during this thesis 
At first, 1*108 cells, which were either freshly prepared from cell cultures, from lymphocyte 
extractions from peripheral blood (PBL) or from cell pellets stored at -70°C, were 
resuspended in 1 mL 1x PBS. Reversible cross-linking of proteins and DNA was taken out by 
incubation with 2 % (v/v) formaldehyde solution at 4°C for 20 min. The cross-linking process 
was stopped by addition of 0.125 M glycine prior to centrifugation of cells for 5 min at 
5.000 rpm and 4°C. Isotonic and lysis buffers used for the following steps were 
supplemented with diverse proteinase inhibitors (aprotinin, benzamidin, leupeptin, 
spermidine and spermine) and with DTT and PMSF, to avoid degradation of proteins and to 
stabilize DNA-protein bounds. The cross-linked cell pellets were resuspended in isotonic 
buffer and incubated for 5 min at 4°C. The buffer was discarded after centrifugation for 
5 min at 5.000 rpm and 4°C and nuclei containing pellets were resuspended in 1 mL lysis 
buffer. Nuclei were ultra-sonicated in 5 pulses for 40 s at 70 % output each, with cooling of 
samples at 4°C between pulses. After ultra-sonication the fragmented chromatin was soluble 
in the lysis buffer. Therefore remaining nuclei and cell debris was pelleted and removed by 
two steps of centrifugation at 13.000 rpm and 4°C for 15 min each. The supernatant 
contained prepared chromatin-fragments and an aliquot of this “input”-fraction was set 
aside. The input chromatin was subjected to three steps of preclearing with 30 µL of protein 
A agarose/salmon sperm DNA beads at 4°C for 15 min each on a rotator to ensure equal 
mixing of the solutions and the beads. In between the preclearing steps the solutions were 
centrifuged at 5.000 rpm for 3 min at 4°C, pelleted preclearing beads were set aside and 
another volume of fresh beads was applied for the subsequent preclearing step. After this 
procedure, an aliquot of “cleared input” chromatin was set aside, and the prepared cleared 
input chromatin was used for precipitation. Chromatin prepared for each ChIP reaction was 
divided into two halves; one half served as “mock precipitate”-fraction to detect unspecific 
binding and the other half was combined with around 5 µg of the precipitating antibody. 
Both fractions were incubated overnight at 4°C on a rotator to allow binding of the antibody 
to target chromatin fragments. Afterwards, the antibody-chromatin complexes were 
precipitated by addition of 80 µL protein A agarose/salmon sperm DNA mix beads for 4 h at 
4°C on a rotator. The same amount of beads was added to the mock precipitate fraction. 
After the incubation for 4 h, fractions were centrifuged for 5 min at 5.000 rpm and 4°C. The 
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supernatant of pelleted beads was saved as “unbound”-fractions for both, the antibody and 
the mock precipitate fractions, to check for unbound target chromatin. The pelleted bead 
fractions were washed stringently three times by addition of 100 µL 1x High salt immune 
complex wash buffer, 100 µL of 1x Low salt immune complex wash buffer and 100 µL of 
1x LiCl immune complex wash buffer, respectively. Centrifugation to pellet beads and 
remove wash buffer at 5000 rpm and 4°C for 3 min was performed after each addition of the 
respective buffer. The pelleted beads of precipitate and mock precipitate fractions were then 
resuspended in 150 µL TE buffer. All aliquots taken during the ChIP procedure (fractions: 
input, cleared input, unbound, precipitate, mock unbound and mock precipitate) were split 
for separate analysis of protein and DNA results. The protein parts of all fractions were 
quantified in BCA-assays and the precipitation of target protein was specifically analyzed by 
Western Blot analysis using the same antibody as for precipitation. 
The DNA-parts of the six ChIP-fractions were first incubated for 4-6 h at 65°C with 20 µL 4 M 
NaCl to reverse cross-links, subsequently, remaining protein debris, protein A and antibody 
was destroyed by incubation with 3 µL of proteinase K (20 mg/mL) and 3 µL of 20 % SDS 
overnight at 56°C. DNA was extracted by phenol-chloroform extraction protocol described in 
chapter 2.16.1 and precipitated by addition of 2.5 volumes of absolute ethanol, 1/10 volume 
of 3 M NaAc (pH 5.2) and 1 µg glycogen as carrier and incubation at -80°C for 30 min. DNA 
was then centrifuged for 20 min at 13.000 rpm and 4°C, washed with 70 % ethanol as 
described below and after drying, DNA was resuspended in 100 µL of TE buffer. The DNA 
amounts in all fractions were quantified by spectrometric measurements (NanoDrop; see 
below) and diluted 1:1000 or 1:500 (for input and unbound fractions) or 1:3 (precipitate 
fractions) prior to analysis by qPCR. 
2.15 Protein analysis 
2.15.1 Protein quantification 
The BCA-Assay is a Biuret reaction where peptide bonds react with copper ions in an alkaline 
solution. The reacted ions in turn react with bicinchonic acid (BCA) to give a violet colour 
which varies in intensity depending on the amount of protein present. Because peptide 
bonds occur with approximately the same frequency per gram of material in every protein, it 
can be used for estimation of protein concentration (Rehm, 2002). Standard curves were 
made by measuring BSA with standard amounts ranging from 2000 µg/mL to 25 µg/mL. The 
Biuret reaction was performed with copper-(II)-sulfate and bicinchonic acid (1:50 copper-
(II)-sulfate:bicinchonic acid). 10 µL of protein solution was added to 200 µL of reaction 
mixture, incubated at 37°C for 30 min and then read out in an ELISA reader at 550 nm 
wavelengths. 
2.15.2 Tris-glycine SDS-PAGE: Tricine-PAGE 
SDS polyacrylamid gel electrophoresis (SDS-PAGE) is a method to separate proteins 
according to their size (Schagger and von Jagow, 1987). Proteins are coated with the 
detergent sodium-dodecyl-sulfate (SDS) that confers a linear shape and a negative charge to 
the proteins. Because of similar shape of the denatured proteins and the fact that the net 
charge depends only on the size of the proteins, the polypeptides can be separated 
according to their molecular weight. In PAGE, the matrix used to separate the proteins is a 
polyacrylamide gel, a polymer that gives a highly reproducible pore size upon polymerisation. 
In subsequent electrophoresis, the charged molecules migrate in an electric field. A 
discontinuous system was used, with a non-restrictive large pore gel stacked on top of the 
resolving gel. Samples were prepared by mixing with 3x Laemmli solution, boiling at 95ºC for 
5-10 min and cooling them before loading together with SeaBlue Plus2 pre-stained protein 
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size standard (Invitrogen, Karlsruhe). The gels for SDS-PAGE were prepared either with Tris-
glycine or with tricine and run in SDS-PAGE running buffer or in tricine running buffer, 
respectively, at 100 mA for 1-2 h depending on the size of the proteins and the percentage 
of polyacrylamide in the gel (histones 1.5 h in 15 %-gels; macroH2A 2-3 h in 15 %-gels). For 
casting and running SDS-PAGE gels the Mini-Protean 3 gel system (BIORAD, Munich) was 
used. 
2.15.3 Protein staining in SDS-PAGE gels 
After separation with SDS-PAGE, the gels were either further processed for Western blot or 
stained with Coomassie brilliant blue R 250 (Merck, Darmstadt). During establishment of 
optimal Western blotting conditions to analyze ChIP-fractions, gels were analyzed after 
blotting by Coomassie staining. Gels were soaked in staining solution (40 % (v/v) Methanol 
+ 10 % (v/v) glacial acetic acid + 50 % (v/v) H2O + 0.05 % (w/v) Coomassie brilliant blue R 
250). Unbound Coomassie was removed by immersion in 250 mL ddH2O/gel and boiling in a 
microwave oven until staining of the gel was optimal for imaging.  
2.15.4 Western blotting 
Western blotting is a method to detect target proteins in a sample with specific antibodies, 
whereby proteins have been previously separated by SDS-PAGE. In Western blotting 
(Burnette, 1981; Renart et al., 1979) the separated proteins are transferred to a membrane 
where the proteins are better accessible for antibodies and can be further analyzed. After 
separating the samples by SDS-PAGE, the Western blot was performed wet; the assembled 
blot was embedded in the blotting buffer and run at 250 mA for 2-4 h on ice. To verify 
transfer of proteins, membranes were stained in Ponceau S (Sigma-Aldrich, Munich) for 
5 min and de-stained by washing 5 min in TBS/Tween washing buffer. Membranes were 
blocked in blocking solution for 1 h at room temperature (RT) or overnight at 4ºC. After 
blocking the primary antibody diluted in 1 % (w/v) BSA solution was applied (at 
concentrations depicted in Table 2-6) and incubated 1 h or overnight at 4ºC. After incubation 
of the primary antibody, membranes were washed twice for 5 min and once for 10 min at RT 
in 1x TBS-Tween. The secondary antibody diluted in blocking solution was applied and 
incubated 1 h at 4ºC. Membranes were washed as above and the blot was developed with 
either ECL or ECL+ Western blot detection kits (Amersham Bioscience, Freiburg) according to 
the instructions by the manufacturer. 
2.16 DNA analysis 
2.16.1 DNA isolation 
DNA was isolated according to the standard phenol-chloroform extraction protocol, which is 
based on the immiscibility of phases produced by phenol, chloroform and isoamylalcohol. 
Homogenization of these liquids is only transient, and after centrifugation, three phases are 
produced: the upper aqueous phase contains all water-soluble molecules including nucleic 
acids, the lower fatty phase contains fatty-soluble proteins and the interphase captures 
proteins and molecules that are neither fatty nor water soluble. Thus a separation of nucleic 
acids from the cellular proteins is achieved and DNA can be isolated. 
After the cellular digestion by proteinase K, cell pellets were combined with an equal volume 
of 25:24:1 phenol-chloroform-isoamylalcohol mixture (around 100 µL) and vortexed until 
homogenized. After a following centrifugation step at 13.000 rpm for 10 min the upper 
aqueous phase was taken and combined with an equal volume 24:1 chloroform-
isoamylalcohol mixture (around 200 µL) for higher purity and further depletion of phenol. 
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After homogenization and centrifugation for 10 min at 13.000 rpm the aqueous upper phase 
was taken and combined with 2.5 volumes of ethanol, 1/10 volume of 3 M NaAc (pH 5.2) 
and 1 µg glycogen as a carrier. This was homogenized and DNA was allowed to precipitate 
at -80°C for 30 min. The precipitated DNA was pelleted by centrifugation for 20 min at 
13.000 rpm and 4°C, and then the pellet was depleted of salts by washing with 200 µL 70 % 
ethanol. After air-drying of the DNA-pellet, it was resuspended in 30 µL ddH2O or TE-buffer. 
2.16.2 Genomic DNA preparation 
Isolation of genomic DNA from cultivated cell lines was prepared according to the phenol-
chloroform extraction protocol described above. Alternatively, genomic DNA was prepared 
according to the manufacturer’s protocol for genomic DNA isolation with columns (Qiuagen 
genomic tip 500, Quiagen, Hilden). 
2.16.3 DNA quantification 
The concentration of DNA solutions was determined by spectrophotometry. This procedure is 
based on the absorption maximum of nucleic acids at 260 nm, which is caused by the 
aromatic ring structures of the nucleotide bases. Standardized, the absorption is usually 
measured in quartz cuvettes with a gage of 1 cm, which facilitates estimation of 
concentrations via the law of Lambert-Beer: 
 
    A = ε*c*d 
 
Following calibration with the appropriate solvent, sample readings should range between 
0.05 and 1 OD (optical density), which is the linear range of common photometric devices. 
The concentration was then determined using the following formula: 
 
    [dsDNA] = OD260*50 µg/mL*dilution factor 
 
The absorption maximum of proteins is at 280 nm due to the absorbance of aromatic amino 
acids. The ratio OD260/OD280 can be used as an indication for the purity of nucleic acid 
solutions. Pure DNA solutions have a ratio of about 1.8, whereas contaminations by phenol 
or proteins cause a decrease of this value. DNA solutions with a ratio smaller than 1.5 were 
considered inappropriate for further analysis. 
The OD of DNA solutions was measured in an automated spectrometric reader (NanoDrop). 
2.16.4 Agarose gel electrophoresis 
Agarose gel electrophoresis was used to separate DNA-fragments in an electric field 
according to their size. The used concentration of agarose was dependent on the size of DNA 
fragments. Usually, 1 % (w/v) agarose gels were used for separating DNA-fragments of 0.5-
4 kb in size. Agarose was melted by boiling in 1x TBE buffer. The solution was filled into a 
gel sled and was allowed to polymerize. For electrophoresis, the agarose-gel was placed into 
a gel chamber and covered with 1x TBE buffer. Probes were mixed with loading buffer and 
loaded into the sluts of the gel. Electrophoresis was run for 0.5-1 h at 120-150 V and 
500 mA. Afterwards, the separated DNA was stained by soaking the gel for 10 min in 
1 µg/mL ethidium bromide at RT. Images were taken with a digital camera device that is 
part of the Gel Documentation System. 
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2.16.5 PCR purification and gel extraction purification 
PCR products and plasmids were purified to remove enzymes, salts and other contaminants. 
Nucleic acids were purified with a PCR purification kit following the manufacturer’s protocol 
(PCR rapid purification kit, Marligen Biosciences, Ijamsville, USA) and usually eluted in 30 µL 
TE-buffer or ddH2O. In order to isolate nucleic acids of distinct sizes, the bands were cut out 
from agarose gels after electrophoresis. To avoid DNA damages of the DNA fragments by gel 
extraction purification, nucleic acids were detected by a low wavelength UV-light. Gel slices 
were processed with the Concert Gel Extraction Kit following the manufacturer’s instructions 
(Marligen Biosciences, Ijamsville, USA). 
2.16.6 Primer design 
For the design of oligonucleotide primers, the conformation of primer dimers was generally 
avoided by considering that the 3’ end of the forward primer and the 3’ end of the reverse 
primer are not able to hybridize by homologous base pairing. The five first and five last 
residues of each primer should contain 2-3 G- or C-residues; if possible the last residue at 
the 3’ end should also be a G or a C to ensure a stable starting position for the enzyme. To 
avoid wrong primer annealing, stretches of more than four residues of the same type were 
prevented. Primers were designed on the basis of genomic sequences of the genes and CpG-
island stretches of the chromosomal region 13q14.3, which were available on the NCBI 
homepage (http://www.ncbi.nlm.nih.gov/). The open source software Primer3 was used to 
design primers to be used in quantitative PCR analyses, as these PCR-products should not 
exceed a size of maximal 200-250 bp. 
2.16.7 PCR 
Chromatin immunoprecipitation analyses were performed to enrich DNA-sequences that are 
specific for a distinct chromatin mark. For example, in ChIP-assays using the antibody anti-
H3K4me2 only DNA sequences bound only to these modified histones H3 were enriched in 
precipitate fractions. Characterization of DNA sequences could be carried out by microarray- 
or PCR-analyses. Analyses of ChIP-DNA with microarrays (“ChIP on chip”) generated a 
genome wide profile of H3K4me2-enrichment. Another possibility to analyze ChIP-DNA was 
to amplify specific sequences of interest by PCR to identify those that show the modification 
analyzed. The latter analysis was only possible because a known chromosomal region 
(13q14.3) should be characterized for epigenetic modifications. In PCR analyses, tested 
ChIP-fractions could be divided into controls that should contain the positive control 
sequence (input-, cleared input- and unbound-fractions) and those controls that should not 
contain any positive control sequence (preclearing beads; mock precipitate). 
 
The polymerase chain reaction (PCR) is a technique to amplify distinct DNA fragments in 
vitro (Mullis et al., 1986). It is based on the ability of DNA-polymerases to generate 
complementary strands of DNA out of a single-stranded DNA template. The enzymes used 
can elongate existing short oligonucleotide primers of 15-25 bp in length. The 
complementarity of the primers to a specific DNA sequence determines the fragment of DNA 
that will be amplified. A standard PCR reaction contains: 
      100 ng  template (DNA/cDNA) 
      10 pmol forward primer 
      10 pmol reverse primer 
      4 µL  dNTP-mix (10 mM of each dNTP) 
      5 µL  10x polymerase buffer 
      1 µL  DNA polymerase (1 U/µL) 
      ad 50 µL ddH2O 
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Standard cycling conditions used for amplification were 96°C for 5 min; 30 cycles of 96°C for 
20 s, 60°C for 20 s and 72°C for 1 min; 72°C for 5 min, hold at 4°C. These standard 
conditions were modified if DNA fragments were only weakly amplified or showed no product 
at all. 
2.16.8 Nested PCR, gradient PCR, colony PCR 
If no DNA product is amplified after the first PCR reaction, a second primer set lying within 
the first amplicon, was used to nest the first PCR. Usually after optimization of the 
hybridization temperature, a specific target product was visible on the agarose gel. 
For the optimization of hybridization temperatures a gradient PCR reaction was used. A 
central temperature together with a temperature gradient was chosen to perform the single 
reactions. In case the temperature was chosen too high, there was no PCR product because 
the primers are not able to anneal to the target sequence. In case the temperature was too 
low, a DNA smear or several bands were visible, due to unspecific binding of the used primer 
pair. 
Colony PCR reactions were used to quickly screen for plasmid inserts of E. coli colonies. This 
technique can be used to determine insert size and/or orientation in the vector depending on 
the choice of primers. PCR reaction mixtures consisted of 5 µL 10x polymerase-buffer, 2 µL 
dNTP-mix (2.5 mM of each dNTP), 0.1 µL forward and reverse primer (100 µM each), 0.5 µL 
of Taq-polymerase (2 U/µL) and 42.3 µL of sterile distilled water in a total volume of 50 µL. 
To each PCR tube containing the PCR reaction a small amount of colony was added by a fine 
yellow pipette tip. The amount of cells should be small, as just a touch will do it. Thermal 
cycling conditions were 96°C for 4 min; 30 cycles of 94°C for 30 s, 58°C for 30 s, 72°C for 
1 min; 72°C for 5 min, hold at 4°C. 
2.16.9 Reverse transcription 
Reverse transcription is the transcription of RNA into single-stranded complementary DNA 
(cDNA). CDNA is much more stable than RNA and can be used for a number of approaches 
like PCR, real-time quantitative PCR or sequencing. For a final volume of 20 µL cDNA 
solution, 1 µg of total RNA (8 µL) was used together with 2 µL of 5x 1st strand buffer and 
1 µL DNase I (10 U/µL) and incubated for 20 min at RT to allow digestion of DNA. 3 µL of 
the mastermix I, which contains in equal amounts EDTA (25 mM), dNTP mix (10 mM each) 
and 300 ng/µL dT primer or random hexamers, were added to the mix and incubated in a 
thermo-cycler for 10 min at 65°C and for 10 min at 25°C to get rid of secondary structures 
and allow the annealing of the primer to the RNA, respectively. After adding 5 µL of the 
second mastermix containing 5x 1st strand buffer, 0.1 M DTT and nuclease-free water at a 
ratio of 2:2:1, the solution is shifted to 42°C for 2 min before adding 1 µL of reverse 
transcriptase (200 U/µL) and 0.2 µL of T4 gene 32 protein. After the reverse transcription 
reaction for 50 min at 42°C, the enzyme was inactivated for 10 min at 95°C. 
2.16.10 Real-time PCR analysis, quantitative PCR 
Real-time PCR analysis was used in this study to quantify DNA of the fractions generated 
during ChIP-experiments. It was used to quantify the precipitated target sequences in 
different samples and to quantify the amount of precipitated sequences at different targets. 
The method of real-time PCR analysis is based on the detection of bound fluorescent dye 
SYBR-Green I to the minor groove of double stranded DNA. In the unbound state, SYBR-
Green I does not emit any fluorescence, but during the elongation step of the PCR, it can 
bind to the double stranded PCR products, whereby it is activated and emits fluorescence. At 
the end of every elongation step, the emitted fluorescence was measured, which allows the 
detection and quantification of PCR products in real time. To get a conclusion about the 
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specificity and sensitivity of the primer used in this reaction, the analysis of dissociation 
curves is indispensable. In these dissociation curves side products and primer dimers would 
be visible as peaks with a low melting temperature. 
PCR reaction mixtures consisted of 6 µL SYBR-Green I mixture, 100 nM forward and 100 nM 
reverse primer and 2 µL template in a reaction volume of 12 µL. Thermal cycling conditions 
comprised an initial enzyme activating step of 15 min at 95°C, 40 cycles of 15 s at 95°C and 
1 min variable annealing/elongation temperature (usually 60°C), depending on the 
respective set of primers. Double-stranded-DNA-specific fluorescence was measured at the 
end of each extention phase. For creation of the dissociation curve data, the mix was hold 
for 15 s at 95°C for denaturation, 15 s at 60°C and was then slowly (within 20 min) heated 
to 95°C, hold for 15 s and cooled down to 4°C. Product-specific amplification was confirmed 
by analysis of dissociation curves. A standard curve consisting of a dilution series of genomic 
DNA was used to determine the efficiency of the PCR reaction. The amount of PCR product 
was plotted against the cycle number in a logarithmic scale. This plot shows at which cycle 
number in the exponential phase a defined threshold is reached by the amplification curves 
of the samples. The intersection of the amplification curve with the defined threshold gives a 
defined CT value for each sample. 
2.16.11 Quantification and normalization of ChIP-DNA by qPCR 
To determine the amount of precipitated DNA at a specific target sequence by qPCR, the 
measured CT-values of different ChIP-fractions were taken to calculate fraction of input 
values. Fraction of input values were calculated from the CT-values determined for input, 
precipitate and mock-precipitate fractions by this equation: 
 
   Fraction of input = (CT(precipitate)-CT(mock))/CT(input) 
 
 
 
Figure 2-2: Outline for setting up qPCR to analyze ChIP DNA. 
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To validate H3K4me2-precipitation of ChIP by qPCR, the amount of DNA was measured at 
the promoter of the housekeeping gene GAPDH and at the promotor of the inactive gene 
MYH1 (i.e. MYH1 is inactive in hematopoietic cells). 
QPCR for GAPDH-promoter served as positive control, because it is an H3K4me2-enriched-
sequence, which should be frequently contained in precipitate-fractions. QPCR for MYH1-
promotor served as negative control as it shows no H3K4me2-enrichment. The same 
principle was used to validate macroH2A-precipitation, using the promoter of the gene IL8 as 
positive control and again the MYH1-promoter as negative control.  
Further normalization of fraction of input values was carried out by dividing the fraction of 
input value of each analyzed 13q14-sequence with the fraction of input value of a second 
positive control sequence, both measured in parallel for every analyzed sample. The second 
positive control sequence was localized in the CDH12 promoter for H3K4me2-ChIPs and in 
the HK2-promoter for macroH2A-ChIPs. Figure 2-2 schematically depicts the general outline 
for the set up of qPCR analysis for ChIP assays. 
The analysis of 39 sequences of 13q14 in each of 27 samples was partially automated. Three 
template plates in 96-well format containing the ChIP-fractions of 27 samples were produced 
in order to automatically pipet the templates along with the PCR-reaction reagents (pre-
loaded in 96-well plates) into a 384-well plate with a pipetting roboter. 
2.16.12 DNA-sequencing 
Sequencing of DNA was done according to the Didesoxy-Sequencing method (Sanger et al., 
1977). This method is a direct, statistically distributed termination of the complementary 
strand synthesis during the cyclic sequencing reaction, in which the amplification takes part 
in a linear matter with only one primer. The reaction mix contains fluorescently labelled 
didesoxy-derivates for all of the four nucleotides (Rosenblum et al., 1997). The detection of 
fragments occurs via laser excitation. Due to initial denaturation steps during the reaction, 
sequencing of dsDNA is possible. The sequencing reaction was done according to the 
manufacturer’s protocol using the PRISM Big DyeDeoxy Terminator Cycle Sequencing Kit 
(Applied Biosystems, Darmstadt). The reaction contains an initial denaturation step for 2 min 
at 96°C and 25 cycles of 5 s at 96°C, 10 s at 55°C and 4 min at 60°C. After this PCR-
reaction, samples were precipitated with 2.5 volumes of ethanol and 1/10 volume of 3 M 
NaAc, washed with 70 % ethanol, dried and resuspended in 10 µL formamide. Subsequently, 
this DNA was used for sequencing in an automatic capillary sequencing machine. 
2.16.13 Detection of monoallelic expression by SNP-analysis  
The SNP-analysis was performed in collaboration with Angela Philippen. First, SNPs within 
the open reading frame (ORF) of genes or within CpG-islands were identified using the 
corresponding web-pages of the National Center of Biotechnology Information (NCBI; 
http://www.ncbi.nlm.nih.gov/). To test monoallelic expression of genes or monoallelic 
histone modifications at CpG-islands, healthy probands that are heterozygous for one or 
more of these SNPs were identified: In a PCR reaction, the sequence containing the SNP was 
amplified using genomic DNA of healthy probands as template (see 2.16.7 and 2.16.8.). 
Subsequently, the DNA-amplicon was sequenced (see 2.16.12), whereby heterozygosity of 
probands could be detected by double peaks at the SNP location. For analysis of monoallelic 
expression of C13ORF1, B- and T-cells were isolated from probands showing these double-
peaks in their SNP-sequences. These B- and T-cells were used for reverse transcription of 
RNA into cDNA (see 2.16.9), amplification of the SNPs by PCR and subsequent sequence 
analysis. 
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2.16.14 Cloning of PCR-fragments into TOPO TA vectors 
PCR amplification of CpG-islands is limited and amplification efficiency varies in each single 
reaction. Therefore, the 13q14-CpG-islands were divided into 1 kb parts, and primers were 
designed to amplify these parts in PCR reactions. These 1 kb-PCR-fragments of the CpG-
islands C, D and E subsequently were cloned into TOPO TA-vectors for stable reamplification. 
The cloned PCR-fragments of the three CpG-islands were also included in a CpG-island array 
produced by B. Radelwimmer (DKFZ, Division Molecular Genetics). 
TOPO TA cloning is a patented technology from Invitrogen (Invitrogen, Karlsruhe) for 
inserting PCR products directly into a TOPO vector. These vectors have topoisomerases 
covalently linked at their ends that twist the insert-DNA into the vector within minutes. TOPO 
TA cloning was used to directly clone the gene-specific PCR amplified products into vectors 
for sequencing and for re-amplification. Typically, 6 μL of cloning reaction consisted of 2 µL 
of purified PCR product, 1 μL of 1.2 M NaCl; 0.06 M MgCl2, 0.5 μL of TOPO TA-vector and 
2.5 μL H2O. Cloning reactions were incubated at RT for 20 min. Afterwards, 3 μL of the 
completed cloning reactions were used to transform one vial of TOP10 chemically competent 
cells (Invitrogen). 
2.17 BioCOBRA 
DNA-methylation at 13q14.3 was determined by BioCOBRA, a modified protocol for 
Combined Bisulfite Restriction Analysis (COBRA) that incorporates an electrophoresis step in 
microfluidics chips. All BioCOBRA experiments discussed in this thesis were carried out by 
Angela Philippen (University Hospital Ulm, AG “Mechanism of Leukemogenesis”) and data 
presented here is courtesy of A. Philippen. 
In order to support or exclude the DNA-methylation data obtained by aPRIMES (see below) 
data generated by BioCOBRA was included in the results and discussion chapters. The 
BioCOBRA experiments were performed as described in (Brena et al., 2006) using the 
REPLI-g Kit, the QIAamp DNA Mini Kit (Qiagen, Hilden) and SSsI methylation. 
2.18 Fluorescence in situ hybridization (FISH) 
Fluorescent in situ hybridization (FISH) is a cytogenetic technique that is used to detect and 
localize the presence or absence of specific DNA sequences on chromosomes. The 
fluorescent probes bind to those parts of the chromosome to which they show a high degree 
of sequence similarity. Afterwards, fluorescence microscopy is used for detection of probe 
hybridization to chromosomes. The probes used in FISH are mostly derived from DNA-
fragments that are cloned as part of bacterial artificial chromosomes (BACs). Short 
fragments from these BACs are amplified by PCR and further translated into FISH-probes. 
Construction of probes needs to fulfil several requirements; which include that the probe has 
to be long enough to hybridize specifically to its target and not to any similar sequence; 
while it should not be too large to impede the hybridization process, furthermore it has to be 
tagged directly with fluorophores that can be targeted by antibodies or biotin (Lichter and 
Ried, 1994). 
For preparation of probes, nick translation and PCR with labelled nucleotides was used. 
Then, an interphase or metaphase chromosome preparation is produced. The chromosomes 
are firmly attached to glass slides and repetitive DNA sequences are blocked by addition of 
short DNA-sequences (CotI DNA) to the sample. The probe is applied to the chromosomal 
DNA on the slides and incubated for ~12 hours while hybridizing. Several wash steps remove 
all unhybridized and partially hybridized probes. The results are then visualized and 
quantified using a microscope that is capable of exciting the dye and recording images. 
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2.18.1 Preparation of FISH probes 
The conventional method for generation of labelled DNA probes is the so-called nick-
translation. DNA is incubated with a limited amount of DNase I, which introduces on the one 
hand single strand breaks (i.e. “nicks”) into the DNA. On the other hand, digestion with 
DNase I leads to delimited double strand breaks, which in turn generates short DNA 
fragments. The enzyme DNase I generates free 3’- and 5’-ends of DNA, which are necessary 
for DNA polymerase action. The latter enzyme is also included in a nick translation reaction, 
because it mediates the incorporation of labelled nucleotides into the DNA sequence. In nick 
translations, template DNA sequences are used to generate short labelled DNA probes for 
FISH, carried out by the combined action of DNase I and DNA polymerase. 
DNase I, polymerase digestion and labelling of template DNA was allowed for at least 1 h at 
15°C in a 100 µL reaction volume including 10 µL NT-buffer, 10 µL of the fluorophores, 
10 µL of 0.1x Mercaptoethanol, 4 µL of DNA-polymerase (1 U/µL) and 4 µL of 1:4000 diluted 
DNase I (10 U/µL). To control digestion efficiency, the DNA was denatured for 2 min at 
100°C and analyzed by agarose gel electrophoresis. The DNA-fragments can be further used 
as probes if they are digested to a size of around 300 to 600 bp. DNase I was inactivated by 
addition of 2 µL 0.5 M EDTA and 1 µL 10 % SDS and incubation at 68°C for 10 min. 
Nonetheless, the remaining enzymes and buffers had to be removed and DNA probes were 
isolated by custom prepared sephadex-columns. These columns were filled with glass wool 
soaked with sephadex buffer, which is prepared by 30 g of sephadex in 500 mL 1x column 
buffer. The probes were applied to the prepared sephadex columns and centrifuged. Only 
DNA-fragments can move through the packed sephadex glass wool within the columns and 
thus DNA was separated from the enzymes. The FISH-probes were transferred to fresh 
tubes and stored at -20°C until further use. For FISH experiments in this work a centromeric 
X-chromosome probe was prepared and labelled with the fluorophore Rhodamine and a 
centromeric Y-chromosome probe was labelled with FITC. 
2.18.2 Preparation of interphase chromosomes 
Around 5 to 10 million cells were extracted from cell cultures and remaining cell culture 
medium was removed by washing in 1x PBS. After centrifugation at 1200 rpm at RT for 
10 min, cell pellets were resuspended in 1 mL 1x PBS. 300 mL of these suspensions were 
applied to poly-L-lysine coated glass slide by a Cytospin3 centrifuge (Shandon). Cells were 
subjected by 5 min Cytospin3-centrifugation at 500 rpm at RT and pre-fixed by incubation in 
dehydrating ethanol dilution series. The interphase chromosomes were incubated in 70 %, 
90 % and absolute ethanol for 5 min each and stored at -70°C. 
2.18.3 Preparation of metaphase chromosomes 
In order to prepare metaphase chromosomes, cultured cell lines are arrested in cell cycle by 
addition of 0.6 % (v/v) colcemid and incubation for 90 min at 37°C and 5 % CO2. Colcemid 
was removed by gentle centrifugation at 1010 rpm and discarding of the supernatant. The 
cell pellets were carefully resupended in 12 mL pre-warmed 1x hypotonic buffer and 
incubated at 37°C for 30 min. The hypotonic buffer was removed by gentle centrifugation at 
860 rpm at RT for 10 min, the supernatant was discarded and pellets were carefully 
resuspended in 2 mL of fixative, which was freshly prepared by combination of methanol and 
acetic acid in a 3:1 ratio. These prepared metaphase chromosomes were incubated for at 
least 30 min to a maximum of 4 h at -20°C followed by gentle centrifugation at 860 rpm and 
RT for 5 min. Pelleted metaphase chromosomes were washed with fixative and centrifuged 
as described above for three times before they were finally resuspended in around 2 mL of 
the fixative and brought onto glass slides in single drops coming from a disposable pipette. 
The glass slides were prepared prior to metaphase dropping by incubation in absolute 
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ethanol and subsequent washing in ddH2O to prepare the surface in such that metaphase 
chromosomes are enabled to spread on the surface of the glass slides. 
2.18.4 FISH protocol 
The pre-fixed metaphase or interphase chromosome slides were dehydrated by incubation in 
ethanol dilutions, starting with 70 % ethanol, to 90 % ethanol to absolute ethanol for 5 min 
each at RT. Pepsin digestion was taken out by incubation of slides in 0.01 N HCl including 
1 mg/mL pepsin at 37°C for 3 min. Residual pepsin or HCl was washed away by incubation 
in 1x PBS for 10 min. Subsequently, slides were post-fixed in 1x PBS containing 10 % (v/v) 
PFA for 5 min at 4°C and washed again in 1x PBS for 10 min. Another step of dehydration in 
three ethanol dilutions at RT as described above was followed by air-drying of slides for 5-
10 min and final incubation at 63°C for 20 min. In order to denature the DNA fixed on the 
slides, they were incubated in 49 mL formamide, 7 mL 20x SSC and 14 mL ddH2O at pH 7.0 
for 2 min and 10 s at 65°C. Prior to application of the respective probes, a third dehydrating 
dilution series with 70 %, 90 % and absolute ethanol for 5 min in each dilution at 4°C was 
carried out. Probes were applicated onto the slides and both were incubated overnight at 
37°C in a humid chamber to allow hybridization. 
Centromeric probes for X and Y chromosomes were precipitated together with 3 µL human 
CotI DNA and 7 µL salmon sperm DNA in 1/20 volume 3 M NaAc and 2.5 volumes absolute 
ethanol for 30 min at -80°C. The probe was precipitated by centrifugation at 13.000 rpm and 
4°C for 20 min, washed with 70 % ethanol and finally dried for 10-15 min at 37°C. In order 
to denature the probe-DNA, de-ionized formamide was added as well as HybMix buffer and 
denaturing was enabled by incubation at 75°C for 6 min. After short incubation at 4°C the 
denatured single-stranded probe DNA was applied to the denatured single-stranded DNA on 
the slide and hybridization was allowed at 37°C overnight. 
Hybridized slides were incubated in Wash A buffer at 42°C for 10 min and three times for 
5 min, whereby after each incubation step the buffer was exchanged. Afterwards, the 
hybridized slides were incubated three times for 5 min at 42°C in pre-warmed Wash B 
buffer. Prior to probe-detection the single stranded DNA on the slides was blocked in 
blocking buffer for 30 min at 37°C in a humid chamber. Subsequently, probe hybridization 
was detected by addition of detection buffer, of the dyes FITC coupled to avidin and antiDig-
Rhodamin and by incubation for 30 min 37°C in the humid chamber. Unbound dyes and 
detection buffers were removed with Wash C buffer added three times for 5 min at 42°C. 
The nuclei were dyed by DAPI, which was contained in the used mounting medium 
(Vectashield). The results were then visualized and quantified using a fluorescence detecting 
microscope that was capable of exciting the dyes, and images were recorded. 
2.19 Microarray based methods 
2.19.1 The CpG-island microarry includes 13q14-CGI clone set 
The CpG-island microarray was designed and constructed by Bernhard Radlwimmer and 
colleagues and included in addition to the described clone library, clones from CpG-islands of 
chromosomal arms 13q and 17p. For the construction of the CpG-island-(CGI)-microarray a 
human library consisting of 10,560 bacterial clones harboring DNA sequences enriched for 
CGIs was purchased from the UK HGMP (http://www.hgmp.mrc.ac.uk/). This clone set is 
part of the original CGI-library, which was generated by Cross et al. (1994). To amplify the 
CGI sequences, library aliquots were grown in 1 mL LB-media including ampicillin 
(50 mg/mL) overnight at 37°C. Subsequently, PCRs were performed in a 96-well format 
(MWG, Ebersberg, Germany) using 2 mL of bacterial culture supplemented with 10 % DMSO, 
180 mM dNTPs, 150 nM of each primer, 1.8 mM MgCl2 and 2 U Eurotaq Polymerase (Biocat, 
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Heidelberg, Germany). Thirty-five amplification cycles were performed including denaturing 
at 94°C for 30 s, annealing at 58°C for 30 s and elongation at 72°C for 60 s. The primers 
used for amplification were pGEM-forward and pGEM-rev. All CpG-island-sequences were 
reamplified by using 5 mL of product of the first PCR as a template for a second PCR under 
identical conditions, because the second PCR resulted in more homogenous product 
quantities for microarray printing (Pfister et al., 2007). 
The CpG-island-clones of 13q14.3 were generated by PCR-amplification specific for 1 kb 
sized parts of the three CpG-islands C, D and E in the region. The CGIs were of variable 
sizes, which resulted in different numbers of fragments: six parts for CGI C; eight parts for 
CGI D and 12 parts for CGI E; all parts were of a size of about 1 kb (range: 900 bp to 
1.3 kb). These PCR-generated 1 kb-CGI-parts of 13q14 had to be cloned into TOPO TA 
vectors to be able to re-amplify them by PCR, which was difficult when using genomic DNA. 
The CGI-parts were amplified under the same PCR conditions described above to generate 
the clones that were finally printed onto the microarray. These CGI-microarrays that included 
the clones for the 13q14-CGIs C, D and E were used together with hybridization conditions of 
the matrixCGH protocol (see below) for all ChIP-on-chip analysis. 
The CGI-microarray production itself was carried out by B. Radlwimmer and colleagues. 
Therefore, only a brief description of the printing procedure should be included here: For 
microarray printing, 30 mL of PCR products was dried in a vacuum centrifuge and 
resuspended in 12 mL spotting buffer (3x SSC, 1.5 M betaine). The PCR products were 
printed onto amino-silane-coated CorningTM Gaps II slides (Corning, Acton, USA) in triplicates 
using a printing robot (OmniGrid, GeneMachines, San Carlos, USA) and 48 (4x12 
configuration) Telechem SMP3 pins (Telechem International, Sunnyvale, USA) at 20°C and 
40 % humidity. After printing, slides were UV cross-linked and baked for 2 h at 80°C (Pfister 
et al., 2007). 
2.19.2 ChIP on chip - (input vs precipitate) 
ChIP-on-chip differs from ChIP and qPCR only in the method of analysis of ChIP-DNA (see 
also Figure 2-3). ChIP-DNA is eluted after reversal of cross-links and the 5’- and 3’-ends are 
repaired with DNA polymerase to generate blunt ends. A linker is applied to each DNA 
fragment to enable PCR amplification. Then, a fluorescent label (Cy3) is incorporated during 
PCR amplification of ChIP precipitate-fractions. Similarly, an aliquot of input DNA is labelled 
with a second fluorophore, Cy5. The two samples are mixed and hybridized onto the CGI-
microarray. In this dual-color approach, enrichment of a specific histone modification is 
established when intensity of precipitate-DNA significantly exceeds that of the input-DNA on 
the array. Statistical analysis software and personal evaluation determine the significance of 
enrichment of the precipitated modification to a specific CGI-regulated gene/motif in the 
region examined. 
The first step in ChIP-on-chip analysis was the labelling of the ChIP-DNA according to the 
matrixCGH-protocol. For the analysis on the CGI-microarray the ChIP-fractions input and 
precipitate of one ChIP-experiment were hybridized onto the CGI-microarray. The labelling of 
genomic DNA-fragments was carried out in a three step protocol. At first, a reaction volume 
of 75 µL per fraction/sample including 500 ng ChIP-DNA, 30 µL 2.5x random primer and 
22 µL 5 M betaine (ad 75 µL ddH2O), which was denatured for 10 min at 95°C and incubated 
at 4°C for 2 min. Then, 7.5 µL 10x dNTPs were added, whereby of dATP, dGTP and dTTP 20 
µL of 100 mM were included, but only 10 µL of 100 mM dCTP, because additional 0.75 µL of 
the dye coupled to dCTP was added. The dye Cy3 was used for the precipitate-fraction and 
the dye Cy5 for the input-fraction. Addition of 0.75 µL exo-Klenow (1 U/µL), the large 
fragment of the E. coli DNA polymerase I and incubation for 12-16 h at 37°C lead to 
incorporation of the dyes into the amplified DNA. This reaction generally yielded 10-12 µg 
labelled genomic DNA fragments. After labeling, equal amounts of Cy3 labeled precipitate-
DNA and Cy5-labeled input-DNA together with 180 µg of CotI-DNA, which blocks repetitive 
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sequences, were combined and precipitated. Precipitation of DNA was enabled by addition of 
1/10 volume of 3 M NaAc (pH 5.2) and 2.5 volumes ethanol and incubation at -80°C for 15-
20 min. The labeled DNA was precipitated by centrifugation at 13.000 rpm and 4°C for 30 
min. Afterwards the DNA was dried and used for hybridization. 
 
For hybridization the labelled DNA samples have to be solved in UltraHyb buffer, of which an 
aliquot was heated to 70°C whilst precipitation of the labeled DNA. 130 µL of UltraHyb buffer 
was added to each DNA-sample and vortexed. To resuspend the DNA pellets in UltraHyb 
buffer, the mixture was incubated for 30 min at 42°C and 500 rpm on a thermo-mixer and 
vortexed every 10 min. Meanwhile, the CGI-microarray was blocked for 15 min at 50°C in 
matrixCGH blocking buffer. The slides were washed twice in ddH2O at RT and dried in 
50-mL-Falcon tubes by centrifugation at 1000 rpm for 3 min. After complete resuspension of 
the DNA-pellet in UltraHyb buffer, the samples were denatured at 75°C for 10 min and re-
annealing was allowed by cooling samples down to 42°C prior to hybridization. 
Subsequently, the DNA mixtures were applied to the microarrays mounted in a GeneTac 
Hybridization Station. The hybridizations were performed for a minimum of 36 h at 42°C in 
the hybridization station. Thereafter, the microarrays were automatically washed at 37°C 
with 2x SSC including 0.05 % (v/v) Tween-20 for 5 min, with Wash A buffer, which includes 
50 % (v/v) formamide, 2x SSC and 0.1 % (v/v) Tween-20, for 5 min, and again with 2x SSC 
including 0.05 % (v/v) Tween-20 for 5 min. Immediately after the final washing step, the 
slides were unmounted and transferred to a glass cuvette containing 2x SSC at 43°C. Slides 
were incubated on a shaker at 80 rpm for 10 min under light-protection. Subsequently, slides 
were transferred to 1x PBS and incubated for 10 min at RT on a shaker at 20 rpm. Finally, 
slides were dried by centrifugation in 50-mL-Falcon tubes for 3 min at 1000 rpm and 
immediately scanned. 
The microarrays were scanned with an Agilent DNA microarray scanner (Agilent 
Technologies, Palo Alto, USA) and images were analyzed using GenePix Pro 6.0 software 
(Axon Instruments, Burlingame, USA). Global normalization was performed in three steps. 
First, a normalization for print-order effects using the loess smoother, as described in (Smyth 
et al., 2003) was applied. In the second step, within-array normalization was done to 
normalize the log2-ratios for each array separately by the use of print-tip loess (Smyth et al., 
2003). Third, to normalize between arrays, quantile normalization was performed. All these 
normalization steps were carried out using zero weights for previously filtered spots and 
according to the instructions of Stefan Pfister as was previously described in (Pfister et al., 
2007). 
 
Data analysis by Ingenuity software 
For analysis of 13q14-data, resulting from ChIP-on-chip experiments with the CGI-
microarray, the web-based software Ingenuity (www.ingenuity.com) was used, which 
detects known pathways and networks the genes regulated by CGI-clones are taking part in. 
These pathways were used as quality control for ChIP-on-chip, to evaluate if their activation 
or inactivation, implied by H3K4me2 or macroH2A-enrichment, respectively, made sense in 
the hematopoietic samples. For genes with described functions the software can analyze 
molecular interactions to other entities, shows functional and disease relationships or the 
occurrence within a canonical pathway. Deregulated genes had to fulfill the following criteria 
to be analyzed by Ingenuity software: The probability to be differentially marked 
(“expressed” within the software) had to be at least 98 %. In addition, the deregulation had 
to be at least 1.5-fold. For the analysis RefSeq numbers were extracted from the microarray 
clone data base within the UCSC-browser (http://data.microarrays.ca/cpg/index.htm) for 
accordant clones. In case no RefSeq number was available, the GenBank number was used 
for identifying genes. Uploaded IDs are then mapped to an Entrez/Gene based database. 
This allows the relation of any uploaded ID to a gene/protein entity in the Knowledge Base 
(KB). Mapped IDs are then queried for molecular interactions to other entities within the KB. 
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In case of interactions to other entities, these networks are displayed in sketches. The 
generated pathways to which most IDs map are ranked by the software. For ChIP-on-chip 
experiments measuring an active chromatin mark, i.e. H3K4me2 enrichment, pathways 
associated with the hematopoietic system that were ranked among the top five pathways 
were considered as validation for the experiment. 
 
To further validate ChIP-on-chip experiments there was no direct and simple control in 
hands, instead literature databases were searched for similar experiments with similar 
results. Seven CpG-island-sequences found to be H3K4me2-enriched in a study by Miao and 
Natarajan (2005) were also on the CpG-island (CGI)-microarray used in the present study. 
Consequently, the enrichment ratios at these seven sequences determined by Miao and 
Natarajan (Miao and Natarajan, 2005) were used as control ratios for H3K4me2-enrichment 
in ChIP-on-chip experiments. 
2.19.3 Array-based profiling of reference-independent methylation 
status (aPRIMES) 
The aPRIMES experiments presented here were carried out in collaboration with Verena 
Fleig. V. Fleig performed hybridization of CLL-tumor samples and B-cell control samples 
according to the protocol described below and acquired and analyzed all genome wide data. 
The data acquired at the same time for 13q14-CGI clones were independently analyzed by 
me and exclusively used in this work. 
In the standard aPRIMES protocol by Pfister et al. (2007) 500 ng genomic DNA was 
restricted to completion with 10 U MseI for 3 h in a final volume of 10 mL in the buffer 
provided by the supplier (New England Biolabs, Beverly, USA). Subsequent heat inactivation 
was carried out at 65°C for 20 min. The MseI-fragments were then subjected to linker-
mediated PCR as essentially described by Klein et al. (1999). Briefly, 1 mL each of 100 mM 
stock solution (MWG, Ebersberg, Germany) primer ddMse11 and primer Lib1 were annealed 
in 1 mL One-Phor-All-Buffer and 3 mL ddH2O. The annealing was started at a temperature of 
65°C and was shifted down to 15°C with a ramp of 18°C/min. At 15°C, 10 mL MseI 
fragments, 2 mL of ATP (10 mM) and 2 mL T4-DNA-Ligase (10 U, Roche) were added, and 
primers and DNA fragments were ligated overnight. Half of the resulting ligated MseI 
fragments were digested with the restriction enzyme McrBC (New England Biolabs, Beverly, 
MA, USA) for 8 h following the conditions recommended by the supplier. The other half of 
the MseI fragments was digested with two methylation-sensitive endonucleases, HpaII 
(recognition site CCGG, 3 h, 37°C) and BstUI (recognition site CGCG, 3 h, 60°C), according 
to the recommendations of the supplier. Digested DNA fragments were then treated with 
1 mL Proteinase K (20mg/mL; Invitrogen, Karlsruhe) for 1 h at 37°C with subsequent heat 
inactivation at 80°C for 10 min. For the following amplification step, 10 mL consisting of 2 
mL 10x Expand Long Template buffer 1 (Boehringer, Mannheim), 1 mL dNTPs (10 mM), 
1 mL Lib1 primer, 1 mL expand long template DNA polymerase mixture (3.5 U/µL; 
Boehringer, Mannheim) and 5 mL ddH2O were added to the 20 mL reaction volume. A MWG 
thermo cycler was programmed to 72°C for 3 min, followed by 20 cycles at 94°C for 30 s, 
62°C for 30 s and 72°C for 90 s. Final elongation was carried out at 72°C for 10 min. The 
PCR products were recovered by ethanol precipitation. DNA was eluted in 30 mL 0.1x TE, 
pH 8 (Pfister et al., 2007). 
Several internal controls are available for aPRIMES: First, spike CGIs from rice were used as 
positive controls for methylation. For this, ten rice CGIs were PCR amplified and printed onto 
the microarray. All sample DNAs for aPRIMES were spiked with ~10 pg of each in vitro 
methylated rice-CGI to control methylation and methylation-sensitive digestion. Mitochondrial 
CGI clones that were present in the original library were used as controls for unmethylated 
and allelically/partially methylated CGIs (Pfister et al., 2007). 
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All Sequence information for CGI clones was obtained from a publicly available database at 
http://data.microarrays.ca/cpg/index.htm. Chromosomal annotation of sequences is based 
on the University of California at Santa Cruz (UCSC) genome database (Freeze, May 2004). 
2.20 Statistical analysis 
Mean values, median values, standard deviations, Student’s t tests, Kolmogorov-Smirnov 
tests and variance of statistical sample sets were calculated in the Excel software (Microsoft, 
USA) by standard formulas included in the software. The statistical analyses performed in 
this study comprised the calculation of p-values to detect significant differences between two 
sample sets. Normalized enrichment values of different sample groups were compared to 
each other by statistical means. All analyzed samples were assigned to distinct (sub-) 
groups, which are listed in Table 2-13. The values for distinct enrichment at several loci that 
belong to one functional element for all samples of one subgroup were analyzed together as 
one sample set in t tests. 
 
Table 2-13: Sample (sub)-groups used for statistical analyses. 
No. Sample group Included samples 
1 CLL H3K4me2-enriched CLL1; CLL2; CLL3; CLL4; CLL5 
2 CLL maroH2A-enriched CLL1; CLL2; CLL3; CLL4; CLL5 
3 Wild type H3K4me2-enriched P1; P2; P3; P4; P5; PB5; PB6; PB7; 
PB17; PB18; PB19 
4 Wild type macroH2A-enriched PL1; PU1; PU2; PB17; PB18 
5 Young wild type H3K4me2-enriched (<45 years) P1; P2; P3; P4; P5 
6 Young wild type macroH2A-enriched (<45 years) PL1; PU1; PU2;  
7 Old wild type H3K4me2-enriched (>45 years) PB5; PB6; PB7; PB17; PB18; PB19 
8 Old wild type macroH2A-enriched (>45 years) PB17; PB18 
9 Wild type B-cells H3K4me2-enriched PB9; PB12 
10 Wild type T-cells H3K4me2-enriched PB9; PB12 
 
Table 2-14 depicts the groups that were compared to each other together with reason for 
comparison and finally, Table 2-15 depicts the analyzed functional elements and the included 
loci of these calculations. 
 
Table 2-14: Sample groups compared by statistical analyses. Numbers of groups are as depicted 
in Table 2-14 
Sample group #1 Sample group #2 Feature/reason 
1 CLL 3 wild type Compare H3K4me2 in CLL vs wild type 
2 CLL 4 wild type Compare macroH2A in CLL vs wild type 
1 CLL 5 young wild type Compare H3K4me2 in CLL vs young wild type 
1 CLL 7 old wild type Compare H3K4me2 in CLL vs old wild type 
2 CLL 6 young wild type Compare macroH2A in CLL vs young wild type 
2 CLL 8 old wild type Compare macroH2A in CLL vs old wild type 
5 young wild type 7 old wild type Compare H3K4me2 in young vs old wild type 
6 young wild type 8 old wild type Compare macroH2A in young vs old wild type 
 
Significant differences (p<0.05) between group 1 and group 2 were determined by Welch’s 
Two sample t-test calculated with the R software package. By using R for calculating p-
values, the software automatically calculated t-values. These t-values were further used to 
determine which sample group contained the higher enrichment. If t>0, the first of the two 
compared groups includes higher values than the second, and if t<0 the second group 
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contains higher values than the first; whereby the t-value itself correlates with the degree of 
value-differences between the two groups. 
 
Table 2-15: Loci included in analyses of functional elements. e = exon; first number depicts 
number of exon of the gene; second number after “.” depicts number of loci within exon 
designed for qPCR. Capitalized letter plus number = CGI and loci within CGI analyzed.  
Functional elements Included loci No. of included loci 
KPNA3 K3e6.1; K3e3.1; K3e1.1 3 
C13ORF1 C13e4.1; C13e3.1; C13e2.1 3 
RFP2 R2e1.1; R2e2.1; R2e3.1 3 
BCMS B1e1.1; B1e2.1; B1e3.1 3 
BCMSUN/DLeu2 B2e2.2; B2e3.1; B2e3.2; B2e4.2 4 
   
CGI A A1; A2; A3 3 
CGI B B2; B3; B4 3 
CGI C C1; C2; C3 3 
CGI D D1; D2; D3; D4; D5 5 
CGI E E1; E2; E3; E4; E5; E6; E7; E12 8 
 
2.20.1 Normal distribution of sample sets 
To fulfill the criteria for statistical t-tests, normal distribution and equal variance of sample 
sets, all analyzed data sets were tested for their distribution and variance. Testing of normal 
distribution was either taken out by visual inspection of qq-plots in the R software or by 
Kolmogorov-Smirnov tests. 
The Kolmogorov-Smirnov test (K-S test) is a nonparametric test of equality of one-
dimensional probability distributions. It was used to compare two samples, because the K-S 
statistics quantify the distance between the empirical distribution functions of two samples. 
The null distribution of this statistic was calculated under the null hypothesis that the 
samples are drawn from the same distribution. These distance values were calculated by the 
K-S formula and compared to standard values. If the calculated value was smaller or equal 
to the standard value a normal distribution of the corresponding sample set was assumed. 
Calculations were carried out in Excel-datasheets for all analyzed combinations of sample 
sets.  
The Kolmogorov-Smirnov statistic, which has the underlying empirical distribution function Fn 
for n = independently and identically distributed observations Xi is defined as: 
 
 
 
2.20.2 Variance of sample sets 
The second criterion for selecting the appropriate t-test was the variance of sample sets. All 
combinations of sample sets were tested for their variance using this function: 
 
 
 
These calculations were carried out in and by the Excel software (Microsoft, USA). The 
formula depicted above describes the population variance of a finite population of the size N, 
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whereby  is the population mean. The variance of tested populations was unequal in all 
cases which is the reason why the Student’s t-test was abolished. Instead, for normally 
distributed sample sets of unequal variance the Welch’s Two sample t-test was applied to 
calculate p-values. 
2.20.3 Welch Two sample t-test 
In statistics, Welch's t-test is an adaptation of Student’s t-test intended for use with two 
samples having possibly unequal variances (Welch, 1947). The Welch’s t-test defines the 
statistic t by the formula: 
 
 
 
where  is the ith sample mean,  is the ith sample variance and Ni is the ith sample size. 
Unlike in Student's t-test, the denominator is not based on a pooled variance estimate. The 
degrees of freedom ν associated with this variance estimate is approximated using the 
Welch-Satterthwaite equation, which was included in the calculations of the R software: 
 
 
 
In this formula νi is Ni−1 and the degrees of freedom are associated with the ith variance 
estimate. 
Using the R software the command “t-test”, computed t and ν together with the t-
distribution to test the null hypothesis that two population means were equal (using a two-
tailed test). In particular, the test yielded a p-value which might or might not give evidence 
sufficient to reject the null hypothesis. The null hypothesis was rejected if p<0.05, which 
corresponds to a tolerated error of 5 %. 
2.20.4 Normalization of ChIP data 
Values determined for CDH12 –CpG-island-promoter sequences were used to normalize data 
generated by H3K4me2-ChIPs and values for HK2-CGI-promoter sequences were used for 
normalization of macroH2A-ChIPs. The normalized values were termed “x-fold enrichment 
versus control sequence”. These control sequences were CDH12 for all H3K4me2-CHIPs and 
HK2 for all macroH2A-ChIPs. X-fold enrichment at all analyzed loci were calculated by the 
equation: 
 
x-fold enrichment vs control = fraction of input (loci)/fraction of input (control) 
 
for qPCR determined values, and by: 
 
x-fold enrichment vs control = ratio (13q-CGI-clone)/ratio (control clone) 
 
for ratios determined by microarray-hybridization of ChIP-DNA in ChIP-on-chip experiments. 
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2.21 Experimental set up 
2.21.1 Analysis of chromosomal region 13q14.3 by several methods 
Figure 2-3 shows exact localization of fragments analyzed by diverse methods for DNA-
methylation (aPRIMES, BioCOBRA) and enrichment of two histone modifications (ChIP; ChIP-
on-chip) in this work. 
The most detailed analysis including several fragments analyzed in at least three exons of 
the five genes and at least three fragments analyzed in CpG-islands of the critical region in 
13q14.3 was carried out by ChIP and qPCR analysis. Fragments analyzed by qPCR ranged in 
size from 50-250 bp. The fragments of CpG-islands C, D and E that are present on the CpG-
island-array, span the respective CpG-island in 1 kb-tiling parts. The CpG-island-microarray 
was used for ChIP-on-chip and aPRIMES analyses. BioCOBRA analyses were performed by A. 
Philippen (see chapter 2.17) and she analyzed one to three fragments within each of the five 
CpG-islands of 13q14.3 and determined restricted DNA-methylation at these fragments. 
Sequence analysis was performed for the three indicated SNPs in Figure 2-3 (by *1-3) in 
heterozygous samples to analyze allele-specific enrichment of the two histone modifications 
(*2 and *3), or to detect monoallelic expression (*1; C13ORF1). 
 
 
Figure 2-3: Overview of localization of analyzed fragments in chromosomal region 
13q14.3 by several methods. 
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3 Results 
The aim of the present study was to identify the epigenetic regulatory mechanism that 
controls expression of candidate tumor suppressor genes from chromosomal region 13q14.3 
and has lost its function in CLL cells. Part of this region is lost in over 50 % of patients 
(Stilgenbauer et al., 1998), pointing to the involvement of the critical region in 13q14.3 in 
the development of CLL. In order to identify epigenetic regulatory elements chromatin 
immunoprecipitation (ChIP) was established and specific epigenetic modifications at CpG-
islands and genes of the region were quantified. Identification of the epigenetic code at 
13q14.3 should elucidate the epigenetic regulatory mechanism of the region and its 
relevance for the pathogenesis of CLL. 
3.1 Establishment and validation of chromatin 
immunoprecipitation (ChIP) 
Chromatin immunoprecipitation (ChIP) is a powerful tool to detect and quantify protein DNA 
interactions and chromatin modifications in different tissues. 
 
 
Figure 3-1: Overview of the outline and optimized steps of ChIP assays. Right side 
(blue): steps of the ChIP protocol that were optimized during this work. 
Numbers in brackets indicate chapters that describe optimization of 
respective steps. 
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In order to use ChIP to analyze chromatin modifications in CLL cells, the protocol needed to 
be adjusted to hematopoietic cells, which is described in this first chapter 3.1. A general 
outline of the ChIP protocol together with optimized steps is summarized in Figure 3-1. 
3.1.1 Preparation of chromatin – nChIp versus xChIP 
Two different protocols for ChIP were tested: “nChIP” (O'Neill and Turner, 2003) and 
“xChIP” (Orlando, 2000; Spencer et al., 2003; see chapter 2.14 for detailed protocols). The 
first step in the outline of the ChIP protocol (see Figure 3-1) had to be optimized in order to 
produce sufficient quality and quantity of chromatin from whole cell extracts for the following 
steps in the ChIP procedure. Using different buffers and different centrifugation steps, 
chromatin was prepared from whole cell extracts. A total of five approaches using different 
chromatin preparation conditions were tested, in order to find out the optimum condition for 
preparing chromatin with high quality and quantity. The resulting protein concentrations, 
served as a control for the efficiency of the respective approach (Table 3-1). 
 
Table 3-1: Protein concentrations measured after chromatin preparation. a-e: Protein concentrations 
[µg/µL] determined after use of different buffers and protocols for chromatin preparation. 
Abbreviations: nd: not done, T: total chromatin, S: soluble chromatin, 10’: digested 
chromatin, Uab: supernatant after precipitation with antibody (unbound); CPab: 
precipitate of indicated antibody, Umock: mock supernatant, CPmock: mock precipitate. 
(see chapters 2.9.1-2.9.3 and chapter 2.14, for composition of buffers and detailed 
protocol). 
a) Total chromatin preparation (nChIP-buffers/protocol)       
T MN10' Input cleared Input Uab CPAb Umock Cpmock Tissue Antibody
1.84 2.06 1.90 0.68 0.83 0 0.62 0.08 HL60 H3K9me3 
0.25 0.85 0.47 0.56 0.65 0.01 0.48 0 HL60 H3K4me3 
0.25 0.85 0.47 0.56 0.84 0.04 0.48 0 HL60 H3 
0.32 0.81 0.36 0.54 0.65 0.02 0.55 0.12 Jurkat H3 
0.42 1.58 0.77 0.98 0.73 0.06 0.89 0.12 Jurkat H3K4me3 
            
b) Without SDS-lysis-buffer preparation (nChIP-buffers+sonication-protocol) 
S 10' Input cleared Input Uab CPAb Umock Cpmock Tissue Antibody
0.75 nd 0.12 0.12 0.40 0 0.17 0 HL60 H3K4me3 
1.27 nd 0.31 0.24 0.39 0 0.21 0 Jurkat H3K4me3 
          
c) SDS-concentration down; Input diluted ( xChIP-protocol with minimal SDS) 
S 10' Input cleared Input Uab CPAb Umock Cpmock Tissue Antibody
0.33 1.18 0.53 0.64 0.76 0 0.65 0 HL60 H3K4me3 
0.34 1.65 0.76 0.79 0.83 0 0.75 0 Jurkat H3K4me3 
          
d) Without SDS-lysis buffer (xChIP-protocol/buffers but without any SDS) 
S 10' Input cleared Input Uab CPAb Umock Cpmock Tissue Antibody
nd nd 0.58 0.69 0.69 1.33 0.65 1.49 HL60 H3K9me3 
nd nd 1.68 1.43 1.39 0.32 1.14 0.41 Jurkat H3 
          
e) Nuclei extraction prep (xCHIP-protocol + nuclei extraction buffers)   
T 10' Input cleared Input Uab CPAb Umock Cpmock Tissue Antibody
4.95 nd 2.67 2.73 2.17 1.18 2.08 0.98 HL60 H3 
2.32 nd 0.75 0.77 1.29 0.69 1.06 0.63 HL60 H3K9me3 
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In the starting ChIP-fractions (i.e. “total”, “soluble” and “MN10’”) protein concentrations 
ranging from 0.25 to 2 µg/µL chromatin were measured. In the first three approaches, 
different buffers were used in order to increase chromatin amounts and quality (Table 3-1 a-
c). Nearly half of the chromatin was lost during processing of “input chromatin” fractions 
(concentrations ranged from 0-0.05 µg/µL) and no protein could be precipitated. Testing the 
xChIP protocol without SDS in the lysis buffer, which is listed in Table 3-1d, led to unspecific 
background precipitation that was higher than precipitation by the indicated antibodies 
themselves (background = “CPmock”: 1.48 µg/µL versus precipitate = “CPab”: 1.3 µg/µL 
and CPmock: 0.41 µg/µL versus CPab: 0.3 µg/µL; Table 3-1d). Fractions prepared with 
appraoch e, which combined the standard xChIP protocol and a nuclei extraction protocol, 
contained sufficient chromatin in input-fractions to subsequently precipitate protein by 
specific antibodies (0.6-1 µg/µL in CPab; Table 3-1e). 
 
 
Figure 3-2: 1 %-agarose gel pictures of DNA isolated from ChIP-fractions analyzed to 
control chromatin preparation. a) DNA results/amounts by xChIP-protocol 
using 3 different amounts of HL60 cells, 1: 1*108, 2: 1*107 & 3: 6*106 
cells; b) same as (a) except for use of nChIP protocol; c) DNA amounts 
after nuclease digestion and input preparation without precipitation, left 
gel: HL60, right gel: Jurkat cells. 
 
DNA content of ChIP-fractions needed to be controlled in parallel to protein levels as ChIP 
implies precipitation of both proteins and DNA. DNA was isolated from all ChIP-fractions (see 
Table 3-1) and analyzed on 1 %-agarose gels by electrophoresis (Figure 3-2). Using the 
xChIP standard protocol (Spencer et al., 2003), DNA could be isolated from all fractions 
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except from precipitates (Figure 3-2). The amounts of DNA varied between approaches 1, 2 
and 3 with different numbers of starting cells being used. Variations of DNA amounts were in 
accordance with the various starting numbers of cells. Comparable amounts of DNA could be 
isolated in all fractions, except for precipitates and mock-precipitates (Figure 3-2a). The use 
of the standard nChIP-protocol (O'Neill and Turner, 2003) led to quite diverse results. Hardly 
any DNA could be detected in the different fractions, regardless of the amount of cells being 
used as starting material (Figure 3-2b). In nChIP-approaches, chromatin was lost during 
preparation of actual input-fractions as seen by testing length of enzymatic digestion (Figure 
3-2c). DNA could be isolated from each digested fraction (Figure 3-2c) but no or not enough 
DNA was contained in input or cleared input fractions. Ineffectiveness of enzymatic digestion 
was visible in total ChIP-fraction in Figure 3-2c that contained whole undigested genomic 
DNA showing as one band at the same height as the 10 kb marker on the left. Preparation of 
chromatin by nChIP-protocol often failed to produce any input-chromatin for actual 
precipitation (Figure 3-2c). It was not possible to prepare chromatin by the nChIP protocol, 
as DNA levels were too low. 
3.1.2 To crosslink or not to crosslink? 
 
 
Figure 3-3: 1 %-agarose gel and Western blot pictures showing ChIP-fractions’ content 
of DNA and protein. ChIP-fractions: 1: total; 2: input; 3-5: preclearing 
beads; 6: (pre)cleared input; 7: unbound; 8: precipitate; 9: mock unbound; 
10: mock precipitate. a) DNA fractions after xChIP. Testing different 
crosslinking conditions: upper panel: 20 min at 4°C, lower panel: 10 min at 
25°C. b) DNA fractions after xChIP without cross-linking; c) Western blot 
analysis of xChIP protein fractions analog to (a). d) Western blot analysis 
of xCHIP- protein fractions analog to (b); precipitating antibody (a-d): α-
H3K9me3. Detection of H3K9m3-amounts in (c) and (d) with α-H3 antibody 
(15 kDa); (a-d): left side: HL60 cells, right side: Jurkat cells. 
 
  ChIP establishment and validation 
 69
The protocols for nChIP and xChIP differ in how the chromatin is prepared (chapter 3.1.2) 
and also in fixation of chromatin, which is only included in the xChIP protocol. Two different 
conditions for the formaldehyde cross-linking step of the xChIP protocol were tested and 
subsequently, DNA and protein content of all xChIP-fractions were analyzed (Figure 3-3). 
DNA content after cross-linking for 20 minutes at 4°C was high and almost identical in all 
fractions (Figure 3-3a, upper panel). DNA content after cross-linking for only 10 minutes at 
room temperature was strikingly lower (Figure 3-3a, lower panel). The variation in the size of 
DNA-fragments was higher with cross-linking as compared to no cross-linking (Figure 3-3a-
b). To test the necessity of the cross-linking itself, the xChIP protocol was taken out 
according to the outline in Figure 3-1, but without the formaldehyde cross-linking step. 
Subsequently, DNA fragments generated by xChIP without cross-linking (Figure 3-3b) ranged 
in size only little between 100 and 400 bp, compared to a range of 100 bp to 1 kb generated 
by xChIP including cross-linking (Figure 3-3a). Moreover, the DNA amount was substantially 
higher in fractions prepared from xChIP approaches that included cross-linking (Figure 3-3a-
b). The protein amounts were found to correlate with the DNA content (Figure 3-3), as high 
amounts of protein could be generated by xChIP-protocol including the cross-linking step 
(Figure 3-3c). Surprisingly, there was also considerably less unspecific binding of cross-linked 
chromatin to beads during preclearing (fractions 3 to 5 in Figure 3-3c-d) compared to 
chromatin without cross-links (Figure 3-3c-d). The benefit of formaldehyde cross-linking, a 
step included in the standard xChIP protocol is twofold, as it stabilizes chromatin and 
somehow reduces unspecific binding in ChIP procedures. 
3.1.3 Chromatin fragmentation – Native nucleosomes versus 
sonicated chromatin fragments 
Chromatin prepared according to the nChIP-protocol was fragmented by Micrococcus 
nuclease (MNase) digestion. In contrast to nChIP, chromatin prepared according to the 
xChIP protocol was stabilized by cross-linking it prior to fragmentation (chapter 3.1.3) and 
therefore could be fragmented into 100 to 1000 bp sized molecules by ultra-sonication. 
Figure 3-4a shows so-called “nucleosomal ladders” resulting from fragments of different 
length of nucleosomes (see chapter 2.14.1) of different nChIP control fractions. Length of 
nuclease digestion incubation time (2 to 10 minutes; Figure 3-4a left) had great impact on 
the amount of DNA later to be isolated. The DNA content of xChIP-fractions which were 
fragmented by ultra-sonication (Figure 3-4b) was higher in all fractions. High amounts of 
DNA fragments that ranged in size from 100 bp to 1 kb were isolated from xChIP, also in the 
precipitate xChIP fractions (insets in Figure 3-4b). The main difference of the two used ChIP-
protocols was based on the fragmentation of chromatin in both procedures. In nChIP, native 
chromatin fragments according to nucleosomes should be generated by enzymatic digestion. 
The performance of the nuclease used to fragment chromatin is highly dependant on salt 
concentrations, amount of chromatin, amount and processivity of the nucleases, for 
instance. On the other hand, ultra-sonication that was performed in xChIP to fragment 
chromatin was a non-biased random process that fragments prior stabilized chromatin into 
reproducible sizes and size ranges once the conditions were optimized. In contrast, the 
enzymatic fragmentation that had the advantage of producing native chromatin-fragments 
according to nucleosomes was highly variable in its performance. 
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Figure 3-4: 1 %-agarose gel pictures to monitor DNA amounts isolated after chromatin 
fragmentation, testing different methods to chop chromatin. a) 
nucleosomal ladders of different nChIP-fractions after digestion with 
MNase. b) DNA fragments of xChIP-fractions after sonication. Insets: 
higher exposure of same DNA agarose gels. 
 
3.1.4 Optimization of the precipitation procedure 
For the precipitation of chromatin-antibody complexes by protein A/G coupled beads, five 
different approaches (bead-type and preclearing conditions) were tested. The aim was to 
achieve the lowest unspecific binding to beads and highest precipitation efficiency. Specific 
precipitation of antibody-chromatin complexes without co-precipitation of unspecific 
chromatin was achieved by use of protein A agarose/salmon sperm DNA pre-mix (Upstate, 
USA) and three times preclearing for 15 minutes at 4°C conditions (lowest line in Figure 
3-5). In this approach, negative control fractions contained no chromatin (black boxes and 
dotted black boxes), while antibody-chromatin complexes were specifically precipitated 
(green box, Figure 3-5). 
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Figure 3-5: Testing of different beads and preclearing conditions to optimize 
precipitation efficiency and minimize background. “beads”: different types 
of beads (sepharose/agarose) and coupled proteins (protein A/G) tested. 
 
3.1.5 Performance of antibodies – Which antibodies precipitate 
chromatin? 
Performance of antibodies is crucial for successful ChIP. It was desirable for antibodies to 
precipitate target chromatin efficiently and detect target protein in Western blot analyses. 
Five of six tested antibodies precipitated target proteins (“+”-bands in Figure 3-6a), except 
for anti-H4. Some antibodies precipitated protein in IPs but no chromatin in ChIP 
experiments, for example anti-H3K4me3 and anti-H3K9me3 (Figure 3-6a-b). Twelve 
antibodies were tested in ChIP for efficient precipitation of target chromatin (Figure 3-6b). 
Anti-Hp1γ (Figure 3-6b) did not detect protein with the expected size in Western blot 
analyses. Anti-CTCF, anti-H3K9me3 and anti-H3K27me3 did not enrich any target chromatin 
in precipitates (see Figure 3-6b). Of the twelve antibodies tested only three precipitated their 
targets sufficiently and reproducible, these were anti-H3K4me2, anti-macroH2A1.2 and anti-
H3 (Figure 3-6b). 
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Figure 3-6: Western blot of IP and ChIP-fractions check of twelve different antibodies. 
a) IP; +: precipitated protein, -: mock, control: cell lysate; Western blot 
(WB) detection with same antibodies used for initial IPs; sizes of proteins in 
WB: H3: ~15 kDa, H3K4me3 & H3K9me3: ~17 kDa, H4: ~11 kDa and 
Ikaros: 50-60 kDa; b) ChIP; relevant Western blot bands were marked with 
numbers: 1 - input, 2 - precipitate, 3 – mock precipitate; sizes of proteins: 
see (a) and CTCF: 82+160 kDa, E2F4: 50-60 kDa, HP1γ: 25 kDa; 
H3K4me2, H3K9me2 & H3K27me3: ~17 kDa and macroH2A1.2: ~42 kDa. 
HL60 cells were used (unless otherwise indicated); arrows indicate target 
proteins. 
 
 
  ChIP establishment and validation 
 73
3.1.6 Optimization of ChIP – How to analyze precipitated DNA? 
In order to determine the enrichment of different chromatin marks at the chromosomal 
region 13q14.3, precipitated ChIP-DNA was first analyzed by end-point PCR. As controls, 
PCRs were established to detect sequences known to be enriched for the respective histone 
modification and also for sequences known not to be enriched and controlled on genomic 
DNA (see “pos. control” in Figure 3-7). Products could be amplified from ChIP-fractions 
containing low amounts of DNA (preclearing beads, precipitate and mock precipitate; Figure 
3-7). 300,000 cells per ChIP-fraction were used per PCR-reaction. However, for unknown 
reasons, no products were amplified in input-, cleared input- and unbound-fractions. 
Furthermore, no quantification of amplified DNA-products was possible by end-point PCR 
analyses. Subsequently, in order to quantify DNA from different ChIP-fractions, quantitative 
PCR (qPCR) was used to analyze ChIP-DNA (see chapter 3.1.9 and Figure 3-9). 
 
 
Figure 3-7: PCR analyses of ChIP-precipitates. a) PCR-analysis of DNA from anti-H3-
xChIP, expected PCR product: MYH1 (110 bp; control); b) PCR-analysis of 
DNA from anti-CTCF-xChIP, expected PCR products: (1) H19-CTCF-binding 
site (385 bp; positive control), (2) cMyc-CTCF-binding site (284 bp; positive 
control), (3) MYH1 (110 bp; negative control); 15 cycles per PCR.  
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3.1.7 Validation of chromatin precipitation in H3K4me2- and 
macroH2A-ChIPs in CLL and non-malignant cells 
 
 
Figure 3-8: Western blot of H3K4me2- and macroH2A-precipitates. a) H3K4me2-
precipitate-, mock- and input-fractions in different samples. MW H3K4me2 
= ~17 kDa. b) macroH2A-precipitates analog to (a). MW macroH2A = 
~42 kDa. Arrows point to target protein in precipitate fractions. Western 
blot detection with same antibody used for initial ChIP. 
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ChIP was used to quantify the presence of two epigenetic marks, H3K4me2 and macroH2A, 
at chromosomal region 13q14.3 in non-malignant and CLL cells (chapters 3.2 and 3.3). 
Specific precipitation of each ChIP-experiment was validated on two levels. First, it was 
tested whether target protein was specifically enriched in precipitate-fractions only, and not 
in mock-fractions (Figure 3-8). Detection by Western blot analyses was performed with the 
same antibodies used for ChIP-precipitation. H3K4me2 was specifically precipitated in 
different CLL patient samples (CLL1-CLL4; Figure 3-8a), in non-malignant B- and T-cells, in 
13 samples of probands of two age groups (“young” and “old”; Figure 3-8a) and in the cell 
lines Namalwa, HL60 and Jurkat. Enrichment of macroH2A in ChIP-fractions was more 
difficult to detect by Western blot analysis, but successfully precipitated macroH2A could be 
detected in CLL patients (CLL1 in Figure 3-8b) and in healthy probands of the two age 
groups (Figure 3-8b). 
 
 
Figure 3-9: Fraction of input of H3K4me2- and macroH2A-ChIP measured by qPCR. a) 
H3K4me2: GAPDH-promoter (green bars; positive control), MYH1-promoter 
(red bars; negative control). b) macroH2A: IL8-promoter (green bars; 
positive control) and MYH1-promoter (red bars; negative control). 
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Second, the DNA-parts of precipitated chromatin were quantified by control-qPCR reactions 
on positive and negative (i.e. according to the enrichment of the analyzed chromatin mark) 
promoter sequences. ChIP was considered valid when the positive control promoter 
sequences were more strongly enriched than negative control promoter sequences and 
secondly, when precipitated fractions were enriched, while mock ChIP-fractions were not. 
Surprisingly, H3K4me-enrichment at the positive control promoter (GAPDH; green bars in 
Figure 3-9a) varied significantly between different tissues. Highest enrichment at GAPDH was 
found in CLL3 and CLL5 (ratio of 1.39 and 1.45), in wild type P3 (0.48) and in wild type T-
cells PB12 (0.2; Figure 3-9a). In contrast, at promoter sequences used as negative control 
(MYH1; red bars in Figure 3-9a), enrichment was significantly lower than at sequences used 
as positive controls in all analyzed samples. 
 
In general, enrichment of macroH2A was significantly lower in all tissues compared to 
H3K4me2-enrichment (Figure 3-9b). The highest ratio of macroH2A-enrichment was 
measured in the sample CLL1 (0.024; Figure 3-9b). Defining negative control promoters for 
macroH2A was slightly more difficult than for H3K4me2-enrichment. This could be seen by 
rather high enrichment of these negative controls measured in qPCR in several samples 
(CLL2, PU1 and PB17 in Figure 3-9b). 
 
Table 3-2: Enrichment of control clones of H3K4me2-ChIP on chip experiments in HL60 used for 
validation. H3K4me2-enrichment ratios (Enr.) and percentiles (Per.) of ChIP-on-chip 
experiments for each sample. Columns: H3K4me2-enriched CpG-islands in THP1 cells 
(Miao and Natarajan, 2005); location of CGI to gene: up (upstream); within or down 
(downstream). Below the actual table a short description of gene functions of the control 
clones is given. 
CpG-clone   29B09 115B10 63F01 33B01 15A04 5B06 13F12 
Gene symbol   TNFRSF7 HOXA10 S100A10 BAT1 RHO6 VDR DR1 
Chromosome   12 7 1 6 12 12 1 
location CGI to 
gene 3’ 5’ 3’ 5’ 3’ 5’ within 
HL60 Enr.  0.459 0.453 0.573 0.387 0.541 0.452 0.364 
  Per. 10th 10th 10th 25th 10th 10th 10th 
CLL1 Enr. NA 0.428 0.053 NA NA NA NA 
  Per. - 25th 50th - - - - 
CLL2 Enr.  1.084 0.671 NA 0.126 NA 1.550 1.471 
  Per. 10th 25th - 50th - 10th 10th 
CLL3 Enr. 0.173 0.723 0.678 -0.093 NA 1.603 0.135 
  Per. 50th 25th 10th 75th - 10th 50th 
CLL4 Enr.  0.813 NA 0.682 -0.387 NA 0.896 0.793 
  Per. 10th - 25th 75th - 10th 10th 
CLL5 Enr. 0.704 NA 0.3190 -0.152 NA 0.464 0.397 
  Per. 10th - 50th 75th - 25th 25th 
P4 Enr.  0.593 NA 0.158 0.376 0.004 0.470 0.152 
  Per. 10th - 75th 25th 50th 90th 75th 
PB17 Enr. -0.101 NA 0.428 0.036 -0.011 0.423 0.085 
  Per. 50th - 90th 50th 75th 90th 75th 
Described 
gene 
function: 
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H3K4me2-ChIP-on-chip experiments were validated by enrichment of seven control promoter 
sequences chosen from the study by Miao and Natarajan (2005) that were also represented 
on the employed CpG-island microarray (CGI-array; see chapter 2.19.1 for details). 
Accordingly, ChIP-on-chip experiments were validated if at least one of these seven clones 
had H3K4m2-enrichment ratios that were among the top ten of respective microarrays in 
one experiment. Subsequently, H3K4me2-ChIP-on-chip experiments in CLL and wild type 
cells detected similar enrichment-ratios for at least one of the seven control promoter clones 
(Table 3-2). In primary cells, enrichment of only one of the control clones was considered 
sufficient for validation of the ChIP-experiment. 
 
Table 3-3: Enrichment of control CpG clones close to CDH12 & HK2. Ratios and percentiles of control 
clones used for normalization of ChIP on chip-generated data. Values marked with 
asterisks (*) were used for normalization of arrays of which CDH12- or HK2-clones gave 
no signal. NA = no signal measured (“not available”). 
Sample Sample Precipitating Ratio  Ratio   
No. type antibody CpG CDH12 Percentile CpG HK2 Percentile
 (tissue)  H3K4me2  macroH2A  
CLL1 CLL H3K4me2 NA - NA - 
CLL2 CLL H3K4me2 0.225* 50th 0.244 50th 
CLL3 CLL H3K4me2 0.203 50th -0.174 75th 
CLL4 CLL H3K4me2 NA - -0.141 75th 
CLL5 CLL H3K4me2 NA - -0.205 75th 
PB17 Wt H3K4me2 1 10th -0.063 75th 
P4 Wt H3K4me2 0.949* 10th 1 10th 
CLL2 CLL macroH2A 0.103 50th 0.977* 10th 
CLL5 CLL macroH2A NA - 1 10th 
PU1 Wt macroH2A NA - NA - 
PB17 Wt macroH2A NA - 0.938* 10th 
 
The last step of normalization of measured ChIP data in order to avoid generation of false-
positives was normalization relative to control sequences (Mathieu et al., 2005). 
Normalization of raw ChIP data was included to achieve better comparability among different 
cell types analyzed and also among different platforms used for ChIP-DNA analysis (i.e. qPCR 
and CGI-array). For this purpose, two control promoters that were enriched in either 
H3K4me2 or macroH2A, but both in non-malignant cells and CLL cells, were identified from 
the ChIP-on-chip experiments (Table 3-3). The two clones selected as positive control 
sequences for H3K4me2- (CDH12) and macroH2A-ChIPs (HK2) fulfilled the criterion that 
they are enriched in both types of analyzed tissue in order to serve as control sequence, 
which was the case for the selected clones CDH12 and HK2 (Table 3-3). 
The same sequences were measured and used as positive control sequences in subsequent 
qPCR analyses (Table A-1; Appendix A). The measured ratios of these positive control clone 
sequences were used for normalization of ChIP-on-chip experiments and analog the 
measured ‘fraction of input’-values were used for normalization of qPCRs (see chapter 2.20.4 
for details). 
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3.2 Chromatin modifications at 13q14.3 in non-malignant 
cells 
Chromatin immunoprecipitation was established (chapter 3.1) to characterize epigenetic 
modifications at chromosomal region 13q14.3 in non-malignant and CLL cells. First, the 
normal chromatin status of the region in wild type cells is described in chapter 3.2. 
3.2.1 Are there differences in enrichment of H3K4me2 between 
genes and promoters of the 13q14.3 region? 
Enrichment of H3K4me2 at chromosomal region 13q14.3 was measured in eleven samples of 
peripheral blood lymphocytes (PBL) from healthy donors in order to identify genes and 
promoters that carry epigenetic marks associated with transcriptional activity. Considering 
the overall H3K4me2-enrichment at all measured loci of the region, samples could be 
assigned to three subgroups according to the level of enrichment of H3K4me2, but 
independently of other characteristics of the samples (Table 2-3). The first group consisted 
of highly H3K4me2-enriched samples (PB18, P3, PB5 and PB17), the second group included 
medium H3K4me2-enriched samples (P5, P2, PB7 and PB6) and the third group consisted of 
samples with only very low detectable enrichment of H3K4me2 (P1, P4 and PB19; Figure 
3-10). However, the members assigned to each of the three groups were heterogeneous 
regarding their gender and age (see Table 2-3) and shared no other similarities. 
 
 
Figure 3-10: H3K4me2-enrichment at chromosomal region 13q14.3 genes (exons; i.e. 
e1-e4) and promoters (CpG-islands; CGI) in eleven wild type samples. 
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The H3K4me2-enrichment varied in different samples (i.e. individuals), but not at different 
genes and promoter CpG-islands of chromosomal region 13q14.3 (Figure 3-10). The pattern 
of H3K4me2-enrichment at distinct loci within promoters and genes was the same in all 
measured samples regardless of the level of enrichment (Figure 3-10). The highest median 
H3K4me2-enrichment in non-malignant cells was detected at CpG-islands B (11.7 to 16.1 
fold enrichment versus CDH12), D (4.4 to 14.7 fold enrichment versus CDH12) and the 
centromeric part of CGI E (E1-E3; 3.3 to 9.5 fold enrichment versus CDH12; Table A-2, 
Appendix A). Highest H3K4me2-enrichment could be measured at CpG-island D (i.e. 225-fold 
enrichment versus CDH12; Figure 3-10). On the other hand, the lowest median H3K4me2-
enrichment was measured at the third and sixth exon of KPNA3 (0.1 and 0.6 fold enrichment 
versus CDH12), at all analyzed exons of C13ORF1 (0.2 to 0.5 fold enrichment versus CDH12) 
and at DLeu2/BCMSUN exons (1.1 to 1.4 fold enrichment versus CDH12; Table A-2, 
Appendix A). Only one locus at 13q14.3 had no H3K4me2 in non-malignant cells: At the third 
exon of KPNA3 no detectable enrichment could be measured in five of the eleven samples. 
In general, promoter CpG-islands and exonic regions had comparable H3K4me2-enrichment, 
except for the CpG-islands B and E that are located in the promoter regions of C13ORF1 and 
DLeu2/BCMSUN, respectively (Figure 3-10; Table A-2, Appendix A). However, a general 
pattern of more H3K4me2 at promoter regions of 13q14.3 (CGIs) than at the exonic regions 
was detected (Figure 3-10). 
 
In summary, medium levels of the active chromatin mark H3K4me2 were found at 13q14.3 
in non-malignant cells. The pattern of H3K4me2-enrichment was the same in all samples; 
however, the levels of H3K4me2 differed interindividually. Remarkably, the exonic region of 
KPNA3 showed almost no detectable H3K4me2, whereas at CGI D the highest measured 
H3K4me2 amount was measured. 
3.2.2 Promoter-restricted H3K4me2-pattern correlates with 
monoallelic expression 
Rougeulle et al. (2003) could show that monoallelically expressed genes are marked by 
promoter-restricted H3K4me2-enrichment. In order to test whether the monoallelically 
expressed genes at 13q14.3 would carry a similar pattern of histone modification; the 
enrichment of H3K4me2 was compared between gene exon and gene promoter regions. 
Significant differences (p<0.05; chapter 2.20) between H3K4me2-enrichment at exons and 
the promoter of each gene could be detected, where promoters showed higher enrichment 
of H3K4me2 compared to the gene exons. Figure 3-11a shows box plots of enrichment of 
H3K4me2 at exons and corresponding promoters at five genes of the chromosomal region 
13q14.3 analyzed in wild type samples. Promoter-restricted H3K4me2-enrichment was 
detected at C13ORF1 (p=0.0001) and at DLeu2/BCMSUN with both promoter-CpG-islands 
localized at transcription start sites of different splicing variants of DLeu2 (Figure 1-11), CGI 
D (p=0.0009) and CGI E (p=0.0014). However, no such differential enrichment could be 
detected at KPNA3 (p=0.4166), BCMS (p=0.5702) or RFP2 (p=0.8356; Figure 3-11a, yellow 
box). Monoallelic expression of C13ORF1 in non-malignant hematopoietic tissue was 
confirmed by sequencing of a SNP (rs9568354) in the coding region of the gene. Sequencing 
of samples heterozygous for this SNP showed that only one allele was expressed in nine out 
of ten healthy probands (Figure 3-11b). Monoallelic expression could be determined for 
C13ORF1 independently of the allelotype at the SNP (Figure 3-11c). Expression status of the 
other four genes has been determined in a previous study by Mertens et al. (2006). 
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Figure 3-11: Promoter-restricted H3K4me2-enrichment at chromosomal region 13q14.3 
and expression status of C13ORF1. a) Box plots for H3K4me2-enrichment 
at exons and promoters. Dotted line within each box plot = mean value; 
bold p-values = p<0.05; first row: complete wild type sample group; blue 
box: wild type subgroups (young, old) and (B-, T-cells). b) Sequence 
analysis of heterozygous wild type samples for SNP (rs9568354; marked 
with *) in the coding sequence of C13ORF1. c) Genotype frequencies of 
SNP rs9568354 in B- and T-cells of healthy probands. 
  Chromatin at 13q14.3 in non-malignant cells 
 81
Briefly, DLeu2/BCMSUN, RFP2 and splicing variants of BCMS were shown to be 
monoallelically expressed, while KPNA3 was biallelically expressed. Four of the five genes in 
chromosomal region 13q14.3 were found to carry the histone mark that reflected their 
expression status, i.e. KPNA3 and the short splicing variants of BCMS showed no restricted 
H3K4me2-enrichment in agreement with their biallelic expression while monoallelically 
expressed genes C13ORF1 and DLeu2/BCMSUN showed promoter restricted H3K4me2-
enrichment (Figure 3-11a). RFP2 was shown to be monoallelically expressed in B- and T-cells 
(Mertens et al., 2006), but does not carry the respective promoter-restricted H3K4me2-
enrichment. 
All wild type samples were further subdivided into four groups related to age or tissue of the 
sample origins. In these subgroups, i.e. young and old wild type, B-cells and T-cells, more or 
less the same pattern as in the complete wild type group was detected with some 
exceptions. The subgroups T-cells and old wild type showed the same promoter restricted 
H3K4me2-enrichment at the same genes, C13ORF1 and DLeu2/BCMSUN, as was detected 
for the complete wild type group. Lack of restricted enrichment was detected at the same 
genes, as well (KPNA3, RFP2 and BCMS; Figure 3-11a, blue box). However, one remarkable 
difference was the lack of detection of the promoter-restricted enrichment of H3K4me2 – the 
mark for monoallelic expression – in probands below the age of 45 years at the 
DLeu2/BCMSUN gene, with neither of the two eligible promoters (CGI D or CGI E; Figure 
3-11a, blue box). In the B-cell subgroup promoter restricted H3K4me2-enrichment at 
DLeu2/BCMSUN could only be detected with one of the two eligible promoters, namely CGI E 
(p=0.0033), and not with CGI D (p=0.0607; Figure 3-11a, blue box). 
 
In no wild type subgroup a pattern of histone modifications specific for monoallelic 
expression was found for RFP2. Neither was promoter restricted H3K4me2-enrichment 
detected at the biallelically expressed genes KPNA3 and BCMS (Figure 3-11a, blue box). The 
epigenetic pattern of monoallelic expression, i.e. promoter-restricted H3K4me2-enrichment, 
correlated with the monoallelic expression of the genes DLeu2/BCMSUN and C13ORF1, which 
was furthermore shown to be indeed monoallelically expressed. Surprisingly, the mark was 
not found at the monoallelically expressed RFP2, but was neither detected at the biallelically 
expressed genes KPNA3 and BCMS. 
3.2.3 MacroH2A-enrichment at 13q14.3 in non-malignant cells 
Enrichment of macroH2A at chromosomal region 13q14.3 was characterized by ChIP and 
qPCR analyses in five PBL samples of healthy donors in order to identify epigenetically 
silenced loci. Overall, macroH2A was detected only in very low amounts at the region (Figure 
3-12 and Table A-3, Appendix A). In two samples (PL2 and PB19) almost no macroH2A-
enrichment at all could be detected with only minor exceptions at several distinct loci within 
exonic regions of BCMS, KPNA3, C13ORF1 and DLeu2/BCMSUN (0.02 to 0.9 fold enrichment 
versus HK2 and within distinct loci within CGI D and CGI E (0.6 and 0.7 fold enrichment 
versus HK2, respectively; Figure 3-12). As seen for H3K4me2-enrichment (chapter 3.2.1) the 
levels of macroH2A-enrichment varied between different samples/individuals, but the pattern 
of distribution was similar at genes and promoter CpG-islands of chromosomal region 
13q14.3 (Figure 3-12). The highest median macroH2A-enrichment in wild type was 
measured at CpG-islands C and D and at exons of the gene DLeu2/BCMSUN (0.9 to 2.2 fold 
enrichment versus HK2; Table A-3, Appendix A). The largest part of the analyzed region 
13q14.3 had no or only very little macroH2A-enrichment in non-malignant cells. Notably, 
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cell-samples that originated from donors of above 45 years of age (i.e. old wild type) had 
more macroH2A than the other samples. 
 
 
Figure 3-12: MacroH2A-enrichment at chromosomal region 13q14.3 genes (exons; i.e. 
e1-e4) and promoters (CpG-islands; CGI) in five wild type samples. 
 
In general, macroH2A was higher enriched at exonic regions than at the CpG-islands in 
promoters of the region (Figure 3-12; Table A-3). Compared to H3K4me2-enrichment at 
chromosomal region 13q14.3, macroH2A was found to be much less enriched (reduced by a 
factor of ten; Figure 3-10 and Figure 3-12). Overall, enrichment of macroH2A at promoters 
and exons was reciprocal to H3K4me2-enrichment; i.e. while H3K4me2 was found at CpG-
islands but not at exons, macroH2A was detected at exons but not at CpG-islands. 
3.2.4 Comparison of histone code and DNA-methylation of 
chromosomal region 13q14.3 
In order to determine the epigenetic code at the critical region in 13q14.3 in non-malignant 
cells, histone modifications were measured and, DNA-methylation was determined. The 
enrichment of the active chromatin mark H3K4me2 and of the repressive mark macroH2A in 
five to eleven non-malignant wild type samples at genes and CpG-islands in the region 
13q14.3 is summarized in Figure 3-13a. The DNA-methylation at 13q14.3 was analyzed in 
nine non-malignant wild type samples by the aPRIMES method (chapter 2.19.3) in 
collaboration with Verena Fleig (Figure 3-13b). The epigenetic code of 13q14.3 was 
determined by correlating these three distinct epigenetic modifications to each other at 
genes and CpG-islands in the region (Figure 3-13). 
KPNA3 and CGI A were neither remarkably enriched with H3K4me2 nor with macroH2A. Only 
one locus within the exons of KPNA3 showed relatively high H3K4me2-enrichment (average 
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40 fold enrichment versus CDH12), whereas one locus in CGI A showed higher macroH2A-
enrichment (average 6 fold enrichment versus HK2) compared to the other loci of KPNA3 
and CGI A (Figure 3-13a). DNA-methylation of CGIs A and B was determined by BioCOBRA 
analysis, which was performed by Angela Philippen. Thereby, 0 % DNA-methylation was 
measured at CGI A in non-malignant cells (data not shown). Thus, no distinct epigenetic 
modifications that could be specifically correlated to the transcriptional status of the gene 
were detected at KPNA3 or CGI A. 
At the exonic region of C13ORF1 no remarkable enrichment, neither of H3K4me2 nor of 
macroH2A, was detected. In contrast, at CGI B located in the promoter region of the gene, 
comparatively high H3K4me2-enrichment (average 50 to 150 fold enrichment versus CDH12) 
and also relatively high macroH2A-enrichment was measured (average 5 to 12 fold 
enrichment versus HK2, Figure 3-13a). Also, DNA-methylation at CGI B varied from 0 % to 
90 % in different samples, with an average of 40 % methylation of the CpG-island. The gene 
C13ORF1 showed promoter-restricted H3K4me2-enrichment that correlates with its 
monoallelic expression status (chapter 3.2.2) and moreover, active and repressive chromatin 
marks were determined together at the promoter region in non-malignant cells. 
 
 
Figure 3-13: Wild type epigenetic modifications at 13q14.3. a) Box plots of histone 
modifications for each analyzed loci of 13q14.3 in wild type. b) Wild type 
DNA-methylation at 13q14.3 measured by aPRIMES. 13q14.3 not drawn to 
scale; relation of loci to each other (in a & b) is correct (compare overview 
of methods and analyzed fragments in Figure 2-3). 
 
No distinct differences between gene and promoter sequences in enrichment of H3K4me2 
and macroH2A were detected at RFP2 and CGI C. Both histone modifications were found to 
be more or less homogeneously distributed in rather low amounts (i.e. H3K4me2: average 
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20 fold enrichment versus CDH12; macroH2A: average 5 fold enrichment versus HK2; Figure 
3-13a). Moreover, no DNA-methylation was measured at CGI C (Figure 3-13b). Again, as 
seen at KPNA3 and CGI A, no distinct epigenetic modifications that could be specifically 
correlated to the transcriptional status of the gene could be detected at RFP2 or CGI A. 
However, in contrast to KPNA3 and CGI A, both chromatin marks were found (in 
comparatively low amounts) at RFP2 and CGI A. 
CGI D and BCMS showed a rather heterogeneous enrichment of H3K4me2, while macroH2A-
enrichment was found to be homogeneously distributed in low amounts at the CpG-island 
and exonic region (Figure 3-13). H3K4me2 was high at the first and third exon of BCMS 
(average 50 to 200 fold enrichment versus CDH12), but was significantly lower at the second 
exon (average 10 fold enrichment versus CDH12) in non-malignant cells. H3K4me2 was high 
at the most centromeric locus within CpG-island D (average 50 to 230 fold enrichment 
versus CDH12) and became gradually less towards its most telomeric part (average of 5 to 
50 fold enrichment versus CDH12, Figure 3-13a). In contrast, macroH2A was medium 
enriched at CGI D with an average of 2 fold enrichment versus HK2 with one exception at 
locus D3 (average of 6 fold up to 12 fold enrichment versus HK2). The DNA-methylation 
determined at CGI D and BCMS divided the CpG-island into two parts: No DNA-methylation 
was found at the centromeric part, but DNA was methylated at the most telomeric part (D7a 
Figure 3-13b). Thus, H3K4me2-enrichment and DNA-methylation were found to be 
significantly different at the most telomeric part of CGI D compared to the (larger) 
centromeric part (Figure 3-13). A similar division into two differentially methylated segments 
was also detected at CGI E. 
The exonic region of the gene DLeu2/BCMSUN was comparable to the other exonic regions 
in 13q14.3; H3K4me2-enrichment was low (average 20 fold enrichment versus CDH12), but 
macroH2A was high with an average of 8 fold enrichment versus HK2 (Figure 3-13a). At the 
CpG-island located within the promoter region of the gene (i.e. CGI E), H3K4me2 enrichment 
could be divided into two halves. The centromeric half of CGI E had high levels of H3K4me2 
(average 40 to 160 fold enrichment versus CDH12), whereas the telomeric part had 
significantly lower levels (average 20 fold enrichment versus CDH12, Figure 3-13a). 
Surprisingly, the centromeric half of CGI E showed low DNA-methylation in non-malignant 
cells, whereas the neighboring telomeric half did not (Figure 3-13b). An abrupt change of 
DNA-methylation was measured between the two halves at locus E6a. At locus E6a the 
average DNA-methylation was around 5 % to 20 %, and up to 80 % in one sample, whereas 
in the neighboring loci of E6a, 0 % DNA-methylation was measured in non-malignant cells. 
Analog to C13ORF1 and CGI B, promoter-restricted H3K4me2-enrichment was determined at 
DLeu2/BCMSUN and CGI E that correlates with monoallelic expression of DLeu2/BCMSUN in 
non-malignant cells (chapter 3.2.2). Furthermore, CGI E could be divided into two halves 
according to epigenetic marks determined and a region of interest that showed special 
chromatin marks at one distinct locus within CGI E was identified. 
 
Remarkably, in both CpG-islands located in the 5’-regions of the two noncoding RNA genes 
of the critical region in 13q14.3, BCMS and BCMSUN, abrupt changes in DNA-methylation 
became evident that divide the CpG-islands into a methylated and an unmethylated part. 
The two distinct loci identified within CGIs D and E were further analyzed to determine 
further characteristics of these putative locus control elements. 
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3.2.5 Allelic modifications of CpG-islands D and E – Is there a 
regulatory element in CGI D or CGI E? 
Locus control regions (LCR) are characterized among other features by differential allelic 
methylation of DNA and by differential allelic histone modifications (Li et al., 2002). ChIP 
experiments were carried out in non-malignant cells that were heterozygous for SNPs within 
the CpG-islands in order to detect differential allelic enrichment of H3K4me2 and macroH2A. 
 
 
Figure 3-14: Allelic enrichment of H3K4me2 and macroH2A at distinct loci within CpG-
islands D and E. a) allelic H3K4me2-enrichment at SNP rs9568354 within 
CGI E (E6); sequences of input DNA versus precipitated DNA, measured in 
n=5 probands. b) Allelic macroH2A-enrichment at CGI E (n=5). c) Allelic 
H3K4me2 at SNP rs12100048 within CGI D measured in n=6 probands; d) 
allelic macroH2A-enrichment at CGI D (n=4). 
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Especially interesting were the loci with abrupt changes of DNA-methylation in CGI D (SNP 
rs12100048) and CGI E (SNP rs9568354; chapter 3.2.4). Allelic H3K4me2-enrichment at 
CpG-island E (was detected in 1 out of 5 wild type samples, with only one allele detectable in 
precipitated sequences (Figure 3-14a). In contrast, no differential enrichment of macroH2A 
was detected at CGI E (Figure 3-14b). CpG-island D was neither significantly differentially 
enriched with H3K4me2 (Figure 3-14c) nor with macroH2A (Figure 3-14d) in any analyzed 
sample. Unfortunately, end-point-PCR reactions performed prior to sequencing in 
collaboration with Angela Philippen were unequally specific in individual samples (Figure 
3-14c and d). Mostly, but not in all cases, the target could be amplified also from the 
unspecifically bound DNA in mock fractions as is exemplified in Figure 3-14d. Two of six 
(H3K4me2) and two of four (macroH2A) analyzed heterozygous probands depicted in Figure 
3-14c and (d) show a preferred enrichment of the chromatin marks at only one of the two 
copies, which was evident in unequal sizes of curves determined at the SNP (*). The size of 
the sequencing curves is correlated with the amount of DNA from the respective allele 
present in the analyzed samples. Thus, in both putative LCR regions of 13q14.3, a tendency 
for monoallelic enrichment of the two histone marks was detected. 
3.2.6 Histone modifications in different age groups – What influence 
has the age on epigenetic modifications at 13q14.3? 
As CLL patients have a median age of 72 years at diagnosis (Dighiero and Hamblin, 2008), 
age-matched wild type samples were measured as appropriate control tissue and compared 
to non-age-matched wild type samples. For neither modification, H3K4me2- and macroH2A- 
enrichment, significant differences could be detected between young (<45 years) and old 
(>45 years) probands at genes and CpG-islands of chromosomal region 13q14.3 (Figure 
3-15; Table 3-4). However, H3K4me2 tended to be stronger enriched in the old age group at 
all genes and CpG-islands analyzed. Calculated t-values were used to determine which 
sample group contained the higher enrichment (Table 3-4). 
 
Table 3-4: T- and p-values calculated by Welch’s two sample t-test; for comparison of young versus 
old subgroups’ enrichment of H3K4me2 and macroH2A. T-values implicate which group 
contains greater values: negative t = young<old; positive t = young> old wild type. 
Young vs old H3K4me2  macroH2A  
wild type p-value t-value p-value t-value 
KPNA3 exons 0.298 -1.062 0.141 -1.671 
CGI A 0.214 -1.270 0.332 1.028 
      
C13ORF1 exons 0.288 1.093 0.502 0.691 
CGI B 0.274 -1.114 0.187 1.438 
      
CGI C 0.234 -1.213 0.466 0.757 
RFP2 exons 0.759 -0.310 0.351 0.972 
      
CGI D 0.246 -1.184 0.110 1.688 
BCMS exons 0.898 0.130 0.519 0.666 
      
BCMSUN exons 0.953 0.060 0.081 1.901 
CGI E 0.126 -1.547 0.914 0.109 
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Only at three loci the young age group showed a higher H3K4me2-enrichment than the old 
age group, these loci were C13ORF1 (t=1.1), BCMS (t=0.1) and DLeu2/BCMSUN (t=0.1; 
Table 3-4). The old age group showed a much higher variance of enrichment ratios at 
distinct genes and CpG-islands than the young age group. This was observed by comparison 
of 95th percentiles in young and old box plots and taking into account the outliners of the 
box plots in each age group (Figure 3-15a). Enrichment of macroH2A at chromosomal region 
13q14.3 was reciprocal to the H3K4me2-enrichment. Higher macroH2A-enrichment was 
detected in the young age group with only one exception at KPNA3 (t=-1.6; Table 3-4 and 
Figure 3-15b). Here the young age group showed a greater variance of enrichment ratios at 
single loci (Figure 3-15b). 
 
 
Figure 3-15: Histone modifications compared in two different age groups. a) Box plots 
comparing H3K4me2-enrichment in young and old wild type groups at five 
genes and CpG-islands of chromosomal region 13q14.3. b) macroH2A-
enrichment as in (a). Dotted line within box plots = mean value. 
 
The comparison of two age groups showed no significant differences regarding histone 
modification changes; only tendencies were observed. Old probands showed stronger 
enrichment of H3K4me2 (Figure 3-15a), while young probands showed higher macroH2A-
enrichment (Figure 3-15b). 
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3.2.7 Differences in H3K4me2-enrichment between B- and T-cells 
CLL is a B-cell disease. In the present study, epigenetic modifications of CLL cells were 
compared to that of non-malignant peripheral blood lymphocytes (PBL), a cell sample that 
includes B-cells, but also T-cells, Natural killer (NK) cells and macrophages. To ensure that 
epigenetic CLL-specific changes could be detected when comparing CLL cells to this mixed 
cell population, H3K4me2-enrichment was also separately determined in CD19+-sorted B-
cells and in T-cells (Figure 3-16). Comparison of H3K4me2-enrichment in B- and in T-cells 
showed that B-cells had around 10 fold more H3K4me2 at 13q14.3 than T-cells (Figure 
3-16). The highest median enrichment in both B- and T-cells was measured at CGI B, CGI D 
and the centromeric half of CGI E (4.1 to 28.3 fold enrichment versus CDH12 in B-cells and 
0.2 to 3.1 fold in T-cells; Table A-2, Appendix A), whereas lowest median H3K4me2-
enrichment was measured at KPNA3, C13ORF1 and DLeu2/BCMSUN (Figure 3-16 and Table 
A-2, Appendix A). Thus, the general pattern of H3K4me2-enrichment was the same in B- and 
T-cells. As previously determined also in PBL samples (chapter 3.2.1), the active chromatin 
mark was higher enriched at CpG-islands than at exonic regions of 13q14.3. 
 
 
Figure 3-16: H3K4me2-enrichment at chromosomal region 13q14.3 in wild type B- 
(black symbols) and T-cells (white symbols). 
 
In summary, no other differences than the general 10-fold higher enrichment of H3K4me2 at 
13q14.3 in B-cells, was detected between B- and T-cells. The enrichment pattern of 
H3K4me2 with high enrichment at CGIs and low enrichment at gene exons was the same in 
B-cells, T-cells and PBL samples (Figure 3-10; Figure 3-16). Therefore, it seemed to be 
feasible to determine aberrations of the epigenetic code of 13q14.3 in CLL by comparison of 
epigenetic modifications of CLL cells to non-malignant PBL samples (chapter 3.3). 
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3.3 Aberrant chromatin of chromosomal region 13q14.3 in 
CLL 
Epigenetic modifications were characterized at chromosomal region 13q14.3 in wild type 
(chapter 3.2) and in CLL samples. Chapter 3.3 describes characterization of two histone 
modifications, H3K4me2- and macroH2A-enrichment, and of DNA-methylation at 13q14.3 in 
CLL samples. Aberrant chromatin and epimutations in CLL were detected by comparing to 
chromatin of non-malignant cells in the region. 
3.3.1 H3K4me2-enrichment at 13q14.3 in CLL 
Enrichment of H3K4me2 at chromosomal region 13q14.3 was characterized in five CLL 
samples to identify epigenetic marks at genes and promoters that reflect the transcriptional 
status of the genes. Overall H3K4me2-enrichment at all measured loci of the region in CLL 
cells was significantly higher (10 to 100 fold) than in non-malignant cells (Figure 3-10) and 
compared to the control promoter CDH12 (up to 1000 fold; Figure 3-17). 
 
 
Figure 3-17: H3K4me2-enrichment at chromosomal region 13q14.3 in five CLL samples. 
 
Highest median H3K4me2-enrichment was detected at CpG-islands B, C and the centromeric 
half of CGI E (27 to 109 fold enrichment versus CDH12). In contrast to non-malignant cells, 
CGI D had no significant high H3K4me2-enrichment in CLL cells (Figure 3-17) whereas high 
H3K4me2 was measured at the genes RFP2 and at BCMS (58 and 28 to 68 fold enrichment 
versus CDH12, respectively; Table A-4, Appendix A). The overall pattern of H3K4me2-
enrichment at 13q14.3 was similar in all CLL cell samples. However, when dividing the CLL 
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samples into subgroups according to genomic aberrations identified in the CLL patients 
(Table A-4, Appendix A), it was determined that del(13q) CLL samples had significantly lower 
H3K4me2-enrichment than CLL samples with retention of both copies (see chapter 3.3.6 
below for details). The pattern of high H3K4me2-enrichment at CGIs and low enrichment at 
exonic regions was generally the same as in non-malignant cells. Interestingly, CGI D and 
CGI A had the lowest measured H3K4me2-levels of all five CGIs analyzed in CLL cells. 
 
In summary, the most striking difference between non-malignant and CLL cells regarding 
enrichment of the active chromatin mark at the region 13q14.3, was quantitative, i.e. 
enrichment of H3K4me2 was at least 10 fold higher in CLL samples. High levels of H3K4me2 
were measured at 13q14.3 in CLL cells and the pattern of H3K4me2-enrichment was the 
same in all samples. However, the levels of H3K4me2 varied largely between individual CLL 
samples analyzed (Figure 3-17). 
3.3.2 Promoter-restricted H3K4me2-pattern correlates with 
monoallelic expression and is not changed in CLL 
The histone pattern of monoallelically expressed genes (Rougeulle et al., 2003) of 13q14 
was already characterized in non-malignant cells (chapter 3.2.2). In an analogous manner, 
promoter-restricted H3K4me2-enrichment at chromosomal region 13q14.3 was characterized 
in CLL cells. Figure 3-18 shows, analogous to Figure 3-11, box plots of ratios determined for 
gene exons and gene promoters of five genes of 13q14.3 analyzed in five CLL samples. 
Promoter-restricted H3K4me2-enrichment in CLL was detected at C13ORF1 (p=0.0238) and 
with high significance at DLeu2/BCMSUN with the promoter CGI E (p=0.0006), but neither at 
DLeu2/BCMSUN with the second eligible promoter (Figure 2-3; CGI D; p=0.2007), nor at 
KPNA3 (p=0.6222), BCMS (p=0.1737) and RFP2 (p=0.29; Figure 3-18). 
 
The epigenetic pattern of monoallelic enrichment was retained in CLL at all genes except for 
one splicing variant of DLeu2/BCMSUN in combination with CpG-island D. Thus, the 
epigenetic mark at one splicing variant of the gene DLeu2/BCMSUN is not detectable in CLL 
cells anymore. 
 
 
Figure 3-18: H3K4me2-enrichment at 13q14.3-genes in CLL at exons and at promoters. 
Dotted line within each box plots shows mean value; p-values calculated by 
Welch’s two sample t-test; bold p values = significant (p<0.05). 
3.3.3 MacroH2A-enrichment at 13q14.3 in CLL 
The enrichment of macroH2A at chromosomal region 13q14.3 was characterized by ChIP and 
qPCR analyses in five CLL samples in order to identify (aberrantly) silenced loci at 
chromosomal region 13q14.3. MacroH2A in CLL cells was high compared to non-malignant 
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cells (Figure 3-12; Figure 3-19). Medium levels of macroH2A (30 fold enrichment versus 
HK2) were distributed over the chromosomal region 13q14.3. Overall, macroH2A was 
detected in lower amounts than H3K4me2 at the 13q14 region in CLL cells (Figure 3-19 and 
Table A-5, Appendix A). The highest median macroH2A-enrichment at 13q14.3 in CLL cells 
was measured at exonic regions of the five genes analyzed (0.5 to 3.5 fold enrichment 
versus HK2; Table A-5, Appendix A). Surprisingly, also CpG-islands A, B, C and E had 
comparatively high macroH2A (0.1 to 3.5 fold enrichment versus HK2), whereas no 
macroH2A was detected at CGI D and at KPNA3 in CLL cells (Figure 3-19; Table A-5, 
Appendix A). Interestingly, the del(13q) subgroup of CLL samples had more macroH2A at 
13q14.3 than the subgroup of CLL samples that retained both copies of the critical region 
(Table A-5, Appendix A). 
 
The change of macroH2A-enrichment in CLL cells compared to non-malignant cells was again 
quantitative, i.e. as seen for H3K4me2 enrichment, also macroH2A enrichment was 
measured in higher amounts at 13q14.3 in CLL cells. Furthermore, the pattern of macroH2A-
enrichment was changed in CLL cells in such that it was found also in high amounts at CGIs 
and not exclusively at exonic regions in 13q14.3. 
 
 
Figure 3-19: MacroH2A-enrichment at chromosomal region 13q14.3 in five CLL samples. 
 
3.3.4 Histone code and DNA-methylation of chromosomal region 
13q14.3 in CLL 
In order to determine the aberrant epigenetic code at the chromosomal region 13q14.3 in 
CLL cells, histone modifications and DNA-methylation were determined at the five genes and 
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CpG-islands in the region. Enrichment of H3K4me2 and macroH2A as well as DNA-
methylation at 13q14.3 is summarized in Figure 3-20. The epigenetic code at 13q14.3 in CLL 
cells was determined by correlating the three marks to each other at genes and promoter 
regions. Subsequently the determined epigenetic code of CLL cells was analyzed for 
correlations to the epigenetic code determined in non-malignant cells (chapter 3.2.4). 
KPNA3 and CGI A were neither remarkably enriched with H3K4me2 nor with macroH2A in 
CLL cells with only two exceptions. In the exonic region of KPNA3 comparatively high 
amounts of H3K4me2 were measured (100 fold enrichment versus CDH12), whereas CGI A 
showed high macroH2A-enrichment (15 fold enrichment versus HK2; Figure 3-20a). In CLL 
cells 0 % DNA-methylation was detected at CGI A (A. Philippen, personal communication). 
Thus, no distinct epigenetic code that marks the transcriptional status of KPNA3 was 
determined in CLL cells. 
Except for comparatively high H3K4me2-enrichment at the fourth exon of C13ORF1 (average 
140 fold enrichment versus CDH12), neither H3K4me2- nor macroH2A-enrichment was 
measured at the exonic region of the gene (Figure 3-20a). H3K4me2-enrichment was found 
to be promoter-restricted in CLL cells, i.e. CGI B was strongly enriched, whereas C13ORF1 
was not. DNA-methylation was observed to be decreased in CLL cells at CGI B. In contrast to 
non-malignant cells where average DNA-methylation was 40 %, methylation was decreased 
to 20 % (range: 0 % to 60 %) in CLL cells. 
 
 
Figure 3-20: Epigenetic modifications at 13q14.3 in CLL samples. a) Box plots of histone 
modifications H3K4me and macroH2A for each fragment of 13q14.3 in five 
CLL samples. b) DNA-methylation at 13q14.3 measured by aPRIMES. 
13q14.3 loci indicated are not drawn to scale, but their relation to each 
other in (a) and (b) is correct. 
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The overall epigenetic code of C13ORF1 in CLL cells was merely the same as determined in 
non-malignant cells (chapter 3.2.4): promoter-restricted H3K4me2-enrichment at C13ORF1 
and CGI B was determined, together with presence of both activating (i.e. H3K4me2) and 
repressive (macroH2A and DNA-methylation) chromatin marks in CLL cells. 
At RFP2 and CGI C that are located within the critical region in 13q14.3, high amounts of 
H3K4me2 (average 200 fold enrichment versus CDH12) and medium macroH2A-enrichment 
was measured in CLL cells (Figure 3-20a). Furthermore, some of the analyzed samples 
showed DNA-methylation at CGI C (Figure 3-20b). Thus, epigenetic modifications in CLL cells 
differ from that in non-malignant cells, where neither DNA-methylation nor H3K4me2-
enrichment was measured (chapter 3.2.4). However, no distinct epigenetic code specific for 
the transcriptional state of RFP2 could be determined in CLL cells as both activating and 
repressive marks were measured at the exonic region and at CGI C (Figure 3-20). 
At CGI D medium H3K4me2- and low macroH2A-enrichment was measured (average of 80 
fold enrichment versus CDH12 and average of 3 fold enrichment versus HK2, respectively) in 
CLL cells. However, at BCMS, which is located in the most telomeric part of the CpG-island D, 
H3K4me2-enrichment was significantly higher and more variable than measured at the 
centromeric CGI. Furthermore, CGI D showed no wide DNA-methylation in the centromeric 
part, only the most telomeric parts showed DNA-methylation in CLL cells (Figure 3-20b). 
DNA-methylation at the telomeric part of CGI D is less abundant in CLL cells than in non-
malignant cells (chapter 3.2.4). A change of the methylation pattern between the two 
adjacent loci, D6a and D7a was evident (Figure 3-20b); at the first locus (D6a) 10 to 100 % 
DNA-methylation was measured, whereas the second locus (D7a) had less methylation 
varying between 0 % and 40 %. The division of CGI D into two different parts according to 
its epigenetic code was determined in CLL cells and in non-malignant cells (Figure 3-20; 
chapter 3.2.4). However, the most telomeric part including the candidate LCR carried 
repressive epigenetic marks in non-malignant cells (Figure 3-13), whereas it had mostly 
active marks in CLL cells (Figure 3-20). 
At the exons of DLeu2/BCMSUN no H3K4me2- and low macroH2A-enrichment was 
measured. The centromeric half of CGI E was comparatively highly enriched with H3K4me2, 
while it was low at the telomeric half (Figure 3-20a). MacroH2A was homogeneously low 
enriched at CGI E with a slightly higher enrichment at the centromeric half (Figure 3-20a). 
Promoter-restricted H3K4me2-enrichment that reflects monoallelic expression of 
DLeu2/BCMSUN was detected in CLL cells. In non-malignant cells the locus E6a showed 
DNA-methylation, while the neighboring loci did not (Figure 3-13b). However, in CLL cells 
E6a and its neighboring loci showed DNA-methylation in the minority of CLL samples 
analyzed (Figure 3-20b). Thus, repressive DNA-methylation but activating histone 
modifications could be determined at the candidate LCR within CGI E in CLL cells, whereas a 
repressive epigenetic code was determined in non-malignant cells (chapter 3.2.4). 
 
In summary, two candidate LCR loci within CGIs D and E that were determined to be 
differentially modified compared to the rest of the respective CGIs in non-malignant cells 
(chapters 3.2.6 and 3.2.7), also showed differential epigenetic modifications in CLL cells. 
Strikingly, the DNA-methylation status of these candidate LCRs is different in CLL compared 
to non-malignant cells (see also below, chapter 3.3.5). Whereas both candidate LCRs in non-
malignant cells had predominantly repressive epigenetic modifications including distinct DNA-
methylation (Figure 3-13), the candidate LCR in CGI D had activating epigenetic 
modifications and the one in CGI E had both active and repressive chromatin marks in CLL 
cells (Figure 3-20). 
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3.3.5 Aberrant chromatin at 13q14.3 in CLL? 
In order to identify aberrant chromatin at 13q14.3 in CLL cells, ratios of H3K4me2- and 
macroH2A-enrichment were compared in CLL and wild type samples by Welch’s Two Sample 
t-test (chapter 2.20.3). Figure 3-21 shows box plots of the ratios determined for analyzed 
CLL samples (CLL) and for analyzed wild type samples (wild type) at distinct loci of 
chromosomal region 13q14.3 (genes and CpG-islands). Significant differences of H3K4me2-
enrichment between CLL and wild type were determined at DLeu2/BCMSUN (p=0.039), CpG-
island B (p=0.0175), CpG-island C (p=0.0155) and CpG-island E (p=0.0006). The significant 
differences resulted in all cases from an aberrantly higher H3K4me2-enrichment in CLL 
samples (Figure 3-21a). Predominantly, aberrant enrichment of H3K4me2 was detected at 
CpG-islands located within gene promoter regions that are responsible for regulation of gene 
expression and not at the coding region of analyzed genes. DLeu2/BCMSUN was the only 
aberrantly H3K4me2-enriched gene of chromosomal region 13q14.3 (Figure 3-21a). 
 
 
Figure 3-21: Differential enrichment of histone modifications at chromosomal region 
13q14.3 in CLL compared to wild type. a) Box plots of differential 
H3K4me2-enrichment for five genes and five CpG-islands of the region, b) 
box plots analog to (a) showing macroH2A-enrichment; dotted lines within 
box plots = mean values; bold p values = significant (p<0.05). 
 
Enrichment of macroH2A at chromosomal region 13q14.3 was merely the same in CLL and 
wild type as no significant differences could be determined. Only two exceptions were 
detected, C13ORF1 (p=0.0158) and CpG-island E (p=0.0039) were significantly differentially 
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macroH2A-enriched in CLL compared to wild type (Figure 3-21b). While macroH2A was 
predominantly detected at the gene exons in non-malignant cells, it was significantly higher 
enriched at CGI E located within the promoter region of the ncRNA gene DLeu2/BCMSUN. 
Similar to H3K4me2-enrichment, macroH2A enrichment was generally higher in CLL samples 
than in wild type samples. However, at most analyzed loci the mean values determined for 
CLL and wild type samples did not differ significantly (Figure 3-21). 
CLL mainly affects elderly adults, as can be seen from the median age of onset of 72 years. 
To this reason, wild type samples that were analyzed to determine aberrations in CLL were 
further subdivided into old and young wild type subgroups (see also chapter 3.2.6; Table 
3-5). The enrichment of both modifications H3K4me2 and macroH2A, in these two wild type 
subgroups were compared to those of the CLL group. The only difference between the whole 
wild type group and the two subgroups, when comparing them to CLL, was determined at 
the gene DLeu2/BCMSUN (yellow fill in Table 3-5). 
However, differential enrichment of H3K4me2 at DLeu2/BCMSUN was not significant 
between the young wild type subgroup and CLL and neither between the old subgroup and 
CLL (p=0.0642 and p=0.089, respectively). All other determined p-values had the same 
tendency as those calculated for the average of all wild type samples versus CLL. Significant 
differences were determined at CGI B, CGI C and CGI E for H3K4me2-enrichment in young 
and old wild type versus CLL and at C13ORF1 and CGI E for macroH2A-enrichment (Table 
3-5). At the same loci significant differences were previously determined for the comparison 
of wild type versus CLL (Figure 3-21). This completes the previous finding in non-malignant 
cells that no significant differences in enrichment of neither H3K4me2 nor macroH2A could 
be detected at 13q14.3 between the two wild type subgroups young and old (Figure 3-15). 
 
Table 3-5: P values determined by Welch’s two sample T test for comparison of the CLL group to wild 
type subgroups young and old. Bold p values = significant (p<0.05). Yellow fill: different 
from CLL versus complete wild type group 
 CLL vs old wild type CLL vs young wild type 
 H3K4me2 mH2A H3K4me2 mH2A 
13q site p-value p-value p-value p-value 
KPNA3 0.8861 0.5196 0.2861 0.0608 
CGI A 0.5615 0.1458 0.1673 0.2771 
C13ORF1 0.1887 0.0211 0.2113 0.0139 
CGI B 0.0344 0.1648 0.0174 0.6276 
CGI C 0.0258 0.6614 0.0147 0.5927 
RFP2 0.1878 0.3855 0.1615 0.8272 
CGI D 0.5972 0.5144 0.2519 0.1718 
BCMS 0.1410 0.2700 0.1508 0.9058 
BCMSUN 0.0642 0.0878 0.0890 0.8824 
CGI E 0.0003 0.0126 0.0001 0.0113 
 
3.3.6 Correlation of macroH2A- and H3K4me2-enrichment at 
13q14.3 with different karyotypes in CLL 
Data before was shown as CLL median values calculated from single CLL samples of five 
different patients. A next interesting was to analyze and compare differences in enrichment 
of histone modifications at 13q14.3 in each single patient (Figure 3-22 and Figure 3-23). 
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Figure 3-22: Differential enrichment of H3K4me2 in five CLL patients. a) qPCR analysis 
of CHIP in samples CLL1-5; b) ChIP-on-chip. Relative localization of 
fragments to each other in (a) and (b) are correct, but not scaled. 
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For the three patients showing a deletion of chromosomal material at 13q14.3 (del(13q); i.e. 
CLL5, CLL2 and CLL4), the minimally deleted region is depicted within the diagrams (red line 
within diagrams; Figure 3-22 and Figure 3-23). 
No differences in the general pattern of distribution of neither H3K4me2 (Figure 3-22) nor 
macroH2A (Figure 3-23) were detected in the five analyzed CLL samples. However, the 
del(13q) CLL samples were distinct from the two CLL samples that derived from patients 
with other genomic aberrations. The del(13q) CLL samples showed overall low enrichment of 
H3K4me2 at 13q14.3. The sample CLL4 had no H3K4me2-enrichment at all, whereas very 
low overall H3K4me2-enrichment at 13q14.3 was determined in samples CLL2 and CLL5 
(Figure 3-22a). In the same CLL samples macroH2A-enrichment at 13q14.3 was 
comparatively high (Figure 3-23) and thus, it was found to be reciprocal to H3K4me2. The 
retained copy of 13q14.3 in del(13q) CLL samples carried exclusively the repressive histone 
modification (macroH2A; Figure 3-23), whereas the analyzed active chromatin mark 
(H3K4me2) was almost completely lost (Figure 3-22). 
In contrast to del(13q) CLL samples, two of the five analyzed CLL samples derived from 
patients that retained both copies of 13q14.3 and these had significantly different histone 
modifications at 13q14.3 compared to the del(13q) CLL samples. The first sample derived 
from a male CLL patient with a normal karyotype (CLL1) and showed the overall highest 
H3K4me2-enrichment ratios at 13q14.3. The highest H3K4me2-enrichment in sample CLL1 
was detected at the candidate LCR locus within the telomeric part of CGI D (300 to 1122 fold 
enrichment versus CDH12; Figure 3-22a). MacroH2A-enrichment was detected only in very 
low amounts at 13q14.3 and was mostly found to be reciprocal to H3K4me2 in sample CLL1. 
Also in the second CLL sample with retention of both alleles of 13q14.3 (CLL3), H3K4me2-
enrichment was significantly higher compared to the del(13q)-samples.  
Sample CLL3 that derived from a male CLL patient with a 17p deletion, showed overall high 
H3K4me2-enrichment at 13q14.3, which was approximately 10 fold lower than in the CLL1 
sample (Figure 3-22a). Analog to the sample CLL1, macroH2A-enrichment at 13q14.3 in 
sample CLL3 was reciprocal to H3K4me2-enrichment and detectable only in low amounts at 
the region. Thus, the retention of both copies of 13q14.3 in CLL cells was correlated with 
significantly higher abundance of the active chromatin mark (H3K4me2) and with loss of the 
repressive mark (macroH2A) at 13q14.3. Thus, the general patterns of enrichment at 
13q14.3 of both analyzed chromatin marks were found to be essentially the same in all five 
patients. However, comparing the analyzed del(13q) CLL samples to those CLL samples with 
retention of both copies, the deletion of genomic material from the chromosomal region 
13q14.3 could be correlated with loss of the active chromatin mark at 13q14.3. Not all data 
generated by qPCR analyses of single CLL samples were completely comparable to data 
obtained from ChIP-on-chip analyses of the same samples (Figure 3-22b; Figure 3-23b). 
In general, less data was obtained in ChIP-on-chip analyses because the CpG-island 
microarray employed included only three of the five CpG-islands of 13q14.3 (CGIs C, D and 
E; see chapter 2.19.1). The most striking differences between both analyses were detected 
in the sample CLL4, which had detectable H3K4me2-enrichment at CGIs C, D and E 
determined by ChIP-on chip in contrast to analyses by qPCR that detected no H3K4me2-
enrichment at all at 13q14.3 (Figure 3-22b). Similarly, macroH2A-enrichment at 13q14.3 in 
samples CLL2 and CLL5 was determined in slightly different amounts by ChIP-on-chip 
compared to qPCR analyses. Using ChIP-on-chip, a high enrichment of macroH2A was 
determined at CGIs C, D and E, which was not detected by qPCRs, whereas no macroH2A 
was measured in CLL5 by ChIP-on-chip, which was measured by qPCRs (Figure 3-23b). 
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Figure 3-23: Differential enrichment of macroH2A in five CLL patients. a) qPCR analysis 
of CHIP in samples CLL1-5; b) ChIP-on-chip in samples CLL2 and CLL5. 
Relative localization of fragments to each other in (a) and (b) are correct, 
but not scaled. 
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Apart from these examples, the general results obtained from ChIP-on chip were comparable 
to results obtained by qPCR for both analyzed histone modifications in CLL cells, which were 
described above. 
3.3.7 Identification of a locus control element in CGI D or E 
Figure 3-24 and Figure 3-25 combine data from Figure 3-13 and Figure 3-20 for a better 
comparison of differential DNA-methylation and enrichment of histone modifications in CLL 
and wild type samples at distinct loci in chromosomal region 13q14.3. 
 
 
Figure 3-24: Summary of DNA-methylation patterns in wild type and CLL samples. DNA-
methylation at 13q14 in wild type (black; n=9) and CLL (red; n=32) 
determined by aPRIMES. Blue boxes indicate loci with distinct epigenetic 
features within CGIs D and E. 
 
Within CpG-islands D and E two small loci characterized as candidate LCRs in chapters 3.2.5 
and 3.3.4, were analyzed. The epigenetic marks of these small regions were very distinct 
from the rest of the respective CpG-islands. These fragments had epigenetic characteristics 
that were not found elsewhere in the chromosomal region 13q14.3 (marked by blue frames 
in Figure 3-24 and Figure 3-25). In CGI D at loci D6a and D7a (Figure 3-24) remarkable 
differences in DNA-methylation between CLL and wild type samples were determined. At D6a 
two of three CLL samples were methylated. Unfortunately, no data were available for DNA-
methylation at D6a in wild type samples, but at the adjacent locus D5a, no DNA-methylation 
was measured in non-malignant cells (Figure 3-24). 
All analyzed wild type samples were methylated at the adjacent locus D7a, whereas some 
CLL samples were not, which reflects a loss of DNA-methylation at D7a in CLL compared to 
wild type. Consecutive BioCOBRA analysis by A. Philippen (see chapter 2.17) at D6a revealed 
hypomethylation of D6a in CLL samples compared to wild type samples (data not shown). 
The wild type samples showed DNA-methylation (70 % to 100 %), whereas CLL samples 
showed a highly variable but reduced DNA-methylation at the candidate LCR within CGI D 
(0 % and 100 %). However, no comparable differential methylation was detected at the 
adjacent locus D7a, where wild type and CLL samples both had a similar extent of DNA-
methylation (0 % to 40 %). In summary, at the second most telomeric part of CGI D 
analyzed (D6a), which harbors one of two candidate LCRs of 13q14.3, DNA-methylation was 
determined in non-malignant cells, whereas this was found to be reduced in CLL cells (Figure 
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3-24). In CpG-island E that harbors the second candidate LCR of 13q14.3, an abrupt change 
of DNA-methylation was detected at loci E5a to E7a. At E5a in both CLL and wild type 
samples, DNA-methylation was measured in some but not in all samples. At E6a no data 
could be obtained and E7a was not methylated in wild type, but in some of the CLL samples 
(Figure 3-24a). BioCOBRA analysis revealed hypermethylation of locus E6a in CLL in contrast 
to wild type (data not shown). At the locus E5a, DNA was methylated in CLL and wild type 
samples (60 % to 100 %), whereas at E6a DNA-methylation was more frequently measured 
in CLL cells. The adjacent locus E7a, however, showed no DNA-methylation, neither in CLL 
nor in wild type samples (data not shown). 
Thus, DNA-methylation at the candidate LCR within CGI E (E6a) was evident in CLL cells but 
not in non-malignant cells (Figure 3-24). It was further analyzed if these differences in DNA-
methylation between CLL and wild type samples at the two candidate LCRs within CpG-
islands D and E were marked as well in the histone code (Figure 3-25). 
 
 
Figure 3-25: Summary H3K4me2- and macroH2A-enrichment in wildtype and CLL 
samples. a) H3K4me2-enrichment in wild type (black; n=11) and CLL (red; 
n=5) and d) macroH2A-enrichment in wild type (black; n=5) and CLL (red; 
n=5) at 13q14.3. Blue boxes indicate breakpoints within CGIs D and E. 
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Within CGI D, H3K4me2-enrichment could be shown to be significantly higher at the 
candidate LCR locus (D6a) and at its adjacent locus (D5a) in CLL samples compared to wild 
type samples (Figure 3-25). Thus, loss of DNA-methylation at D6a was detected together 
with a gain of an active chromatin mark at the candidate LCR within CpG-island D in CLL 
cells. Surprisingly, also within CpG-island E the candidate LCR locus and its two adjacent loci 
(E5a to E7a) were significantly higher H3K4me2-enriched in CLL samples compared to wild 
type samples (Figure 3-25). 
 
Interestingly, the lowest H3K4me2-enrichment was measured at the candidate LCR locus 
itself (E6a) compared to the rest of the centromeric half of CGI E in CLL cells (Figure 3-25a). 
In contrast to the candidate LCR in CGI D, the second candidate LCR within CGI E had 
contrary epigenetic modifications in CLL cells, but not in non-malignant cells (Figure 3-24; 
Figure 3-25). Unlike H3K4me2-enrichment and DNA-methylation determined at the two 
candidate LCRs in 13q14.3, macroH2A-enrichment was homogeneous in comparatively low 
amounts at both CpG-islands. No differential macroH2A-enrichment could be determined, 
neither between CLL and wild type samples, nor between the candidate LCRs and the whole 
CpG-islands. 
 
 
It was shown that most but not all genes in the region 13q14.3 showed an epigenetic code 
that reflected their transcriptional status in non-malignant cells. At two genes, C13ORF1 and 
DLeu2/BCMSUN, promoter-restricted H3K4me2-enrichment was determined in non-malignant 
cells, which was in line with their monoallelic expression. The promoter-restricted H3K4me2-
pattern specific for monoallelic expression was not changed in CLL cells.  
In CLL cell samples derived from CLL patients with different karyotypes, a deletion of 
genomic material from 13q14.3 (del(13q)) and loss of active chromatin marks could be 
correlated. 
Strikingly, two candidate locus control regions (LCRs) were identified by their special 
epigenetic features in non-malignant cells that could be shown to be differentially marked in 
CLL and non-malignant cells. The LCRs are located in the 5’-regions of the two large 
noncoding RNA genes, therefore, the LCRs might be involved in regulation of transcription of 
the ncRNAs. Differential epigenetic modification in non-malignant and CLL cells at these LCRs 
is of special interest as this could be an epimutation in 13q14.3 that has impact on the 
regulation of the region. Identification of candidate LCRs in 13q14.3 was a step towards 
elucidation of the regulatory mechanism in the critical region in 13q14.3. 
Aberrant epigenetic modifications of 13q14.3 in CLL cells were most evident at the candidate 
LCRs, but furthermore a significant general gain of the active chromatin mark H3K4me2 at 
13q14.3 was measured in CLL cells. The detailed analysis of the epigenetic code in non-
malignant cells could help to determine the regulatory mechanism in 13q14.3 and 
furthermore, to identify epigenetic aberrations at 13q14.3 in CLL cells that might be relevant 
for the pathogenesis of CLL. 
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4 Discussion 
CLL is the most common leukemia among adults in the Western world. Still, the molecular 
pathomechanism remains unknown. CLL is is characterized by a defined set of well described 
genomic abnormalities, most of which have been shown to predict the survival of patients. 
The most frequent genomic aberration in CLL is a deletion of a critical region in 13q14.3 
(del(13q)), which occurs in over 50 % of patients (Döhner et al., 2000). Apart from CLL 
tumors, the critical region in 13q14.3 is lost in a number of other tumors in high frequencies, 
for example around 60 % of patients with Mantle Cell Lymphoma (MCL) show a deletion of 
13q14.3, which is the secondmost frequent genomic aberration in MCL (Bentz et al., 2000). 
In addition to hematological malignancies also other tumor entities show frequent loss of 
13q14.3, including prostate carcinomas (Chen et al., 2001), squamous cell carcinomas 
(Ogawara et al., 1998) and leiomyosarcomas (Wang et al., 2003). The high frequency of 
deletion of 13q14 in CLL cells and in a large variety of other tumor cells suggests that this 
region harbors a central pathomechanism involved in malignant transformation. 
Del(13q) in CLL has been correlated with a good prognosis unlike deletions in chromosomal 
regions like 11q22-23 and 17p13, which are associated with short (79 months) and very 
short (32 months) survival times, respectively (Döhner et al., 2000). Deletion of the first 
copy of 13q14 is always observed as first aberration and never as an acquired secondary 
aberration during clonal evolution in CLL (Stilgenbauer et al., 2007). However, biallelic loss of 
13q14.3, i.e. additional loss of the second copy, is the second-most common additionally 
acquired aberration during clonal evolution in CLL after deletion of 17p13 (Stilgenbauer et 
al., 2007). The critical region in 13q14.3 seems to be of major importance in suppression of 
tumor development. Furthermore, it is likely that the regulation of expression of the 
candidate genes in the region is involved in the tumor suppressor mechanism of 13q14.3. 
The high frequency of 13q14 deletions in CLL patients and the observation that del(13q14) is 
possibly a causative aberration in CLL, point to a central role of the tumor suppressor 
mechanism in 13q14. Although the tumor suppressor mechanism in 13q14 is deleted in more 
than 50 % of CLL patients, it remains largely unclear how the mechanism functions and how 
a defective mechanism prevents tumorigenesis. To date, epigenetic silencing of one copy of 
13q14.3 was shown indirectly by genomewide demethylation and deacetylation of the critical 
region in 13q14.3 in tumor cell lines (Mertens et al., 2006). Global demethylation as well as 
global deacetylation in tumor cell lines resulted in reactivation of expression of 
monoallelically silenced genes at 13q14.3. Strikingly, biallelic expression of a splicing variant 
of the ncRNA gene BCMS in the critical region in 13q14.3 could be reactivated by 
demethylation of CGI E. Therefore, it was important to gain insight into epigenetic regulation 
of the tumor suppressor mechanism in 13q14.3. The analysis and quantification of epigenetic 
modifications at the regulatory regions (CpG-islands; CGIs) and genes in 13q14.3 in non-
malignant hematopoietic cells of healthy donors provides insight into the epigenetically 
regulated transcriptional state of the genes in the region. Identification of active and silenced 
genes and/or alleles in 13q14.3, i.e. of the distinct epigenetic code of 13q14.3 in non-
malignant cells, can support the model of two differentially marked copies of 13q14.3 and 
the hypothesis of loss of the active copy in CLL. 
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4.1 Epigenetic regulation of 13q14.3? 
The molecular functions of the genes within and in direct neighborhood of the critical region 
in 13q14.3 are mostly unclear. To date, the functions of 13q14.3 candidate proteins can only 
be inferred from homology of single protein domains of the protein coding genes in the 
region (KPNA3, C13ORF1, RFP2 and KCNRG), which suggest potential functions of the 
proteins. Genes homologous to 13q14 genes are functionally involved in several pathways 
including NFκB-signaling, repression of transcription, hematopoiesis and inhibition of 
proliferation (Tschuch, 2006). Previous studies showed that 13q14 candidate proteins 
interact with each other and with additional proteins that are involved in various cellular 
processes including regulation of translation and regulation of gene expression (Serra-
Barrionuevo, 2008). These two studies indicate that the genes in the critical region in 
13q14.3 might form a functional gene cluster, which is involved in cellular pathways that 
could contribute to CLL pathogenesis. Thus it is likely, that the candidate genes of 13q14.3 
are involved in the pathomechanism of CLL. 
The 13q14 candidate genes were shown to be downregulated in CLL cells (Mertens 2002), 
but despite extensive sequence analyses of the critical region in CLL no pathogenic point 
mutations could be identified that would lead to loss of function of a potential tumor 
suppressor gene in the region (Liu et al., 1997; Stilgenbauer et al., 1998). Additionally, the 
candidate genes are monoallelically expressed in non-malignant B- and T-cells. Together 
with the finding that 13q14.3 replicates asynchronously due to differential chromatin 
packaging of the two alleles (Mertens et al., 2006) these are strong indications for an 
epigenetic regulatory tumor suppressor mechanism in 13q14.3. 
In this thesis, it was shown that promoter-restricted enrichment of H3K4me2, which is a 
chromatin mark for monoallelically expressed genes (Rougeulle et al., 2003), was stably 
detected at the 13q14.3 genes C13ORF1 and DLeu/BCMSUN in non-malignant cells (Figure 
3-11) and the chromatin pattern at these two genes was also retained in CLL cells (Figure 
3-18). The chromatin pattern of monoallelic expression was expected to be present at the 
gene DLeu2/BCMSUN, as it was previously shown to be monoallelically expressed in B- and 
T-cells of healthy donors (Mertens et al., 2006). Unexpectedly, we detected this chromatin 
pattern also at C13ORF1 and subsequently, it was shown that the gene is indeed 
monoallelically expressed in B- and T-cells. 
Thus, it was determined that the monoallelic expression status of the protein-coding gene 
C13ORF1 and of the ncRNA gene DLeu2/BCMSUN is marked in the histone code (Figure 3-
11). These findings point to further epigenetic regulation of the tumor suppressor 
mechanism and to an epimutation in 13q14.3 that leads to its inactivation in CLL cells. In 
order to elucidate the epigenetic regulatory pathomechanism of CLL, it was important to 
determine the epigenetic modifications at 13q14.3 in non-malignant and CLL cells. 
 
4.2 Analysis of epigenetic modifications at 13q14.3 
Chromatin remodeling, histone modifications and other chromatin-related processes play a 
crucial role in gene regulation. Chromatin immunoprecipitation (ChIP) has been recognized 
as useful technique to study these processes (Haring et al., 2007). In the last years, 
evidence has accumulated that suggests that the histone marks in cancer cells are similarly 
deregulated as has been shown for DNA-methylation in cancer cells (Fraga et al., 2005b). 
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Moreover, analogous to a pattern of global DNA-hypomethylation coupled to promoter 
hypermethylation that is found in cancer cells (Gargiulo and Minucci, 2008), specific histone 
modifications are thought to be changed in cancer cells into distinct patterns that are 
correlated to the tumor type (Fraga et al., 2005b).  
ChIP-analyses of epigenetic modifications in non-malignant and CLL cells were performed in 
order to be able to identify an aberrant epigenetic code of 13q14.3 that can be correlated 
with the deregulated gene expression related to CLL pathogenesis. The strategy to identify 
the histone modifications at 13q14.3 was to quantify active and repressive chromatin marks 
at the critical region to determine the transcriptional status of the candidate genes. Using 
ChIP active and repressive chromatin marks were quantified at the CpG-islands (CGIs) and 
genes in the critical region in 13q14.3. However, quantification of three epigenetic marks 
determines only a part of the epigenetic code of 13q14. Nonetheless, repressive histone 
modifications together with DNA-methylation were considered as strong indication of 
transcriptional silencing of the measured loci. In order to quantify one activating (H3K4me2) 
and one repressive (macroH2A) histone modification at the critical region in 13q14.3, the 
chromatin immunoprecipitation (ChIP) technique was established. 
4.2.1 Establishment of the ChIP protocol 
Several steps had to be optimized during establishment of the ChIP protocol in order to use 
it with primary hematopoietic cells (Figure 3-1). Virtually every step of the procedure had to 
be optimized carefully and was modified for primary hematopoietic cells. Here, it is 
suggested to modify the common ChIP protocol (Orlando, 2000) for each application, each 
antibody and each cell type of interest as this was essential to achieve successful chromatin 
precipitations, which was also recently described by others (Papantonis and Lecanidou, 
2008; Hanlon and Lieb, 2004; Clayton et al., 2006). 
Large cell numbers are necessary for each ChIP experiment to compensate for i) loss of cell 
material after reversion of cross-links, ii) loss of cell material to surfaces throughout the 
procedure, and iii) impaired signal to noise ratio upon reduction of input material (Collas and 
Dahl, 2008). However, the primary material from tumors is very limited; therefore several 
cell lines were needed for ChIP optimization. As cell lines deriving from CLL tumors (MEC1 
and MEC2) were not growing sufficiently well in culture, cell lines deriving from other 
hematological tumors that were rapidly growing into large cell numbers were used for 
establishment of ChIP. Three different cell lines were used to establish the ChIP procedures, 
which were HL60 (AML tumor of female origin), Jurkat (T-cell leukemia of male origin), and 
Namalwa (Burkitt’s lymphoma of male origin). It remains uncertain whether aberrant 
epigenetic modifications determined by ChIP are specific for the original tumor or are rather 
derived from cultivational artifacts. Moreover, the cell lines used in the present study did not 
derive from CLL so the measured epigenetic modifications in HL60, Jurkat and Namalwa cells 
might serve as potential epigenetic profile in AML, in T-cell leukemia and in Burkitt’s 
lymphoma, respectively and can therefore not be used to compare them to CLL profiles. All 
three cell lines showed reduced enrichment ratios of active and repressive chromatin marks 
at 13q14.3 loci compared to primary CLL cells and the distribution patterns of both marks 
differed from those determined in CLL cells (data not shown). One explanation for these 
observations is that the epigenetic profiles of 13q14.3 differ among various tumor entities, 
which would indicate that epigenetic profiles of 13q14.3 might be used to distinguish 
between different tumor entities. Another explanation for different profiles determined in 
primary CLL cells and cancer cell lines is that epigenetic modifications might change over 
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time in cultivated cells. Smiraglia and colleagues studied hypermethylation phenotypes of 
cancer cell lines in comparison to the primary malignancies (Smiraglia et al., 2001) and 
found that the cell lines exhibit significantly higher levels of CpG-island-hypermethylation 
than the primary malignancies they represent. 
Thus, it becomes clear that cell lines might not be the ideal model system for the analysis of 
aberrant epigenetic modifications in cancer. However, further analyses are needed to answer 
the questions of whether the epigenetic profiles of the cell lines used here are indeed 
representative of the original tumor or not, and whether epigenetics of AML or Burkitt 
Lymphoma are different from CLL profiles. The focus of the current work was to analyze the 
epigenetic profile of 13q14.3 in CLL and non-malignant cells. 
 
The first step of the ChIP protocol that had to be optimized in order to extract sufficient 
amounts of chromatin from hematopoietic cells is the chromatin preparation step (Figure 
3-1). As Spencer et al. (2003) noted it was essential, which salt and/or detergents are 
included in ChIP-buffers, because each detergent/salt concentration can make a difference in 
the accuracy of determining the distribution of a protein along a specific DNA-sequence. 
Here, it was tested whether the SDS content of buffers was crucial for quality and quantity 
of prepared chromatin in ChIP. It was seen that the amount of input chromatin in nChIP-
approaches (O'Neill and Turner, 2003) was significantly higher than that prepared in xChIP 
approaches. The two protocols differ in preparation of chromatin, in the fragmentation of 
chromatin and in the spectrum of analyzable chromatin modifications: Using the nChIP 
protocol, chromatin is prepared that can be fragmented by nuclease digestion into native 
chromatin fragments determined by nucleosomes. While native chromatin can be used to 
analyze histone modifications, chromatin prepared and fragmented by ultra-sonication using 
the xChIP approach can be used to analyze in addition to histone modifications also 
transcription factors or other chromatin-binding proteins that are fixed to the chromatin 
during the procedure. The main difference between the two protocols to this end was the 
buffers, because nChIP buffers where composed in such way that enzymatic digestion of 
chromatin is allowed. However, quality and/or quantity of nChIP-chromatin were not 
sufficient as it was not possible to precipitate targets efficiently (Table 3-1a-c). Moreover, a 
large disadvantage of the nChIP procedure is that only histone modifications can be analyzed 
with native chromatin. Analysis of transcription factors is impossible due to the lack of 
fixation to chromatin, which is included in the xChIP protocol. However, the broader 
application of ChIP is mainly interesting for future applications and so optimization of nChIP 
protocol was not immediately stopped. The standard xChIP protocol (Orlando, 2000) had the 
large disadvantage that the quantity of chromatin in fractions prepared from hematopoietic 
cells varied largely and no precipitation of chromatin could be achieved (Figure 3-2). It 
became clear that it was necessary to first enrich chromatin rather than use whole cell 
extracts for ChIP. Chromatin from whole cell extract thus was enriched by the use of nuclei 
extraction protocol originally developed for standard immunoprecipitation (IP). 
The implementation of the nuclei extraction protocol prior to chromatin preparation enriched 
cell nuclei and depleted the cell debris, which was beneficial for the quality and the quantity 
of chromatin. The enrichment of nuclei stably produced sufficient and reproducible quality 
and quantity of chromatin, which could be used for subsequent precipitation in ChIP. 
 
Formaldehyde cross-linking was assumed to be unnecessary when analyzing histone 
modifications, because chromatin is very stable and would need no further stabilization of 
histone-DNA-bonds. However, cross-linking ensures preservation of the chromatin structure 
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throughout isolation and ChIP procedures (Haring et al., 2007) and proved to be 
advantagous for the ChIP results. If cross-linking was included in xChIP procedures the 
chromatin was preserved as could be seen by the amount of DNA and protein that could be 
isolated afterwards (Figure 3-3). Moreover, a bias of DNA-fragment sizes was avoided 
(Figure 3-3a), compared to xChIP-protocol applied without cross-linking (Figure 3-3b), where 
an unexpected and unreproducible bias of DNA-fragments was produced. When comparing 
the two standard protocols nChIP and xChIP, it became evident that without cross-linking 
(i.e. as in nChIP) it is more likely that the DNA from chromatin fractions is lost and only 
proteins can be precipitated (Figure 3-3). 
In this study, using the nChIP-protocol failed to precipitate chromatin without cross-linking 
(Figure 3-3). Therefore, the cross-linking step of the xChIP protocol proves to be essential 
for success. It was also noted by others that they systematically failed to obtain significant 
amounts of precipitate without cross-linking (Haring et al., 2007). 
 
The third and last step that showed superiority of the xChIP over the nChIP protocol was the 
fragmentation of chromatin. In nChIP, fragmentation was carried out by nuclease digestion, 
which produced fragments that are multiples of nucleosomal DNA length of 146 bp in size 
(Figure 3-4a). The advantage of digesting chromatin is that the chromatin is digested into 
native fragments, i.e. the native chromatin structure provided by the nucleosomes is 
retained. On the other side, fragmentation by ultra-sonication is a completely random 
process that generates chromatin fragments with sizes varying from 100 bp to 1 kb (Figure 
3-4b) with the bulk of fragments having a size between 500-900 bp. The fragments 
produced by ultra-sonication were more reproducible in size and quantities compared to 
enzymatic digestion, which resulted in higher variability of fragments. The nucleosomal 
ladders were not reproducible, which might be due to variation in the performance of the 
used enzymes. A second disadvantage of nuclease digestion of chromatin was that no cross-
linking could be included as chromatin would not be recognized by the nuclease anymore. 
Ultra-sonication thus proved to be a robust tool that yielded reproducible and comparable 
amounts of chromatin fragments that could be used for precipitation in ChIP. 
It was shown in this study that chromatin has to be stabilized by cross-linking with 
formaldehyde and that chromatin fragments are produced more robust by ultra-sonication 
than by enzymatic digestion. This led to the use of an optimized standard xChIP protocol for 
the analysis of hematopoietic cells because nChIP-protocol failed to include these essential 
steps. The chromatin prepared for ChIP was enriched from nuclei of whole cell extracts by 
the use of nuclei extraction procedures and buffers, which substitute the SDS-lysis buffer 
and preparation of chromatin procedures from the original xChIP protocol (Orlando, 2000). 
 
Efficient precipitation of target chromatin is essentially dependent on the antibodies used. 
Nonetheless, also the choice of agarose beads and conditions for preclearing and 
precipitation is essential to minimize the binding of unspecific chromatin to agarose beads. 
Three sequential steps of preclearing with little amount of agarose beads proved to 
circumvent most efficiently the binding and co-precipitation of unspecific chromatin (Figure 
3-5). The quality of the primary antibody used for ChIP is the most critical part for successful 
precipitations (Spencer et al., 2003). Not every antibody that worked well in standard 
immunoprecipitation reactions, worked as well in ChIP as was seen for several tested 
antibodies including α-H3K4me3, α-H3K9me3 and α-Ikaros (Figure 3-6a) and also noted by 
others (Taneyhill and Adams, 2008). This can partially be explained by the fact that epitopes 
to which antibodies bind may be masked by chromatin architecture and/or are altered 
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beyond antibody recognition after cross-linking. Nine of the twelve antibodies tested here 
had to be excluded from further analysis, because they could not be used for Western blot 
detection of precipitated chromatin (i.e. α-HP1γ) and/or because they did not enrich target 
chromatin in precipitates (i.e. α-H3K9me3, α-CTCF or α-H3K27me3; Figure 3-6). 
The remaining three of twelve tested antibodies, α-H3K4me2, α-macroH2A and α-H3 (Figure 
3-6), could be used for quantification of histone modifications at chromosomal region 
13q14.3 as only these three precipitated their respective targets efficiently and reproducibly. 
Antibodies that precipitate chromatin in ChIP were all polyclonal antibodies. The superiority 
of polyclonal over monoclonal antibodies can be explained by the characteristic of polyclonal 
antibodies, which recognize different epitopes of the same target. Thus, polyclonal 
antibodies are in principle able to precipitate more of the target chromatin even when one or 
several epitopes of the chromatin are masked following formaldehyde cross-linking. In 
contrast, monoclonal antibodies only can recognize one epitope and are therefore prone to 
be influenced by epitope masking. 
 
In order to validate successful precipitation of target proteins two methods were applied. 
First, the proteins precipitated in ChIP were analyzed in Western blots for specific and 
efficient precipitation of the target. Second, precipitated DNA was analyzed by qPCR to 
ensure specific enrichment of control sequences. Western blot detection by the anti-
macroH2A antibody was inefficient compared to anti-H3K4me2 and anti-H3 antibodies. The 
anti-macroH2A antibody only detected macroH2A in Western blot when it was highly 
enriched as in the ChIP-precipitates. Non-enriched amounts of macroH2A could not be 
detected with satisfying results (Figure 3-8b). As it was suggested that endogenous 
macroH2A is not detectable in cross-linked chromatin fractions by Western blots (A. 
Ladurner, personal communication) reversion of cross-links was performed prior to Western 
blot analysis. However, the reversion of cross-links also did not produce satisfying Western 
blot results (data not shown). Thus, only the precipitations with anti-H3K4me2 could be 
sufficiently validated by Western blots (Figure 3-8a). 
The latter antibody also precipitated its target H3K4me2 more efficiently, as was seen from 
qPCR quantification of precipitated sequences (Figure 3-9). Resulting enrichment was 
calculated as “fraction of input”, which was also measured by qPCR (Figure 3-9; see also 
chapter 2.16.10). The antibody anti-H3K4me2 precipitated its target by a factor of 10-100 
more efficiently than did the anti-macroH2A antibody. This can be due to either a more 
efficient precipitation by the antibody used or to a higher abundance of H3K4me2 in the 
analyzed cells, whereby most likely both reasons apply here. MacroH2A1.2 is detected in 
lower quantities (1/10) in non-malignant hematopoietic cells and CLL cells than H3K4me2, 
and this is most likely due to lower endogenous amounts of macroH2A in general. 
This observation suggests that active chromatin marks (H3K4me2) are widely established in 
the epigenome, whereas the exchange of histone variants for canonical histones (i.e. 
macroH2A is a variant of canonical H2A) is more uncommon as an inactive chromatin mark. 
This might be the reason why macroH2A had been detected more frequently at distinct sites 
only, e.g. at inactivated X-chromosomal genes (Changolkar and Pehrson, 2006). MacroH2A 
occurrence only at the inactivated X-chromosomal genes also points to a monoallelic 
enrichment of macroH2A. Also, macroH2A plays a role at imprinted loci, which are rare 
(Choo et al., 2006), and this would explain the generally lower abundance of the histone 
variant. However, macroH2A could be detected at the analyzed loci in this study, for example 
at the positive control sequence of the IL8 promoter region, which was used as positive 
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control (Figure 3-9b, green bars), and also at several loci of the critical region in 13q14.3, 
which will be discussed in more detail below. 
 
As the ChIP-procedure is susceptible for generation of false-positive signals by unspecific 
precipitation, it is essential to normalize qPCR and microarray measured raw data. Three 
normalization steps were performed before interpretation of the ChIP-data: i) subtraction of 
background (i.e. subtraction of CT-values of mock- from precipitate-fractions; (see also 
Mutskov and Felsenfeld, 2004)); ii) relation of precipitate to input (fraction of input; (Tariq et 
al., 2003)) and iii) normalization relative to control sequences (x-fold enrichment versus 
control; (Mathieu et al., 2005, see chapter 2.20.4 for details). These three steps were used 
in order to generate valid data for the quantification of epigenetic marks at distinct genomic 
regions. The normalization steps were included after every ChIP experiment to achieve 
better comparability among different cell samples and also among different platforms used 
for analysis of ChIP-DNA (i.e. ChIP-on chip-and ChIP and qPCR). Control sequences used for 
the third normalization step were selected from ChIP-on-chip experiments with the CGI-
microarray. Two clones were selected as positive control sequences for H3K4me2- (CDH12) 
and macroH2A-ChIPs (HK2) and had to fulfill the criterion that they were enriched in both 
types of analyzed tissue, i.e. non-malignant and CLL cells, in order to serve as control 
sequence. The sequences found in promoter CpG-islands of the genes CDH12 and HK2 
fulfilled this criterion and consecutively, these sequences were used as positive control for 
normalization. Only after (three-fold) normalization, statistical analyses were performed and 
resulting data was interpreted. 
Normalization of ChIP-data is necessary, because it cannot be controlled by other means. For 
instance in expression analyses, normalization can be performed by testing expression levels 
of housekeeping genes in different tissues. However, levels of expression do not necessarily 
reflect changes in histone modifications (Haring et al., 2007). Thus, the described three 
steps of normalization of data were performed in order to link validated epigenetic 
modifications to transcriptional state of genes at 13q14.3. 
 
The ChIP methodology was established to quantitfy epigenetic modifications at the critical 
region in 13q14.3 in non-malignant and CLL cells. It was noted also by others that it is 
essential to establish and optimize each step of the protocol to the cell system and to 
antibodies that are intended to be used. Although the ChIP methodology appears to be 
simple, it is indeed a complicated procedure. In the present as well as in other studies 
several factors had to be optimized in order to successfully precipitate chromatin of interest 
by ChIP in a given system (Spencer et al., 2003; Haring et al., 2007; Collas and Dahl, 2008). 
These factors include the quality of the primary antibody, the degree of sample ultra-
sonication and formaldehyde cross-linking, the amount of protein A agarose, and the types 
of salt and/or detergent washes, which have been discussed above. Consequently, ChIP 
could be used as valuable tool for studying the chromatin modifications that are involved in 
the processing of DNA from the critical region in 13q14.3. 
4.2.2 Why of all histone modifications quantify H3K4me2 and 
macroH2A at 13q14.3? 
ChIP was used to characterize two histone modifications at 13q14.3, which are at first glance 
more uncommon: enrichment of H3K4me2 and macroH2A. However, they were chosen for 
several specific reasons. 
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The activating mark H3K4me2 is distributed specifically at active genes, but more broadly as 
the more commonly analyzed mark H3K4me3, which is enriched only at the transcription 
start sites of active genes (Wysocka et al., 2006). It was repeatedly shown that H3K4me3 
correlates with the onset of transcription (Bernstein et al., 2005; Pokholok et al., 2005; 
Santos-Rosa et al., 2002), while H3K4me2 resides elsewhere in the vicinity of active genes 
(Schubeler et al., 2004). As the main interest in this work was to characterize CpG-islands 
(CGIs), noncoding sequence and exogenic regions in 13q14.3, quantification of H3K4me2 
was chosen as it was described to be also enriched at these regions of active genes (Mellor 
et al., 2008). Thus, the chance of detecting the active chromatin mark at the small analyzed 
13q14 loci was maximized. Support for this choice came from recent studies that analyzed 
the genome-wide distribution of up to 20 histone modifications in parallel by a method called 
“ChIP-Seq” that combines ChIP with next-generation sequencing (Barski et al., 2007; Mellor 
et al., 2008). ChIP-Seq allows genome-wide screening of the epigenetic code at functional 
elements, i.e at transcription start sites (TSSs), at enhancers, at promoters and at intergenic 
and exonic regions. The screen by Barski et al. (2007) included genome-wide quantification 
of H3K4me2-enrichment and 18 other histone modifications. In the screen, H3K4me2 was 
found to be enriched at TSSs and also at intergenic regions in a distinct pattern similar to 
H3K4me3, but with a much broader distribution than H3K4me3. 
Therefore, H3K4me2 enrichment can be considered as sufficiently significant mark of active 
genes as it was found together with H3K4me3, which is significantly correlated to 
transcriptional activity (Barski et al., 2007; Wysocka et al., 2006). 
 
Analysis of macroH2A-enrichment was chosen to detect inactive chromatin sites at 13q14, 
because it was shown to be allelically enriched at imprinted loci (Choo et al., 2006) in 
addition to its abundance at silenced loci. MacroH2A is found for example at the inactive X 
chromosome in female mammals (Costanzi and Pehrson, 1998). The allelic deposition of 
macroH2A is of special interest as the current model for the tumor suppressor mechanism in 
13q14 involves differential chromatin packaging of the two copies of 13q14.3 (Mertens et al., 
2006), which results in one active and one inactive copy. Although 13q14 is not imprinted, it 
has several features of imprinted loci that includes monoallelic expression of two large 
noncoding RNA genes that span the critical region, and that promoter-restricted H3K4me2-
enrichment is detected at monoallelically expressed genes (Figure 3-11; Figure 3-18), a 
pattern that was first recognized at imprinted and monoallelically expressed genes 
(Rougeulle et al., 2003). A fourth characteristic of imprinted regions in the critical region in 
13q14.3 is, supposedly, the localization of a locus control region (LCR), analogous to 
imprinting control regions (ICEs) in imprinted loci, in one of the two CGIs in the 5’ regions of 
the two large noncoding RNA genes. 
On the basis of these similarities to imprinted loci it was feasible to assume that macroH2A 
can be detected at 13q14. As the model of epigenetic regulation of the critical region in 
13q14.3 suggests differential chromatin packaging of the two copies, macroH2A- as well as 
H3K4me2-enrichment was analyzed for monoallelic enrichment at 13q14.3 (Figure 3-16). 
Detailed characterization of H3K4me2- and macroH2A-enrichment at the genes and CpG-
islands in the critical region in 13q14.3 was used to determine active and inactive chromatin 
marks of the region in non-malignant cells and epigenetic aberrations in CLL cells. 
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4.3 Epigenetic modifications at 13q14.3 in non-malignant 
hematopoietic cells  
Quantification of the two histone modifications H3K4me2 and macroH2A together with DNA-
methylation at the critical region in 13q14.3 in non-malignant cells was analyzed in several 
aspects. The following pivotal questions will be discussed in the following sub-chapters: 
 
i) What is the epigenetic state of the candidate genes in the critical region in 
13q14.3? (Chapter 4.3.1). 
ii) Is the monoallelic expression of candidate genes reflected in the histone code? Is 
this true for all candidate genes? What are the exceptions? (Chapter 4.3.2). 
iii) Epigenetic modifications are changed during cellular aging. Do we observe 
epigenetic differences between cells derived from young healthy donors and older 
ones? What are the differences? (Chapter 4.3.3). 
iv) Epigenetic modifications are tissue-dependent and differ between different cell 
types. In the present study, peripheral blood lymphocyte (PBL) samples were 
analyzed as non-malignant control cell material even though they are not 
primarily composed of B-cells. Does it make sense to compare these non-
malignant PBLs to CLL cells that are derived from B-cells? Are there different 
epigenetic profiles detectable in non-malignant B- and T-cells? (Chapter 4.3.4). 
v) The current model of the epigenetically regulated tumor suppressor mechanism in 
13q14.3 includes monoallelic expression of the candidate genes, differential 
chromatin packaging and asynchronous replication timing of the two alleles 
(Mertens et al., 2006). Do chromatin marks also show preferential allelic 
enrichment at 13q14.3 that would support the model of one active and one silent 
13q14.3 copy? Furthermore, is there a locus control element/region (LCR) located 
in one of the CpG-islands? (Chapters 4.3.5 and 4.4.4). 
 
4.3.1 The epigenetic code of 13q14.3 in non-malignant 
hematopoietic cells 
It was proposed that each cell type within every tissue carries a distinct epigenome (Esteller, 
2007; Fraga and Esteller, 2005), which is specifically altered during malignant 
transformation. Thus, in order to analyze the epigenetic changes in CLL cells, first the wild 
type epigenetic code of 13q14.3 was determined in B-cells and in a mixture of hematopoietic 
cells. Two histone modifications (i.e. H3K4me2 and macroH2A) were analyzed in detail at 36 
loci within 13q14.3 (Figure 2-3) in non-malignant cells from eleven healthy donors.  
The genome wide distribution of H3K4me2 is strongly correlated with the distribution of 
H3K4me3, which is enriched specifically at active genes (Barski et al., 2007). Here, 
H3K4me2-enrichment was analyzed in order to identify CpG-islands (CGIs) in the 5’-regions 
of 13q14.3 candidate genes that are actively marked. Astonishingly, the overall pattern of 
H3K4me2-enrichment at all single loci in the critical region in 13q14.3 is the same or nearly 
the same in all analyzed cells (Figure 3-10). Considering H3K4me2 at 13q14.3 alone, the 
observation of an identical distribution pattern of the active histone mark in cells derived 
from eleven donors supports the existence of the above described tissue-specific epigenome. 
When considering only one histone modification, it is questionable whether the 
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transcriptional state of a gene can be determined. However, the active chromatin mark is 
found most frequently at three CGIs in 13q14.3: CGIs B, D and E showed highest enrichment 
of the active chromatin mark (Figure 3-10). CGIs A and C in 13q14.3 only showed reduced 
levels of the active mark. Moreover, several analyzed loci in 13q14.3 are located in the exons 
of candidate genes (Figure 2-3) and these were shown to generally contain fewer active 
marks than the 5’ regions of the genes (i.e. the CGIs; Figure 3-10). Thus, a first analysis of 
the distribution of the active chromatin mark at 13q14.3 suggests that the three CGIs B, D 
and E are actively marked whereas CGIs A and C are not. Whether A and C are silenced can 
only be decided after analysis of more than one epigenetic mark. Therefore, macroH2A-
enrichment was analyzed as inactive chromatin mark at the same loci in 13q14.3. MacroH2A 
is higher enriched at CGIs A and C than at CGIs B, D and E, which is in accordance with 
H3K4me2-enrichment. High enrichment of macroH2A together with lack of H3K4me2 at CGIs 
A and C suggests that both CGIs might be marked as inactive. However, when considering 
also the DNA-methylation at these two CGIs, silencing is not supported or not (yet) further 
stabilized by DNA-methylation. CGI A and CGI C do not show any (or only very little) DNA-
methylation in non-malignant cells (Figure 3-13 and A. Philippen, personal communication). 
The two histone modifications both suggest inactivity of the CGIs, but DNA-methylation does 
not support silencing of the CGIs. Moreover, the genes KPNA3 and RFP2 are both expressed 
in non-malignant cells (Mertens et al., 2006), which excludes at least complete silencing of 
the two CGIs in the promoter region of the genes. The enrichment of macroH2A at 13q14 
was generally lower (by factor 10-100) than that of H3K4me2. This can be due to the finding 
that macroH2A-enrichment can be allele-specific at imprinted loci (Choo et al., 2006) and 
suggests that it might indeed be enriched at only one copy of the monoallelically expressed 
13q14 region. Furthermore, it was detected that macroH2A is especially lower enriched in 
non-malignant cells derived from probands that are above 45 years old. This suggests that 
enrichment of macroH2A might decrease during aging or is correlated with the aging process 
(see chapter 4.3.3). 
Quantification of two histone marks and of DNA-methylation at the CpG-islands of 13q14.3 
showed an unequal occurrence of activating and repressive chromatin marks at the five CGIs 
and also at the two copies of 13q14.3. This unequal distribution of chromatin marks suggests 
a distinct epigenetic code at 13q14.3 that regulates expression of the candidate genes. 
 
Epigenetic marks that constitute the epigenome of a given cell (Fraga and Esteller, 2005), 
specifically mark the transcription status of genes at the genes promoter region. Therefore 
all three epigenetic modifications analyzed here, were considered if they constitute a distinct 
transcriptional state of the genes in the critical region in 13q14.3 in the chromatin. No 
distinct epigenetic mark was detected for KPNA3. Only medium and non-significant 
enrichment of the active and silent histone marks was detected along with a lack of DNA-
methylation at CGI A in non-malignant cells (Figure 3-13). KPNA3 and CGI A are located 
outside of the critical region in 13q14.3 and lack a distinct epigenetic mark, which suggest 
that KPNA3 is also outside of the epigenetic regulation in 13q14.3. 
In contrast, at the C13ORF1 locus, a gene located within the critical region, promoter-
restricted enrichment of H3K4me2 was detected (Figure 3-11) that is correlated with 
monoallelic expression of the gene (see chapter 4.3.2). Furthermore, a comparatively high 
macroH2A-enrichment is detected at CGI B. This may point to a bivalent mark of the 
C13ORF1 promoter, which might be the reason for selective monoallelic expression of the 
gene in most but not all healthy probands and of most but not all splice variants of 
C13ORF1. The DNA-methylation at CGI B also reflects a potential bivalent epigenetic code at 
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the sequences of the promoter and the gene, as DNA-methylation was found to be highly 
variable ranging from 0 % to 80 % (A. Philippen, personal communication). These observed 
interindividual differences might reflect allelic differences in DNA-methylation, but also age 
differences or tissue differences as samples containing diverse lymphocytes (PBL) derived 
from healthy probands with an age between 23 and 54 years were analyzed. 
The epigenetic code of CGI B and C13ORF1 points to an important role of the candidate 
gene in the pathomechanism of CLL. Its protein function is not clear yet, but it has been 
shown to be involved in NFκB-signaling, in NOTCH-signaling and in AKT-signaling, which are 
pathways that regulate B-cell development, hematopoiesis and proliferation, respectively 
(Tschuch, 2006). Deregulation of these signaling pathways by C13ORF1 can directly be 
linked to the pathogenesis of CLL, which points to major importance of C13ORF1 for the 
CLL-pathomechanism. 
The first and second exons of RFP2, of which the sequence overlaps with the sequence of 
CGI C (Figure 1-11), show minor DNA-methylation (Figure 3-13). However, this is contrasted 
by distribution of the histone modifications. H3K4me2 is equally distributed along the 
sequence of RFP2 exons and CGI C, and so is macroH2A. Only one locus within CGI C 
(Figure 3-13) shows the highest detected enrichment of macroH2A in this region. The 
candidate gene RFP2 behaves very peculiar when considering the analyzed epigenetic 
modifications together with the known transcriptional state of the gene. RFP2 is 
monoallelically expressed in non-malignant B- and T-cells and also in CLL cells (Mertens et 
al., 2002). However, in contrast to C13ORF1, the monoallelic expression is not reflected in 
the histone code, as no significant promoter-restricted H3K4me2-enrichment was detected 
(see below, and Figure 3-11). Neither was a distinct epigenetic code determined for RFP2 
and CGI C. All three analyzed epigenetic marks are found at RFP2 and CGI C in medium 
levels, but none of them points to a distinct transcriptional state of the gene (i.e. RFP2 is 
neither marked as active nor as inactive). The lack of an unambiguous epigenetic mark at 
RFP2 and CGI C on the other hand supports the model of two epigenetically distinct copies 
of 13q14.3. As the abundance of active and inactive marks in medium amounts, may reflect 
that each mark is enriched at only one of the two copies. If one copy carries only active 
marks and the other only inactive, the performed analysis that cannot discriminate between 
the two alleles but measures the marks of both copies together would produce the observed 
results. RFP2 could therefore be an interesting candidate to be analyzed in more detail with 
respect to differential chromatin packaging of the two 13q14.3 copies. It will be interesting 
to learn how the two alleles are differentially marked at the RFP2 locus and how monoallelic 
expression of the gene is epigenetically regulated. 
Interestingly, the two ncRNA genes and the CGIs D and E that are located in the 5’-regions 
of the ncRNA genes show a special distribution of epigenetic marks that was not observed 
anywhere else in the critical region in 13q14.3 (Figure 3-13). Regarding the epigenetic 
modifications at CGI D, the CpG-island is divided into two parts. Most of CGI D is actively 
marked (Figure 3-13). In the centromeric part we find high enrichment of H3K4me2, low 
macroH2A-enrichment and no DNA-methylation. This abruptly changes at the most telomeric 
part of the CGI, which overlaps with the first and second exons of BCMS. Here significant 
silencing was measured, as H3K4me2-enrichment is comparatively low and DNA is heavily 
methylated (Figure 3-13). The silencing is apparently not stabilized via macroH2A-
enrichment, which is very low allover the sequence of CGI D (Figure 3-13a). 
CGI E again shows a mix of active and silent segments, but this pattern is not as clear 
concerning the distinct modifications as was described for CGI D. H3K4me2-enrichment is 
high allover CGI E, except at two loci located in the middle of CGI E where it is significantly 
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lower (Figure 3-13a). Starting at locus “E4a” DNA-methylation in non-malignant cells is 
observed in a stretch within the CGI, which is about 3000 bp in length (Figure 3-13b; A. 
Philippen, personal communication). No significant macroH2A-enrichment could be detected 
at the whole CGI E (Figure 3-13a, lower panel). 
In summary, CGIs D and E show a mixture of activating and inactively marked parts in non-
malignant cells. CGI D is marked with chromatin modifications associated with active genes 
except for the most telomeric part of CGI D, which overlaps with exons of BCMS. All three 
analyzed marks, H3K4me2-, macroH2A-enrichment and DNA-methylation, are in 
concordance with active euchromatin at the centromeric larger part of CGI D. However, the 
most telomeric part, within exon two of BCMS, shows marks corresponding to a silent state. 
As was seen for the centromeric larger part of CGI D, all analyzed chromatin marks are in 
concordance with each other and mark the most telomeric part of CGI D as silenced. CGI E 
can be considered as divided into two halves: The centromeric half, which is marked as 
active, and the telomeric half, which is less active and shows some marks for silencing. The 
special epigenetic features of these two distinct loci within CGIs D and E suggest the 
localization of LCRs within these loci, which will be discussed in more detail below (chapter 
4.3.5). 
 
A model for epigenetic regulation of the gene expression from the critical region in 13q14.3 
is summarized in Figure 4-1 at the end of chapter 4.3. The epigenetic code of the critical 
region in 13q14.3 determined by the analyzed chromatin marks in the present study is 
summarized in Table 4-1. At the five analyzed genes and CpG-islands in their promoter 
regions in 13q14.3, no exclusive marks for transcriptional activity or silencing were detected. 
However, when considering that only three epigenetic modifications of many more that 
constitute the epigenetic code (Figure 1-5), were analyzed here, it is possible that some 
specificities may be missed. 
 
Table 4-1: Summary of epigenetic marks at the genes and CGIs located in the chromosomal region 
13q14.3. +: respective mark was found; -: no mark; /: not measured. 
Gene/CGI in 
13q14.3 
Active mark 
(H3K4me2) 
Inactive mark 
(macroH2A) 
DNA-
methylation 
Sum of epigenetic 
marks 
KPNA3 + + / active?/inactive? 
CGI A + + - active?/inactive? 
C13ORF1 - ++ / “monoallelic active” 
CGI B +++ + -(+)  
RFP2 - ++ - inactive 
CGI C + + + active?/inactive? 
BCMS - ++ + inactive 
CGI D 
LCR1 
++ 
(+) 
+ 
++ 
- 
+ 
active 
LCR1: inactive 
BCMSUN - ++ / “monoallelic active”  
CGI E 
LCR2 
++ 
(+) 
+ 
+ 
- 
+ 
 
LCR2: inactive 
 
In summary, the three marks together point to active chromatin marks at the CGIs within 
the 5’ regions of the genes KPNA3, C13ORF1, RFP2 and BCMS in non-malignant cells (Table 
4-1). The active marks at these genes correlate with their transcriptional activity. Moreover, 
the occurrence of chromatin marks with contrary transcriptional impact at the same positions 
could point to allelic differences of the two 13q14 copies. The procedure applied here did not 
allow differentiation between the two copies; therefore, differential packaging of the alleles 
  Epigenetic code of 13q14.3 in wild type 
 
 
115
can only be concluded from the observation that supposedly opposing epigenetic 
modifications are detected when analyzing both alleles together. This conclusion is supported 
by earlier findings that suggested differential chromatin packaging of the two 13q14-copies 
that leads to asynchronous replication timing of the two alleles (Mertens et al., 2006). 
Accordingly, the genes in the critical region are monoallelically expressed from the active 
copy of 13q14.3, whereas the second copy is silent in non-malignant cells. 
4.3.2 Histone code of monoallelic expression at 13q14.3 
Most genes carry chromatin marks reflecting their expression status. Rougeulle et al. (2003) 
showed that imprinted and monoallelically expressed genes have promoter-restricted 
H3K4me2-enrichment that correlates with monoallelic expression of the genes. In order to 
test whether the pattern could be detected at the monoallelically expressed genes at 
13q14.3, H3K4me2-enrichment was determined at genes and promoter regions. The 
chromatin pattern of monoallelic expression as described by (Rougeulle et al., 2003) was 
found at the genes DLeu2/BCMSUN and C13ORF1 in the critical region in 13q14.3. 
DLeu2/BCMSUN was earlier described to be indeed monoallelically expressed (Mertens et al., 
2006). However, the analysis of the chromatin pattern for monoallelic expression led to 
identification of another gene in the region that carries this mark, i.e. C13ORF1. Here we 
could show that C13ORF1 is another gene in the critical region that is monoallelically 
expressed in non-malignant cells (Figure 3-11). Thus, it became clear that almost all genes 
in the critical region in 13q14 are monoallelically expressed in non-malignant cells. 
Monoallelic expression is determined for the genes C13ORF1, DLeu2/BCMSUN, RFP2 and 
splicing variants of BCMS (see Figure 3-11b and Mertens et al., 2006)), while KPNA3 is 
biallelically expressed. All of these genes but RFP2 were found to carry the histone mark that 
reflects their expression status. Except for the biallelically expressed KPNA3 and the short 
splicing variant of BCMS that showed no restricted H3K4me2-enrichment, monoallelically 
expressed genes like C13ORF1 and DLeu2/BCMSUN showed promoter-restricted H3K4me2-
enrichment (Figure 3-11). RFP2 was shown to be monoallelically expressed in B- and T-cells 
(Mertens et al., 2006), but promoter restricted H3K4me2-enrichment was not detected. 
The chromatin modification pattern that was correlated with monoallelic expression is 
remarkably stable regarding different tissue types and different ages of analyzed cells. It was 
found to be exactly the same in almost all subgroups of healthy probands, i.e. in probands 
below and above the age of 45 years (young and old wild type subgroup) and also in B- and 
T-cells. Nonetheless, two exceptions were detected. The first exception is observed at 
DLeu2/BCMSUN with both eligible promoters (CGI D and E), where promoter-restricted 
H3K4me2 could not be detected in probands below the age of 45 years despite the fact that 
the gene is monoallelically expressed (Figure 3-12). The second exception is found in the B-
cell subgroup, where the promoter-restricted H3K4me2-enrichment at DLeu2/BCMSUN could 
only be detected when taking CGI E into account and not with CGI D. These observations 
suggest that promoter-restricted enrichment of H3K4me2 might be dynamic. The chromatin 
mark for monoallelic expression might be set up at DLeu2/BCMSUN at a later point in lifetime 
(after the age of 45 years) and not early in development as has been described for other 
chromatin marks and for the epigenetic code of imprinted genomic regions (Choo et al., 
2006; Wood and Oakey, 2006; Reik et al., 2001; Santos et al., 2002). The epigenetic code 
for monoallelic expression that is found at DLeu2/BCMSUN with the promoter consisting of 
CGI D might on the other hand also be tissue-specific. The pattern for monoallelic expression 
is found at a potential TSS of a splicing variant of DLeu2/BCMSUN in T-cells only. The finding 
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suggests specific monoallelic expression of this variant in T-cells, as it was not found in the 
B-cell subgroup. It remains to be determined whether the “loss” of the chromatin mark for 
monoallelic expression in B-cells is due to tissue-specificity of monoallelic expression of the 
DLEU2/BCMSUN splicing variant. 
 
The promoter-restricted H3K4me2-enrichment of monoallelically expressed genes in 13q14.3 
is not changed in CLL cells (Figure 3-18). The chromatin mark was detected at the 
monoallelically expressed genes C13ORF1 and DLeu2/BCMSUN also in CLL cells and it was 
not detected at any biallelically expressed gene of 13q14. The chromatin pattern that reflects 
the expression status of the genes therefore seems not to be affected by an epimutation or 
aberrant epigenetic changes in CLL. 
4.3.3 Are epigenetic marks at 13q14.3 changed during aging? 
Some epigenetic changes can be assigned to environmental and stochastic changes that 
occur during the lifetime of an organism (Fraga et al., 2005a). Changes in the epigenetic 
landscape that have been associated with aging include DNA-methylation changes and 
changes in histone modifications H4K16ac and H4K20me3 (Fraga and Esteller, 2007). 
Therefore, it was essential to determine epigenetic modifications in age-matched non-
malignant cell samples in order to be able to later distinguish epigenetic aberrations related 
to CLL from epigenetic changes that occur during aging. Healthy probands were stratified 
according to age with a threshold set at 45 years. The “young” subgroup included five 
samples of probands below the age of 45 years. The mean age of the young subgroup was 
32 years with a range of 23 to 43 years. The “old” subgroup contained six samples of 
probands with an age of 45 years and above. The mean age of the old subgroup was 50 
years with a range of 48 to 54 years. Unfortunately, an ideal CLL age-matched group of 
probands with a mean age of 65 years was not available. The differences of the age of 
probands subjected to the two subgroups may not be sufficient to detect significant 
differences between the subgroups. Neither H3K4me2- nor macroH2A-enrichment at 
13q14.3 was significantly changed in young or old subgroups compared to each other 
(Figure 3-14;  
Table 3-4). No significant differences could be measured between the subgroups; however, 
some tendencies were noted. First, H3K4me2-enrichment tended to be higher in the old 
subgroup at most 13q14 genes and CGIs, except for the genes C13ORF1, BCMS and 
DLeu2/BCMSUN. This indicates epigenetic changes at 13q14.3 that occur during aging. At 
the exonic regions of three genes aging-related epigenetic modifications were correlated with 
a modest gain of active chromatin marks. Nevertheless, the differences in enrichment were 
not significant and thus they can also be related to interindividual differences of epigenetic 
modifications. Second, macroH2A-enrichment was higher enriched in the young subgroup. 
MacroH2A was higher at four of the genes in 13q14.3 and at all five CGIs, the only exception 
was KPNA3, which was higher macroH2A-enriched in the old subgroup. Thus, the inactive 
chromatin mark seems to get lost during aging. 
No significant pvalues to describe differences between the subgroups could be calculated ( 
Table 3-4); this might, in addition to other reasons, be due to the similarity of the two age 
groups. The majority of the eleven analyzed healthy probands was between 42 to 50 years 
old. The small variation of the age of the probands led to the cut-off threshold for the young 
subgroup and the starting age of the old subgroup of 45 years. Thus, the selection of the 
threshold was limited by the available sample variation. However, these probands may be 
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too similar regarding their aging-related epigenetic modifications, to allow detection of 
differences between the two subgroups. Another explanation might be that the threshold of 
45 years was either not high enough or too high. The epigenetic changes during aging are 
maybe occurring rarely and more slowly so that no changes are detectable in 10 years time 
period. 
In order to detect epigenetic changes during aging in hematopoietic cells or B-cells, it will be 
necessary to analyze more samples in each age group and maybe to redefine the threshold 
used to stratify the groups. Another possibility to gain insight into the aging related 
epigenetic changes might be to analyze a healthy “old” group with a median age of 65 years 
(i.e. with the same median age as CLL patients). However, this age group is usually not 
amenable to sampling, especially not via blood donation. It would further be interesting to 
analyze several healthy young age groups with a median age below 20 years and below 10 
years, for instance. Again, the problem could be sampling, especially with the very young 
probands. However, if samples could be collected, it would be possible to detect significant 
differences of epigenetic modifications in non-malignant cells that are related to the aging 
process. In addition, with this kind of set-up it would be possible to determine at which age 
the first epigenetic changes appear in lifetime. 
It is not clear to which extent the observed changes in histone modifications at 13q14 have 
an impact on altered expression of the genes. It is well possible that these epigenetic marks 
are only accumulating during the cellular aging process, without direct effects on 
transcriptional regulation, unless they reach a specific threshold. However, it is highly likely 
that the epigenetic differences observed in old cells when compared to young, predispose 
these aged cells to the tumorigenic transformation process as was already described (Fraga 
et al., 2007). H3K4me2 enrichment is higher in older cells and therefore it could be easier to 
transform these cells towards CLL, where a significantly higher H3K4me2-enrichment was 
detected (Figure 3-17; chapter 4.4). The aberrant H3K4me2-enrichment in CLL cells leads 
most likely to up-regulation of expression of the noncoding RNA, which in turn might induce 
aberrant regulation of the critical region in 13q14. Meanwhile, a repressive mark is lost 
during the aging process, which might contribute to aberrant activation of distinct promoters 
of the critical region in 13q14.3 observed in CLL cells. 
 
In the present study, evidence was found that the epigenetic changes of non-malignant cells 
during aging predispose aged cells to tumorigenic transformation. In hematopoietic cells, 
these changes include a modest gain of an active chromatin mark at the CpG-islands in 
13q14.3 along with modest loss of an inactive mark at the critical region. With the 
experimental set-up chosen here, no significant differences between young and aged non-
malignant cells could be detected. However, both changes of epigenetic modifications are 
determined as substantial aberrations in transformed CLL cells (chapter 4.4.1). 
4.3.4 Tissue-specificity of epigenetic marks at 13q14.3. Are there 
differences between B- and T-cells? 
Cell types of different tissues hold specific epigenomes, which is the key through which 
multicellular organisms can exist where different cell types harbor an identical genome. The 
components of epigenomes are DNA-methylation, post-translational modifications of histones 
(PTM) and high order organization of chromatin in cell nuclei (Gargiulo and Minucci, 2008). 
CLL is a B-cell disease, i.e. aberrant CLL cells are derived from B-cells. However, the genes 
located in the critical region in 13q14.3 were shown to be monoallelically expressed in both 
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B- and T-cells derived from healthy probands (Mertens et al., 2006). As the expression 
pattern of 13q14.3 genes is essentially the same in B- and T-cells the epigenetic mark that 
regulates the expression has to be set early in development. The epigenetic regulation of 
monoallelic expression of 13q14.3-genes is set most likely at the stage of a lymphocyte 
progenitor cell state, and maintained during further differentiation into B- and T-lymphocytes 
(Figure 1-6). Therefore, with respect to monoallelic expression of the 13q14.3 candidate 
genes, it was interesting to also determine epigenetic modifications in both B- and T-cells. 
Additionally, the fact that malignant CLL cells are derived from B-cells poses the questions 
whether samples consisting of unselected peripheral blood lymphocytes (PBLs), which were 
used as non-malignant control, are the right control tissue to be able to detect epigenetic 
differences or aberrations in CLL cells. In order to address these questions, two samples of 
CD19+-sorted B-cells and of T-cells derived from two healthy donors were analyzed for 
H3K4me2-enrichment at 13q14. The detected B-cell profile of H3K4me2-enrichment of 
13q14 is similar to the PBL profiles determined earlier (Figure 3-10; Figure 3-15). When 
comparing B- to T-cell profiles (Figure 3-15), a generally up to ten-fold higher H3K4me2-
enrichment was determined in B-cells at 13q14.3. Interestingly, the greatest enrichment 
fold-changes are evident at CGI B, D and E where the differences reach a factor of ten. In 
contrast, the overall pattern of H3K4me2-distribution at 13q14.3 is the same in B- and T-
cells. However, the H3K4me2-enrichment in T-cells never reached a value of 10 fold 
enrichment versus CDH12. These results suggest that the T-cell influence in PBL control 
samples for CLL is negligible as it was found to be generally below ten-fold enrichment 
versus CDH12. Moreover, H3K4me2-enrichment was found to be significantly lower in T-cells 
when compared to B-cells. Interestingly, the lower enrichment of the active chromatin mark 
H3K4me2 at 13q14.3 was in line with the previously described lower expression of the 
candidate genes of 13q14 in T-cells (Mertens et al., 2002). It will be interesting to further 
analyze if epigenetic modifications are different in B- and T-cells and if differential 
modifications have an impact on the differential gene expression in these cell types. 
It can be concluded that the T-cell-specific influence in PBL samples is negligible and that 
PBL samples can thus be used as control tissue for CLL cell samples. It seemed thus feasible 
to compare the PBL profiles of epigenetic modifications at 13q14.3 to CLL profiles, with the 
purpose to identify epigenetic aberrations in CLL cells. 
4.3.5 Differential epigenetic marks at the two 13q14 copies? Model 
of the epigenetically regulated tumor suppressor mechanism in 
the critical region in 13q14.3. 
Analysis of allelic variation in gene expression and of allelic variation in epigenetic 
modifications helps to identify regulatory single nucleotide polymorphisms (SNPs) and 
regulatory genomic elements (Kadota et al., 2007). The most characteristic features of locus 
control elements (LCRs) that regulate transcription of gene clusters in mammalian genomes, 
are differential epigenetic modifications of the two alleles (Li et al., 2002). Differential 
epigenetic modifications include DNA-methylation, but also histone modifications. LCRs are 
described further to be differentially methylated (and probably modified) with respect to the 
region they are localized. 
In this thesis, two candidate LCRs in the critical region in 13q14.3 could be identified, the 
first within a telomeric 2 kb part of CGI D and the second within a 2 kb part in the middle of 
CGI E (chapter 4.3.1; Figure 3-13). Next, healthy probands were recruited that are 
heterozygous for a SNP located nearby the candidate LCR locus. Allelic enrichment of both 
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macroH2A and H3K4me2 was determined by ChIP combined with subsequent sequencing of 
the identified SNPs (LCRs). Thus, potential differential allelic enrichment of the two 
chromatin marks could be detected at the LCRs in samples derived from heterozygous 
probands. Analysis of these heterozygous samples allowed discrimination of the two copies 
and thus sequencing of ChIP-DNA precipitates could be used to detect differential 
enrichment at the two copies. Clear allelic differences were only detected at the candidate 
LCR within CGI E (Figure 3-16). At the locus in CGI E H3K4me2 was indeed enriched at only 
one copy of 13q14.3 in one of five probands (Figure 3-16a). A tendency for monoallelic 
enrichment of H3K4me2 could also be detected at the second potential LCR within CGI D, 
because only one of the two copies was found to preferentially carry the active chromatin 
mark in two of six analyzed probands (Figure 3-16c). Surprisingly, macroH2A-enrichment 
showed no clear differential enrichment between the two copies of 13q14.3 at CGI E (Figure 
3-16b) and a preference for monoallelic enrichment in two of four probands at CGI D (Figure 
3-16d). The allelic differential enrichment of H3K4me2 and macroH2A point to involvement 
of these specifically marked loci in the regulation of the tumor suppressor mechanism. 
However, allelic enrichment of H3K4me2 could only be detected in one out of five probands, 
and a preference for monoallelic enrichment of H3K4me2 in two out of six probands, which 
might be due to the location of the analyzed SNP. The SNPs are probably located near but 
not exactly in the LCRs. Unfortunately, allelic enrichment cannot be further analyzed because 
no other SNPs are available in the determined candidate LCR regions. 
 
In addition to characterization of epigenetic regulation by candidate LCRs in the critical 
region in 13q14.3, the candidate genes in the region are mostly monoallelically expressed, 
except for KPNA3 and BCMS (Figure 3-11 and (Mertens et al., 2006). Both candidate LCRs 
are found within CGIs that are located in the 5’ region of the two large noncoding RNA genes 
BCMS and BCMSUN. Several large noncoding RNA (ncRNA) species have been described to 
control gene expression (Zaratiegui et al., 2007; Andersen and Panning, 2003; Shamovsky 
and Nudler, 2006) with one of the best described examples for a ncRNA that regulates 
expression of an imprinted gene cluster being the ncRNA Air (Rougeulle and Heard, 2002). 
Moreover, the majority of large ncRNAs have been described to be involved in regulation of 
expression of other genes in cis (Mattick, 2003). Imprinted genes have been shown to be 
organized as linkage groups in gene clusters (Lafon-Hughes et al., 2008), which might be 
true also for the candidate genes in the critical region 13q14.3 as these share several 
similarities with imprinted loci, although the region is not imprinted (Mertens et al., 2006). 
Furthermore, it has been shown that transcription of regulatory ncRNAs located in imprinted 
gene clusters, are regulated by so-called imprinting control elements (ICEs), which belong to 
the family of LCRs (Pauler et al., 2007; Li et al., 2002). Methylation of CpG-dinucleotides in 
imprinted regions create differentially methylated regions (DMRs) either in the active or the 
inactive copy (Lafon-Hughes et al., 2008). 
Thus, a potential functional gene cluster in the critical region in 13q14.3 is postulated, where 
the transcription of the genes is interdependent and/or depending on epigenetic regulation. 
The postulation of a functional gene cluster in 13q14.3 comes from several findings within 
our group. The identification of candidate LCRs in the critical region in 13q14.3 that regulate 
the transcription of the large ncRNA genes indicates a regulatory role of these ncRNAs. If the 
two large ncRNAs are involved in the regulation of the candidate genes, the genes are most 
likely regulated together as a gene cluster. Moreover, (Tschuch, 2006) found the genes to be 
involved in the same signaling pathways in a functional study of the candidate genes. 
Recently, (Serra-Barrionuevo, 2008) also showed interaction of the proteins from 13q14.3 in 
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a yeast-two hybrid screen and furthermore, cooperation of these proteins in large protein 
complexes and in the same signaling pathways. The findings of cooperative involvement of 
the proteins in the same signaling pathways and/or in the same protein complexes point to 
their functional relationship with each other. 
 
Considering the epigenetic modifications detected in the present study at the gene cluster 
and at functional elements in the critical region, a model of epigenetic regulation at 13q14 is 
suggested that consists of three features: 
 
i) 13q14 is present in one active copy and one silent copy in non-malignant cells, 
ii) The large ncRNAs BCMS and BCMSUN most likely are involved in the regulation 
(in cis) of expression of the other genes in 13q14, and  
iii) Differential epigenetic modifications of a candidate LCR region controls 
transcription of the large ncRNA genes, and via regulation of the ncRNAs the LCR 
controls transcription of the gene cluster in the critical region (Figure 4-1). 
 
Evidence for this model, especially for the existence of one active and one silent 13q14.3 
copy comes on the one hand from the monoallelic expression of the genes, which was 
shown for all genes but KPNA3 in the region (Figure 3-11; and (Mertens et al., 2006)). On 
the other hand the determined allelic variation in the enrichment of histone modifications at 
the candidate LCRs in CpG-islands D and E are strong hints that support the model for 
epigenetic regulation of the tumor suppressor mechanism in 13q14.3. 
4.3.6 Consequences of the epigenetic code at 13q14.3 for the tumor 
suppressor mechanism in the critical region 13q14.3 
The epigenetic marks determined in this study are not distinct on a gene-level (Table 4-1), 
except for the promoter-restricted H3K4me2-enrichment at CGI B and C13ORF1, which is a 
distinct chromatin mark of monoallelic expression of C13ORF1. At most other CpG-islands in 
the critical region in 13q14.3, a bivalent epigenetic pattern is determined, as both marks for 
active and inactive transcription were detected (Table 4-1; summarized in Figure 4-1). The 
existence of bivalent promoters was suggested primarily in embryonic stem cells, where 
bivalent chromatin domains carrying both repressive and activating histone modifications 
mark promoters of developmental regulator genes (Ku et al., 2008). The finding of ‘bivalent’ 
marks at CpG-islands located within promoter regions in 13q14.3 in differentiated non-
malignant cells, however, rather point to differential modifications at the two copies of 
13q14. Allelic variation of enrichment of active and inactive chromatin marks was shown for 
a small locus in CGI E (chapter 4.3.5; Figure 3-16). The observation of activating and 
repressive chromatin marks at the same gene locus identified two types of loci; the first were 
imprinted loci and abundance of contrary marks is explained by allelic differences. The 
second includes loci that were known or suspected to be regulated by antisense interfering 
transcripts that arise from CpG-islands at the 3’-region or by LCR-controlled ncRNAs (Mellor 
et al., 2008). 
Whether these modifications are mutually exclusive or both present on the same allele 
awaits further analysis of SNPs in the region. On the other hand, the ‘bivalent’-like pattern in 
promoter regions (CGIs) of the genes in the critical region may also point to incomplete 
epigenetic silencing/activation of the respective gene locus. Nonetheless, the expression 
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status of the genes in the critical region in 13q14 is reflected in the epigenetic modifications 
detected at the CGIs in their 5’-regions (Figure 4-1a). 
 
Figure 4-1: Epigenetic modifications at 13q14.3 in non-malignant cells. Model of the 
epigenetic regulatory mechanism in 13q14.3; white circles = active 
chromatin mark; black circles = inactive chromatin mark. (a) Schematic 
summary of epigenetic modifications at genes and CGIs of 13q. (b) 
Proposed model of resulting gene expression from two copies of 13q14. 
The regulatory impact of the ncRNAs is omitted in the figure. 
 
The epigenetic pattern for monoallelic expression (Rougeulle et al., 2003) was found at the 
monoallelically expressed genes C13ORF1 and BCMSUN, but not at the biallelically expressed 
genes KPNA3 and BCMS. RFP2 was previously described to be monoallelically expressed 
(Mertens et al., 2006); still, promoter-restricted H3K4me2-enrichment at RFP2 and CGI C 
could not be detected in the present study (Figure 3-11). 
The epigenetic code of the two large ncRNA genes and the two CGIs in their 5’-regions that 
span the critical region in 13q14.3 show peculiarities that are not observed anywhere else in 
the region. Both CGIs are divided into a centromeric active part and a telomeric inactive part 
(i.e. half in the case of CGI E; Figure 4-1a; Figure 3-13). Moreover, evidence for differential 
allelic enrichment at breakpoints within the CGIs was detected (Figure 3-16). The abrupt 
change in chromatin marks within the CGIs suggests the existence of candidate LCRs that 
could be involved in regulation of transcription in 13q14.3. The transcription of the ncRNAs 
seems to depend on the epigenetic modification status of the LCRs that determine whether it 
is active or inactive. Thus, the epigenetic status of the LCRs could determine the 
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transcriptional status of the ncRNAs, which in turn regulate expression of the other genes in 
the critical region of 13q14.3. This model of regulation is analogous to models described for 
imprinted loci that are regulated by transcriptional regulation of large noncoding RNAs 
(Rougeulle and Avner, 2004). Further investigations are important to determine exact 
functions and regulation of the tumor suppressor mechanism in 13q14.3. Overexpression of 
the ncRNAs in tumor cell lines has no effect on the expression of the other genes in 13q14.3 
(D. Mertens, personal communication). Therefore, in order to determine the regulatory 
function of the ncRNAs, it will be necessary to transplant the whole genomic region into B-
cell progenitor cells, and to analyze the resulting epigenetic modifications and the expression 
of the other genes in the critical region. For linking differential chromatin modifications at the 
potential LCRs in 13q14.3 to transcription of the ncRNA genes, further studies implying 
modulation of epigenetic modifications at the LCRs in cancer cell lines are needed. The 
proposed studies would need to demonstrate significant correlation of the epigenetic status 
of the LCR with the transcription rate of the ncRNA genes. 
 
Finally, the epigenetically regulated tumor suppressor mechanism in 13q14.3 is not an 
imprinting mechanism, but results in monoallelic expression of the genes in the critical 
region. The regulatory impact of the epigenetically controlled transcription of the ncRNA 
genes in the critical region in 13q14.3 has not yet been fully understood. However, the 
findings of this study suggest that in non-malignant B- and T-lymphocytes derived from 
healthy probands the two 13q14.3-alleles differ, which results in one active and one silent 
copy. Thus, differential chromatin packaging of the two copies of 13q14.3 leads to the 
observed monoallelic expression of the candidate genes in the region (Figure 4-1). 
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4.4 The aberrant epigenetic code of 13q14.3 in CLL 
The development of cancer in humans is the result of a multi-step process that involves 
activation of oncogenes and/or inactivation of tumor suppressor genes (TSGs) (Hanahan and 
Weinberg, 2000). These two steps arise not only due to mutations, but also as the result of a 
translocation or an altered transcription rate (Spannhoff et al., 2008). Histone modifications 
and DNA-methylation have been recognized as important features and markers of 
tumorigenic transformation of cancer cells (Esteller, 2006). To date, several studies provided 
important insights into epigenetic alterations of cancer cells and into the contribution of 
epigenetic alterations in the pathogenesis of tumors (Gargiulo and Minucci, 2008). 
Several genomic aberrations have been well described in CLL and could be linked to 
prognosis and survival of CLL patients (Döhner et al., 2000). The high frequency of deletion 
of a critical region of chromosomal band 13q14.3 in the majority of CLL patients points to a 
tumor suppressor mechanism in the region that is causally involved in the pathogenesis of 
CLL (chapter 4.3.6). The genetic aberrations in CLL have been characterized in detail in the 
last decades by many groups (Liu et al., 1993; Döhner et al., 1997; Liu et al., 1997; 
Kapanadze et al., 1998; Stilgenbauer et al., 1998; Döhner et al., 1999; Hamblin et al., 1999; 
Döhner et al., 2000; Kapanadze et al., 2000). However, these extensive studies failed to 
detect a pathogenic point mutation of a putative tumor suppressor gene in 13q14 in CLL 
cells. The absence of pathogenic mutations within candidate genes from analysis of patients 
with monoallelic loss at 13q14 suggests either haploinsufficiency or epigenetic suppression of 
the retained allele. Recent data support the latter suggestion as favoured mechanism 
(Dickinson et al., 2006; Haslinger et al., 2004; Kienle et al., 2005; Mertens et al., 2006). An 
epigenetic tumor suppressor mechanism in 13q14 was postulated (Mertens et al., 2006) that 
results in monoallelic expression of the gene cluster in the critical region and allelic silencing 
of 13q14 in non-malignant cells (chapter 4.3). This tumor suppressor mechanism would 
explain the almost complete downregulation of candidate genes and microRNAs observed in 
CLL (Calin et al., 2002; Cotter and Auer, 2007; Mertens et al., 2002). To date, none of the 
described targets of the microRNAs including BCL2 (Cimmino et al., 2005) and CCND1 (Chen 
et al., 2008), was shown to be specifically down-regulated by the miRNAs in CLL cells. Calin 
et al. (2002) showed that absence of miR15/miR16 in CLL is associated with mutated IgVH-
genes and with deletions from the critical region in 13q14.3. Normally, miR15/miR16 are 
involved in the control of gene expression of their proposed target BCL2 (Cimmino et al., 
2005). Thus, their absence in CLL could play a major role in the prevention of apoptosis that 
is observed in CLL cells. However, the absence of miR15/miR16 was not confirmed in 
another study focusing on these two microRNAs in CLL: Fulci et al. (2007) found low 
expression of the miRNAs in only 12 % of patients analyzed, despite 54 % having a deletion 
of 13q14.3. All biallelically deleted del(13q) patients showed striking downregulation of 
miR15. However, this pronounced downregulation of both miRNAs was not paralleled by any 
significant increase in BCL2 expression (Fulci et al., 2007). 
Therefore, the link of the microRNAs and CLL pathogenesis is considered to be a part of 
inactivation of the tumor suppressor mechanism in 13q14.3 rather than the cause for 
inactivation in CLL. The microRNAs are most likely co-regulated by the large ncRNAs in the 
critical region as part of the functional gene cluster. The postulated model for the tumor 
suppressor mechanism involves co-regulation of candidate genes including the protein 
coding and microRNA genes, by the two large noncoding RNAs, BCMS and BCMSUN that 
span the critical region. 
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In the current study, epigenetic modifications at 13q14.3, including H3K4me2- and 
macroH2A-enrichment as well as DNA-methylation, were analyzed in CLL cells to identify an 
epimutation that can lead to deregulation and subsequent inactivation of the postulated 
tumor suppressor mechanism in 13q14.3 in CLL patients. The aging process could possibly 
account for epigenetic changes occurring later in life time. Also, tissue specific differences 
between B- and T-cells might account for interindividual differences in the epigenetic code 
detected in non-malignant cells, but no significant differences could be determined when 
comparing B- and T-cells of healthy probands. 
 
Hence, the determined epigenetic features of the critical region in non-malignant cells 
(Figure 4-1) together with the proposed model of epigenetic regulation of 13q14.3 (chapter 
4.3.6) can now be used to identify epigenetic aberrations at 13q14.3 in CLL cells. Elucidation 
of the epigenetic regulatory mechanism was used to determine aberrations in CLL that might 
lead to deregulation or inactivation of the epigenetic tumor suppressor mechanism in 13q14. 
By comparison of modification patterns in CLL and in non-malignant cells, aberrations of 
13q14 in CLL cells could be identified. These aberrations will be discussed in the following 
chapter and possible effects on the function and regulation of the tumor suppressor 
mechanism will be considered. 
4.4.1 Aberrant chromatin modifications at 13q14.3 in CLL 
Global DNA-hypomethylation coupled with promoter hypermethylation has been accepted as 
supplementary hallmark of cancer (Gargiulo and Minucci, 2008; Esteller, 2006). Additionally, 
it has been suggested that histone marks are also specifically deregulated in cancer cells 
(Fraga et al., 2005b) and all kinds of epigenetic modifications constitute a tumor epigenome 
that distinguishes cancer cells from non-malignant cells (Esteller, 2007). Thus, alterations of 
the epigenetic code are directly linked to an aberrant gene expression in tumor cells. To 
date, epigenetic aberrations detected in CLL include global DNA hypomethylation (Wahlfors 
et al., 1992), promoter hypermethylation and consecutive silencing of the death-associated 
protein kinase 1 (DAPK1) gene (Raval et al., 2007), of the transcription factor TWIST2 (Raval 
et al., 2005), and also genome wide promoter hypermethylation (Raval et al., 2006). 
Furthermore, the epigenetic alterations described in CLL lead to deregulation of the genes 
ID4 (Yu et al., 2005), secreted frizzled-related protein 4 (SFRP4) (Liu et al., 2006) and of 
various other genes (Smiraglia and Plass, 2002). 
Some of the above mentioned genes as well as the microRNAs could be linked to CLL 
pathogenesis. The first example is SFRP4, which was shown to be involved in Wnt-signaling 
(Liu et al., 2006). Wnt-signaling controls apoptosis and is required for normal B-cell 
development, whereas aberrant activation of this pathway has been observed in CLL 
(Rosenwald et al., 2001; Lu et al., 2004). Liu et al. (2006) showed aberrant DNA-methylation 
and silencing of SFRP4 as well as of additional SFRP family members in primary CLL samples. 
The family member SFRP1 was hypermethylated and down-regulated in analyzed CLL 
samples suggesting this epigenetic event as critical step during leukemogenesis. Silencing of 
SFRPs in CLL by CpG-island-hypermethylation is one possible mechanism contributing to 
aberrant activation of the Wnt signaling pathway in CLL that results in defective apoptosis of 
CLL cells. Two hallmarks in the pathogenesis of CLL are the escape of CLL cells from 
apoptosis and the low proliferative activity of CLL cells due to their escape from the cell cycle 
arrest in G0/G1 phase. The result of the defective apoptosis in vivo is accumulation of CLL 
cells in the peripheral blood of patients (Dighiero and Hamblin, 2008). 
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Regarding the proposed functions and interactions of the candidate genes of the critical 
region in 13q14.3 (see chapter 1.3.2), their CpG-island-hypermethylation and epigenetic 
silencing (due to histone modifications) might lead analog to aberrant activation of Wnt-
signaling pathways by SFRPs, to disturbed NFκB-signaling by 13q14.3 candidate genes 
(Tschuch, 2006), which constitutes another critical step during the pathogenesis of CLL. 
 
Here, two histone modifications and DNA-methylation at 13q14.3 were analyzed in CLL, to 
detect epigenetic aberrations in CLL cells that could lead to identification of an epimutation 
responsible for the inactivation of the tumor suppressor mechanism in CLL. 
The most striking epigenetic aberration detected in CLL cells is the significantly higher 
enrichment of H3K4me2 at all analyzed loci in 13q14.3. Surprisingly, a significant and drastic 
gain of the active mark was determined at the tumor suppressor locus 13q14.3 in CLL. This 
was rather unexpected because with the definition of the epigenetic regulation of the tumor 
suppressor mechanism in 13q14.3, whereby one copy is active and the second is inactive, it 
was assumed that the active copy along with active epigenetic marks would be lost in CLL 
cells. As a loss of function of the tumor suppressive mechanism is evident in CLL cells, it was 
expected that the inactive copy would be retained in CLL patients. However, the significant 
enrichment of chromatin marks associated with transcriptional activity at 13q14 was 
determined as median value from all CLL samples analyzed, which derived from three 
del(13q) patients and two patients that retained both copies. Individual differences between 
these patients will be discussed below (chapter 4.4.3). 
The general gain of activating chromatin marks at 13q14.3 was analyzed in more detail and 
showed aberrant patterns in CLL at CGI B, CGI C and CGI E. These three CGIs showed 
significantly higher H3K4me2-enichment in CLL compared to non-malignant cells (Figure 
3-23), which was not detected at CGI A and CGI D (Figure 3-17; Figure 3-23). In relation to 
the other analyzed CpG-islands in 13q14.3, at CGI D a lower enrichment of the active mark 
was detected in CLL cells compared to non-malignant cells (Figure 3-17). Furthermore, a 
slight increase of inactive chromatin marks at CGI D could be measured in CLL, which can 
lead to inactivation of one of the two large ncRNA genes, most likely of BCMS, as CGI D is 
located in the 5’-region of the BCMS. Also, a gain of active chromatin at CGI C was detected 
in CLL cells, which can lead to aberrant activation of the gene RFP2. The significant higher 
enrichment of H3K4me2 detected at CGIs B and E, which are located in the 5’-regions of the 
monoallelically expressed genes C13ORF1 and DLeu2/BCMSUN, respectively, may lead to 
upregulation of the genes. 
 
In summary, a general 10-1000-fold higher enrichment of H3K4me2 and a loss of the 
distinct distribution of H3K4me2 observed in non-malignant cells could be detected at 13q14 
in CLL (Figure 3-17). Moreover, loss of active chromatin marks at CGI D was detected, which 
might be linked to aberrant silencing of CGI D in CLL cells. The last finding indicates a loss of 
activity of one regulatory ncRNA that might be subject to specific epigenetic silencing in CLL. 
In contrast to non-malignant cells, macroH2A is enriched at CGI D in CLL, which supports 
the aberrant silencing of CGI D in CLL. Indeed, one of the splicing variants of this ncRNA 
gene was earlier shown to be significantly down-regulated in CLL patients (Mertens et al., 
2002). Loss of activity of the ncRNA might have great impact on the regulation of the critical 
region in 13q14.3, because the ncRNA was proposed to be involved in the epigenetic 
regulation of the tumor suppressor mechanism in in 13q14.3 (chapter 4.3.5). The exact 
regulatory function of the ncRNA still has to be determined, but in the present study and in 
previous studies (Mertens et al., 2002; Tschuch, 2006; Serra-Barrionuevo, 2008; Wolf et al., 
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2001) the importance of this ncRNA gene for the pathomechanism of CLL was shown directly 
and indirectly. 
 
As a marker for repressive chromatin, enrichment of macroH2A was measured at 13q14.3. 
Similar to findings in non-malignant cells (chapter 4.3.1), the enrichment of macroH2A at 
13q14.3 was found to be significantly lower than that of H3K4me2 also in CLL cells. In CLL a 
distinct pattern of macroH2A enrichment differing from that seen in non-malignant cells 
becomes apparent: MacroH2A is highly enriched at exonic regions and generally lower at 
CGIs (Figure 3-19). This was not detected in non-malignant cells, where macroH2A is spread 
more or less homogenously over the whole region 13q14.3 at low levels (Figure 3-12). A 
modest gain of the repressive mark in CLL cells, however, points to potential aberrant allelic 
silencing of 13q14.3 in CLL cells. As seen already in non-malignant cells, enrichment of 
macroH2A at promoters and genes is reciprocal to H3K4me2-enrichment. While H3K4me2 
can be found in high amounts at the promoter regions and not at gene exons, macroH2A 
was detected in high amounts at exons and not, or only in lower amounts, at the promoters. 
The abundance of macroH2A at exonic regions points to a possible silencing role of 
macroH2A itself. MacroH2A might be involved in recruitment of the chromatin to 
heterochromatic regions, in recruitment of silencing factors and in the prevention of binding 
of transcriptional activators, which would lead to repression of transcription of underlying 
genes. 
 
Some evidence is available that suggests DNA-methylation in cancer cells is not involved in 
the silencing of active genes, but occurs at genes that are already silent in order to silence 
them permanently (Lafon-Hughes et al., 2008). This observation might explain the 
discordance of DNA-methylation and histone modification patterns detected at some parts of 
the region 13q14.3 in CLL cells. The CGIs A and C are not methylated in CLL and non-
malignant cells. DNA-methylation at CGI B is found in a range between 0 and 90 % in non-
malignant cells, but is slightly reduced in CLL cells to a range between 0 % and 70 % (Figure 
3-20). Differences in DNA-methylation at 13q14.3 between non-malignant cells and CLL cells 
are found at CGIs D and E. In non-malignant cells CGI D shows DNA-methylation at its most 
telomeric parts, whereas in CLL cells methylation at these loci is partially lost. Some CLL 
patients have completely lost the methylation at this locus, whereas others still maintain the 
same degree of methylation that was observed in non-malignant cells (70-100 %). 
The same phenomenon was observed in CGI E. DNA-methylation is lost in CLL at locus “E5a” 
(Figure 3-23), which is methylated in all analyzed non-malignant cell samples, but only in 
half of the CLL samples. Thus, analysis of DNA-methylation (Figure 3-23) indicates potential 
silencing of the candidate LCR in CLL cells. The DNA-methylation patterns determined at the 
candidate LCR in CGI E are not distinct, nonetheless, all findings both in non-malignant and 
CLL cells at candidate LCRs within CGIs D and E, point to a unique function of these loci that 
are potentially involved in regulatory control of gene expression from the critical region in 
13q14.3 and are thus candidate LCRs. 
 
When considering the epigenetic code of 13q14.3 that is constituted by the three analyzed 
chromatin marks, differences between non-malignant and CLL cells can be detected that 
lead to identification of epimutations in CLL (Table 4-2). 
In CLL cells the chromatin at CGI A in the 5’ region of the gene KPNA3 in 13q14 is not clearly 
marked. Figure 3-20 shows abundance of the active chromatin mark (H3K4me2-enrichment) 
together with comparatively high enrichment of the inactive mark macroH2A. However, no 
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DNA-methylation was detected at CGI A (data not shown). Altogether the three different 
epigenetic marks do not fit the current models of a clear epigenetic code at CGI A, which 
could lead to impaired expression of KPNA3 in CLL. In non-malignant cells, at CGI A no 
significant level of any of the three epigenetic marks was detected (Table 4-1). 
 
Table 4-2: Summary of epigenetic marks at the genes and CGIs located in the chromosomal region 
13q14.3 in CLL cells. +: respective mark was found; -: no mark; /: not analyzed. 
Gene/CGI 
in 
13q14.3 
Active mark 
(H3K4me2) 
Inactive 
mark 
(macroH2A) 
DNA-
methylation
Sum of 
epigenetic marks 
Aberrations 
compared to 
non-malignant 
cells 
(epimutations) 
KPNA3 (+) ++ / (active?)/inactive? more macroH2A 
CGI A (+) ++ - (active?)/inactive? less H3K4me2 
C13ORF1 - ++ / “monoallelic active” none 
CGI B +++ + -(+) active  
RFP2 (+) (+) - active more H3K4me2 
CGI C +++ (+) + active less macroH2A 
BCMS (+) (+) + inactive silenced 
CGI D 
LCR1 
(+) 
+++ 
(+) 
(+) 
- 
- 
inactive? 
LCR1: active 
localized 
activation 
BCMSUN - ++ / “monoallelic active” none 
CGI E 
LCR2 
+++ 
++ 
+ 
(+) 
+ 
+ 
active? 
LCR2: inactive 
localized 
activation 
 
In CLL cells, however, H3K4me2 is detected in comparably low amounts along with a 
significantly high enrichment of macroH2A. MacroH2A enrichment suggests aberrant 
silencing of the promoter region, but enrichment of macroH2A does not coincide with DNA-
methylation. However, enrichment of macroH2A could explain the aberrant silencing of 
KPNA3 in CLL (Mertens et al., 2002). Silencing of KPNA3 is interesting as it is one of the 
genes in 13q14 linked to NFκB-signaling. It has been shown to be a potential carrier protein 
that shuttles NFκB into the nucleus (Tschuch, 2006; Fagerlund et al., 2005; Fagerlund et al., 
2008). This points to a potential selective advantage of CLL cell clones that have partially lost 
KPNA3 and are therefore less efficient in translocating NFκB into the nucleus, where NFκB 
regulates expression of its target genes. This would explain how NFκB-function might be lost 
in CLL cells. 
The epigenetic marks at CGI B, C13ORF1, CGI C, RFP2 and BCMSUN remain unchanged in 
CLL cells compared to non-malignant cells, except for the overall 10 to 100 fold higher 
enrichment of histone modifications described earlier. The chromatin mark of monoallelic 
expression at C13ORF1 (and CGI B) is unaffectedly stable in CLL cells. RFP2 carries active 
marks and no inactive mark (no macroH2A and no DNA-methylation) and BCMSUN exons are 
marked as silent with no H3K4me2- and high macroH2A-enrichment (Figure 3-20).  
 
The overall epigenetic code of candidate genes in 13q14.3 in and outside of the critical 
region is practically the same in non-malignant and CLL cells. Nonetheless, also aberrant 
chromatin modifications at 13q14.3 were detected when comparing CLL cells to non-
malignant cells. A general higher H3K4me2- and a higher macroH2A-enrichment were 
detected in CLL cells. Significant differences of enrichment of chromatin marks between non-
malignant and CLL cells, are detected at CGIs B, C and E and at the exonic region of 
BCMSUN (Figure 3-23). Finally, distinct epimutations in CLL cells are detected at candidate 
LCRs located within CGIs D and E in the 5’-regions of the ncRNA genes in the critical region. 
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Thus, the aberrant modifications in CLL are most evident at the promoter regions in 13q14 
and at the sequence of ncRNA gene itself. 
Aberrations affecting promoter or regulatory regions in diseases are quite common, as these 
directly control gene expression. However, activation of genomic loci by epigenetic marks is 
usually not achieved by alteration of only one histone mark. The histone code seems to be 
far more complex (Jenuwein and Allis, 2001; Jost and Galm, 2007; Strahl and Allis, 2000). 
Nonetheless, the significantly stronger enrichment of H3K4me2 at 13q14 in CLL is quite 
striking. It is highly likely that this has an effect on gene expression, but the effect appears 
not to be direct, as it is not measurable by upregulated expression of the candidate genes in 
CLL. On the other hand, also significant higher enrichment of macroH2A at CGI E and 
C13ORF1 is detected in CLL cells, which could result in aberrant silencing (Figure 3-23). 
C13ORF1 shows significant levels of macroH2A enrichment only in CLL patients. Nonetheless, 
the gene is monoallelically expressed in non-malignant and CLL cells and furthermore, the 
chromatin mark for monoallelic expression remains unchanged in CLL. 
 
Considering the model of the epigenetic regulatory mechanism in 13q14.3 (chapter 4.3.6), 
pronounced de-regulation of the ncRNAs might have an indirect but drastic effect on the 
gene expression of the other genes in the critical region. The proper expression of the 
ncRNAs could be crucial for maintenance of the tumor suppressor mechanism in 13q14. 
Importantly, the expression of the ncRNA might be changed in CLL by an epimutation within 
their promoter region, which might have impact on the deregulation of the whole tumor 
suppressor mechanism in 13q14 in CLL and it might further lead to inactivation of the tumor 
suppressive function of 13q14. Loss of this function might be a hallmark in the process of 
malignant transformation to CLL. 
 
In summary, the generally higher enrichment of both activating and repressive chromatin 
marks presents as an epigenetic aberration in CLL cells. They might affect the ncRNA genes 
as they include loss of the monoallelic chromatin mark at DLeu2/BCMSUN in CLL and 
aberrant macroH2A-enrichment at CGI E, which might lead to silencing of the ncRNA. 
Whether the loss of chromatin marks associated with monoallelic expression is the cause or 
the consequence for aberrant macroH2A at the second promoter region including CGI E is 
not known. Furthermore, the distinct aberrant epigenetic activation of the two candidate 
LCRs in 13q14.3 points to an epimutation in CLL that affects most likely the transcription of 
one or both ncRNA genes that span the critical region. Finally, deregulated transcription of 
the ncRNA(s) would suffice for deregulation and subsequent inactivation of the postulated 
tumor suppressor mechanism in the critical region in 13q14.3. 
4.4.2 Epimutations or aging-related changes at 13q14.3? 
Several changes of the epigenome of a particular cell can be associated with cellular 
senescence and the aging process itself (Fraga et al., 2005a; Issa, 2003). Moreover 
connections between aging and cancer have been made, whereby the link of these 
processes is the epigenetic language (Fraga et al., 2007). CLL is a disease that mainly affects 
elderly people with a median age of 72 years (Dighiero and Hamblin, 2008). To control for 
epigenetic changes that occur during aging and are, thus, unrelated to the disease itself, 
H3K4me2- and macroH2A-enrichment in non-malignant cells (“old wild type”) that derived 
from an “old” organism with a median age of 51 years were analyzed and epigenetic profile 
of this group was compared to the CLL profile (Table 3-5). Only modest epigenetic 
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alterations of these “old” non-malignant cells were detected that can be related to the aging 
process (chapter 4.3.3). The epigenetic alterations that seem to accumulate during aging of 
non-malignant cells are significantly different from aberrations that are observed in CLL cells 
(Table 3-5). Nonetheless, the epigenetic modifications observed in “old” non-malignant cells 
are similar to the detected epigenetic changes in CLL cells. A modest higher enrichment of 
both activating and repressive marks was detected when comparing “old” to “young” non-
malignant cells ( 
Table 3-4), but differences were not significant. Moreover, when comparing these young and 
old wild type subgroups to CLL (Table 3-5), no significant differences can be detected that 
are related to the age of the subgroups (Figure 3-21). 
 
So, indeed, an aging-related epigenetic code that is similar to the epigenetic aberrations 
characteristic of CLL cells, was detected in non-malignant cells. Thus, the altered epigenome 
determined in “old” non-malignant cells might present a predisposition of these cells to turn 
into CLL cells. 
4.4.3 Correlation of epigenetic aberrations at 13q14.3 and genomic 
aberrations in five CLL patients 
Genomic aberrations of CLL patients can be correlated to prognosis and survival in CLL 
(Döhner et al., 2000). Here, epigenetic modifications at 13q14.3 in CLL cells of five patients 
were analyzed. Even though statistical significance could not be reached when comparing 
this limited number of CLL samples, observations and tendencies inferred from these five 
cases will be discussed in this chapter. Some of these observations might provide a basis for 
further investigations and possible limitations of future experiments. 
The five patients can be grouped according to their karyotypes into CLL with only one copy 
of 13q14 ((del)13q), and CLL patients that retain both copies, whereof one patient had a 
deletion of 17p13 ((del)17p) and the other one had a no genomic aberrations (norm). 
Considering these two CLL-patient subgroups, it was possible to analyze whether loss of 
genetic material from the critical region in 13q14.3 is linked to the observed epigenetic 
aberrations in CLL. The question arises whether epigenetic modifications at 13q14.3 would 
correlate with the deletion status of the region. The proposed model of epigenetic regulation 
of 13q14.3 comprises the differentiation of the two copies into one active and one silent 
copy. Depending on whether the active or the silent allele is lost in del(13q) patients, 
quantification of the active mark in these patients is expected to result in either equal 
amounts, or in no or lower detected amounts as determined in the first group. Accordingly, 
all three analyzed del(13q) patients (CLL2, CLL4 and CLL5; Figure 3-22), supposedly lost the 
active copy as these have only very low H3K4me2-enrichment at 13q14.3. Surprisingly, 
those two patients that retained both 13q14 copies do not have amounts of the active mark 
that are comparable to that of non-malignant cells. Instead, they show H3K4me2-enrichment 
that is around 10 to 1000-fold higher than in non-malignant cells and also 3 to 100 fold 
higher than in (del)13q patients (Figure 3-22). The high enrichment of H3K4me2 at 13q14 in 
cells that retain both copies points to further established differences between the two copies 
in these CLL patients. 
In principle, this finding supports the model of an active and an inactive copy of 13q14.3, 
which was already found in non-malignant cells. The inactive copy in CLL cells, however, is 
marked by a lesser amount of active chromatin marks and additionally by higher amounts of 
the inactive chromatin mark, which was not detected in non-malignant cells. Moreover, 
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compared to amounts in non-malignant cells, the CLL cells with retention of both copies also 
gained active chromatin marks. 
The analyzed del(13q) patients seem to have lost the active copy, which would explain the 
strong reduction of H3K4me2-enrichment detected at 13q14. Support for this finding comes 
from the analyzed repressive chromatin mark, macroH2A-enrichment at 13q14 (Figure 3-23): 
The three del(13q) patients show macroH2A enrichment at 13q14. At some analyzed loci in 
13q14.3 macroH2A was found in high amounts, which resembles a selected gain of 
repressive marks at 13q14.3 compared to non-malignant cells. In contrast, the normal and 
del(17p) patients have almost no detectable macroH2A enrichment at the critical region in 
13q14.3. 
 
In conclusion, CLL cells with both copies of the critical region show a gain of the activating 
chromatin mark that is coupled to reduction of the repressive mark and all analyzed del(13q) 
patients lost the active copy. In summary, the findings suggest that in patients with 
retention of both copies, 13q14.3 is strongly activated by strong H3K4me2 enrichment and 
reduction of macroH2A. 
 
However, the active chromatin mark in 13q14 is not equally distributed at the region neither 
in non-malignant cells, nor in the CLL patients analyzed. It is not only differentially enriched 
when comparing promoter regions to exonic sequences, but differs also within particular 
CpG-islands analyzed (Figure 3-10; Figure 3-22). Only one distinct locus is heavily activated 
in CLL cells, which is the candidate LCR within CGI D (Figure 3-22). Furthermore, the second 
candidate LCR located in CGI E shows also significantly higher enrichment of the active 
chromatin mark. In contrast to the distinct activation of the LCR locus in CGI D, the 
activation at the second candidate LCR affects the complete centromeric half of CGI E 
(Figure 3-22), pointing to CGI D harbouring the effective LCR in the region. The activation of 
the candidate LCR that controls expression of the regulatory ncRNA in the critical region in 
13q14.3, can lead to deregulation of the ncRNA. 
Considering the model for the epigenetic regulatory mechanism in the critical region in 
13q14.3 (chapter 4.3.6), aberrant upregulation of the regulatory ncRNA might lead to 
complete silencing of other genes in the region, which are initially only downregulated upon 
loss of one copy. Complete inactivation of the tumor suppressor mechanism in 13q14.3 can 
be either caused by epigenetic deregulation of the retained copy described above or by 
biallelic deletions of 13q14.3 during clonal evolution. 
 
These findings suggest an epimutation in 13q14 being responsible for the inactivation of the 
epigenetic regulatory mechanism of 13q14 in CLL. Inactivation of the candidate genes in the 
critical region likely plays a role for the pathogenesis of CLL, as the genes could be linked to 
essential pathways that support and control normal B-cell development (Mertens et al., 
2006; Serra-Barrionuevo, 2008; Tschuch et al., 2008; Chen et al., 2008). Further, the 
findings in the present study suggest that the regulatory impact of the ncRNA, the LCR or 
another part of the critical region in 13q14 might be affected by this epimutation and thus 
lead to deregulation and inactivation of the tumor suppressive function of 13q14 and to 
development of CLL. 
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4.4.4 Identification of a potential epimutation in the postulated LCR 
of the critical region in 13q14.3 
Generally, locus control regions (LCR) are described to regulate expression of gene clusters 
within imprinted regions (Li et al., 2002). Commonly, these LCRs are differentially DNA-
methylated on the two copies and also have differential chromatin marks on the two copies. 
The organization of the critical region in 13q14.3 with the two large ncRNA genes and 
evident monoallelic expression of the genes is very similar to that of imprinted loci. However, 
the region was shown not to be imprinted (Mertens et al., 2006). Still, the topological 
organization suggests the existence of an LCR that (co-) regulates the transcription rate of 
the region (chapter 4.3.5). 
In the present study, both promoter regions of the two large ncRNA genes were shown to 
contain distinct loci that have differential allelic epigenetic marks (Figure 3-16). Moreover, 
specific aberrant activation of the candidate LCR within CGI D was detected and also 
activation of the candidate LCR along with aberrant activation of the centromeric half of CGI 
E in CLL cells. 
For instance, CGI D carries no significant amount of the repressive chromatin mark 
macroH2A; most of the CpG-island neither shows H3K4me2-enrichment and/or DNA-
methylation. Only at the most telomeric loci analyzed in CGI D (Table 4-2; Figure 3-20), 
H3K4me2-enrichment in 13q14.3 was detected. Also DNA-methylation was detected in CLL 
cells at the most telomeric part of CGI D. However, DNA-methylation was less abundant in 
CLL cells than in non-malignant cells, which might point to loss of differential DNA-
methylation at this locus. The loss of DNA-methylation reflects a loss of silencing and 
together with the gain of the active chromatin mark; this reflects an activation of the most 
telomeric part of CGI D, i.e. of the candidate LCR in CLL. The aberrant activation of the 
candidate LCR in the promoter region of the ncRNA genes would lead to aberrant 
transcription of the ncRNA(s), i.e. either up- or down-regulation of their transcriptional rates. 
Aberrant transcription of the regulatory ncRNA in the critical region would lead to 
deregulated expression of the other genes in 13q14.3, regardless of whether the ncRNA is 
activated or repressed. Measurable effects of this deregulation of the tumor suppressor 
mechanism might include the observed significant down-regulation of RFP2. Analogous to 
the epigenetic aberrations detected at the candidate LCR in CGI D, the second potential LCR 
within CGI E shows aberrant epigenetic modifications (Figure 3-20) that might lead to 
deregulation of an ncRNA in the critical region and to subsequent inactivation of the tumor 
suppressor mechanism. 
 
In summary, two candidate LCRs in the 5’-regions of both ncRNA genes spanning the critical 
region in 13q14.3 could be determined. Still, functionality of these LCRs has to be further 
determined. However, epimutations in CLL cells were detected that specifically affect only 
these distinct candidate LCR loci, which points to their functional involvement in controlling 
the transcription of other regulatory genes, most likely the ncRNA genes, in 13q14.3. Thus, it 
can be explained how the detected epimutation in 13q14.3 can lead to deregulation and 
inactivation of the tumor suppressor mechanism. Finally, as these epimutations do not affect 
the complete CpG-islands or other already described functional elements in the region, but 
rather reside within the noncoding sequence, it becomes clear why the epimutations were 
not detected earlier. 
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4.4.5 Model of epigenetic deregulation of the tumor suppressor 
mechanism in 13q14.3 in CLL 
Unlike other leukemias, CLL is a heterogeneous disease without a common disease-causing 
translocation, deletion or mutation (D'Arena et al., 2003). There are a few well characterized 
genomic aberrations that could be linked to prognosis and survival of CLL patients (Döhner 
et al., 2000). However, the pathomechanism of CLL is still unclear. Recently, epigenetic 
modifications have been recognized as hallmarks of tumorigenesis (Esteller, 2008). Unlike 
other hallmarks of tumorigenic transformation in cancer cells, epimutations are in principle 
reversible and thus, they are potential targets for effective new treatments in cancer. Some 
common epigenetic alterations have been described that specifically affect CLL cells. Several 
studies showed differential aberrant DNA-methylation in CLL compared to non-malignant 
cells (Raval et al., 2007; Plass et al., 2007; Raval et al., 2006; Yu, 2006; Rush et al., 2004; 
Raval et al., 2005). However, DNA-methylation is only one component of epigenetic 
modulation in chromatin remodeling and transcriptional regulation. Important additional 
components include expression of histone methyltransferases, methyl-CpG-binding proteins 
and histone modifications that potentially direct interaction of histone methyltransferases 
(HMTs) with chromatin and chromatin associated proteins and histone acetylases and 
deacetylases (Yu, 2006). Recently, it has been recognized that there are connections 
between histone methylation patterns and cancer progression and therefore, specific histone 
methyltransferases present as promising targets for future cancer treatment (Spannhoff et 
al., 2008). SETDB2 encodes a putative HMT that is located just centromeric to the 
chromosomal region 13q14.3 (Serra-Barrionuevo, 2008; Yu, 2006). The substrate specificity 
of this putative HMT has not yet been identified. However, immunofluorescent staining of 
manipulated cells that over-express SETDB2 showed predominant localization of the protein 
in the cytoplasm (Tschuch, 2006). This makes a role of SETDB2 for trimethylating histone H3 
at lysine 9 (H3K9me3) not impossible but unlikely (Tschuch, 2006). 
Nonetheless, the HMT-activity of SETDB2 presents a potential link between the aberrant 
histone methylation determined in CLL and molecular function of a candidate gene from the 
genomic region of 13q14.3. If SETDB2 or another HMT with specificity for dimethylation of 
H3K4 would be envisaged as target for future cancer treatment, first the substrate specificity 
of the HMT activity and its potential involvement in alterations of the histone modifications at 
13q14.3, have to be determined. Their identification represents a promising target for future 
treatment of CLL, as their elimination or activation could be used to restore the tumor 
suppressor mechanism at 13q14.3. 
 
The involvement of aberrant histone modifications in the progression of CLL have not been 
fully adressed here. However, putative deregulatory effects on the tumor suppressor 
mechanism in 13q14.3 caused by epimutations of candidate LCRs within the region were 
determined in CLL cells (chapter 4.4.3 and 4.4.5). The tumor suppressor mechanism in the 
critical region in 13q14.3 is epigenetically regulated, which is suggested by differential 
chromatin packaging of the two alleles (chapter 4.3.5) and results in the detected 
monoallelic expression of the genes in non-malignant cells (chapters 3.2.2 and 3.2.7, 
Mertens et al., 2006). Loss of the single active copy of 13q14.3 in CLL patients would suffice 
for complete loss of function of the tumor suppressor mechnaism in the critical region 
(Figure 4-1) and results in the observed downregulation of candidate genes and miRNA 
genes in CLL cells (Calin et al., 2002; Mertens et al., 2002). Here, it was determined that loss 
of function of the tumor suppressor mechanism can be caused either by the genomic 
deletion of the active copy or by epigenetic deregulation of the region caused by an 
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epimutation in candidate LCRs in the critical region (chapter 4.4.4). The epimutation in the 
LCR most probably leads to deregulated transcription of a regulatory ncRNA that is 
suggested to control the expression of the other genes in the critical region in 13q14.3 
(chapter 4.3.6). Consequently, the loss of regulated expression of the genes in 13q14.3 
would lead to inactivation of the tumor suppressive function in CLL cells. Deregulation and 
subsequent inactivation of the tumor suppressor mechanism by epimutations in the critical 
region in 13q14.3 would explain the downregulation of the candidate genes and microRNA 
genes determined in del(13q) CLL patients and may be causative for the pathogenesis of 
CLL. 
 
In conclusion, a specific epigenetic code at 13q14.3 was identified in this thesis that is 
changed in CLL and could therefore regulate the tumor suppressor mechanism in the critical 
region in 13q14.3. Epigenetic marks were found that are specific for the previously 
uncovered monoallelic expression of 13q14.3 candidate genes in non-malignant cells. 
Evidence is presented for a model of epigenetic regulation that implies differential chromatin 
packaging of the two copies of 13q14.3. Moreover, the elimination of technical hurdles in the 
analysis of epigenetic modifications in primary hematopoietic and CLL cells is a step forward 
towards complete understanding of how cellular functions are regulated by the epigenome in 
health and disease. The established ChIP-method can be used in future for detailed and 
complete characterization of the epigenetic features at 13q14.3 and will help to fully 
elucidate the complex epigenetic regulatory network that controls the tumor suppressor 
mechanism in 13q14.3. Next steps should be to fully understand the pathogenecity of 
deregulation of the 13q14.3 tumor suppressor mechanism in CLL and thereby provide a basis 
for development of more efficient and specific therapies for CLL in the future. 
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Summary 
B-cell chronic lymphocytic leukemia (CLL) is the most common leukemia among adults in the 
Western world with a median age of 72 years of CLL patients at diagnosis. The most 
common genomic aberration in CLL is the deletion of a critical region in chromosomal band 
13q14.3, which is deleted in more than 50 % of patients. The high frequency of deletions of 
13q14.3 in CLL and other tumors points to a tumor suppressor mechanism localized in the 
critical region. The candidate genes localized in the critical region in 13q14.3 have been 
shown to be monoallelically expressed. Towards elucidation of the tumor suppressor 
mechanism in 13q14.3, the epigenetic modifications of genes and CpG-islands in the region 
were analyzed in this thesis. Monoallelic expression of almost all genes in the critical region 
in 13q14.3 in non-malignant cells was detected to be marked by epigenetic modifications at 
promoter and exonic regions of these genes. A chromatin pattern specific for monoallelically 
expressed and imprinted genes, which is promoter-restricted enrichment of dimethylated 
lysine 4 of histone H3 (H3K4me2), was detected at the genes DLeu2/BCMSUN and C13ORF1. 
Detection of this specific chromatin pattern led to identification of a novel monoallelically 
expressed gene in the region: C13ORF1. Here, C13ORF1 was in addition to RFP2 and 
DLeu2/BCMSUN, shown to be monoallelically expressed in B- and T-cells from healthy 
donors. 
The chromatin immunoprecipitation (ChIP) methodology was established in order to quantify 
two chromatin modifications at the critical region. ChIP was technically established and 
optimized to analyze enrichment of the histone mark H3K4me2 that is correlated with an 
active transcription state, and of the histone variant macroH2A, which was shown to be 
allelically enriched at monoallelically silenced loci, at 13q14.3. In addition, also DNA-
methylation of the CpG-islands was analyzed. Thus, an epigenetic code of the candidate 
genes that correlates with their transcription status was determined in non-malignant 
hematopoietic and CLL cells. In non-malignant cells, the epigenetic code identifies one active 
and one inactive copy of the critical region in 13q14.3. Thereby, the genes DLeu2/BCMSUN 
and C13ORF1 are monoallelically expressed from the epigenetically active allele and their 
expression status is marked by a distinct chromatin pattern. In contrast, the distinct 
chromatin pattern could not be detected at the gene RFP2 that was earlier shown to be 
monoallelically expressed. The quantification of H3K4me2 and macroH2A occurrence at RFP2 
points to allelic differences of enrichment at the gene locus, although this could not be 
further defined by the chosen methods. However, allelic enrichment of chromatin marks 
could be detected at two distinct loci in the 5’-regions of the large noncoding RNA genes, 
BCMS and DLeu2/BCMSUN, in samples derived from healthy probands. Thereby, in this 
study, two candidate locus control regions (LCRs) were identified that are located in the 
CpG-islands D and E in the promoter region of the two large ncRNAs and showed differential 
DNA-methylation and histone modifications. The differential epigenetic code and the 
localization of the candidate LCRs suggest their involvement in the regulation of expression 
of the two large ncRNA genes that span the critical region in 13q14.3. In summary these 
findings suggest a model of the epigenetically regulated tumor suppressor mechanism in 
13q14.3 that leads to monoallelic expression of the candidate genes in the region. This 
model consists of the features that i) 13q14.3 is present in one active and one silent 
chromosome copy in non-malignant healthy cells, ii) the large ncRNAs BCMS and BCMSUN 
are likely involved in the regulation (in cis) of expression of the other genes in 13q14.3, and 
iii) differential epigenetic modifications of candidate LCRs control transcription of the large 
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ncRNA genes. Accordingly, the epigenetic status of the LCRs is critical for transcription of the 
ncRNAs that in turn regulate the expression of the candidate genes in the critical region. 
Surprisingly, the most evident epigenetic aberration at 13q14.3 was the generally higher 
enrichment of the active chromatin mark at the region in CLL cells. However, also the 
inactive chromatin mark was increased at 13q14.3 in CLL cells. Significant differences of 
enrichment of H3K4me2 and macroH2A between non-malignant and CLL cells, were 
detected at CpG-islands B, C and E and at the exonic region of DLeu2/BCMSUN, which 
clearly showed that the aberrant modifications in CLL are most evident at the promoter 
regions of the genes C13ORF1, RFP2 and DLeu2/BCMSUN, respectively. The chromatin 
pattern that marks monoallelic expression at C13ORF1 and DLeu2/BCMSUN remained 
unchanged in the analyzed CLL cells. However, in CLL cells derived from patients with 
different genomic aberrations, the deletion of genomic material from 13q14.3 and loss of 
active chromatin marks could be correlated. This suggests that in del(13q) CLL patients, 
indeed the active copy of 13q14.3 is lost, which would explain downregulation of expression 
of the genes in the critical region observed in these patients. In line with the proposed model 
of the tumor suppressor mechanism in 13q14.3, the most evident aberrant epigenetic 
modifications of 13q14.3 in CLL cells were detected at the two candidate LCRs, where 
distinct epimutations were detected. Thus, an epimutation in 13q14.3 was shown that could 
be responsible for the inactivation of the epigenetic regulatory mechanism of 13q14.3 in CLL 
cells. Further, these findings suggest that the regulatory impact of the ncRNAs, the LCR or 
another yet unidentified part of the critical region in 13q14.3 is affected by this epimutation, 
which leads to deregulation and inactivation of the tumor suppressive function of 13q14.3. 
 
In conclusion, a specific epigenetic code at the genes in the critical region in 13q14.3 was 
determined that is correlated with their transcriptional state. Evidence was obtained for a 
model of epigenetic regulation that implies differential chromatin packaging of the two 
copies of 13q14.3 and results in monoallelic expression of the candidate genes in healthy B- 
and T-cells. Furthermore, two candidate LCRs were identified in the critical region in 13q14.3 
in non-malignant cells that showed distinct epimutations in CLL cells. The localization and the 
detected epimutations of the LCRs in CLL point to their role in regulation of the ncRNA genes 
that most likely regulate expression of the other genes in the critical region. On the basis of 
these findings, further characterization of epigenetic features at 13q14.3 will help to fully 
elucidate the complex epigenetic regulatory network that controls the tumor suppressor 
mechanism in 13q14.3. The findings presented here will help to understand the 
pathogenicity of (epigenetic) inactivation of the tumor suppressor mechanism in CLL and 
thereby provide the basis for development of more efficient and specific therapies for CLL in 
the future. 
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Zusammenfassung 
Die chronisch lymphatische Leukämie des B-Zell Typs (B-CLL) ist in den westlichen Ländern 
die am häufigsten auftretende Leukämie bei Erwachsenen. Durchschnittlich sind die 
Patienten zum Zeitpunkt der Diagnose 72 Jahre alt. Die häufigste genomische Veränderung 
bei Patienten ist die Deletion einer kritischen Region in der chromosomalen Bande 13q14.3, 
die bei über 50 % aller B-CLL Patienten auftritt. Die Häufigkeit des Verlusts der kritischen 
Region in 13q14.3 in B-CLL und anderen Tumoren deutet auf einen wichtigen 
Tumorsuppressormechanismus hin, der in der kritischen Region lokalisiert ist. Außerdem 
konnte bisher für fast alle Kandidatengene der Region 13q14.3 monoallelische Expression 
nachgewiesen werden. 
In der vorliegenden Arbeit wurden epigenetische Modifikationen an Genen und CpG-Inseln 
der chromosomalen Region untersucht, um zur Aufklärung des 
Tumorsuppressormechanismus beizutragen. Die monoallelische Genexpression der kritischen 
Region in 13q14.3 ist durch epigenetische Modifikationen des Chromatins der Promotoren 
und Genregionen markiert. Ein Chromatinmodifikationsmuster, das spezifische monoallelisch 
exprimierte und auch geprägte Gene markiert, ist die Anreicherung von dimethyliertem Lysin 
4 des Histons H3 (H3K4me2), die eng auf den Promoterbereich begrenzt ist. Dieses 
spezifische Muster wurde an den Genen C13ORF1 und DLeu2/BCMSUN entdeckt und führte 
zur Identifizierung eines weiteren monoallelisch exprimierten Gens der Region 13q14.3. 
Zusätzlich zu den bereits gezeigten Genen RFP2 und DLeu2/BCMSUN, konnte auch für 
C13ORF1 eine monoallelische Expression in gesunden B- und T-Zellen gezeigt werden. 
Die Chromatin Immunopräzipitation (ChIP) Methode wurde etabliert, um zwei 
Chromatinmodifikationen an der chromosomalen Bande 13q14.3 zu quantifizieren. Hierfür 
musste die ChIP-Methode zunächst technisch etabliert und optimiert werden, um die 
Anreicherung von H3K4me2, was mit einem aktiven Transkriptionsstatus korreliert, und von 
der Histonvariante macroH2A, welche mit einem reprimiertem Transkriptionsstatus und 
allelisch unterschiedlicher Anreicherung korreliert, analysieren zu können. Zusätzlich wurde 
auch die DNA-Methylierung der Region 13q14.3 untersucht. Auf diese Weise wurde der 
epigenetische Code der Kandidatengene, der mit deren Transkriptionsstatus korreliert ist, in 
gesunden hämatopoetischen Zellen und in B-CLL Zellen identifiziert. In gesunden 
hämatopoetischen Zellen markieren die epigenetischen Modifikationen eine aktive und eine 
inaktive Kopie der kritischen Region in der chromosomalen Bande 13q14.3. Die Gene 
C13ORF1 und DLeu2/BCMSUN werden allein von der aktiven Kopie exprimiert und ihr 
monoallelischer Transkriptionsstatus ist im Chromatin markiert. Für das bereits als 
monoallelisch exprimiert beschriebene Gen RFP2 konnte dieses spezifische Chromatinmuster 
in der vorliegenden Arbeit nicht gefunden werden. Allerdings deutet die Quantifizierung von 
H3K4me2 und macroH2A darauf hin, dass es auch an diesem Genlocus allelische 
Unterschiede gibt, welche mit der angewendeten Methode jedoch nicht näher definiert 
werden konnten. Im Gegensatz zum RFP2 Locus, konnte eine allelische Anreicherung der 
untersuchten Chromatinmodifikationen an zwei definierten Loci in der 5’-Region der 
nichtkodierenden RNA (ncRNA) Gene, BCMS und DLeu2/BCMSUN, in gesunden Zellen gezeigt 
werden. Mittels der in der vorliegenden Studie definierten, allelisch unterschiedlichen 
Anreicherung der Histonmodifikationen und auch der DNA-Methylierung, wurden zwei 
Kandidaten-Locus-Kontroll-Regionen (LCR) identifiziert, die in den CpG-Inseln D und E in den 
Promoterregionen der beiden großen ncRNA Gene lokalisiert sind. Ihr differentieller 
epigenetische Code sowie die Lokalisierung der Kandidaten-LCRs spricht für ihre Beteiligung 
an der Expressionsregulation der beiden ncRNA Gene, die die gesamte kritische Region 
überspannen. 
Zusammenfassung 
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Zusammenfassend führen diese Ergebnisse zu einem Model des epigenetisch regulierten 
Tumorsuppressormechanismus in 13q14.3, der zur monoallelischen Expression der 
Kandidatengene führt. Das Model besteht bisher aus drei ermittelten Merkmalen: i) die 
chromosomale Region 13q14.3 liegt in einer aktiven und einer inaktiven Kopie in gesunden 
hämatopoietischen Zellen vor, ii) die großen ncRNA Gene, BCMS und DLeu2/BCMSUN, sind 
wahrscheinlich an der Expressionsregulation der anderen Gene der Region (in cis) beteiligt 
und iii) die differentiellen epigenetischen Modifikationen der Kandidaten-LCRs kontrollieren 
die Transkription der großen ncRNA Gene. Somit wäre der epigenetische Status der LCRs 
entscheidend für die Transkription der ncRNA Gene, welche wiederum die Expression der 
Kandidatengene regulieren. 
In B-CLL Zellen war die auffälligste epigenetische Aberration in 13q14.3 ein allgemein starker 
Anstieg der Anreicherung der aktivierenden aber auch der repressiven Chromatinmarkierung. 
Signifikante Unterschiede in der Anreicherung von H3K4me2 und macroH2A zwischen 
gesunden und B-CLL Zellen wurden an den CpG-Inseln B, C und D, sowie an der exonischen 
Region des Gens DLeu2/BCMSUN gefunden. Dies zeigte klar, dass aberrante Modifikationen 
in B-CLL am deutlichsten an den Promoterregionen der Gene C13ORF1, RFP2 und 
DLeu2/BCMSUN auftreten. Das Chromatinmodifikationsmuster, das die monoallelisch 
exprimierten Gene C13ORF1 und DLeu2/BCMSUN markiert, blieb in den analysierten B-CLL 
Zellen unverändert bestehen. Darüber hinaus konnte in B-CLL Zellen von Patienten mit 
unterschiedlichen genomischen Aberrationen die Deletion von genomischem Material der 
chromosomalen Region 13q14.3 mit dem Verlust der aktivierenden Chromatinmarkierungen 
korreliert werden. Dies deutet darauf hin, dass tatsächlich die aktive Kopie von 13q14.3 in 
monoallelisch deletierten Patienten mit B-CLL verloren gegangen ist, was auch die starke 
Herunterregulierung der Genexpression in der kritischen Region erklärt, die in diesen 
Patienten beobachtet wurde. In Übereinstimmung mit dem Modell des 
Tumorsuppressormechanismus in 13q14.3 wurde die auffälligste epigenetische Aberration an 
13q14.3 in B-CLL Zellen an den Kandidaten-LCRs gefunden. Somit wurde eine Epimutation in 
13q14.3 entdeckt, die für die Inaktivierung des Tumorsuppressormechanismus in 13q14.3 in 
B-CLL Zellen verantwortlich sein könnte. Die vorliegenden Ergebnisse zeigen weiterhin, dass 
der regulatorische Einfluss der ncRNAs, der LCRs oder einem anderen noch nicht näher 
identifizierten Bereichs der kritischen Region in 13q14.3 von dieser Epimutation betroffen 
sein könnte, und diese so zur Deregulierung und Inaktivierung der Tumorsuppressorfunktion 
in 13q14.3 führt. 
 
Zusammenfassend konnte ein spezifischer epigenetischer Code der Gene in der kritischen 
Region in 13q14.3 identifiziert werden, der mit deren Transkriptionsstatus korreliert. Die hier 
gefundenen Ergebnisse unterstützen das Modell der epigenetischen Regulation, das 
differentielle Chromatinverpackung der beiden Kopien von 13q14.3 einschließt und zur 
monoallelischen Expression der Kandidatengene in gesunden B- und T-Zellen führt. 
Zusätzlich konnten zwei Kandidaten-LCRs in den Promoterregionen der beiden großen ncRNA 
Gene in der kritischen Region identifiziert werden, die distinkte Epimutationen in B-CLL 
Zellen aufweisen. Die Lokalisierung sowie die gefundenen Epimutationen der LCRs in B-CLL 
deuten auf eine wichtige Rolle der LCRs bei der Transkriptionsregulation der großen ncRNA 
Gene hin, die wahrscheinlich die Genexpression in der kritischen Region regulieren. Auf Basis 
der vorliegenden Ergebnisse ist nun eine weitere Charakterisierung des komplexen 
epigenetischen Netzwerks möglich, das den Tumorsuppressormechanismus in 13q14.3 
kontrolliert. Die Ergebnisse der vorliegenden Studie tragen dazu bei, die Pathogenität der 
epigenetischen Inaktivierung des Tumorsuppressormechansimus in B-CLL zu verstehen und 
können somit eine Basis für die zukünftige Entwicklung von effizienteren und spezifischeren 
Therapien der B-CLL bilden. 
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Appendix A – Additional tables 
 
Table A-1: ChIP and qPCR measured fraction of input-values of control CpG-island-promoters CDH12 
& HK2 used for normalization. ** used for normalization of qPCR data. * calculated from 
duplicate qPCR reactions. 
 precipitating control fraction of input standard 
Sample No. antibody promoter value** deviation* 
CLL1 H3K4me2 CDH12 0.0016 0.0001 
CLL2 H3K4me2 CDH12 0.0022 0.0002 
CLL3 H3K4me2 CDH12 0.0088 0.0017 
CLL4 H3K4me2 CDH12 0.0048 0.0006 
CLL5 H3K4me2 CDH12 0.0301 0.0059 
P1 H3K4me2 CDH12 0.0436 0.0263 
P2 H3K4me2 CDH12 0.0096 0.0072 
P3 H3K4me2 CDH12 0.0036 0.0028 
P4 H3K4me2 CDH12 0.0390 0.0068 
P5 H3K4me2 CDH12 0.0049 0.0007 
PB5 H3K4me2 CDH12 0.0001 0.0000 
PB6 H3K4me2 CDH12 0.0030 0.0005 
PB7 H3K4me2 CDH12 0.0051 0.0021 
PB17 H3K4me2 CDH12 0.0012 0.0001 
PB18 H3K4me2 CDH12 0.0004 0.0000 
PB19 H3K4me2 CDH12 0.0059 0.0039 
PB9 – B-cells H3K4me2 CDH12 0.0016 0.0003 
PB12 – B-cells H3K4me2 CDH12 0.0052 0.0014 
PB9 – T-cells H3K4me2 CDH12 0.0452 0.0018 
PB12 – T-cells H3K4me2 CDH12 0.0022 0.0001 
CLL1 macroH2A1.2 HK2 0.0006 0.0003 
CLL2 macroH2A1.2 HK2 0.0027 0.0005 
CLL3 macroH2A1.2 HK2 0.0005 0.0002 
CLL4 macroH2A1.2 HK2 0.0015 0.0002 
CLL5 macroH2A1.2 HK2 0.0000 0.0001 
PU1 macroH2A1.2 HK2 0.0011 0.0001 
PU2 macroH2A1.2 HK2 0.0008 0.0001 
PL2 macroH2A1.2 HK2 0.0015 0.0003 
PB17 macroH2A1.2 HK2 0.0011 0.0001 
PB19 macroH2A1.2 HK2 0.0025 0.0006 
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Table A-2: Median H3K4me2-enrichment in wild type and several wild type subgroups. *Median 
values = x-fold enrichment vs. CDH12, wt = wild type, **CGI = CpG-island. 
amplicon #   Median*   gene/CGI** 
 wild type young wt old wt B-cells T-cells  
KPNA3e6.1 0.645 0.645 0.873 1.313 0.053 KPNA3 
KPNA3e3.1 0.121 0.000 1.051 1.951 0.028   
KPNA3e1.1 7.294 7.294 16.371 6.120 0.325   
A1.2 2.414 3.457 5.676 5.136 0.536 CGI A 
A2.1 1.869 1.869 5.347 11.303 0.118   
A3.1 4.266 1.003 9.982 7.757 0.189   
A3 0.553 0.553 1.707 0.609 0.111 non- 
A4 1.240 1.984 0.853 2.557 0.110 related 
A2 2.931 1.376 7.077 8.556 0.271 CGI 
C13orf1e4.1 0.196 0.590 0.116 0.570 0.098 C13ORF1 
C13orf1e3.1 0.484 0.603 0.057 1.216 0.279   
C13orf1e2.1 0.545 0.545 0.596 2.177 0.106   
B3 12.304 12.629 31.495 14.580 3.113 CGI B 
B2 16.102 21.415 33.479 17.163 1.404   
B4 11.744 11.744 28.968 15.551 2.495   
RFP2e1.1 5.586 5.586 12.917 10.223 0.578 RFP2 
C1 4.086 4.086 6.309 6.605 0.029 CGI C 
C2 4.325 4.325 13.127 6.428 0.546   
C3 4.860 6.461 10.947 9.129 0.893   
RFP2e2.1 4.574 13.267 10.111 7.281 0.294 RFP2 
RFP2e3.1 0.831 0.831 0.695 1.469 0.198   
BCMSUNe4.2 1.241 1.545 1.697 1.508 0.080 BCMSUN/ 
BCMSUNe3.1 1.413 1.477 2.288 1.754 0.000 DLeu2 
BCMSUNe3.2 1.411 1.411 1.587 1.171 0.101   
BCMSUNe2.2 1.141 3.984 2.590 3.630 0.170   
D1 4.458 3.320 23.793 28.262 2.269 CGI D 
D3 10.175 20.125 34.658 16.750 1.697   
D4 14.742 19.659 35.972 11.296 2.289   
D2 4.408 6.624 3.015 4.164 0.232   
D5 8.238 12.062 12.482 5.425 0.408   
BCMSe1.1 8.074 16.102 19.865 9.603 0.817 BCMS/ 
BCMse2.1 5.863 12.048 11.887 7.966 0.519 DLeu1 
BCMSe3.1 1.123 0.325 1.737 2.675 0.053   
E1 7.227 25.928 7.389 10.731 0.402 CGI E 
E1.1 nd 9.368 nd nd nd   
E12 9.154 14.138 17.853 12.142 1.551   
E1.2 nd 11.471 nd nd nd   
E2 9.557 26.213 18.537 13.056 1.031   
E3 3.338 2.040 10.801 9.404 1.550   
E4 1.225 1.644 2.843 1.604 0.079   
E5 4.738 7.641 5.039 9.338 0.215   
E6 1.809 3.453 11.663 4.730 0.887   
E7 2.577 2.121 3.246 5.802 0.105   
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Table A-3: Median values of macroH2A-enrichment in wild type and two wild type-subgroups. 
*Median [x-fold enrichment vs. HK2], wt = wild type, **CGI = CpG-island. 
amplicon #  Median*  gene/CGI** 
 wild type young wt old wt  
KPNA3e6.1 0.121 0.000 0.966 KPNA3 
KPNA3e3.1 0.000 0.000 1.047   
KPNA3e1.1 0.000 0.000 0.941   
A1.2 0.000 0.000 0.903 CGI A 
A2.1 0.000 0.000 0.725   
A3.1 0.000 0.000 0.511   
A3 1.956 7.518 0.978 non- 
A4 2.227 6.305 1.113 related 
A2 0.000 0.000 1.353 CGI 
C13orf1e4.1 0.000 0.000 0.407 C13ORF1 
C13orf1e3.1 0.000 0.000 0.836   
C13orf1e2.1 0.000 0.000 0.617   
B3 1.828 4.581 0.914 CGI B 
B2 0.000 0.000 0.887   
B4 0.000 0.000 0.917   
RFP2e1.1 0.000 0.000 0.886 RFP2 
C1 1.082 1.082 2.894 CGI C 
C2 0.000 0.000 0.711   
C3 1.816 2.677 0.908   
RFP2e2.1 0.000 0.000 1.242 RFP2 
RFP2e3.1 1.963 2.897 0.982   
BCMSUNe4.2 1.836 6.400 0.918 BCMSUN/ 
BCMSUNe3.1 1.156 1.156 0.697 DLeu2 
BCMSUNe3.2 0.962 0.402 1.743   
BCMSUNe2.2 2.183 2.183 1.563   
D1 0.572 0.572 0.554 CGI D 
D3 2.011 8.679 1.006   
D4 0.000 0.000 0.880   
D2 0.000 0.000 0.801   
D5 0.000 0.000 1.164   
BCMSe1.1 0.000 0.000 0.857 BCMS/ 
BCMse2.1 0.024 0.024 0.829 DLeu1 
BCMSe3.1 0.000 0.000 0.766   
E1 0.000 0.000 0.824 CGI E 
E1.1 nd nd nd   
E12 0.000 0.000 1.284   
E1.2 nd nd nd   
E2 0.000 0.000 1.181   
E3 0.000 0.000 0.801   
E4 0.000 0.000 0.813   
E5 0.000 0.000 0.752   
E6 0.000 0.000 0.267   
E7 0.000 0.000 1.012   
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Table A-4: Median H3K4me2-enrichment in CLL and two CLL-subgroups. *Median [x-fold enrichment 
vs CDH12], **17pdel = deletion of 17p, NK = normal karyotype +CGI = CpG-island. 
amplicon #  Median*  gene/CGI+ 
 CLL (all) Del(13q) CLL Del(17p)/NK** CLL  
KPNA3e6.1 0.526 0.000 5.666 KPNA3 
KPNA3e3.1 0.288 0.000 17.507   
KPNA3e1.1 14.699 9.484 121.026   
A1.2 7.448 2.756 26.323 CGI A 
A2.1 6.336 2.692 37.715   
A3.1 2.022 0.316 34.539   
A3 0.560 0.000 12.129 non- 
A4 1.116 0.000 14.783 related 
A2 5.920 4.581 58.832 CGI 
C13orf1e4.1 27.467 14.720 252.176 C13ORF1 
C13orf1e3.1 0.537 0.000 9.741   
C13orf1e2.1 0.832 0.000 11.622   
B3 75.399 64.997 377.080 CGI B 
B2 40.604 37.430 590.605   
B4 86.261 28.272 431.714   
RFP2e1.1 12.364 11.132 91.714 RFP2 
C1 27.309 9.603 282.237 CGI C 
C2 45.326 20.092 313.145   
C3 37.123 14.179 202.285   
RFP2e2.1 58.018 17.481 319.237 RFP2 
RFP2e3.1 1.472 0.000 11.014   
BCMSUNe4.2 3.864 0.000 11.655 BCMSUN/ 
BCMSUNe3.1 17.547 0.000 25.181 DLeu2 
BCMSUNe3.2 15.254 0.000 31.823   
BCMSUNe2.2 20.734 17.430 88.166   
D1 16.749 16.043 136.715 CGI D 
D3 12.810 8.333 78.578   
D4 13.971 11.052 114.536   
D2 3.865 1.705 45.351   
D5 4.101 0.154 17.669   
BCMSe1.1 28.398 26.149 228.556 BCMS/ 
BCMse2.1 68.226 21.488 729.070 DLeu1 
BCMSe3.1 8.194 0.000 43.449   
E1 109.017 32.291 517.415 CGI E 
E1.1 34.841 34.710 359.928   
E12 59.811 30.251 391.235   
E1.2 29.248 25.842 152.242   
E2 78.688 56.109 489.433   
E3 58.847 17.115 400.422   
E4 7.750 5.353 139.709   
E5 44.850 38.590 523.384   
E6 30.839 19.547 128.860   
E7 17.062 0.308 92.650   
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Table A-5: Median values of macroH2A-enrichment in CLL and two CLL-subgroups (subdivided by 
karyotype). *Median [x-fold enrichment vs HK2], **17pdel = patient with deletion of 
chromosomal arm 17p, NK = patient with normal karyotype; +CGI = CpG-island. 
amplicon #  Median*  gene/CGI+ 
 CLL (all) Del(13q) CLL Del(17p)/NK** CLL  
KPNA3e6.1 0.091 2.160 0.046 KPNA3 
KPNA3e3.1 0.000 1.804 0.000  
KPNA3e1.1 0.540 2.575 0.270  
A1.2 2.724 4.616 0.000 CGI A 
A2.1 2.438 5.463 0.000  
A3.1 1.780 5.265 0.000  
A3 3.285 4.435 0.645 non- 
A4 0.899 3.307 0.450 related 
A2 1.571 3.005 0.000 CGI 
C13orf1e4.1 1.265 1.265 7.652 C13ORF1 
C13orf1e3.1 2.018 2.018 7.666  
C13orf1e2.1 3.527 3.527 4.867  
B3 1.924 2.395 0.000 CGI B 
B2 3.067 3.494 0.296  
B4 1.730 1.739 0.865  
RFP2e1.1 0.000 1.908 0.000 RFP2 
C1 1.178 2.708 0.589 CGI C 
C2 0.000 2.835 0.000  
C3 2.593 2.702 0.170  
RFP2e2.1 1.761 1.761 1.791 RFP2 
RFP2e3.1 0.000 3.454 0.000  
BCMSUNe4.2 2.785 2.785 4.222 BCMSUN/ 
BCMSUNe3.1 1.955 2.058 0.000 DLeu2 
BCMSUNe3.2 1.080 1.574 0.000  
BCMSUNe2.2 1.213 2.734 0.469  
D1 0.000 2.142 0.000 CGI D 
D3 0.000 2.362 0.000  
D4 0.000 2.686 0.000  
D2 0.000 2.924 0.000  
D5 0.874 3.165 0.100  
BCMSe1.1 0.000 3.014 0.000 BCMS/ 
BCMse2.1 2.409 2.778 0.000 DLeu1 
BCMSe3.1 0.082 1.908 0.041  
E1 0.121 3.080 0.000 CGI E 
E1.1 nd nd nd  
E12 1.847 2.109 0.200  
E1.2 nd nd nd  
E2 1.207 2.462 0.604  
E3 3.518 4.147 0.544  
E4 1.844 2.877 0.922  
E5 0.452 2.217 0.226  
E6 3.174 3.391 0.000  
E7 2.502 5.313 1.020  
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Appendix B – Primer sequences 
Gene Primer forward 5’-3’- forward sequence 
CpG-island     Primer reverse     5’-3’-reverse sequence 
   
CpG-island A A1.2fwd gcggaagcacactcacttc 
     A1.2rev     agaaccccagcttggagaac 
CpG-island A A2.1fwd gacctggcgacttttactgc 
     A2.1rev     ggcattctcctcgttctcac 
CpG-island A A3.1fwd gtgtcgcccagtttcttcat 
     A3.1rev     tgctgcctgaaggctaagat 
KPNA3 KPNA3e1.1_fwd GCAGTAAAAGTCGCCAGGTCC 
     KPNA3e1.1_rev     GGGCTATACGTGCCCGTTG 
KPNA3 KPNA3e3.1_fwd AACAAAAGAGATGAACACTTATTGAAAAA 
     KPNA3e3.1_rev     AACATCTGAATCTTCTAGACTTTCTTCTTG 
KPNA3 KPNA3e6.1_fwd AAAACTGTTATCCAGTGACAGAAATCC 
     KPNA3e6.1_rev     TTGACTAGAATTGGTAAAATCCCAGAT 
CpG-island B B2fwd CTTGAACACAGAACCGGGCCCA 
     B2rev     ACGCTGCGCCGACACCATTT 
CpG-island B B3fwd CGCCCATTCGCGATGACAGACA 
     B3rev     TCGCAGATCTCTCCAGAAGCCG 
CpG-island B B4fwd CGGCATCTCCTTCAGAGGGATGTG 
     B4rev     ATGGCCACCTCGGTGTTGTGCT 
C13ORF1 C13ORF1e2.1_fwd GTTGTTATTGTAAAGAATGGAAGAAGAATATGT
     C13ORF1e2.1_rev     TGTAAAGGTGCGCTGGCTAAA 
C13ORF1 C13ORF1e3.1_fwd AATCAGATTCCTCTTGGCCGA 
     C13ORF1e3.1_rev     GCTCCATCATTTCTCATCACCAG 
C13ORF1 C13ORF1e4.1_fwd TGACCATGTCGAATTAAATGTATACTTGA 
     C13ORF1e4.1_rev     CCCTCGTATACCTGATGCTGGA 
C13ORF1 C13ORF1e5.1_fwd TCATGACCCTGAGTCTTTGCCT 
     C13ORF1e5.1_rev     GGGCGTTAACTAAAGGACAGTGATT 
CpG-island C C1fwd CGGAGCCGCGAGTCCATTTT 
     C1rev     TTCGAGGACCACCCCGCTTT 
CpG-island C C2fwd CAGAAACCAGCGGGGCACTGTCAT 
     C2rev     CGGACGGAGCAGGTTTTCTGGA 
CpG-island C C3fwd GCTACCAGCGTCTCCACATCCCCTA 
     C3rev     ATGCAACCAAACGCTGGCGG 
CpG-island C C1a_fwd TAGAATGGGAGGCAGGTTTG 
     C1a_rev     ccgttgactaataatgcttagcc 
CpG-island C C2a_fwd ggctaagcattattagtcaacgg 
     C2a_rev     cgttccttccggcgtctc 
CpG-island C C3a_fwd gagacgccggaaggaacg 
     C3a_rev     cctacaagctgatgtatttggca 
CpG-island C C4a_fwd tgccaaatacatcagcttgtagg 
     C4a_rev     gatgggatttcaccatattggtc 
CpG-island C C5a_fwd gaccaatatggtgaaatcccatc 
     C5a_rev     taggtttaacaggctctctagtgaag 
CpG-island C C6a_fwd cttcactagagagcctgttaaaccta 
     C6a_rev     ataatcacatcagcaagaaatcac 
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Gene Primer forward 5’-3’- forward sequence 
CpG-island     Primer reverse     5’-3’-reverse sequence 
   
RFP2 RFP2e1.1fwd GTACCGTGCGGTCCCTGTAGTTGGA 
     RFP2e1.1rev     CTAGTGGGAAAGGCCGCGCG 
RFP2 RFP2e1.2fwd TACCGTGCGGTCCCTGTAGTTGGA 
     RFP2e1.2rev     TCGCTGAAGGTTCGAGGACCAC 
RFP2 RFP2e2.1fwd TCGCTGAAGGTTCGAGGACCAC 
     RFP2e2.1rev     GCTGATGTATTTGGCAGGGT 
RFP2 RFP2e3.1fwd TGCTTGAAGAAGATCTCACATGCCC 
     RFP2e3.1rev     GGAATTCCGCACACTCCCTTCTAAG 
RFP2 RFP2e3.2fwd TGGAGACCAGCTCCATTCAAGTGTC 
     RFP2e3.2rev     TGCATACTGGCATTTTGGGAGAGAT 
CpG-island D D1fwd GCAGCCAGGGCTTGGGAAACTCTT 
     D1rev     CCGCCTTTTCTCGCCGTTTT 
CpG-island D D2fwd ACAGGTTATCCTGTCTCTCCCGCT 
     D2rev     CGGGGTTGGCTCTAACGAATTT 
CpG-island D D3fwd CAGACGCCCAAGTTGCCCCTAA 
     D3rev     GGCGCGGGGTCTACTCTCACTTAAT 
CpG-island D D4fwd TCCCGAGTCCCGCTCTGCTACTTCT 
     D4rev     TACTTGGAGCAAAGGGCAGTCGGC 
CpG-island D D5fwd GGCTGCCTCCACAGCTGTCAATACC 
     D5rev     GGTTGGAGTTTGCGCATGCGTA 
CpG-island D D1a_fwd aaattagttgcctggcatacaatg 
     D1a_rev     cttcaaatttgagaatacactagcg 
CpG-island D D2a_fwd cgctagtgtattctcaaatttgaag 
     D2a_rev     tgctaattcagtaactgcagtgaac 
CpG-island D D3a_fwd gttcactgcagttactgaattagca 
     D3a_rev     ctggtggtttctatcaattcttactc 
CpG-island D D4a_fwd gagtaagaattgatagaaaccaccag 
     D4a_rev     GGTCTACTCTCACTTAATCGCGA 
CpG-island D D5a_fwd TCGCGATTAAGTGAGAGTAGACC 
     D5a_rev     GGTTGAATCGTACAGCGTGGT 
CpG-island D D6a_fwd ACCACGCTGTACGATTCAACC 
     D6a_rev     TGCTACCCTTCTCCCACTTC 
CpG-island D D7a_fwd GTGCCTGAAGTACTAATAAGGAAGTG 
     D7a_rev     taacatccttatttgcctaacagg 
BCMS BCMSe1.1fwd TTTTGCAAAGCCGCGGAGGT 
     BCMSe1.1rev     GGTAGCTATAAGACGACCCCTCGGC 
BCMS BCMSe1.2fwd GCCCACAGGCATTTAGTCTACGTTG 
     BCMSe1.2rev     TTTCTTTTCTCCTAAGCAGGACCCG 
BCMS BCMSe2.1fwd ATGAGGACACCTGAGGTTCAGA 
     BCMSe2.1rev     TTCTAAGACTTTGGGGCAGA 
BCMS BCMSe3.1fwd CCTTCAGGAATTGAGTCACAATGCA 
     BCMSe3.1rev     AAAAGGGAAAGAATGGCTGGCAA 
BCMS BCMSe3.2fwd TCTGGCAATAATAAAGTTGGGCAGC 
     BCMSe3.2rev     GGAAAGGGCCAAGAAACTGCTGT 
CpG-island E E1fwd TACCTCCTGGATTTACAAACTGGG 
     E1rev     TCTTCAACAGTGTATAAATGCTACACAAAC 
CpG-island E E1.1fwd CTTTCAGTTGTTGCCTCCAAACGG 
     E1.1rev     CGCGGTGAGCGCTATTTATAGGTAG 
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Gene Primer forward 5’-3’- forward sequence 
CpG-island     Primer reverse     5’-3’-reverse sequence 
   
CpG-island E E12fwd GCGCCTCGTTCTATTTTTCCT 
     E12rev     GGTCAGTCCGTACCGCCC 
CpG-island E E1.2fwd GAACCCCCCGGCTCGATTTT 
     E1.2rev     TCCGCCTTCTCCTTTTCGCAA 
CpG-island E E2fwd GGGAGTTTGCAGACCGGAG 
     E2rev     TCGTCATAAGGCTTTGAAGGAAAG 
CpG-island E E3fwd CAGCACTCCTAAGACGGCG 
     E3rev     TGCAGCTTGGCGCGA 
CpG-island E E4fwd AATCTGGTCAGCTTAAAAGTGTCCTC 
     E4rev     TGGACTCATTTAGGATCACCAGAT 
CpG-island E E5fwd GTTCAGACTTCAGTACCTAAAACGTTATG 
     E5rev     GACTCTAAATCGAGGTTTCTGATGCT 
CpG-island E E6fwd CGCTAGTCTAGCCCAGCGT 
     E6rev     TCCTAACTCTTTGGGTCCCTGTAA 
CpG-island E E7fwd CTGCTACAGCAGGCTTCGC 
     E7rev     AGTGCTACAAACTCTTTCTCCATTTTCT 
CpG-island E E8fwd ACTCCAGTGGTCTGCAAGCC 
     E8rev     GGCAAGCGATTGATTCCG 
CpG-island E E9fwd GTGCATCCTGGTTAGAATTGGG 
     E9rev     GGCAAGCGATTGATTCCG 
CpG-island E E10fwd AGGGAATTCTGTATTCTAGTTGTGGATCT 
     E10rev     TTGAACGACCTTGGGCCA 
CpG-island E E11fwd TGTTAACTCAAGGCCGATTACCTT 
     E11rev     ttccctccacactcttcctaca 
CpG-island E E1a_fwd tctctcttaacatctacctcctggat 
     E1a_rev     GACGCGTCCCATTGTGTGA 
CpG-island E E2a_fwd TCACACAATGGGACGCGTC 
     E2a_rev     GACAGGTCAGTCCGTACCGC 
CpG-island E E3a_fwd GCGGTACGGACTGACCTGTC 
     E3a_rev     TCTCACATCTAACTTCCAGTAACTTCTC 
CpG-island E E4a_fwd GAGAAGTTACTGGAAGTTAGATGTGAGA 
     E4a_rev     CGCCGTCTTAGGAGTGCTG 
CpG-island E E5a_fwd CAGCACTCCTAAGACGGCG 
     E5a_rev     TGGACTCATTTAGGATCACCAGAT 
CpG-island E E6a_fwd atctggtgatcctaaatgagtcca 
     E6a_rev     taggtactgaagtctgaacctagcc 
CpG-island E E7a_fwd ggctaggttcagacttcagtaccta 
     E7a_rev     AGACGTGCAATAGCCACCG 
CpG-island E E8a_fwd CGGTGGCTATTGCACGTCT 
     E8a_rev     ACGCTGGGCTAGACTAGCG 
CpG-island E E9a_fwd CGCTAGTCTAGCCCAGCGT 
     E9a_rev     GCGAAGCCTGCTGTAGCAG 
CpG-island E E10a_fwd CTGCTACAGCAGGCTTCGC 
     E10a_rev     GGCAAGCGATTGATTCCG 
CpG-island E E11a_fwd CGGAATCAATCGCTTGCC 
     E11a_rev     ttccctccacactcttcctaca 
CpG-island E E12a_fwd CGGAATCAATCGCTTGCC 
     E12a_rev     caaggatactgaagttcttgtaagtagc 
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Gene Primer forward 5’-3’- forward sequence 
CpG-island     Primer reverse     5’-3’-reverse sequence 
   
BCMSUN BCMSUNe2.2fwd TCTCATGTCATGTTCCAATGCA 
     BCMSUNe2.2rev     GGAGAACAGCCTCACTTCTTTGA 
BCMSUN BCMSUNe3.1fwd TTGTAAAAACGGATGGGTGCA 
     BCMSUNe3.1rev     TCGATGCTGCTTGTCAGCTG 
BCMSUN BCMSUNe3.2fwd CTTTGGCCACCATTATTGCATATT 
     BCMSUNe3.2rev     ATCGATGCTGCTTGTCAGCTGt 
BCMSUN BCMSUNe4.2fwd GACCAGAAAGCAACTATATGATTACCTTT 
     BCMSUNe4.2rev     AAAGTTTGACATTTGCAATAGCATTC 
GAPDH GAPDHprom_fwd CCGGGATTGTCTGCCCTAAT 
     GAPDHprom_rev     GCACGGAAGGTCACGATGT 
MYH1 MYH1prom_fwd ACCACGATTTCAGCAAGAATG 
     MYH1prom_rev     GAGCAGGAAAATCGCAGAAC 
CDH12 CDH12a96F04_fwd tgccatgtggagatgagaag 
     CDH12a96F04_rev     acccaacattccaccaaatg 
CDH12 CDH12b96F04_fwd gaccactgaaaagaaaggcatta 
     CDH12b96F04_rev     acccaacattccaccaaatg 
HK2 HK2c4F11_fwd tctcgttccatgccttctct 
     HK2c4F11_rev     aaatccaagcattcctgacg 
HK2 HK2d4F11_fwd tttgtccctcacctttcctg 
     HK2d4F11_rev     gagagaaggcatggaacgag 
HPRT HPRTprom1_fwd CCATTTGCTGACTGTACTGTCCTAAGT 
     HPRTprom1_rev     ATTAGAGGAGTATAGGTATGCGTGTGTGT 
HPRT HPRTprom2_fwd GATGACTGGAACCCGAAGAGC 
     HPRTprom2_rev     CCTTTCCCTCCCAACTCAGTCT 
HPRT HPRTe2.1_fwd ACCTAATCATTATGCTGAGGATTTGG 
     HPRTe2.1_rev     TGTCCATAATTAGTCCATGAGGAATAAAC 
HPRT HPRTe3.1_fwd TTGTAGCCCTCTGTGTGCTCAA 
     HPRTe3.1_rev     CCAGCAGGTCAGCAAAGAATTTAT 
HPRT HPRTe4.1_fwd GGGACATAAAAGTAATTGGTGGAGAT 
     HPRTe4.1_rev     TTTTCTTCCCTTTCAAGATACATACCTT 
HPRT HPRTe8.1_fwd TTTGTAATGCCCTGTAGTCTCTCTGTAT 
     HPRTe8.1_rev     GTCTGGCTTATATCCAACACTTCGT 
cMYC cMYCprom1_fwd CGCGCTCTCCAAGTATACGTG 
     cMYCprom1_rev     GGAAAACGATGCCTAGAATGATTAAA 
cMYC cMYCprom2_fwd GGGCAGCTGTTCCGCC 
     cMYCprom2_rev     TCTCCCTTTCTCTGCTGCTCC 
cMYC cMYCprom3_fwd CCCAAAGCAGAGGGCGT 
     cMYCprom3_rev     AGCCGTCCAGACCCTCG 
cMYC cMYCe1.1_fwd GGCTTGGCGGGAAAAAGA 
     cMYCe1.1_rev     CGAGTTAGATAAAGCCCCGAAAA 
cMYC cMYCe2.1_fwd CACCAACAGGAACTATGACCTCG 
     cMYCe2.1_rev     GCTCGAATTTCTTCCAGATATCCTC 
cMYC cMYCe2.2_fwd TGGTCTTCCCCTACCCTCTCA 
     cMYCe2.2_rev     ACTCCGTCGAGGAGAGCAGA 
cMYC cMYCe3.1_fwd GCCTCCCTCCACTCGGAA 
     cMYCe3.1_rev     GGCTGGTGCATTTTCGGTT 
cMYC cMYCe3.2_fwd TGGACTTTGGGCATAAAAGAACTT 
     cMYCe3.2_rev    CATTTAATGGCAATATTTACAGAGAAACAT 
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Gene Primer forward 5’-3’- forward sequence 
CpG-island     Primer reverse     5’-3’-reverse sequence 
   
TUBB TUBBprom1_fwd CACTCAATTTTTCCCCCATCAAT 
     TUBBprom1_rev     GCAACTCTGCAAGAGACCCAGTAT 
TUBB TUBBprom2_fwd AAGTTCATGCCTTGGGTCACC 
     TUBBprom2_rev     GCTCCCAGCTGCAGTACCTCT 
TUBB TUBBprom3_fwd GCCAATGGACGCCTGGTAC 
     TUBBprom3_rev     GGAGACAAAGCCTCATCGAGC 
TUBB TUBBe1.1_fwd CTTATTTTCTTGCCCCATACATACCTT 
     TUBBe1.1_rev     GCACGATTTCCCTCATGGTTAA 
TUBB TUBBe2.1_fwd GACCCGCTGCACATATCCA 
     TUBBe2.1_rev     GCCACACCCTTCCCCTAGA 
TUBB TUBBe3.1_fwd GGGAGGTGATCAGTGATGAACAT 
     TUBBe3.1_rev     CATTGTAGTACACAGAGATGCGGTC 
TUBB TUBBe4.1_fwd AGCCATCCAGGAGCTCTTCAA 
     TUBBe4.1_rev     TCCATGCCCTCGCCTGT 
TUBB TUBBe4.2_fwd CCCATCTCAGCTTCAAGGGAG 
     TUBBe4.2_rev     AGGAGCTGAGTGAGGGAGGTAGA 
ACTB ACTBprom5_fwd GAAGTGGCCAGGGCGG 
     ACTBprom5_rev     GCTGCGAGAATAGCCGGG 
ACTB ACTBe2.1_fwd CCAACTGGGACGACATGGAG 
     ACTBe2.1_rev     GCAGCTCATTGTAGAAGGTGTGG 
ACTB ACTBe3.1_fwd ACCTTCAACACCCCAGCCA 
     ACTBe3.1_rev     GAGGCGTACAGGGATAGCACAG 
ACTB ACTBe4.1_fwd AGGCATGGAGTCCTGTGGC 
     ACTBe4.1_rev     CACTTCATGATGGAGTTGAAGGTAGTT 
ACTB ACTBe5.1_fwd CACTGACTTGAGACCAGTTGAATAAAAG 
     ACTBe5.1_rev     TGGCCTCATTTTTAAGGTGTGC 
UBE3A UBE3Aprom1_fwd AAGTTGCAAGTTGTAACACTATGAATTGT 
     UBE3Aprom1_rev     GGTACCAGGGTCACCATTTTAAAA 
UBE3A UBE3Aprom4_fwd GGGTCACAGACAGCAGAAACTAAAA 
     UBE3Aprom4_rev     GCGACTGGACAGAAAGGGTAATC 
UBE3A UBE3Ae1.1_fwd AGATCCGTGTGTCTCCCAAG 
     UBE3Ae1.1_rev     CCCCGTCGTCTCCTGTAGT 
UBE3A UBE3Ae2.1_fwd GAGCCTGATTTTAGAATTCACCA 
     UBE3Ae2.1_rev     ACCATATTTCGCCAAACTTCTG 
UBE3A UBE3Ae3.1_fwd GCCTACGCTCAGATCAAGGT 
     UBE3Ae3.1_rev     TTTTACAAGCTGTGGCCATTC 
UBE3A UBE3Ae7.1_fwd AACTGAGGGCTGTGGAAATG 
     UBE3Ae7.1_rev     GGAGGGATGAGGATCACAGA 
UBE3A UBE3Ae8.1_fwd GTGACTTACTTAACAGAAGAGAAGGTATATGAAAT
     UBE3Ae8.1_rev     TGTACCAATGCCTCAGCACTAGAA 
PEG3 PEG3prom1_fwd AATTTCTTGCCTACCTTTCCAACAG 
     PEG3prom1_rev     GGTAAGTGTTTTCTCATTTATTTGTTTTTTAAG 
PEG3 PEG3prom4_fwd ACGCAGTGGAAGGTCTGTATTGA 
     PEG3prom4_rev     TCACACACTACTGAGTTGTTTCCCA 
PEG3 PEG3e4.1_fwd GGCCCCAAATCTGTATGAGCTAG 
     PEG3prome4.1_rev     GACATCCGGCTCCTTAGTCAAGT 
PEG3 PEG3e9.2_fwd GCCACTCATCAAGATCCAAGAGA 
     PEG3prome9.2_rev     TGCCTCCTGCTTACCTCGAC 
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Gene Primer forward 5’-3’- forward sequence 
CpG-island     Primer reverse     5’-3’-reverse sequence 
   
Xist Xistprom1_fwd TGGCTTTTATATGAGCTTTTTCTTCCT 
      Xistprom1_rev     CATATGACACAGTAGTGAAGTTGACCCT 
Xist Xistprom3_fwd CCCTTTTTTGTCCTTACTGGGTAAA 
      Xistprom3_rev     TGAGGGCGGAGAGAGCATAA 
Xist Xiste1.1_fwd GTTCAGATTGTGGAGGAAAAGTGG 
      Xiste1.1_rev     CAAACGACTAGCCCTAAGCCG 
Xist Xiste1.3_fwd TTCTTCATCTGGAGCACCTGC 
      Xiste1.3_rev     AGCACCTCTGCATATGTTCCCT 
Xist Xiste3.1_fwd ACAGCTATAAGAGGCTCCAAATTAATCA 
      Xiste3.1_rev     CCAGATTCTCAAAGGGAAAGATATGA 
Xist Xiste4.1_fwd CAGTGTTAGTGATCCATTCCCTTTG 
     Xiste4.1_rev     CCTCATGCCCCATCTCCAC 
H19 H19CTCFbs_fwd CTCCTTCGGTCTCACCGCCTGGAT 
     H19CTCFbs_rev     CCTTAGACGGAGTCGGAGCTG 
H19 H19CTCFbs2_fwd GAGGTGAATTTGCCCACAGG 
     H19CTCFbs2_rev     CCCAAAGGAAATACTCCGGAA 
HOXA9 HOXA9posK27_fwd CTCAGGAGCCTCGTGTCTTT 
     HOXA9posK27_rev     GTGACCAGGTGGAGGTGTGT 
HOXD12 HOXD12posK27_fwd GAACCTGCAGGCAAAGTTTC 
     HOXD12posK27_rev     AGAGACTGCGCTCACACATC 
PAX6 PAX6e5posK27_fwd TCTTCTCTTCTTTTCCCCTTTC 
     PAX6e5posK27_rev     AGACACCACCGAGCTGATTC 
CRHR2 CRHR2posK27_fwd CTTCAACGGCGTCAAGTACA 
     CRHR2posK27_rev     GGGTCCGGAATCCTCTTTAC 
ZMND1 ZMND1neg1K27_fwd TGCACGTACGTAGCCTTCAC 
     ZMND1negK27_rev     TCCGAAATTTGTTGGAGCAT 
PCK1 PCK1neg1K27_fwd CCCACTGGGAACACAAACTT 
     PCK1negK27_rev     CCTTTCTTCTCTTTGGATGATCT 
APRT APRTneg1K27_fwd GCCTTGACTCGCACTTTTGT 
     APRTnegK27_rev     TAGGCGCCATCGATTTTAAG 
MXD1 MXD1neg1K27_fwd GAGATGGTGAGTCGGGGATA 
     MXD1negK27_rev     AACCACGCTCGACAAGAGAG 
IL8 IL8mH2Apos1_fwd TTATAATTTATACCATGTAGC 
     IL8mH2Apos1_rev     GGGTATCTTTAAACCAGACAGG 
IL8 IL8mH2Apos2_fwd ATTTGATAAGGAACAAATAGGAAGTG 
     IL8mH2Apos2_rev     GTGGCTTTTTATATCATCACCC 
IL8 IL8mH2Aneg1_fwd TCTTCTTCTGATAGACCAAACTCTTTAAGG 
     IL8mH2Aneg1_rev     GATGGTGAAGATAAGCCAGCC 
IL8 IL8mH2Aneg2_fwd AAGCTTCTAGGACAAGAGCCAGG 
     IL8mH2Aneg2_rev     GGTCAGAAAGATGTGCTTACC 
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